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Summary of the thesis 
Background: In the era of large-scale biobanks and detailed multi-omic and clinical phenotyping, 
it is now possible to simultaneously measure several thousands of biological traits and test their 
associations with health outcomes. The unprecedented scale of the available epidemiological data 
has led to a surge in the number of proposed risk factors for cardiometabolic and other diseases 
identified through observational research. However, prominent failures of randomised controlled 
trials to replicate observational findings highlight that new approaches are urgently required to 
prioritise risk factors for interventional studies based on their likelihood of causality.  
 
Aim: Genetic evidence provides the opportunity to obtain unconfounded associations in an 
observational setting and can help to efficiently identify causal, aetiological pathways to 
cardiometabolic diseases. This work aims to identify and prioritise causal pathways to 
cardiometabolic diseases by integrating genetic data with detailed metabolic phenotypes, including 
blood metabolites and objective measures of body size and composition. 
 
Methods: The first chapter summarises and critically evaluates existing genetic strategies for 
assessing causality in an observational setting and reviews the literature on reported associations 
between blood metabolites and incident type 2 diabetes (T2D). As a proof-of-concept, I then 
adopt a genetic approach to a) generate genetic predictors and b) assess evidence of causality for 
T2D and coronary heart disease (CHD) risk for a selected metabolite (glycine), for which 
consistent observational evidence suggests protective associations with T2D and CHD 
development. The approach is then extended to move beyond studying simple indices of obesity 
and enable causal assessment of refined anthropometric traits. For this, I have led collaborative 
efforts to develop genetic instruments for overall and regional fat and lean mass. 
 
Findings: Genetic approaches to studying causality in an observational setting rely on important 
assumptions that are sensitive to violations, particularly in the context of highly correlated ‘omic’ 
measures. Existing methods generally consider overall risk factor “levels”, rather than assessing 
the causality of the distinct mechanisms contributing to levels. I provide genetic evidence for a 
causal cardio-protective effect of the glycine pathway in men and women, with blood pressure as 
a potential mediating factor. In contrast, no strong evidence for a causal link between glycine and 
T2D was found, with evidence suggesting that the inverse glycine-to-T2D association is the 
consequence of a glycine-lowering effect of insulin resistance. Despite total body fat percentage 
 vi 
 
(BF%) and fat-free mass index (FFMI) being strongly observationally and genetically correlated 
with BMI, I identify 16 loci associated with higher BF% and lower FFMI but not BMI. Based on 
observational and genetic studies of regional fat and lean mass, I identify patterns of fat distribution 
which may not be captured by traditional anthropometric phenotypes, such as fat mass in the arms 
and in the subcutaneous android region. Fat mass in the arms and subcutaneous android region 
were observationally only weakly correlated with BMI, WHR and other fat compartments, and 
genetic loci specific to arm and subcutaneous android fat mass were identified. Conversely, no 
evidence was found that genetic loci associated with lean mass have heterogeneous effects on lean 
mass in different regions of the body.  
 
Conclusion: This thesis demonstrates how the integration of large-scale genetic, metabolomic 
and clinical data can not only prioritise novel aetiological pathways to cardiometabolic conditions, 
but also formulate hypotheses regarding the underlying physiological mechanisms. The genetic 
factors identified for refined anthropometric traits, such as a high relative body fat mass in the 
absence of overweight, allow for a causal assessment of novel and specific body size and 
composition traits. In summary, this thesis demonstrates and utilises the opportunities that arise 
from integrating genetic data with refined phenotypes at scale to identify novel targets for the 
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The central aim of this PhD thesis is to identify novel aetiological pathways to cardiometabolic 
diseases based on the integration of large-scale genome-wide data with detailed metabolic 
phenotypes obtained with -omics methods and refined body composition analysis techniques. The 
primary focus is on the aetiology of type 2 diabetes (T2D), but this focus is extended to coronary 
heart disease (CHD) in some sections of the thesis. 
 
I will address the following sub-aims and objectives: 
 
v Sub-aim 1: To review the current state of genetic and omics-based research on the aetiology 
of T2D. 
§ Objective 1.A: To review and critically evaluate the literature on genetic approaches to 
identify aetiological pathways to T2D 
§ Objective 1.B: To conduct a systematic literature review of longitudinal 
epidemiological studies on metabolomics and incident T2D. 
 
v Sub-aim 2: To develop and implement a genetics-based approach to investigate metabolic 
pathways as aetiological factors for cardiometabolic conditions, using the glycine pathway as 
an example. 
§ Objective 2.A: To construct and validate genetic instruments for the glycine pathway 
§ Objective 2.B: To assess the observational and genetic, unconfounded associations of 
glycine levels with T2D and CHD 
§ Objective 2.C: To identify the biological mechanisms driving the associations of the 
glycine pathway with T2D and CHD. 
 
v Sub-aim 3: To construct genetic instruments associated with total body composition 
phenotypes. 
§ Objective 3.A: To conduct exome chip meta-analyses for total body fat percentage 
(BF%) and fat-free mass index (FFMI) 
§ Objective 3.B: To conduct genome-wide association studies (GWAS) for BF% and 
FFMI in a large British cohort 
§ Objective 3.C: To identify loci for BF%, FFMI and BMI which disproportionately 




v Sub-aim 4: To build genetic instruments for fat and lean mass compartments and distribution 
patterns. 
§ Objective 4.A: To conduct meta-analyses of GWAS for regional fat and lean mass and 
fat and lean mass distribution 
§ Objective 4.B: To characterise the fat and lean mass distribution patterns associated 








Outline of the thesis  
Chapter 1 gives an overview of the relevant literature. I commence with a brief outline of 
general concepts of T2D, including its definition, pathophysiology and global impact. Next, I 
provide an overview and critical evaluation of recent genetic and -omics approaches to identifying 
causal risk factors for T2D, including a systematic literature review of longitudinal epidemiological 
studies of metabolomics and T2D. 
Chapter 2 describes an approach to assessing the causality of metabolic pathways as 
aetiological risk factors for cardiometabolic illnesses, based on large-scale genetic, metabolomic 
and clinical data, using the glycine pathway as an example. An in-depth study of the glycine pathway 
as a potential aetiological factor for T2D and CHD is presented. I construct genetic instruments 
for glycine based on a meta-analysis of GWAS for glycine in up to 80,000 participants, conduct 
Mendelian randomisation (MR) analyses to assess the causality of low glycine levels for T2D and 
CHD in both sexes combined and by sex, and use the MR framework to generate hypotheses 
about the biological factors driving associations of the glycine pathway with cardiometabolic 
diseases.  
Chapter 3 focuses on the identification of genetic instruments associated with refined 
phenotypes of overall body composition, i.e., BF% and FFMI. I describe a consortium project, in 
which I took a leading role, which aims to identify the genetic determinants of BF% and FFMI 
through exome chip meta-analyses including up to 112,443 participants and GWAS on UK 
Biobank participants of European ancestry. I conduct quantitative assessments of the 
proportionality of the effect sizes of genetic loci for BF%, FFMI and BMI on fat and lean mass in 
order to identify loci which disproportionately affect fat or lean mass. 
Chapter 4 describes genetic analyses on fat and lean mass compartments and distribution, 
based on dual-energy X-ray absorptiometry (DEXA) imaging. I perform meta-analyses of GWAS 
for 9 fat compartments and 7 lean mass compartments, including up to 25,452 participants from 
5 cohorts. I characterise the fat and lean mass distribution patterns associated with each of the 
identified loci, and investigate the overall with loci known for standard anthropometric traits. 
The concluding discussion summarises the empirical findings, outlines the general 







Technological innovations and reduced costs of high-throughput and refined phenotyping 
methods have led to the availability of phenotypic and clinical data of unprecedented granularity 
and scale in epidemiological cohorts and biobanks. “Omics” technologies, such as metabolomics 
and proteomics, have enabled the hypothesis-free measurement of thousands to tens of thousands 
of molecular markers simultaneously, while imaging techniques such as DEXA imaging have made 
it possible to obtain detailed body composition measurements at a relatively low cost and high 
speed. 
The surge in the scale and depth of available phenotypic and clinical data in epidemiological 
cohorts has created the opportunity to conduct large-scale investigations, in which up to several 
thousands of potential risk factors are tested simultaneously for multiple outcomes in a hypothesis-
free manner. This emerging new approach to risk factor discovery is rapidly gaining territory in 
epidemiological research, in which for a long time the predominant strategy has been to conduct 
studies of one or a limited set of pre-selected risk factors for one particular outcome and in 
isolation of other risk factors. 
As the hypothesis-free strategy to risk factor discovery has become increasingly popular, this has 
led to an exponential increase in the number of proposed risk factors for disease outcomes. 
However, this surge in proposed risk factors has thus far not been met by a similar increase in the 
identification of confirmed causal risk factors, for two main reasons. First, the increasing coverage 
of the phenome comes with more pronounced correlation patterns between the proposed risk 
factors, which makes it challenging to distinguish causal factors from the many phenotypes with 
which they are correlated. Secondly, several high-profile failures of intervention studies set up to 
validate the causal role of risk factors consistently reported by epidemiological research have 
highlighted that causality cannot be reliably assessed in observational settings. New strategies are 
therefore needed to prioritise the proposed risk factors that are likely to be causal.  
Genetics can be used to prioritise proposed risk factors that are likely to be causal for disease risk. 
Genetics-based causality assessment is being facilitated by the recent, drastic increase in the 
availability of genome-wide data obtained through array-based genotyping or whole-genome or 
exome sequencing in large population-based cohorts and disease-specific consortia. This facilitates 
causal inference in observational settings using genetic approaches such as Mendelian 
randomisation, which has gained tremendous popularity in assessing the causality of traditional 





This availability of phenotypic and genome-wide data at an unprecedented scale offer a timely 
opportunity to investigate metabolic pathways as aetiological pathways to cardiometabolic diseases 
and to deepen our understanding of the relationship between body composition and 
cardiometabolic health. Although metabolic disturbances are key processes in the pathophysiology 
of T2D and CHD, most research on metabolic risk factors has focused on a handful of markers, 
including fasting glucose and blood lipid fractions. The emergence of metabolomics in 
epidemiological studies on cardiometabolic diseases has created the opportunity to study virtually 
every metabolic pathway in relation to cardiometabolic disease risk. While overweight and obesity, 
based on simple, crude measures such as body mass index (BMI) and waist-to-hip ratio (WHR), 
are widely accepted as major culprits for the secular increase in incidence of cardiometabolic 
diseases, the aetiological relevance of overall and regional body composition is far less understood. 
The adoption of more advanced anthropometric assessment techniques such as bio-impedance 
analysis and imaging-based methods in the baseline health assessment protocol of biobanks and 
epidemiological cohorts enable research on specific body composition phenotypes, such as overall 
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Publications related to this chapter 
Parts of this literature overview has been published as a review article: 
L. B. L. Wittemans, L. A. Lotta & C. Langenberg. Prioritising Risk Factors for Type 2 
Diabetes: Causal Inference through Genetic Approaches. Current Diabetes Reports (2018) 
18: 40.  
Abstract 
Purpose of the literature review: Causality has been demonstrated for few of the many putative 
risk factors for type 2 diabetes (T2D) emerging from observational epidemiological research. 
Genetic approaches are increasingly being used to infer causality. In this literature review, I discuss 
how genetic discoveries have shaped our understanding of the causal role of factors associated 
with T2D. 
Outline and recent findings: I start with a brief introduction which outlines the definitions, 
global impact, risk factors and pathophysiology of diabetes. Next, I highlight the need to prioritise 
proposed risk factors for T2D and discuss genetic approaches that allow for causal assessment in 
an observational setting.  
I then use three illustrative examples to highlight how genetics can be used to prioritise novel 
aetiological factors for T2D and refine our understanding of established risk factors: 
• I outline how observational studies using a multitude of genetic approaches, have revealed a 
complex role of lipid metabolism in the aetiology of T2D. 
• I describe how the integration of genetic and refined phenotypic data has led to a more 
nuanced understanding of the effect of overall adiposity on T2D risk and has proposed 
peripheral fat storage capacity as a protective factor for T2D.  
• Finally, I highlight how “-omics” methods have led to a surge in proposed risk factors for T2D 
by conducting a systematic literature review of metabolomics studies on T2D, and, using 
examples from the literature, I describe how genetics can help to identify and prioritise causal 
pathways among the multitude of established and emerging biomarkers. 
Summary: Genome-wide association studies of T2D and metabolic traits coupled with high-
throughput molecular phenotyping and in-depth characterisation and follow-up of individual loci 
have provided better understanding of aetiological factors contributing to T2D. 





Definition of diabetes mellitus 
Diabetes Mellitus is a chronic condition characterised by elevated blood glucose levels caused by a lack of 
insulin production or the inability of the body to adequately respond to insulin1,2. According to the World 
Health Organisation’s (WHO) guidelines, diabetes can be diagnosed if at least one of the 3 criteria pointing 
to hyperglycaemia are met (Table 1.1)3.  
 
Table 1.1: The World Health Organisation's (WHO) diagnostic criteria for diabetes. Only one of the 3 criteria needs to be 
met for a diabetes diagnosis.  HbA1c: haemoglobin A1c. Adapted from the Global Report on Diabetes (2017) published by the 
WHO3. 
Marker Threshold 
Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) 
Two-hour plasma glucose ≥ 11.1 mmol/L (200 mg/dL) 
HbA1C ≥ 6.5% 
 
Type 2 diabetes (T2D) is the most prevalent of three common types of diabetes, with 90% of all 
cases being type 2 diabetic1. In T2D patients, hyperglycaemia arises from a relative insufficiency in 
insulin secretion in the context of varying degrees of insulin resistance. It is often related to 
overweight as a consequence of a long-term positive energy balance and is most commonly 
diagnosed in middle-aged individuals. In contrast, type 1 diabetes is predominantly diagnosed in 
children and adolescents and results from the autoimmune-mediated destruction of the insulin-
producing β cells of the pancreas, leading to an incapability of the body to produce insulin4. 
Gestational diabetes is the third common type of diabetes and is characterised by hyperglycaemia 
during pregnancy, possibly caused by the interference of hormones secreted by the placenta with 
insulin action5. 
 
The global impact of type 2 diabetes 
Estimates by the International Diabetes Federation show that in 2017, 8.8% of the population, or 
425 million people worldwide, were affected by diabetes, and prevalence is expected to increase to 
9.9% by 20451. Nearly 11% of the global all-cause mortality among people aged 20-79 years could 
be attributed to diabetes in 2017, and 46% of these deaths occurred before the age of 601. With 
80% of the total burden of diabetes lying in low to middle-income countries1, diabetes can no 
longer be considered a disease of affluence and poses a serious threat to public health worldwide.  
Chapter 1: Literature Overview 
 14 
 
Most disability and mortality associated with T2D is due to complications caused by 
hyperglycaemia-induced macro- or microvascular damage, of which cardiovascular, renal and eye 
conditions are the most common chronic complications. Patients with T2D are at 2 to 3 times 
higher risk of developing a cardiovascular disease, including peripheral artery disease, coronary 
heart disease, cardiac failure and ischemic stroke6. Risk of a cardiovascular disease among T2D 
patients is closely correlated with glucose control7. T2D is also the most common cause of chronic 
kidney disease worldwide and, together with hypertension, accounts for 80% of all cases. Diabetic 
retinopathies caused by damage to the microvasculature of the retina due to high glucose are the 
leading cause of reduced vision among the adult population of working age and affect around 1 in 
3 diabetic patients1,8. Diabetes has also been shown to have large economic impacts at the level of 
the individual patient and their family9, as well as on health care systems and national 
economies10,11. Altogether, this emphasises the need for a better understanding of T2D, and the 
development of better prevention and treatment strategies worldwide, and the importance of 
strategies targeted to low and middle-income settings.  
 
Glucose homeostasis, risk factors for type 2 diabetes and pathophysiology 
The peptide hormone insulin, which is synthesised by and secreted from the islet β cells of the 
pancreas, is the master regulator of glucose homeostasis12. In healthy individuals who are in a fasted 
state, insulin secretion is low, and glucose is produced endogenously, primarily through 
glycogenolysis and gluconeogenesis in the liver, to maintain blood glucose levels within the normal 
range and provide glucose as a source of energy for the brain. Glucose uptake by the muscles and 
adipose tissue is low during fasting to preserve glucose for the brain. After carbohydrate ingestion 
and uptake through the gut, blood glucose levels will rise and signal the islet β cells to start secreting 
insulin. Insulin travels through the blood stream to insulin-sensitive tissues, where it will stimulate 
the uptake of glucose by the muscles and adipose tissue, inhibit glucose and lipid secretion by the 
liver and downregulate lipolysis in adipose tissue. This integrated insulin-induced response ensures 
that glucose levels return to its fasted concentration within two hours of a meal12.  
 
Insulin resistance is a pathological state in which the insulin-sensitive tissues become less 
responsive to normal insulin levels13. The development of insulin resistance often co-occurs with, 
or is preceded by a long-term positive energy balance, due to the overconsumption of energy-
dense foods, lack of physical activity, or both. In the fed state, insulin resistance is characterised 
by a reduced uptake of glucose in the muscles and adipose tissue for a given level of insulin, a 
relative incomplete inhibition of glucose and lipid production by the liver and incomplete 
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suppression of lipolysis12. To maintain normal glucose levels in an insulin-resistant state, the β cells 
will respond by increasing insulin secretion, which will lead to hyperinsulinaemia. If the β cell mass 
starts to reduce and/or β cell function becomes compromised, insulin levels will at some point 
become insufficient to maintain glucose levels within the normal range after a meal and/or in a 
fasted state. Because of this mismatch between the levels of insulin required to maintain euglycemia 
and the capacity of the β cells to keep producing sufficient levels of insulin, T2D eventually 
develops. The degree of insulin resistance at which the β cells start to decompensate is believed to 
be highly variable between individuals13. For example, maturity onset diabetes of the young 
(MODY) is a heterogeneous group of monogenic forms of diabetes, in which diabetes develops 
by β cell dysfunction in the absence of insulin resistance14. On the other side of the spectrum, the 
Donohue’s syndrome, caused by severe loss-of-function mutations in the insulin receptor, is 
characterised by extreme insulin resistance and hyperinsulinemia15. Common forms of T2D are 
characterised by a relative insulin insufficiency12,13, and genetic evidence indicates that the level of 
insulin resistance at which β cell decompensation starts to occur may be largely genetically 
determined16. 
Although unmodifiable risk factors such as family history of T2D17 and ethnic background18 
explain a substantial proportion of the variance in incidence, several lifestyle-related risk factors, 
including overweight, obesity and abdominal adiposity19,20, lack of physical exercise19,21, sedentary 
lifestyle22,23, unbalanced diet4,15 and smoking21 have been identified through epidemiological 
observational research as important predictors of disease incidence. Multiple lifestyle intervention 
studies have confirmed that acting on these risk factors can be effective in reducing risk of 
T2D19,25,26.  
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Genetic approaches to study the aetiology of type 2 diabetes 
The urgency to prioritise proposed risk factors 
While causality has been demonstrated for a limited set of lifestyle-related risk factors19,25–28, the 
causal relevance for most risk factors proposed for T2D, especially for those emerging from -
omics and other deep phenotyping-based studies, remains unknown29–31. Randomised controlled 
trials are the “gold-standard” for causality assessment but are expensive and time-consuming, and 
may not be feasible (e.g., birth weight, epigenetic markers) or ethical (e.g., alcohol consumption, 
smoking) for some exposures. Examples of high-profile failures to replicate interventions that 
were prioritised on the basis of observational evidence highlight the limited ability of even 
rigorously conducted observational studies to limit the influence of bias and confounding and to 
draw causal inferences about observed statistical associations32,33. While risk factors that are not 
causally associated with a disease, for example markers of the subclinical disease process, can be 
useful for disease prediction, this is not the case if the aim is to identify targets for intervention. 
Hence, new ways to prioritise risk factors on the basis of their causal likelihood are needed.  
Genetic evidence through genotyping and sequencing of patients is expected to reduce the high 
rate of late-stage failures in drug development to translate laboratory models into the clinic34–36. 
Similarly, genetic insights may help to generate evidence about causal relevance and prioritise risk 
factors for testing in trials. The two most commonly adopted genetic approaches to identifying 
aetiological pathways to disease are genome-wide association studies (GWAS), based on either 
array-based genotyping or whole-genome sequencing, and Mendelian randomisation. The next two 
sections describe GWAS and Mendelian randomisation in the context of T2D.  
Genome-wide association studies have linked more than 200 genetic regions to 
T2D susceptibility 
Hypothesis-free testing for associations of germline genetic variants across the genome with T2D 
can identify genes involved in disease risk, and therefore has the potential to improve our 
understanding of the aetiological mechanisms of T2D and facilitate the prioritisation of novel 
targets for treatment and prevention. Such large-scale genetic studies including up to tens of 
thousands T2D cases have been conducted based on array-based genome37–39 and exome-wide40 
genotype data and on whole-genome or exome sequence data41.  
Over the past decade, several consortium efforts have combined array-based genome-wide 
association data from large numbers of studies to identify the genetic determinants of T2D, with 
sample sizes and genome coverage continuously increasing over time16,37–39,42–45. In one of the latest 
and thus far largest meta-analysis of GWAS, 27 million genetic variants in up to 74,000 T2D cases 
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and 824,000 controls of European ancestry were tested16 and more than 240 independent genetic 
loci reached genome-wide significance.  
Sequencing and array-based genome and exome-wide association studies have taught us that the 
genetic predisposition to T2D is predominantly driven by common variants, of which most are 
located in intergenic regions and have a small effect size on disease risk16,40,41. Furthermore, cross-
trait association analyses for genetic loci identified for T2D have corroborated the importance of 
established aetiological pathways, in particular islet β cell function, adiposity and insulin 
resistance16,40,46. Cross-trait analyses in combination with the integration of islet regulatory 
annotations suggest that a large proportion of the T2D loci is associated with β cell dysfunction 
and that only a small subset acts through insulin resistance, which suggests that the genetic 
predisposition to T2D is strongly driven by insulin secretion defects16.  
Although a few GWAS on individuals of non-European ancestry have been conducted 39,42,44,45, the 
current genetic research on T2D is still vastly dominated by studies on European individuals, both 
in terms of sample sizes and the number of conducted studies. This bias towards European 
ancestry forms a prominent limitation of current genetic research on T2D. The lack of 
understanding of potential ancestry differences in the genetic architecture of T2D limits 
investigations into aetiological pathways that are specific to, or play a more prominent role in non-
European ancestries. As a disproportionate share of the total burden of T2D is carried by non-
European ancestries, larger-scale GWAS on non-European ancestries are urgently needed.  
The identification of the causal variant(s) and effector gene(s) corresponding to GWAS loci forms 
another important challenge in the field of GWAS for T2D and other complex phenotypes. Lack 
of understanding of the causal genes and variants has been one of the main limiting factors for the 
translation of GWAS findings to novel biological insights and targets for disease treatment or 
prevention. In recent years, however, tremendous progress has been made in this area. Genetic 
fine-mapping techniques47 have allowed narrowing down the likely causal window at GWAS loci 
for T2D16 and other traits48,49, and ongoing trans-ethnic efforts are expected to lead to further 
progress in this area of research, as ancestry-specific linkage disequilibrium (LD) structures at the 
T2D loci can be leveraged for genetic fine-mapping. Substantial progress has also been made in 
the identification of effector genes corresponding to GWAS loci using a range of strategies, 
including statistical colocalisation of GWAS signals and cis-expression (eQTL)50 and protein-
quantitative trait loci (pQTL)51, the integration of tissue-specific regulatory and epigenetic 
annotations16,52, and bioinformatics tools that implement some of these aspects and can be run on 
summary-level GWAS data, such as DEPICT53 and MetaXScan54.  
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Mendelian randomisation to prioritise proposed risk factors for type 2 diabetes 
Genetic approaches can support causal inference because genetic variants are less correlated with 
many of the measured and unmeasured factors that can confound observational exposure-to-
disease associations, provided important assumptions are met. The genetic approach to causal 
inference visualised in Figure 1.3, referred to as “Mendelian randomisation” (MR), was originally 
proposed to investigate the association between fibrinogen and CHD by Keavney55 and has since 
gained popularity and been the subject of numerous studies and reviews56–59. MR uses a genetic 
score, or in some cases a single genetic variant, as an instrumental variable for the exposure in 
order to assess the unconfounded effect size of an exposure-outcome association. In its simplest 
form, MR estimates the causal effect size of the exposure on the outcome by taking the ratio of 
the effect size of the genetic score for the exposure on the outcome, and the effect size of the 
genetic score on the exposure itself. This estimate represents the long-term causal influence of the 
exposure on the outcome, under the condition that the genetic instrument for the exposure fulfils 
the so-called instrumental variable assumptions, which are the following: 
1. The instrument is associated with the exposure. 
2. The instrument is not associated with any of the confounders of the exposure-outcome 
association. 
3. There is no conditional association between the instrument and the outcome, given the 
exposure and all confounders. 
As the instrumental variable assumptions are not fully empirically testable, one has to be cautious 
when interpreting the results of an MR analysis, especially if the biological mechanisms through 
which the genetic variants influence the exposure are unknown. Robust MR methods which rely 
on a set of more relaxed assumptions have been developed, but these methods come at the cost 
of reduced power58–60. For example, MR-Egger still produces consistent causal estimates when all 
genetic variants in the score violate the IV assumptions but instead meet the so-called “Instrument 
Strength Independent of Direct Effect” (InSIDE) assumption, which states that the pleiotropic 
effect sizes of the genetic variants in the score have to be independent of their effect sizes on the 
exposure58. Weighted median MR methods allow for consistent causal estimates even if up to 50% 
of the weight contributed comes from genetic variants that violate the IV assumptions59. 
Genetic approaches to estimating causal effect sizes require estimates of genetic associations with 
exposures of interest and outcomes. For many risk factors, these data have already been generated 
through GWAS, and results for T2D are publicly available via the online type 2 diabetes knowledge 
portal (http://www.type2diabetesgenetics.org)61. Therefore, the cost and time investments of 
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genetics-based causal investigations are small, especially compared to the costs, duration and 
participant burden of clinical trials.  
 
 
Figure 1.3: Schematic overview of the Mendelian randomisation framework. βvar-RF: Per-allele effect size of genetic variant 
on risk factor; βvar-T2D: Per-allele effect size of genetic variant on T2D. Figure published in Wittemans, Lotta and Langenberg, 
Current Diabetes Reports (2018)62.  
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The complex interplay between blood lipid fractions and T2D 
Genetics-based causality assessments of blood lipids as diabetes risk factors 
After meta-analyses of randomised controlled trials of statins revealed that this major class of low-
density lipoprotein cholesterol-lowering drugs modestly increases risk of T2D63, a series of genetic 
studies focusing on the contribution of lipid fractions to diabetes risk was conducted. Early MR 
studies investigating the causality of the blood lipid fractions focused on the separate contributions 
of three major lipid fractions: total triglycerides, high-, and low-density lipoprotein (HDL, LDL) 
cholesterol64–66. Because levels of these fractions are regulated by partially overlapping physiological 
processes, genetic scores were not specific to one lipid fraction only, and therefore specific causal 
inference is limited. To disentangle the causal effect of genetically related risk factors, so-called 
multivariable MR methods have been developed67, which estimate independent effect sizes of 
genetically correlated risk factors on the outcome in one model by taking the genetic correlation 
between them into account. High HDL cholesterol has been consistently associated with lower 
incidence of T2D, both observationally68–70 and in multivariable MR studies71,72, but recent 
evidence highlights that the extent to which LDL cholesterol and total triglycerides levels influence 
diabetes risk may be mechanism-dependent.  
Complex relationships between LDL cholesterol and diabetes risk 
While there is no doubt that higher LDL cholesterol increases the risk of diseases of the heart and 
vasculature, strong evidence is now available that some mechanisms lowering LDL cholesterol 
increase the risk of T2D71,72. Using multivariable MR, two recent publications suggested that higher 
levels of LDL cholesterol are causally related to lower diabetes risk, in line with evidence of statin 
trials63 and a study of patients with familial hypercholesterolaemia, reporting a lower incidence of 
T2D, compared to their unaffected family members73. In contrast, familial hypercholesterolaemia 
was not associated with lower diabetes risk in an Amish population74. Differences in the genetic 
background, identification, and management of these Dutch and Amish patient populations may 
have contributed to these discrepant findings.  
The extent to which levels of LDL cholesterol influence diabetes risk may depend on the 
physiological mechanism that contributes to differences in lipid levels75,76. For a given effect on 
LDL, the effect size of the associations between genetically predicted LDL cholesterol and T2D 
was shown to differ depending on the gene in which LDL variants are located when variants in 
current or prospective LDL-lowering drug targets, including PCSK9, HMGCR, NPC1L1, 
ABCG5/G8 and LDLR, were compared75. This is in contrast to the effect of LDL cholesterol on 
risk of coronary heart disease, which follows a clear log-linear pattern, in observational, genetic75,77 
and intervention studies78.   
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The role of total triglycerides may be mechanism-dependent 
Although total triglycerides have been consistently associated with higher incidence of T2D68–70, 
results for total triglycerides from genetics-based causal assessments are inconsistent71,72. Genetic 
evidence suggests that triglycerides may be ambiguously associated with diabetes risk, with 
protective or detrimental effects depending on the physiological mechanism driving triglyceride 
levels. Triglyceride-lowering genes involved in intravascular lipolysis, including intravascular 
lipoprotein lipase (LPL) and its inhibitor angiopoietin-like 4 (ANGPTL4), have been associated 
with lower risk of T2D76,79,80, while triglyceride-lowering variants in genes involved in the hepatic 
production of triglyceride-rich lipoprotein particles are linked to higher risks of diabetes and fatty 
liver76. In contrast, there is strong genetic evidence that several triglyceride-raising mechanisms are 
causally related to risk of CHD76,81,82.  
Moving beyond Mendelian randomisation 
These recent findings demonstrate how different genetic approaches can help to investigate and 
better understand the complex relationships between dyslipidaemia and diabetes risk by looking 
not only at risk factor levels, but specific mechanisms underlying these differences. Investigating 
combined genetic scores that encompass a large range of biological mechanisms affecting overall 
lipid concentrations may help general causal inference about the exposure in question but cannot 
reveal insight into the complexity underlying regulation of lipid metabolism. Given that LDL loci 
(for a given effect on LDL) differ in their association with diabetes risk, locus-specific results may 
also help to better estimate the effect of interventions that target levels through different 
mechanisms will have on different outcomes. Pleiotropy and heterogeneity of genetic loci is 
considered a limitation of MR but studies on the role of lipid metabolism for diabetes aetiology 
highlight that biologically relevant insights can be obtained by investigating individual genetic loci 
that are pleiotropic or have, given their effect on the exposure, a disproportionate effect size on 
the outcome.  
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The central role of peripheral fat in the aetiology of T2D 
Adiposity and body composition are major risk factors for T2D 
Overweight and obesity are strong modifiable risk factor for T2D19,25–28 and responsible for the 
secular increase in the diabetes prevalence. Weight loss interventions have been shown to reduce 
diabetes risk19,25–28, and are even able to revert glycaemia in patients with T2D to non-diabetic 
levels83. Genetic evidence supports the causal role of overall adiposity. The major BMI locus near 
FTO was the first found to exert its diabetes risk-raising effect entirely by increasing BMI84. More 
recently, the largest European-ancestry focused GWAS of T2D, which tested 27 million variants 
and included more than 74,000 cases, showed that 26 of the more than 400 conditionally 
independent variants at the identified loci for T2D predominantly increase risk through their effect 
on BMI, including established adiposity loci such as FTO, MC4R and TMEM1816. Independent 
causal roles of overall adiposity and abdominal fat accumulation has also been supported by MR 
studies85–87. 
Genetic loci link low adiposity to high diabetes risk 
Evidence is emerging that not all mechanisms leading to reduced fat accumulation are uniformly 
beneficial to metabolic health. Loci near IRS1 and COBLL1/GRB14 identified for lower total 
body fat percentage were found to be associated with higher risk of T2D88,89. Similarly, a coding 
variant in the CREBRF gene was found to increase BMI by 1.32-1.46 kg/m2 per allele but reduce 
diabetes risk by 40% in a Polynesian population90. In line with this, the most recent T2D GWAS 
showed that for a subset of the identified loci the associations with T2D risk were strengthened 
following adjustment for BMI. Among these were signals previously shown to be associated with 
lower capacity of adipose tissue generation and expansion79, including PPARG – a gene involved 
in Mendelian forms of partial lipodystrophy91. Together, these results suggest that, when focusing 
on distinct pathways connecting adiposity and diabetes, certain biological processes may reduce 
fat accumulation while increasing risk of T2D, while others will reduce risk.  
Lipodystrophy-like mechanisms may contribute to insulin resistance 
Genetic research on metabolic risk factors demonstrates that distinct pathways linking low 
adiposity to diabetes risk may be driven by insulin resistance79,92. It was recognised early on that 
discovery of loci associated with insulin resistance is facilitated by accounting for differences in 
obesity levels93; GWAS of insulin resistance have since been conducted based on fasting insulin 
levels adjusted for BMI79,93–95. Research on the relationship between insulin resistance and refined 
measures of body composition measured by DEXA shows associations between genetic 
determinants of insulin resistance and reduced fat accumulation in the legs and other peripheral 
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compartments79,95. Positive relationships of insulin resistance with visceral fat mass and liver 
enzymes79,95,96 suggests that genetic predisposition to insulin resistance, not primarily driven by a 
long-term positive energy balance, is linked to a body fat distribution pattern that favours visceral 
and ectopic fat deposition over deposition in peripheral body compartments. Questions remain 
over whether impaired peripheral fat and enhanced central fat distribution are independent 
mechanisms.  
Lotta et al. found that the 53 loci associated with hallmarks of common insulin resistance are also 
enriched in patients with familial partial lipodystrophy type 1, which is a rare condition 
characterised by extreme insulin resistance and the limited ability to store fat peripherally79. These 
loci identified for common insulin resistance are enriched with causal genes involved in monogenic 
forms of lipodystrophy, including PPARG, PIK3R1 and INSR 15. This suggests the presence of 
shared mechanisms between common and rare forms of insulin resistance, and that lipodystrophy-
like mechanisms may contribute to common forms of insulin resistance, and metabolic and 
cardiovascular disease. 
The majority of genetic studies has been conducted in participants of European ancestry. Many 
people who develop T2D in South-East Asia, the middle East and sub-Saharan Africa are not 
overweight or obese97–99. It is likely that fat distribution is important, but the causal role of the 
relative contributions of greater abdominal and lack of gluteo-femoral fat have not been 
investigated.  
The adipose tissue expandability hypothesis 
Altogether, these findings support the so-called adipose tissue expandability hypothesis, which 
states that each individual has a limited capacity to store excess energy in adipose tissue; once that 
threshold has been reached, excess energy in the form of lipids may accumulate ectopically in 
diabetes-relevant tissues such as the liver, muscles and the pancreas, where they may contribute to 
tissue dysfunction and diminished insulin action100,101. Individuals with a larger capacity to 
peripherally accumulate fat may therefore be more protected from the cardiometabolic 
consequences of a long-term positive energy balance. In support of this hypothesis, longitudinal 
data on weight change have demonstrated that people with a higher burden of insulin resistance-
increasing alleles tend to expand their hip fat depot less as they gain weight than people at low 
genetic risk to develop insulin resistance79. Refined imaging methods, including DEXA and 
magnetic resonance imaging (MRI), will help to further confirm this hypothesis and the specific 
contribution of these mechanisms to the broader relationship between fat distribution and 
metabolic risk in men and women and across ethnic groups.  
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Using genetics to prioritise causal pathways amongst the multitude of 
reported biomarker associations  
Biomarkers as causal candidates 
Interest into the potential causality of biomarkers for T2D has grown, as they can point to novel 
disease pathways and help to identify potential targets for intervention, provided they are causal. 
A systematic literature review has shown that more than 160 biomarkers measured in blood or 
urine have been associated with T2D, but for a small minority has an assessment of causality been 
attempted or demonstrated102. No evidence for causality has been found for the majority of the 
biomarkers that have been investigated using genetic approaches, including vitamin D103 , 
adiponectin104,105, uric acid106, C-reactive protein107 and gamma-glutamyl transferase108–110. However, 
for a few biomarkers, including sex hormone-binding globulin111,112, B and A-type natriuretic 
peptide systems113,114 and bilirubin115, suggestive evidence for a causal relationship with T2D has 
been reported. Historically, some of the older studies investigating one biomarker at a time were 
based on comparatively small sample sizes and a limited understanding of the specificity of the 
genetic instrument. Replication of these findings is needed using genetic prediction models that 
maximise exposure variance explained, utilise the largest available GWAS summary statistics, test 
generalisability across different ancestries where possible and investigate specificity of genetic 
variants in adequately powered studies with comprehensive coverage of relevant biological 
pathways. 
New wave of omics-based biomarkers 
Omics methods have enabled the high-throughput assessment of molecular traits in large 
epidemiological studies, including the metabolome, proteome and lipidome. This has led to a new 
wave and scale of observational diabetes “biomarker” discoveries, including metabolites29,116–119, 
lipid species120–123, proteins124 and methylation markers125.  
Metabolomics is the –omics method that focuses on measuring the entire collection of small 
molecules or metabolites, or a subset thereof, in a biological sample, which in epidemiological 
studies is often plasma or serum. Metabolomic profiling thereby enables a comprehensive insight 
into the metabolic state of an individual126,127. Liquid and gas chromatography, mass spectrometry 
(MS), or a combination of both, and hydrogen nuclear magnetic resonance (1H-NMR) are the most 
commonly used analytical techniques in metabolomics126.  
Although the hallmark of T2D is disrupted glucose homeostasis – meaning T2D is in essence a 
metabolic condition – the relationship of metabolic pathways other than glucose and lipid 
metabolism with T2D is largely unknown. With metabolomics and lipidomics being increasingly 
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implemented in population-based and T2D-specific epidemiological studies, novel insights on 
metabolic disturbances other than disruption of glucose homeostasis and dyslipidaemia to T2D 
are starting to emerge. Besides numerous reported associations of the metabolome with T2D, 
several metabolomics studies focusing on T2D-related metabolic risk factors, including insulin 
resistance128–132 and overweight, obesity and weight gain133–135, revealed multiple associations across 
the metabolome.  
Metabolomics and type 2 diabetes: a systematic literature review 
In order to create an overview of the available literature on blood-based metabolites linked to 
incidence of T2D, I conducted a systematic literature search of PubMed up to and including 23 
April 2018. I searched for epidemiological studies investigating the link between the serum or 
plasma metabolome and T2D, using a combination of three search term strings: one for T2D, one 
for epidemiological studies and one for metabolomics and the two most commonly used 
measurement techniques for metabolomics, i.e., proton nuclear magnetic resonance and mass 
spectrometry (Supplementary Table 1.1). From the 1,805 titles initially found in PubMed, 85 
studies, of which 43 were cross-sectional and 42 were longitudinal, were retrieved (Figure 1.4). 
 
Figure 1.4: PRISMA diagram of systematic literature review on the metabolomic signature of type 2 diabetes. NMR: 
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The 42 retrieved longitudinal studies on metabolomics and T2D varied greatly in terms of study 
design, adopted measurement techniques, studied metabolite classes and statistical methods (Table 
1.2). Among the 42 studies, there were 24 prospective cohort studies, 10 case-cohort studies, 13 
nested case-control studies and 1 retrospective study. A variety of metabolomics techniques was 
used. In the majority of the studies, a combination of a chromatographic method (gas (GC), liquid 
(LC), high performance liquid (HPLC) or ultra performance liquid chromatography (UPLC)) with 
mass spectrometry (MS) or tandem mass spectrometry (MS/MS) was adopted, while 3 studies used 
chromatography only and one study used tandem mass spectrometry only. Seven other studies 
relied on proton nuclear magnetic resonance (1H-NMR). In six studies, metabolite profiling was 
done using commercial metabolomics platforms, more specifically the Biocrates AbsoluteIDQ® 
platform (Biocrates Life Sciences, Innsbruck, Austria)29,136,137 and the Metabolon DiscoveryHD4® 
platform (Metabolon, Inc., Durham, USA)138–140 (Table 1.2).  
Studied metabolite classes and species varied considerably between studies. Nine studies117–119,128,138–
143 used an untargeted approach based on one or multiple measurement techniques, in order to 
cover the broadest possible spectrum of metabolites and avoid bias towards certain pre-selected 
metabolite classes (Table 1.2). Four other studies used a targeted approach to cover a wide range 
of metabolic pathways to achieve near-metabolome-wide coverage29,137,144,145, while 7 studies 
focused on aqueous metabolites only146–152 and 8 studies covered a broad range of lipid classes31,121–
123,144,153–155. Of the studies on lipid metabolism, 4 studies used NMR-based refined measures of 
lipoprotein particle size and composition31,144,153,154. Other studies were set up to investigate the role 
of a specific metabolic pathway or a very limited set of metabolites for which there was a prior 
interest, such as specific nutritional biomarkers156, saturated fatty acids in phospholipids120,  
testosterone metabolites157,158, ceramides159, sphyngoid bases160,161 and omega 6 fatty acids162 (Table 
1.2). 
A wide range of statistical methods were used in the 42 identified studies. The vast majority of 
studies adopted univariate methods in which one metabolite at a time was tested for a statistical 
association with incident T2D. The logistic regression model was the most commonly adopted 
univariate method, and a smaller proportion of the studies used time-to-event analyses based on 
Cox proportional hazards model. The main limitation of using univariate models is that these 
implicitly assume that each metabolite influences the outcome independently of all other 
metabolites. In reality, however, groups of metabolites are likely to jointly influence the outcome 
and effect sizes obtained from simple regression models are therefore likely to be overestimated. 
An alternative approach to assess associations between the metabolome and T2D is to use 
regularised multiple regression models in which the associations of all metabolites are tested in one 
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model while taking into account the correlations between the metabolites. Effect size estimates 
for each metabolite obtained from this type of model are adjusted for all other metabolites. In 
some of the more recently published studies, regularised multivariate methods, such as least 
absolute shrinkage and selection operator (LASSO) and regularised least squares regression, have 
been used to identify subsets of metabolites significantly and independently associated with 
T2D118,139,144,147. 
In total, circulating levels of more than 230 unique metabolites have been associated with future 
onset of T2D (Figure 1.5). In virtually every studied metabolic pathway, metabolite species have 
been associated with incidence of T2D. Amino acids, carbohydrates, di- and triglycerides, 
phospholipids, acyl carnitines, fatty acids and lipoproteins are among the most commonly studied 
and reported metabolite classes for T2D (Figure 1.5).   
 
Figure 1.5: Overview of metabolites that have been reported for incidence of type 2 diabetes. Metabolites reported for 
incident T2D were reported by metabolite class. The pink boxes contain metabolites which have been positively associated with 
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Table 1.2: Longitudinal studies on metabolomic signatures of incident type 2 diabetes 
Publication Study design Study population Incident cases Follow-up Measurement technique 
or platform 
Measured metabolite classes 
146Chen 2016 Nested case-control and 
case-subcohort 
Shanghai Diabetes Study 51 10 years UPLC-MS Amino acids 
163de Mello 2015 Prospective cohort Finnish Diabetes Prevention Study 130 8 years GC-MS Non-cholesterol sterols 
141Drogan 2015 Nested case-control EPIC-Potsdam 300 6 years UPLC-MS Untargeted approach  
128Fall 2016 Prospective cohort and 
nested case-cohort 
ULSAM, PIVUS TwinGene, KORA S4 358 Not 
reported 
UPLC-MS Untargeted approach 
158Fenske 2015 Prospective cohort Study of Health in Pomerania 226 5 years LC-MS androstenedione, total tostesterone 
153Festa 2005 Prospective cohort Insulin resistance atherosclerosis study (IRAS) 130 5.2 years 1H-NMR Lipoprotein particles 
29Floegel 2013 Case-cohort EPIC-Potsdam 800 7 years AbsoluteIDQ p150 
Biocrates 
Hexose, acylcarnitines, amino acids, hexose and 
phosphatidylcholines 
120Forouhi 2014 Case-cohort EPIC-InterAct 12,132 7.8 years GC Saturated fatty acids in plasma phospholipids 
154Hodge 2009 Case-cohort Melbourne Collaborative Cohort Study 59 4 years 1H-NMR Lipoprotein particles 
157Joyce 2017 Prospective cohort Cardiovascular Health Study 112 9.8 years LC-MS Testosterone and dihydrotestosterone 
144Liu 2017 Prospective cohort Erasmus Rucphen Family study 137 11.3 years LC-MS, NMR triglycerides, glycerophospholipids, ceramides, amino 
acids and other low-weight molecules, lipoprotein 
particle size sub-fractions 
119Lu 2016 Nested case-control Singapore Chinese Health Study 197 6 years LC-MS, GC-MS Untargeted approach 
123Lu 2018 Nested case-control Singapore Chinese Health Study 160 6 years HPLC-MS lysophosphatidylinositols, non-esterified fatty acids, 
acylcarnitines 
155Mahendran 2013 Prospective cohort METSIM 176 4.5 years 1H-NMR Glycerol and fatty acids 
147Merino 2018 Prospective cohort Framingham Heart Study Offspring cohort 95 20 years LC-MS Amino acids, amines and other polar metabolites 
136Molnos 2018 Prospective cohort, 
nested case-control 
KORA and EPIC-Potsdam 910 7 years AbsoluteIDQ p150 
Biocrates 
Metabolite ratios 
31Mora 2010 Prospective cohort Women’s Health Study 1,687 13 years 1H-NMR Lipoprotein particles 
160Mwinyi 2017 Nested case-control CoLaus 251 5 years LC-MS Sphingoid bases 
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Publication Study design Study population Incident cases Follow-up Measurement technique 
or platform 
Measured metabolite classes 
161Othman 2015 Prospective cohort CAD patients 32 8 years LC-MS Sphingoid bases 
142Padberg 2014 Retrospective study Blood donors from the Bavarian Red Cross 28 6 years MxPTM Broad Profiling 
Platform 
Untargeted approach and targeted measurement of 
eicosanoids 
129Palmer 2015 Prospective cohort IRAS 76 5 years MS/MS Amino acids and acylcarnitines 
118Peddinti 2017 Nested case-cohort Botnia Prospective Study 146 10 years UHPLC-MS, GC-MS Untargeted approach  
145Qiu 2016 Nested case-control Dongfeng-Tongji and Jiangsu Non-
communicable Disease cohorts 
1,039 
+520 
4.6 and 7.6 
years 
HPLC-MS Amino acids, acylcarnitines, cholines, amines, purine 
and indole derivatives, B vitamins 
138Rebholz 2018 Prospective cohort ARIC 1,126 20 years DiscoveryHD4 platform 
Metabolon 
Untargeted approach 
122Rhee 2011 Nested case-control Framingham Heart Study 189 12 years LC-MS Triglycerides, cholesterol esters, 
phosphatidylcholines, 
lysophosphatidylethanolamines, diglycerides and 
sphingomyelines 
164Savolainen 2017 Prospective cohort Cohort of Swedish women 69 5.5 years GC-MS α- and δ-tocopherol, alkylresorcinols, β-alanine, 
CMPF, fatty acids 
156Savolainen 2017 Prospective cohort Cohort of Swedish women 69 5.5 years GC-MS Not specified 
117Shi 2018 Nested case-control Västerbotten Intervention Programme cohort 503 7 years HPLC-MS Untargeted approach 
148Stančáková 2012 Prospective cohort METSIM 151 4.7 years 1H-NMR Amino acids 
165Sun 2016 Prospective cohort Nutrition and Health of Aging Pop- ulation in 
China study 
507 6 years LC-MS Acylcarnitines 
121Suvitaival 2018 Prospective cohort METSIM 107 5 years UPLC-MS glycerophospholipids, triacylglycerols, 
cholesterolesters, sphingomyelins and ceramides 
149Svingen 2016 Prospective cohort Norwegian cohort of patients undergoing 
coronary angiography for stable angina 
pectoris 
233 7.5 years LC-MS, GC-MS TMAO, choline, betaine, dimethylglycine and 
sarcosine 
166Tillin 2015 Prospective cohort SABRE 340 19 years 1H-NMR Amino acids 
150Wang 2011 Nested case-control Framingham Heart Study 189 12 years LC-MS Amino acids, amines and other polar metabolites 
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Publication Study design Study population Incident cases Follow-up Measurement technique 
or platform 
Measured metabolite classes 




Prospective cohort Cooperative Health Research in the Region of 
Augsburg (KORA) 
91 7 years AbsoluteIDQ p180 
Biocrates 
Hexose, acylcarnitines, amino acids, biogenic amines, 
sphingomyelins and phosphatidylcholines 
159Wigger 2017 Nested case-cohort, 
nested case-control 
D.E.S.I.R. and CoLaus 189 and 147 9 and 5 
years 
UPLC-MS Ceramides and dihydroceramides 
162Wu 2017 Prospective cohort, case-
cohort, nested case-
control 
20 studies 4,347 3.4-21.4 
years 
GC, GLC Linoleic acid and arachidonic acid 
152Yamakado 2015 Prospective cohort Japanese population-based cohort 174 4 years HPLC-MS Amino acids 
139Yengo 2016 Case-cohort D.E.S.I.R. 231 9 years DiscoveryHD4 platform 
Metabolon 
Untargeted approach 





143Zhao 2015 Case-cohort Strong Heart Family Study 133 5.5 years LC-MS Untargeted approach  
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Challenges of observational metabolomics and other -omics studies 
Large-scale metabolomic profiling in observational epidemiological studies has led to a surge in 
the number of potential novel biomarkers for T2D. However, these findings have only marginally 
improved our understanding of biological mechanisms leading to T2D, due to several limitations 
from which the currently available studies suffer. First, very few of the metabolites that have been 
associated with incident T2D have been reported in more than one study. Moreover, substantial 
heterogeneity between studies in terms of study design, adopted measurement techniques and 
statistical methods limit the comparability of the same metabolite reported in different studies. 
These limitations are particularly applicable to lipid species, as no study has systematically 
investigated lipids across all different lipid classes, and because limited resolution in the measured 
molecular structure of lipids makes comparison between different studies even more challenging. 
Because of this lack of replication and heterogeneity among the studies, a comprehensive overview 
of the metabolomic signature of incident T2D is still lacking, despite the considerable number of 
conducted studies. 
A second important limitation of the current studies on metabolomic patterns of T2D is that the 
causality of the associations is not assessed. Although only longitudinal associations between 
metabolite levels and T2D were considered in this literature review, the reported associations may 
not reflect causal relationships for reasons of unmeasured confounding, reverse causality or 
chance. In order for these metabolite patterns to contribute to a better understanding of 
pathophysiological processes related to T2D, it is essential to identify from this new pool of 
biomarkers those metabolites that reflect causal pathways.  
Molecular traits, such as metabolites, often represent the same biological pathway. Large subsets 
of metabolites can therefore be strongly correlated with each other. Cohort studies assessing 
different outcomes have shown that individual metabolites can be associated with multiple disease 
outcomes 150,167,168. The lack of specificity with regard to the exposure and outcome highlights that 
large-scale parallel assessment of metabolites and other -omics-based biomarkers in an 
observational setting is even more prone to false positive discovery by multiple testing than 
traditional biomarker studies. Integration of genetic data can be a helpful tool to prioritise potential 
causal pathways from the dense network of molecular trait-to-disease associations. 
Omics integration 
Several GWAS on the metabolome have been conducted169–171, with larger-scale efforts underway. 
The results of these studies show that, due to close biological proximity, genetic loci explain large 
proportions of the variance of a given metabolite and relevant biological mechanisms can be 
identified in relatively small sample sizes. For example, in a study on the genetic architecture of 
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the human plasma metabolome, GWAS were conducted for 529 metabolites, based on 7,824 
participants51. Despite the modest sample size, associations of more than 145 genetic loci with 400 
metabolites were found. The median variance in metabolite levels explained by the genetic variants 
was 6.9% (range 1-62%), which is higher than the total variance in BMI explained by over 550 
signals identified in a GWAS of around 700,000 participants172.  
Integration of genetic markers with large-scale molecular phenotyping can enable the identification 
of novel molecular aetiological pathways. For example, GWAS in combination with metabolomics 
was recently used to assess the causality of the widely reported associations between branched-
chain amino acids and incidence of T2D150. Based on a genetic score including variants in the 
PPM1K gene, which encodes the activator for the enzyme catalysing the rate-limiting step in 
branched-chain amino acid breakdown, evidence was found that branched-chain amino acid 
catabolism and T2D may be bidirectionally causally related173.  
As -omics technologies are becoming more widely implemented in epidemiological studies of 
increasing size, opportunities to obtain an even more comprehensive insight into disease 
mechanisms may arise by integrating multiple layers of -omics data, such as proteomics.  
Conclusion of the literature overview 
Rapid progress in the identification of the genetic basis of T2D and related phenotypes, together 
with technological advances that facilitate high-throughput and refined phenotyping at scale, 
provide important opportunities for epidemiological research to identify novel aetiological 
pathways and enhance causal understanding of potential risk factors that are amenable to 
intervention. Better-powered studies now provide greater sensitivity to investigating pleiotropy 
that may have previously been overlooked and may have confounded effect sizes of genetically 
predicted exposures. Traditional genetic approaches to inferring causality have generally focused 
on average effects, sometimes estimated from large polygenic scores. Recent examples have 
highlighted opportunities that arise from distinguishing the effects of specific mechanisms 
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Contributions and collaborations 
I performed all analyses described in this chapter, with the exception of the GWAS for glycine 
levels in the INTERVAL study, which was conducted by Dr Clare Oliver-Williams and Dr Adam 
Butterworth (Cardiovascular Epidemiology Unit, University of Cambridge) and the GWAS for 
blood pressure traits in the UK Biobank, which were conducted by Dr Joanna Howson, Dr 
Praveen Surendran and Savita Karthikeyan (Cardiovascular Epidemiology Unit, University of 
Cambridge).  
 
Publications related to this chapter 
The analyses on the role of glycine as an aetiological factor for coronary heart disease presented in 
this chapter has been submitted to Nature Communications: 
 
L. B. L. Wittemans, L. A. Lotta, C. Olliver-Williams, [19 authors], C. Langenberg. Assessing the 
causal association of glycine with risk of coronary heart disease. Nature Communications 
10:1060 (2019). doi: 10.1038/s41467-019-08936-1. 
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Abstract 
Background: Through high-throughput metabolic profiling, virtually every metabolic pathway 
has been linked to T2D, but the causality of these proposed risk factors remains largely unknown. 
Identifying those metabolic pathways which play an aetiological role in cardiometabolic diseases 
may point to novel strategies to treat or prevent disease in individuals who are at high risk. Multiple 
studies have reported that a higher serum concentration of glycine is associated with lower 
incidence of T2D and CHD, but the causality of these observational findings and the underlying 
biological mechanisms are incompletely understood.  
 
Aims: This chapter aims to develop an MR-based approach to assess the aetiological role of 
metabolic pathways for cardiometabolic diseases and to characterise the biological mechanisms 
underlying causal relationships between the metabolome and disease incidence. Using glycine 
metabolism as an example, I a) construct and validate genetic instruments for glycine levels, b) 
assess the role of glycine as a causal pathway to T2D and CHD and c) identify the physiological 
mechanisms that drive the associations between glycine levels and incidence of T2D and CHD. 
 
Methods: Meta-analyses of GWAS on serum levels of glycine were conducted in up to 80,003 
participants. MR analyses for glycine as the exposure and CHD and T2D as outcomes were 
performed using 4 genetic scores with different levels of specificity to glycine. Reverse MR 
experiments were conducted to assess the causal associations of 3 T2D risk factors with glycine 
levels, and the role of CHD risk factors as mediators of the effect of glycine on CHD was assessed 
using multivariable MR. 
 
Findings: 27 genetic loci reached genome-wide significance (p≤5×10-8) for glycine levels, 
including 6 near genes with enzymatic functions in glycine metabolism, and of which 22 have not 
previously been linked to glycine. Significant heterogeneity between the effect sizes for men and 
women was found for 3 loci, including CPS1. Genetically predicted levels of glycine were not 
associated with T2D risk (sexes combined: OR [95% CI] per 1 SD genetically predicted increase 
in glycine = 1.00 [0.97, 1.04]) based on a genetic score comprised of all 24 common loci for glycine, 
despite the consistently reported inverse observational association. However, when using a genetic 
score comprised of two loci which were highly specific to the glycine pathway and were located in 
genes of the glycine cleavage system, a significant inverse association of genetically predicted 
glycine with T2D risk was found (OR for T2D per SD glycine= 0.79 [0.68,0.92], p=0.002). 
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Genetically higher fasting insulin was significantly associated with lower glycine levels, but BMI 
and insulin secretion were not.  
Conversely, significant associations of genetically predicted glycine with CHD risk were found 
(OR [95% CI] per 1 SD genetically predicted glycine=0.95 [0.92,0.98]) based on 4 distinct genetic 
scores with different levels of specificity to the glycine pathway, and no evidence was found that 
this effect size differs between men and women (p for heterogeneity =0.74). The inverse genetic 
relationship between glycine levels and CHD was attenuated when adjusting for genetically 
predicted blood pressure.  
 
Conclusion: This chapter provides new insight into the genetic architecture of glycine metabolism 
and the findings indicate a potential protective role of glycine levels for CHD, with blood pressure 
as a potential mediating factor. Conversely, we found evidence that the causal effect of glycine on 
T2D may be pathway-specific and that the strong inverse observational glycine-to-T2D association 
is a consequence of insulin resistance. 
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Introduction 
Glycine – the metabolically versatile, smallest amino acid 
Glycine is the simplest amino acid in the human body and is non-essential, as it can be synthesised 
from serine and betaine, but it is also taken up through the diet174. Glycine is an intermediate of a 
wide range of metabolic pathways174, including one-carbon metabolism, serine, glutathione and 
purine biosynthesis, lipid metabolism and detoxification reactions. Over the past decade, multiple 
studies have ascribed a protective role against cardiometabolic diseases to glycine, but these 
findings are mostly based on observational epidemiological research29,175, or experimental findings 
on rodents176–178.  
Glycine and type 2 diabetes 
Observational epidemiological studies have consistently linked low glycine levels to higher 
prevalence and incidence of T2D29,129,147 and to diabetes-related pathophysiological processes, 
including insulin resistance179,180, reduced insulin secretion181 and adiposity180,182. To assess the 
causality of the inverse glycine-to-T2D association, Xie et al. conducted a genetics-based 
assessment of the causality of glycine on insulin resistance and on T2D based on one locus for 
glycine in carbamoyl phosphate synthase 1 (CPS1), but did not find conclusive evidence for a 
causal role of glycine183. In a recent study by Merino et al., a protective effect of glycine on T2D 
risk was suggested based on a significant association of a genetic score comprised of 5 reported 
loci for glycine, including CPS1, with genetic risk of T2D, based on 11,600 T2D cases and 33,000 
controls147. However, this association was mostly driven by the locus in CPS1, which has been 
reported to be highly pleiotropic169,184, and the observed association could therefore have been 
driven by glycine-independent pathways. Altogether, no conclusive evidence on the causality of 
low glycine levels for T2D risk has been found. 
Glycine and coronary heart disease 
Glycine was recently found to be inversely associated with risk of acute myocardial infarction in a 
prospective cohort study of stable angina patients175 and cardio-protective effects have been 
reported for glycine based on studies in mammalian model systems185,186 and in vitro experiments187. 
A genetic study suggested a sex-specific genetic association of glycine metabolism with risk of 
coronary heart disease (CHD)188 , based on a genetic variant associated with higher levels of glycine 
and lower risk of CHD in women but not men. However, this study focused on a single variant in 
CPS1, a gene known to be more strongly associated with levels of glycine189 and other 
metabolites184 in women, compared to men. Uncertainty about the role of glycine metabolism in 
risk of CHD and its potential sex-specific nature therefore remains. 
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Genome-wide association studies for glycine 
GWAS for plasma glycine levels aiming to identify genetic regions involved in glycine metabolism 
have been previously conducted in up to 25,000 participants, identifying 5 genetic loci in/near 
CPS1, GLDC, GCSH, ALDH1L1 and PPP1R3B, associated with glycine levels169–171,184. A strong 
sex difference in the effect size of the CPS1 locus has been reported189 but potential sex differences 
in the effect sizes of these loci have not been systematically assessed. A larger GWAS of glycine 
levels could increase the number of genetic loci robustly associated with glycine, thereby improving 
our understanding of the genetic determinants of glycine metabolism and provide genetic 
instruments to assess the causality of glycine on T2D, CHD and their risk factors, using the 
Mendelian randomisation framework56.  
Objectives 
In this chapter, I aim to (1) identify genetic determinants of plasma levels of glycine, (2) investigate 
the likelihood of a causal role of glycine levels on risk of T2D and CHD in men and women, using 
novel and sex-specific genetic scores for glycine, and (3) characterise the biological pathways 
underlying the glycine-to-disease associations, using summary-level GWAS results derived from 
large-scale epidemiological studies.  
  





The European Prospective Investigation into Cancer and nutrition (EPIC) is an ongoing multi-
centre European cohort study which was originally set up to study the role of nutrition in cancer 
risk190. More than half a million participants were recruited over the 10 participating countries and 
26 study centres. Several sub-studies of EPIC have been set up to study the risk factors of other 
complex diseases, including T2D and cardiovascular diseases.  
 
The EPIC-Norfolk study is a cohort of 25,000 middle-aged individuals from the general 
population of Norfolk (East England)191, and is one of the 2 EPIC study centres in the UK. 
Untargeted metabolomics measurements using the DiscoveryHD4® platform (Metabolon, Inc., 
Durham, USA) on non-fasted plasma samples have been completed in two sub-cohorts of 
randomly selected participants – 5,989 randomly selected participants in sub-cohort A and 5,977 
participants in sub-cohort B – and on a T2D case-sub-cohort study which included all 586 T2D 
cases and another 746 participants randomly selected from the entire cohort. There was no overlap 
between sub-cohorts A and B and the T2D case-sub-cohort. In total, 999 metabolites were 
measured in both sub-cohorts A and B, of which 894 were measured in at least 50% of the 
combined sample size. Further details about the metabolomics measurements have been described 
elsewhere173. Genome-wide genotyping was done using the Affymetrix UK Biobank Axiom array 
and genotype data were imputed based on a combined reference panel (Haplotype Reference 
Consortium192, UK10K193 and 1000 Genomes Phase 3194) and using IMPUTE2195. Data from 
EPIC-Norfolk were used to conduct a GWAS for glycine, to estimate sex-specific effect sizes of 
the glycine variants with glycine levels, to test associations of the genetic scores and variants for 
glycine across the metabolome, and to assess the observational association of glycine levels with 
incident T2D, CHD, myocardial infarction, stroke and stroke sub-types.   
 
EPIC-CVD, another sub-study of EPIC, is a prospective case-sub-cohort focusing on the risk 
factors of cardiovascular diseases and includes nearly 14,000 incident CHD cases and sub-cohort 
comprised of 18,249 randomly selected participants. Details about the participants, phenotype 
measurements and disease case ascertainment have previously been described196. Genotyping was 
performed using the HumanCoreExome array, the Quad 660 genotyping chip and the Infinium 
OmniExpressExome array (all from Illumina) and genotyped data were imputed to a joint 1000 
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Genomes Phase 3197 (May 2013)-UK10K193 reference imputation panel. Data on 28,217 
participants (33.7% CHD cases) of the EPIC-CVD study were used to assess the effect sizes of 
the genetic variants for glycine with CHD, for both sexes combined and separately.  
 
The InterAct study is a T2D case-cohort study nested within EPIC, which was designed to study 
the interaction between lifestyle and genetic factors in relation to T2D198. The study includes 12,403 
incident cases of T2D and a randomly selected sub-cohort of 16,154 individuals from 9 European 
countries. Genome-wide genotyping was done using the HumanCoreExome array. Genome-wide 
genotyped data were imputed to the European 1000 Genomes reference panel (March, 2012 
release) using IMPUTE2. Data from the InterAct study were used to assess the sex-combined and 
sex-specific associations of the genetic loci for glycine with risk of T2D. 
 
Fenland 
The Fenland study is a longitudinal cohort study including more than 12,400 participants from the 
general population of Cambridgeshire (UK)173. Fasted plasma concentrations of 174 metabolites 
were measured using the AbsoluteIDQ® p180 Kit (Biocrates Life Sciences, Innsbruck, Austria) 
and more details on the measurement, processing and QC have been described elsewehere173. 
Genome-wide genotyping of the Fenland participants was done in three waves; the first 1,400 
individuals were genotyped using the Affymetrix Genome-Wide Human SNP Array 5.0, the next 
9,369 participants on the Affymetrix UK Biobank Axiom Array and the final group of 1,118 
participants on the Illumina Infinium CoreExome Array. The same imputation strategy as for the 
EPIC-Norfolk study was used. GWAS for glycine and assessment of the sex-specific effect sizes 
of the glycine variants were run in the Fenland study.  
 
INTERVAL 
The INTERVAL study is a randomised trial of approximately 50,000 whole blood donors enrolled 
from all 25 static centres of NHS Blood and Transplant199. For the present study, non-fasting 
serum blood samples were provided by 40,509 unrelated individuals from the INTERVAL trial. 
The samples were analysed using a high-throughput serum NMR metabolomics platform200,201, 
which provided information on 230 metabolites, including glycine. We removed participants with 
more than >30% of metabolite measures missing, duplicated individuals, and metabolic data more 
than 10 SDs from the mean. Genotyping was conducted using the Affymetrix UK Biobank Axiom 
array. Prior to imputation, SNPs missing in more than 1% of the samples or failing in more than 
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one batch were excluded. Monomorphic and multi-allelic variants and variants that failed to pass 
the threshold on clustering quality, were intensity outliers or deviated from Hardy-Weinberg 
equilibrium were omitted. The data were imputed to a joint 1000 Genomes Phase 3 (May 2013)-
UK10K reference imputation panel. Data from INTERVAL participants with glycine measures 
were used to run a GWAS for glycine and to assess the sex-specific effect sizes of the glycine 
variants on glycine.  
UK Biobank 
The UK Biobank study is a longitudinal cohort study of more than 500,000 participants from 
across the UK202. Genotyping was performed using the UK Biobank Axiom Array and imputation 
was based on the reference panel from the haplotype reference consortium, using IMPUTE2. Sex-
combined and sex-specific associations of the genetic variants for glycine with CHD, T2D and 
blood pressure were assessed in the UK Biobank. 
Participants of all studies gave written informed consent and all studies were approved by local 
ethics committees.  
 
Genome-wide association analyses for glycine levels in the EPIC-Norfolk, Fenland 
and INTERVAL studies 
Genome-wide association studies (GWAS) for glycine levels were conducted in the Fenland 
(N=9,324), EPIC-Norfolk (N=5,840) and INTERVAL (N=40,509) studies. For the Fenland 
study, separate GWAS were run for the three different genotyping arrays. The GWAS in EPIC-
Norfolk only included sub-cohort A as at the time the GWAS were conducted metabolite 
measurements in sub-cohort B were not yet available. Glycine levels were natural log transformed, 
winsorized at 5 SDs and transformed to the Z score. Analyses were conducted based on 
generalised linear mixed models adjusted for age, sex and the first four principal components, 
using BOLT-LMM203. Genetic variants were excluded if the standard error (SE) >10, the absolute 
value of beta >5, p-value for the Hardy-Weinberg equilibrium <1×10-6 or info score < 0.3. 
Meta-GWAS of glycine levels 
Results of the Fenland, EPIC-Norfolk and INTERVAL studies were meta-analysed with publicly 
available summary-level GWAS results from KORA and TwinsUK204 (downloaded from 
http://mips.helmholtz-muenchen.de/proj/GWAS/ gwas/index.php?task=download) and an 
NMR-based multi-cohort discovery170 (downloaded from 
http://www.computationalmedicine.fi/data#NMR_GWAS), resulting in a total sample size of up 
to 80,003 individuals. Meta-analysis of the 5 studies was conducted using METAL205 and was based 
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on the p-values, directions of effect and sample sizes, to minimize the effect of heterogeneity due 
to differences in analytical decisions and between metabolomics platforms. Variants were omitted 
if they were measured in less than half the total sample size or in fewer than 3 of the 5 studies, or 
if MAF<0.5%. Pooled effect sizes and SEs were generated through an effect size-based meta-
analysis of the Fenland, EPIC-Norfolk (sub-cohort A only) and INTERVAL studies (total 
N=55,673) in METAL.  
 
Identification of primary and secondary signals 
Distance-based clumping using 1Mb windows was used to identify independent loci significantly 
associated with glycine (p-value<5×10-8). Because of the very strong and wide signal at CPS1, a 
window of 3 Mb on both sides of the lead variant rs715 was used to capture the entire locus.  
Secondary signals were identified through approximate conditional analyses using GCTA-
COJO206. To maximise the sample size, this analysis was conducted on the pooled Z scores 
generated in the p-value-based meta-GWAS. Variants with MAF<1% were omitted from the 
conditional analyses. HRC-imputed genome-wide data from 19,318 EPIC-Norfolk participants 
were used as an LD reference panel and a joint p-value threshold of 5×10-8 was used to identify 
secondary signals. Of the 73 variants selected through the approximate conditional analysis, 11 
were in LD (R2>0.05) with another selected variant and were therefore omitted. At the CPS1 locus, 
44 secondary signals remained of which 27 were low frequency variants. A second LD filter to 
remove variants in high LD with the common sentinel variant (D’<0.05) was applied, after which 
only 5 variants at the CPS1 locus remained. 
Sex-specific effect sizes of glycine loci  
Sex-specific effect sizes for lead SNPs at the 27 loci on glycine levels standardised by sex were 
estimated in the INTERVAL, Fenland and EPIC-Norfolk studies (sub-cohorts A and B) (in total 
30,226 men and 31,957 women) and meta-analysed using the R package ‘metafor’207. As a 
sensitivity analysis, sex-specific effect sizes on natural-log transformed instead of within-sex 
standardised glycine levels were estimated in the Fenland and EPIC-Norfolk studies (9,927 men 
and 11,284 women). 
Associations of glycine variants with T2D, CHD and related phenotypes 
Associations of the genetic variants for glycine with T2D for both sexes combined were estimated 
in the InterAct study (4,712 female and 4,596 male cases; 7,190 female and 4,333 male controls) 
and the UK Biobank (7,301 female and 12,318 male cases; 181,442 female and 149,249 male 
controls), and extracted from published summary-level GWAS results by the DIAGRAM 
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consortium37 (34,840 cases and 114,981 controls). Sex-combined and sex-specific GWAS for T2D 
in the InterAct study were run using SNPTEST, based on logistic regression models adjusted for 
age, sex, assessment centre and the first 4 genetic principal components calculated in PLINK208. 
In the UK Biobank, associations of the SNP dosages with prevalent and incident T2D, identified 
based on ICD10 codes, were estimated by fitting logistic regression models adjusted for age, sex, 
4 genetic principal components and genotyping chip in STATA v15.0 (StataCorp, College Station, 
Texas, USA). Only UK Biobank participants from the subset of unrelated British ancestry 
participants were included. The sex-specific associations were estimated in the InterAct study and 
UK Biobank only, and meta-analyses of the effect sizes were conducted using the R package 
‘metafor’207.  
Sex-combined and sex-specific effect estimates of the glycine variants on CHD were assessed in 
the EPIC-CVD study and the UK Biobank, and obtained as lookups from 
CARDIoGRAMplusC4D209 for the sex-combined associations (60,801 cases and 123,504 controls) 
and from the German MI family studies209–212 for sex-specific associations (994 female and 2,804 
male cases; 2,752 female and 2,554 male controls). The associations of the genetic variants for 
glycine with CHD were tested in EPIC-CVD based on Cox proportional hazards models and using 
Prentice weighting and robust standard errors (3,712 female and 5,786 male cases; 14,764 female 
and 13,453 male controls). Models were adjusted for age, genotyping array, testing centre, the first 
four genetic principle components and sex for the sex-combined analyses. In the UK Biobank, 
logistic regression models adjusted for age, the first 10 principal components, genotyping chip and 
sex (for sex-combined analyses) were run on 18,501 incident and prevalent CHD cases (5,147 
women) and 333,545 controls (184,608 women) from the unrelated subset of participants of 
British ancestry, identified based on a combination of self-reported and genetically determined 
ancestry (UK Biobank data field 22006)213.  
The effects of the glycine variants on SBP and DBP were assessed using data from 203,943 male 
and 241,417 female European participants of the UK Biobank. Participants of European ancestry 
were identified based on K-means clustering of the first 4 principal components calculated from 
genome-wide SNP genotypes. Individuals who fell within the European cluster but self-identified 
as non-European were omitted from the genetically-defined European ancestry group. GWAS on 
rank-based inverse normally transformed SBP and DBP were conducted within sex and using 
BOLT-LMM.  Analyses were adjusted for age, age2, BMI and genotyping array. For variants both 
genotyped and imputed, imputed probabilities were used if the variant was imputed well 
(INFO>0.7) and the genotyping call rate was less than 98%. Sex-combined estimates were 
generated through fixed-effect meta-analyses of the sex-specific estimates.  
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Associations of the glycine variants with triglycerides, LDL, HDL and total cholesterol were 
obtained from publicly available GWAS summary-results based on up to 188,577 participants from 
the Global Lipids Genetics Consortium214 (downloaded from http: 
//csg.sph.umich.edu/abecasis/public/lipids2013/). Look-ups for 13 blood cell traits came from 
publicly available GWAS summary results based on a genetic discovery in 173,480 participants215 
(downloaded from http://www.bloodcellgenetics.org/). 
 
Mendelian randomisation methods 
Mendelian randomisation (MR) analyses to assess the causal effect estimate for glycine on cardio-
metabolic disease risk  were based on four genetic scores for glycine with different levels of power 
versus specificity to glycine. MR analyses were based on summary-level data and four different 
methods: inverse variance-weighted MR216, MR-Egger58, weighted median MR and penalised 
weighted median MR59. Heterogeneity in the effects of the genetic variants on the outcome were 
assessed based on the Cochran’s Q statistic, and directional pleiotropy was estimated based on the 
MR-Egger intercept. Priority was given to the results of weighted median MR if there was evidence 
for heterogeneity and/or directional pleiotropy (p-value for Cochran’s Q <0.05 and/or p-value 
for Egger’s intercept <0.05). The advantage of the weighted median MR method is that it can 
produce unbiased causal estimates, even if up to 50% of the information comes from invalid 
genetic instruments. The MR-Egger method was not used for the 2 SNP score.  
Reverse MR analyses were conducted to assess the causality of risk factors for T2D on glycine 
levels using the same analytical approach as for the forward MR analyses. Previously published 
and validated genetic scores by the GIANT and MAGIC consortia were used for BMI217 (97 
genetic variants), fasting insulin adjusted for BMI as a marker of insulin resistance95 (10 genetic 
variants) and insulin levels at 30 minutes during an oral glucose tolerance test as a marker for early-
phase insulin secretion95,218 (21 genetic variants). Effect sizes of the variants in the genetic scores 
on glycine levels were based on the effect size-based meta-analysis of the GWAS for glycine in 
INTERVAL, Fenland and EPIC-Norfolk. 
Two-sample summary level data multivariable MR analyses were run to obtain the effect size of 
glycine levels adjusted for blood pressure on CHD as previously described by Day et al.219. In brief, 
weighted multilinear models were fitted with the effect sizes of the glycine SNPs on glycine and 
on the SBP and/or DBP as the explanatory variables and the effect sizes of the glycine SNPs on 
CHD as the independent variable. Weighting was based on the inverse variance of the effect sizes 
of the genetic variants for glycine on CHD.  
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Cox proportional hazards models to test the associations of observational glycine 
levels with CHD, MI and stroke 
Cox proportional hazards models with robust standard errors were fitted to estimate the hazard 
ratios for T2D based on 1 SD increase in glycine levels. Age at recruitment was used as the 
underlying timescale, and the model was adjusted for sex, BMI, waist-hip ratio, educational 
attainment, smoking, alcohol consumption, physical activity, blood pressure and blood lipids. The 
models for T2D were run in the T2D case-sub-cohort (586 T2D cases and 746 random cohort 
participants); therefore prentice weighting was applied.  
We tested if glycine levels at baseline were associated with incidence of CHD, MI and stroke in 
11,966 participants of the EPIC-Norfolk study (sub-cohorts A and B). During follow-up, 2,053 
participants developed CHD; 659 and 1,163 participants had a myocardial infarction and stroke, 
respectively. 212 stroke events were confirmed to be haemorrhagic whereas 569 were confirmed 
to be ischemic. Cox proportional hazards models were fitted to estimate the hazard ratios for 
CHD, myocardial infarction and stroke based on 1 SD increase in glycine levels. Age at recruitment 
was used as the underlying timescale, and models were adjusted for sex. Sex-specific analyses were 
conducted on within-sex standardised glycine levels. Analyses were performed in sub-cohorts A 
and B separately and meta-analysed using a fixed-effects model using the R package ‘metafor’207. 
Pooling observational evidence for glycine to incident T2D 
We meta-analysed risk ratio estimates for T2D based on 1 SD increase in glycine from the EPIC-
Norfolk T2D case-cohort study with previously reported risk ratios estimated for KORA137, EPIC-
Potsdam29, SABRE166, IRAS129 and a Japanese population-based cohort study152. We conducted a 
fixed and random-effects meta-analysis and estimated the heterogeneity between studies based on 
the I2 statistic in Stata v14.0 using Metan (StataCorp, College Station, Texas, USA). 
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Results 
Meta-GWAS identifies 22 novel loci for glycine levels 
We conducted a meta-analysis of GWAS (meta-GWAS) for glycine levels in up to 80,003 
participants, including 55,673 participants from the Fenland173, EPIC-Norfolk191 and 
INTERVAL199 studies, and two publicly available summary-level GWAS datasets169,170. We 
identified 27 genetic loci for glycine levels at genome-wide significance level (p-value<5×10-8), of 
which 22 have not previously been reported for glycine (Figure 2.1, Table 2.1). A total of 20 
secondary signals at 8 loci were identified through approximate conditional association analyses 
(Supplementary Table 2.1).  
 
Figure 2.1: Manhattan plot of meta-GWAS for glycine levels. Loci in blue have not previously been reported for 
glycine. P-value for CPS1 locus = 3×10-1632 
Six of the 27 loci are in (or near) genes encoding enzymes involved in glycine metabolism (Figure 
2.2): glycine decarboxylase (GLDC, intronic single nucleotide polymorphism (SNP) rs17591030), 
glycine cleavage system protein H (GCSH, intergenic variant rs9923732 9 kb downstream of gene), 
phosphoserine phosphatase (PSPH, rs4947534 in 3’ UTR region), phosphoglycerate 
dehydrogenase (PHGDH, rs561931 in 5’ UTR region), carbamoyl phosphate synthase 1 (CPS1, 
rs715 in 3’ UTR region) and aldehyde dehydrogenase 1 family member L1 (ALDH1L1, rs9862438, 
intronic variant in anti-sense non-coding RNA of ALDH1L1).  
 
 
Chapter 2: Glycine and cardiometabolic diseases 
 50 
Table 2.1: 27 genetic loci reaching genome-wide significance for glycine levels in a p-value-based meta-analysis of GWAS in up to 80,003 participants. Chromosome (chr) and base pair 
position (pos) according to genome build GRCh37. a p-value-based meta-analysis of all 5 studies, bmeta-analysis of the sex-combined betas and SEs from the INTERVAL, EPIC-Norfolk and Fenland 
studies, c meta-analysis of the sex-specific betas and SEs from the INTERVAL, EPIC-Norfolk and Fenland studies. † loci previously reported for glycine; * loci not reported for any metabolite. EA: 
effect allele, OA: other allele, EAF: effect allele frequency from p-value-based meta-analysis, N: sample size, SE: standard error.  
Sentinel variant Chr:pos EA OA EAF 
Variant type and 
nearest gene 
P-value-based meta-analysisa 
Meta-analyses of effect sizes and SEs 
sex-combb menc womenc 
p N HetPval Beta SE Beta SE Beta SE 
rs4646961 1:76,217,169 A G 0.297 intronic variant in 
ACADM 
8.4E-19 79,999 0.62 0.048 0.006 0.045 0.007 0.050 0.009 
rs561931 1:120,254,506 G A 0.593 5’ UTR variant of 
PHGDH 
7.6E-14 79,998 0.65 0.033 0.006 0.033 0.007 0.028 0.009 
rs10184004 2:165,508,389 T C 0.400 Intergenic variant near 
COBLL1 (28 kb) and 
GRB14 (30 kb) 
1.5E-09 80,002 0.20 0.036 0.006 0.020 0.007 0.056 0.009 
rs715 † 2:211,543,055 C T 0.313 3’UTR variant of CPS1 3E-
1632 
80,000 3.8E-32 0.444 0.006 0.233 0.007 0.691 0.009 
rs9862438 † 3:12,591,0381 T C 0.416 ncRNA intronic variant 
in ALDH1L1-AS2 
1.1E-30 80,001 0.10 0.058 0.006 0.057 0.007 0.065 0.009 
rs148685782 4:155,533,035 G C 0.996 Synonymous variant in 
FGG 
2.0E-10 55,673 0.02 0.309 0.049 0.170 0.056 0.362 0.072 
rs71640034 4:187,161,048 A G 0.511 intronic variant in 
KLKB1 
5.6E-10 74,406 0.19 0.034 0.006 0.022 0.007 0.031 0.009 
rs156380 5:53,378,450 C T 0.807 intronic variant in 
ARL15 
4.5E-08 79,998 0.74 0.031 0.007 0.020 0.009 0.036 0.011 
rs3105793 5:90,226,061 A G 0.273 intronic variant in 
ADGRV1 
4.0E-08 79,998 0.20 0.028 0.006 0.024 0.008 0.034 0.010 
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Sentinel variant Chr:pos EA OA EAF 
Variant type and 
nearest gene 
P-value-based meta-analysisa 
Meta-analyses of effect sizes and SEs 
sex-combb menc womenc 
p N HetPval Beta SE Beta SE Beta SE 
rs10900807 5:131,757,480 G C 0.805 ncRNA intronic variant 
in C5orf56 
1.3E-09 79,999 0.81 0.036 0.007 0.029 0.009 0.041 0.011 
rs2545801 5:176,841,339 C T 0.747 intergenic variant near 
F12 (5 kb) and GRK6 (12 
kb) 
7.2E-14 74,404 0.56 0.042 0.007 0.015 0.008 0.054 0.010 
rs543159 6:160,776,017 A C 0.482 intronic variant in 
SLC22A3 
4.2E-10 74,405 0.39 0.035 0.006 0.027 0.007 0.035 0.009 
rs4947534 7:56,079,094 C T 0.760 3’ UTR variant of PSPH 7.1E-34 79,998 0.08 0.072 0.007 0.061 0.008 0.085 0.010 
rs9987289 8:9,183,358 A G 0.100 ncRNA intronic variant 
in LOC157273 
1.7E-49 79,999 0.07 0.124 0.01 0.118 0.012 0.124 0.015 
rs28601761 8:126,500,031 G C 0.416 intergenic variant near 
TRIB1 (49kb) and 
LINC00861 (435 kb) 
8.5E-30 73,832 0.13 0.063 0.006 0.080 0.007 0.060 0.009 
rs17591030 † 9:6,550,024 C T 0.715 intron variant in GLDC 1.9E-40 80,000 0.03 0.08 0.006 0.055 0.008 0.118 0.010 
rs676996 9:136,146,077 T G 0.668 intron variant in ABO 4.4E-15 74,403 0.32 0.04 0.006 0.034 0.007 0.033 0.009 
rs190595610 * 10:32,274,880 A G 0.997 Intergenic variant near 
ARHGAP12 (57 kb) 
and KIF5B (23 kb) 
9.0E-09 70,912 0.11 0.253 0.056 0.132 0.066 0.279 0.084 
rs10740134 10:65,315,433 T C 0.515 intron variant in REEP3 1.2E-12 80,001 0.06 0.038 0.006 0.016 0.007 0.044 0.009 
rs12297321 12:47,109,387 T C 0.152 Intergenic variant near 
SLC38A4 (38 kb) and 
LOC100288798 (630 kb) 
7.4E-13 79,999 0.67 0.048 0.008 0.036 0.009 0.058 0.012 
rs2638314 12:56,866,334 A T 0.182 intronic variant in GLS2 1.5E-08 74,402 0.23 0.042 0.007 0.040 0.009 0.048 0.011 
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Sentinel variant Chr:pos EA OA EAF 
Variant type and 
nearest gene 
P-value-based meta-analysisa 
Meta-analyses of effect sizes and SEs 
sex-combb menc womenc 
p N HetPval Beta SE Beta SE Beta SE 
rs9514191 13:104,520,138 C G 0.312 intergenic variant near 
LINC01309 (440 kb) 
and DAOA-AS1(159 
kb) 
3.1E-08 74,402 0.58 0.034 0.006 0.020 0.007 0.040 0.009 
rs201393666 * 15:43,677,979 A C 0.029 intronic variant in 
TUBGCP4 
2.6E-08 54,724 0.43 0.097 0.017 0.105 0.020 0.049 0.026 
rs2280195 15:58,467,095 A G 0.441 intronic variant in AQP9 3.2E-09 80,000 0.72 0.028 0.006 0.032 0.007 0.015 0.009 
rs9923732 † 16:81,110,903 A G 0.914 Upstream variant of 
C16orf46, 9 kb 
downstream of GCSH 
1.2E-41 80,001 0.58 0.119 0.011 0.127 0.013 0.110 0.016 
rs8078686 17:45,735,706 C T 0.509 intron variant in KPNB1 3.7E-11 80,001 0.78 0.035 0.006 0.036 0.007 0.021 0.009 
rs273510 19:18,223,350 A G 0.708 intron variant in MAST3 3.6E-09 74,403 0.90 0.034 0.006 0.026 0.007 0.040 0.010 
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Figure 2.2: Schematic overview of glycine metabolism and 6 glycine loci in or near genes encoding enzymes related to 
glycine metabolism. GLDC and GCSH are part of the glycine cleavage system, the major enzyme complex responsible for glycine 
degradation. PHGDH and PSPH encode enzymes involved in de novo biosynthesis of serine, which can be converted into and 
synthesised from glycine.  The interconversion of glycine and serine serves as an important source of methyl groups in the folate 
cycle, a metabolic pathway of which the enzyme encoded by ALDH1L1 is a component. CPS1 encodes the enzyme responsible 
for the rate-limiting step of the urea cycle which is responsible for the detoxification of ammonia. Glycine breakdown produces 
ammonia; changes in the efficiency of the urea cycle are therefore likely to have upstream effects on glycine metabolism. GCSH: 
glycine cleavage system protein H, GLDC: glycine decarboxylase, CPS1: carbamoyl-phosphate synthase 1, ALDH1L1: aldehyde 
dehydrogenase 1 family member L1, PSPH: phosphoserine phosphatase, PHGDH: phosphoglycerate dehydrogenase. THF: 
tetrahydrofolate, 5,10-MTHF: N5-N10-methylene-tetrahydrofolate, 10-FTHF: 10-formyl-tetrahydrofolate. 
 
Nine of the 27 loci (COBLL1-GRB14, CPS1, SLC22A3, LOC157273, TRIB1, ABO, REEP3 and 
KPNB1) have previously been reported for blood lipid fractions214 (low and high-density 
lipoprotein (LDL and HDL)-cholesterol, total cholesterol and total triglycerides), but the direction 
of association with lipid traits relative to the glycine-raising allele differed between loci 
(Supplementary Table 2.2). Six loci are known to be associated with coagulation-related traits, such 
as plasma fibrinogen levels220–222 (CPS1, FGG, C5orf56) and activated partial thromboplastin 
time223–225 (KLKB1, F12, ABO). Glycine-raising alleles at KLKB1, C5orf5 and F12 were associated 
with higher coagulation while the glycine-raising alleles at CPS1, FGG and ABO were associated 
with lower coagulation. Three loci are established loci for T2D or glycaemic traits; the signal at 
LOC157273 has been reported for higher fasting glucose and insulin93, GLS2 for higher fasting 
glucose94 and COBLL1-GRB14 has been reported for lower risk of T2D37 and lower fasting insulin 
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levels94. Finally, TRIB1 is an established CHD risk-raising locus226 (Supplementary Table 2.2). 
Apart from CPS1, none of the lipid, coagulation or cardio-metabolic disease-associated loci have 
a known role in glycine metabolism and effect sizes of these loci on glycine levels were generally 
small compared to the effects of loci near genes encoding enzymes of glycine metabolism (Figure 
2.6A). 
Per-allele effect sizes of the common loci (minor allele frequency (MAF) > 5%) were between 0.03 
and 0.12 standard deviations (SDs) of glycine levels, with the exception of the association near 
CPS1, of which each allele of the lead variant rs715 was associated with 0.444±0.006 higher SDs 
of glycine. This variant explained 13.7% of the variance in glycine and is in high linkage 
disequilibrium (LD) (r2=0.904) with a missense variant (rs1047891, 4217C>A, Thr1406Asn, 2.5 
kb upstream of rs715). Conditioning on rs1047891 in EPIC-Norfolk showed that the effect of 
rs715 was entirely driven by rs1047891 (beta±SE on glycine before adjustment = 0.565±0.013, p-
value<2×10-302; after adjustment for rs1047891: beta±SE=0.032±0.049, p-value=0.52). 
Previous studies highlighted sex differences in the effect size of the CPS1 locus on glycine levels189; 
we therefore compared sex-specific effect sizes across all loci on glycine levels standardised by sex 
(Bonferroni-corrected p-value threshold for sex difference <0.002) (Figure 2.3A, Table 2.1). We 
confirmed that the effect of the CPS1 locus is nearly three times stronger in women than in men 
(women: beta±SE=0.691±0.009, men: beta±SE=0.233±0.007, p-value for sex difference <2×10-
302) and found similar significant sex differences in effect size for rs17591030 (GLDC, women: 
beta±SE=0.118±0.010, men: beta±SE=0.055±0.008, p-value for sex difference=3.3×10-7) and 
rs10184004 (TRIB1, women: beta±SE=0.060±0.009, men: beta±SE=0.080±0.007, p-
value=0.001). Suggestively stronger effect sizes in women were observed for rs148685782 (FGG, 
p-value=0.04) and rs2545801 (F12, p-value=0.0023), while a suggestively stronger effect in men 
was found at rs10740134 (REEP3, p-value=0.01) (Figure 2.3A, Table 2.1). As the distribution of 
glycine levels itself is sex-specific (women: mean±SD=1.137±0.321, men: 
mean±SD=0.966±0.195 (arbitrary units); p-value for sex difference<2.2×10-16), we assessed 
differences in effect sizes on log-transformed in place of within-sex standardised glycine levels as 
a sensitivity analysis, which gave similar results (Supplementary Table 2.3). Due to larger effect size 
of rs715 in women, the cumulative variance in glycine levels explained by the 27 variants was nearly 
2.5 times higher in women (25.1%) than in men (10.6%) (Figure 2.3B). The sex difference in effect 
sizes of rs715 was also observed for 65 other metabolites significantly associated with rs715 in the 
EPIC-Norfolk study (Supplementary Figure 2.1).  
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Figure 2.3: Sex-specific effect sizes and cumulative variance explained by lead SNPs at the 27 genetic loci associated 
with glycine. A| Sex-specific effect sizes of lead SNPs at the significant loci for glycine levels, based on a meta-analysis of the 
Fenland, EPIC-Norfolk and INTERVAL studies, including 30,226 men and 31,957 women. B| Cumulative variance in glycine 
levels explained by lead SNPs at all 27 loci in men (N=5,086) and women (N=5,706) of the EPIC-Norfolk study.  
 
Genetic scores predict glycine levels: trade-off between power and specificity 
We generated a genetic score comprising lead SNPs at the loci significantly associated with glycine 
levels and tested its specificity for glycine metabolism. Three variants — rs201393666 in 
TUBGCP4, rs148685782 in FGG and rs190595610 near KIF5B — were excluded from the score 
as look-ups for these were not available in all summary-level GWAS datasets for CHD. The effect 
size-weighted genetic score including the 24 remaining loci was robustly associated with glycine 
levels, explaining 15.6% of the total variance after adjustment for age, sex and batch effects, and 
10.0% and 24.9% in men and women, respectively.  
The 24 loci were within 1 Mb of loci previously reported for other metabolites, for 9 of which the 
lead variant we identified for glycine was not in high LD (r2≥0.8) with the reported lead variant(s) 
(Supplementary Table 2.2). We therefore tested if the glycine score affected metabolic pathways 
unrelated to glycine metabolism. Among the 894 metabolites measured in at least half of the 
sample size of the EPIC-Norfolk study (Bonferroni-corrected p-value threshold <5.6×10-5), the 
glycine score was most strongly associated with glycine but also with 70 other metabolites, of 
which the majority were either strongly correlated with glycine levels (several glycine-conjugated 
metabolites) or metabolically related to glycine, including urea cycle and choline metabolites, 
serine, creatine, and glycine-conjugated fatty acids. The glycine score was also associated with 33 
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metabolites not directly related to glycine, including unknown metabolites, phospholipids and acyl 
carnitines (Supplementary Table 2.4).  
We constructed three additional genetic scores for glycine with decreasing numbers of loci but 
increasing specificity to glycine metabolism. The ‘glycine-related’ score was comprised of the 6 loci 
near genes encoding enzymes related to glycine metabolism (Figure 2.2), explained 14.9% of the 
glycine variance and remained associated with 66 metabolites (Supplementary Table 2.4). The 
CPS1 locus by itself was significantly associated with all but four of these 66 metabolites; we 
therefore generated a third score that excluded the pleiotropic CPS1 locus. This score explained 
1.2% of the glycine variance and was associated with 10 metabolites, of which 7 were linked to 
glycine (γ-glutamylglycine, N-acetylglycine, propionylglycine, N-palmitoylglycine, 
isovalerylglycine, serine and cinnamoylglycine) and three were unknown metabolites. Finally, we 
constructed a 2 SNP score, based on the two loci at GCSH and GLDC encoding enzymes of the 
glycine cleavage system. The 2 SNP score explained 0.6% of the variance in glycine and was 
associated with γ-glutamylglycine, N-isovalerylglycine, 3-methylglutaconate and its carnitine 
conjugate, and one unknown metabolite. 
Glycine levels are inversely associated with incidence of T2D 
The strength of association between standard deviations (SDs) of serum levels of glycine and 
incidence of T2D was available in 5 of the 42 longitudinal studies identified in the systematic 
literature review on metabolomics studies for T2D, of which one reported the association for 
Europeans and South-Asians separately. In the 4 cohorts including participants of European 
ancestry, glycine levels were strongly and inversely associated with incident T2D, but this 
association was not significant in the Japanese152 and South-Asian cohorts166. The lack of 
association in the latter could have been due to the adjustment for HOMA-IR, which was not 
included as a covariate in the other studies. We investigated the association between glycine and 
incident T2D in the EPIC-Norfolk study (N=1,332 of which 586 incident T2D cases) and found 
a 42% lower incidence of T2D per SD higher glycine levels (hazard ratio (HR) [95% CI] for T2D 
per SD increase in glycine = 0.58 [0.47, 0.70]). We next pooled effect estimates of circulating 
glycine levels on incident T2D of seven cohorts and found a significant inverse association 
between glycine levels and disease incidence (fixed-effect pooled OR per 1 SD higher glycine =0.78 
[0.72, 0.84]; random effect estimate [95% CI] = 0.77 [0.66, 0.90], based on 2,067 T2D cases), 
although there was substantial heterogeneity between the studies (I2=28.0%, p=0.001). As a 
sensitivity analysis, we excluded non-European cohorts, which led to a stronger association of 
glycine with incident T2D and non-significant heterogeneity (I2=73.9%, p=0.235, OR=0.70 
[0.64,0.77], 1,840 T2D cases) (Figure 2.4). 
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Figure 2.4: Forest plot of pooled and study-level observational risk ratio estimates for T2D per 1 SD higher levels of 
glycine based on 7 studies. Eur: Europeans, SA: South-Asians. CI: confidence intervals. SD: standard deviation, * Adjusted for 
HOMA-IR. 
 
The association of genetically predicted glycine levels with T2D risk is pathway-
specific  
Based on Mendelian randomisation analyses including up to 63,767 T2D cases and 457,195 
controls and the full genetic score for glycine comprised of 24 loci, genetically predicted glycine 
levels were not associated with T2D risk (OR [95% CI] for T2D per genetically predicted SD 
higher levels of glycine = 1.00 [0.97, 1.04], p= 0.84) (Figure 2.5 and 2.6A, Supplementary Table 
2.5). Sex-specific analyses in up to 12,013 female and 16,914 male T2D cases indicated that 
genetically predicted glycine levels were also not associated with T2D risk in men or women only 
(OR [95% CI] in women = 1.01 [0.94, 1.09]; OR [95% CI] in men = 1.04 [0.98, 1.10], p-value for 
sex difference=0.54) (Figure 2.5, Supplementary Figures 2.2A and 2.3A for sex-specific dosage 
plots, Supplementary Table 2.5 for full results). As there was evidence for moderate heterogeneity 
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Egger’s intercept =0.03), the median weighted method was used for the main analyses. Causal 
effect estimates were very similar across all four MR methods and when using the 6 SNP score, 
which only included loci in/near loci encoding enzymes related to glycine metabolism (Figure 
2.6B, Supplementary Figure 2.2B, and 2.3B, Supplementary Table 2.5). No evidence was found 
for heterogeneity nor for directional pleiotropy when using the 6 SNP score.  
 
 
Figure 2.5: Forest plot of the odds ratios ± 95% confidence intervals for type 2 diabetes per standard deviation genetically 
predicted higher levels of glycine using 4 different genetic instruments for glycine. Genetic estimates are based on 63,767 
T2D cases and 457,195 controls from InterAct, UK Biobank and DIAGRAM for sex-combined analyses. Sex-specific genetic 
analyses included 12,013 female and 16,914 male T2D cases and 202,124 female and 164,944 male controls from InterAct and UK 
Biobank. For the sex-specific analyses, the standard deviations of the sex-specific glycine distributions were used, which were 0.321 
and 0.195 (arbitrary units) for women and men in the EPIC-Norfolk study, respectively. The full score was comprised of all 24 
common loci for glycine, the 6 SNP score only included loci in/near genes encoding enzymes related to glycine metabolism, the 5 
SNP score excluded the CPS1 locus and the 2 SNP score only included loci near GLDC and GCSH. 
 
However, after removing the strong but non-specific CPS1 locus from the 6 SNP score for glycine, 
the association of genetically predicted glycine with T2D reached significance in the sex-combined 
analyses (sex-combined: OR=0.868 [0.757,0.996], p=0.044; women: OR=0.928 [0.767,1.123], 
p=0.45; men: OR=0.908 [0.730,1.129], p=0.39) (Figures 2.5 and 2.6C, Supplementary Figures 2.2C 
and 2.3C). When using the 2 SNP score which only included the two loci near GCSH and GLDC 
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OR=0.792 [0.682,0.919], p=0.002) (Figure 2.5 and 2.6D) and no heterogeneity by sex was found 
(women: OR=0.855 [0.661,1.106], p=0.23; men: OR=0.774 [0.620,0.966][, p=0.024; p for 
heterogeneity by sex=0.57) (Supplementary Figures 2.2D and 2.3D). 
 
 
Figure 2.6: Dosage plots of the effect sizes of genetic variants for glycine on standard deviations of glycine levels versus 
the log odds for type 2 diabetes for sex-combined analyses. A| For the full glycine score, B| the score comprising 6 loci 
in/near enzymes related to glycine metabolism, C| a score comprising 5 glycine-related loci without the CPS1 locus and, D| a 2 
SNP score including GCSH and GLDC genes encoding enzymes part of the glycine cleavage system. The orange line represents 
the slope estimated using the weighted median method. SD: standard deviation, T2D: type 2 diabetes. 
 
Genetically higher fasting insulin is inversely associated with genetically predicted 
glycine levels 
To investigate if the association between low levels of glycine and high incidence of T2D could be 
a consequence of early disease processes of T2D, we assessed the causality of three risk factors for 
T2D – elevated body mass index (BMI), reduced early-phase insulin secretion (IS) and insulin 
resistance (IR) – on circulating levels of glycine. We found that genetically higher IR was associated 
with genetically predicted lower levels of glycine (beta [95%CI] on SDs of glycine levels per 
genetically predicted unit of fasting insulin levels = -0.960 [-1.376, -0.544], p =5.98×10-6), while 
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[-0.10,0.02], p=0.169) and IS (beta per genetically predicted units of insulin at 30 minutes during 
an oral glucose tolerance test on SDs of glycine levels =0.02 [-0.04,0.09], p=0.52) were not 
associated with glycine levels (Figure 2.7). No evidence for heterogeneity or directional pleiotropy 
was found. The inverse-variance weighted MR analyses were therefore used as the main analyses, 
but similar effect sizes were found using the MR-EGGER, median weighted and penalized median 
weighted MR (Supplementary Table 2.6). 
 
Figure 2.7: Forest plot of the genetic associations of insulin resistance (IR), early-phase insulin secretion (IS) and body 
mass index (BMI) with glycine levels. Analyses were based on the inverse variance-weighted MR method and previously 
identified genetic scores for BMI (96 SNPs, Locke et al.217) , fasting insulin adjusted for BMI (10 SNPs, Scott et al.95) and 30-minute 
insulin during an oral glucose tolerance test (21 SNPs, Scott et al.95).  
 
High glycine levels are genetically and observationally associated with lower 
incidence of CHD in both women and men 
Based on Mendelian randomisation analyses in up to 88,800 CHD cases and 485,266 controls and 
using the genetic score for glycine comprised of 24 variants, we estimated that each SD increase 
in genetically predicted glycine levels was associated with a 5.2% reduction in risk of CHD (odds 
ratio (OR) [95% confidence intervals (CI)] =0.948 [0.918, 0.979], p-value=0.001) (Figure 2.8 and 
2.9A, Supplementary Table 2.7). Sex-specific analyses in up to 9,852 female and 21,994 male CHD 
cases showed that the effect sizes of glycine on CHD risk were similar between women and men 
(OR [95% CI] = 0.95 [0.91,1.00] and 0.93 [0.84,1.02], respectively; p-value for sex difference=0.60) 
(Figure 2.8 and Supplementary Figures 2.4A and 2.5A). After taking into account the sex-specific 
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sex (women: OR [95% CI] =0.96 [0.91,1.00], men: OR [95% CI] =0.94 [0.85,1.03], p-value for sex 
difference=0.74). 
	
Figure 2.8: Forest plot of the odds ratios for CHD per standard deviation observationally or genetically predicted higher 
levels of glycine. Genetic estimates are based on 88,800 CHD cases and 485,266 controls from EPIC-CVD, UK Biobank and 
CARDIoGRAMplusC4D for sex-combined analyses. Sex-specific genetic analyses included 9,852 female and 21,994 male CHD 
cases and 202,124 female and 164,944 male controls for from UK Biobank, EPIC-CVD and the German Family MI studies. For 
the sex-specific analyses, sex-specific standard deviations were used, which were 0.321 and 0.195 (arbitrary units) for women and 
men in EPIC-Norfolk, respectively. Observational analyses were based on 11,147 participants (4,989 men and 6,158 women) from 
the EPIC-Norfolk study, of which 2,053 (1,223 men and 830 women) were incident CHD cases. 
 
Visual inspection of the scatter plots (Figure 2.9), statistical tests for heterogeneity and pleiotropy 
(Egger’s intercept p-value=0.003; men-only: Cochran’s Q p-value=0.09) (Supplementary Table 
2.6) and the presence of several variants within the score known to be associated with other traits, 
suggest that the effect sizes of the 24 glycine-raising genetic variants on CHD risk may be 
heterogeneous. To reduce the influence of potential pleiotropic variants on the causal estimate, we 
used the weighted median method for the main analyses. To verify if the inverse association of 
genetically predicted glycine with genetic risk of CHD was driven by metabolites unrelated to 
glycine metabolism or other pleiotropic mechanisms, we conducted a series of sensitivity analyses 
using the three genetic scores that are subsets of the full score with increasing specificity to glycine 
metabolism. When using the glycine-related score which included the 6 loci with a known 
biological link to glycine, similar effect estimates for glycine on CHD risk were found and the 
heterogeneity decreased (Egger’s intercept p-value=0.44; men-only: Cochran’s Q p-value=0.80) 
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(Figure 2.9B, Supplementary Figures 2.4B and 2.5B, Supplementary Table 2.7). Removing the 
strong but non-specific CPS1 locus from the glycine-related score increased the causal effect 
estimate of glycine on CHD risk (sex-combined: OR=0.80 [0.71,0.91], p-value=4.8×10-4) (Figure 
2.9C), and a similar effect estimate was obtained when using the	2 SNP score (GCSH and GLDC) 
(sex-combined: OR=0.80 [0.69,0.92], p-value=1.7×10-3) (Figure 2.9D, Supplementary Table 2.7, 
Supplementary Figures 2.4 C-D and 2.5 C-D). 
 
Figure 2.9: Dosage plots of the effect sizes of genetic variants for glycine on standard deviations of glycine levels versus 
the log odds for coronary heart disease. For the full glycine score (A), the score comprising 6 loci in/near enzymes related to 
glycine metabolism (B), a score comprising 5 glycine-related loci without the CPS1 locus (C) and a 2 SNP score including GCSH 
and GLDC- genes encoding enzymes part of the glycine cleavage system (D). The orange line represents the slope estimated using 
the weighted median method. SD: standard deviation, CHD: coronary heart disease. 
In a non-genetic analysis of the EPIC-Norfolk study using Cox proportional hazards models, 
higher glycine levels were associated with lower incidence of CHD (hazard ratio [95% CI] for 
CHD per 1 SD higher glycine = 0.92 [0.87,0.96], p-value=4.7×10-4). This observational association 
was similar to the genetically predicted association (Figure 2.8). Similar observational associations 
were found with myocardial infarction (HR=0.89 [0.82,0.97], p-value=5.5×10-3), but glycine was 
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not associated with stroke (HR= 0.99 [0.93,1.05], p-value=0.70) or stroke sub-types 
(Supplementary Table 2.8). Associations of glycine with both CHD and myocardial infarction (MI) 
tended to be stronger in men than in women, but sex differences were not statistically significant 
(CHD: p-value for sex difference=0.22, MI: p-value=0.10) (Figure 2.8). Using log-transformed in 
place of within-sex standardised glycine measures as the exposure gave similar results 
(Supplementary Table 2.8). 
 
Characterising the biological pathways mediating the protective effect of glycine 
on CHD 
To explore the biological mechanisms through which glycine may influence risk of CHD, we 
investigated the downstream effects of genetic differences in glycine levels on CHD risk factors 
and assessed the extent to which the inverse genetic association of glycine levels with CHD risk 
may be driven by known aetiological mechanisms of CHD.  
Using novel and published GWAS summary results, we assessed associations of genetically 
predicted glycine levels with systolic (SBP) and diastolic blood pressure (DBP), blood lipid 
fractions (triglycerides, HDL, LDL and total cholesterol) and 13 potentially relevant blood cell 
traits (Bonferroni-corrected significance threshold for 19 tests: p-value<2.6×10-3). Genetically 
predicted glycine levels based on the full genetic score were significantly associated with lower 
genetically predicted SBP (beta±SE per SD glycine on SD of SBP=-0.028±0.007, p-value=1.5×10-
5) and nominally with lower genetically predicted DBP (beta±SE=-0.019±0.009, p-value=0.039). 
Similar effect sizes were found for men and women separately (Figure 2.10, Supplementary Table 
2.9). Effect estimates using the glycine-related score were similar as when using the full score. 
When using the glycine-related score without the CPS1 locus or the 2 SNP score, effect sizes 
tended to increase (Figure 2.10, Supplementary Table 2.9). 
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Figure 2.10: Genetically predicted effect of glycine on diastolic and systolic blood pressure, in sex-combined and sex-
specific analyses, using 4 different genetic scores for glycine. The full score includes all 24 common loci associated with 
glycine, the 6 SNP score only includes loci in/near genes encoding enzymes related to glycine metabolism, the 5 SNP score excludes 
the CPS1 locus, and the 2 SNP score only includes loci near genes encoding enzymes that are part of the glycine cleavage system. 
Associations of the genetic scores for glycine with blood pressure were based on 203,943 male and 241,417 female white European 
participants of the UK Biobank. 
Genetically predicted glycine levels were not associated with genetically predicted blood lipids and 
blood cell traits. Associations with lower HDL cholesterol (beta±SE=-0.056±0.010, p-
value=7.4×10-9) and 5 blood cell traits (lower platelet, neutrophil and lymphocyte count; higher 
platelet distribution width and mean corpuscular volume) reached significance when using the full 
genetic score, but the effect sizes drastically decreased when using the 5 or 2 SNP scores, 
suggesting that the associations were driven by CPS1 only (Supplementary Table 2.9, 
Supplementary Figure 2.6).  
To test if the genetic glycine-to-CHD association was mediated through lowering blood pressure, 
we adjusted the effect of genetically predicted glycine on CHD for genetically predicted SBP and 
DBP in a multivariable inverse variance-weighted Mendelian randomisation analysis. We used the 
5 SNP score for glycine levels to reduce the likelihood of glycine-unrelated mechanisms. Adjusting 
for SBP and DBP separately and together progressively reduced the effect estimate of genetically 
predicted glycine on CHD risk (Figure 2.11). This suggests that the genetic association of glycine 
with CHD risk is mediated through blood pressure.  
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Figure 2.11: Forest plot of the odds ratios for coronary heart disease per genetically predicted standard deviation of 
glycine, unadjusted, adjusted for blood pressure. Analyses were based on the 5 SNP score for glycine levels, using summary-
level inverse variance-weighted multivariable Mendelian randomisation. CHD: coronary heart disease, DBP: diastolic blood 
pressure, SBP: systolic blood pressure, SD: standard deviation, CI: confidence interval. 
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Discussion 
Novel loci for glycine in genes involved in the de novo synthesis of serine 
With the largest genetic discovery for glycine levels to date, I identified 22 loci not previously 
reported for glycine and replicated the five known loci. Two novel loci were located in the genes 
phosphoglycerate dehydrogenase (PHGDH) and phosphoserine phosphatase (PSPH), which 
encode the first and last enzymes catalysing the de novo biosynthesis of serine, a pathway which has 
not previously been genetically associated with glycine. Serine can be synthesised from and 
converted into glycine227, and the associations of PHGDH and PSPH with glycine suggest that 
changes in the efficiency of the de novo biosynthesis of serine also affect glycine levels. 
Eight and five of the novel loci coincide or are in high LD with loci reported for blood lipids 
(COBLL1-GRB14, SLC22A3, LOC157273, TRIB1, ABO, REEP3 and KPNB1) and coagulation-
related traits (FGG, C5orf56, KLKB1, F12, ABO), respectively. The direction of association with 
lipid and coagulation traits relative to the glycine-raising allele is not consistent between loci, which 
indicates that these pleiotropic loci do not reflect an overall shared genetic control of glycine, blood 
lipids and coagulation. Loci near tubulin gamma complex associated protein 4 (TUBGCP4, 
MAF=2.9%) and Kinesin Family Member 5B (KIF5B, MAF=0.3%), both involved in microtubule 
function, have to our knowledge not previously been reported for any trait. 
 
The role of glycine in risk of T2D may be pathway-specific 
Results of the Mendelian randomisation analyses on the causality of low glycine levels for T2D 
risk differed depending on the genetic instrument used for glycine. Analyses based on the two 
genetic scores which were most powered for but less specific to glycine indicated no causal effect 
of glycine on risk of T2D. This lack of association was mainly driven by the CPS1 locus, which 
was the locus most strongly associated with glycine but did not alter T2D risk. After excluding the 
CPS1 locus, a significant inverse association of genetically predicted glycine with lower risk of T2D 
was observed, and this association was driven by the two loci which were located near genes – 
glycine cleavage system protein H (GCSH) and glycine decarboxylase (GLDC) – encoding enzymes 
of the glycine cleavage system.  
Our findings contradict the recently reported protective effect of glycine on T2D based on a 
Mendelian randomisation analysis using 5 loci for glycine, which included CPS1, GLDC and 
GCSH147. In this study, the significant inverse genetic association of glycine with T2D risk was 
largely driven by the CPS1 locus, of which the glycine-raising allele was nominally associated with 
lower T2D risk in the 11,600 T2D cases and 33,000 controls of the GoT2D consortium. Our 
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analyses based on up to 63,767 T2D cases and 457,195 controls did not replicate a nominal 
association with T2D for CPS1 nor for the genetic scores for glycine that included CPS1. 
These findings suggest that overall levels of glycine may not be causal for T2D but that low glycine 
levels due to changes in the catalytic efficiency of the glycine cleavage system may cause higher 
risk of T2D. The glycine cleavage system is a protein complex comprised of four enzymes which 
catalyses the major catabolic pathway of glycine into ammonia and carbon dioxide227. Rare, severe 
mutations in genes of the glycine cleavage system have been identified as the cause of non-ketotic 
hyperglycinemia, a rare autosomal recessive inborn error of metabolism causing severe 
neurological symptoms, including seizures, apnea, hypotonia and spasms228. Due to the drastically 
shortened lifespan of most patients with non-ketotic hyperglycinemia and the rarity of this 
conditio229,230, it is unknown if rare mutations in genes encoding enzymes of the glycine cleavage 
system affect risk of cardio-metabolic disease.  Coding mutations in genes of the glycine cleavage 
system have also been linked to higher risk of neural tube defects231. To the best of our knowledge, 
this enzyme complex has not previously been linked to common metabolic diseases, such as T2D.  
An alternative interpretation of our findings is that overall glycine levels are causally associated 
with T2D risk, but that this association was not observed when using the full or 6 SNP score due 
to the strong pleiotropic effects of CPS1. Carbamoyl-phosphate synthase 1 (CPS1) encodes the 
enzyme that catalyzes the first step of the urea cycle, which is responsible for the detoxification of 
ammonia, i.e., the breakdown product of glycine. The CPS1 locus had widespread effects on the 
metabolome, which were not restricted to the glycine pathway, and of which some, including 
glycine, may protect against T2D while others could increase T2D risk. As CPS1 had a more than 
10 times stronger effect on glycine than most other glycine loci, the two genetic instruments for 
glycine which included CPS1 in fact mostly represented the effect of CPS1. Therefore, the 
pleiotropic effects of CPS1 could overshadow the genetic association of glycine levels with T2D 
risk.  
In a few small-scale intervention studies, glycine has been suggested to increase insulin secretion 
after glucose intake232,233. In vitro experiments on islet β cells from donors with and without T2D 
indicated that glycine stimulated insulin secretion by binding with the glycine receptor expressed 
on the β cell membrane234. Islet β cells from donors with T2D had lower expression levels of the 
glycine receptor and responded more weakly to glycine234. Another small intervention study 
reported that glycine supplementation  reduced HbA1C and pro-inflammatory cytokines in T2D 
patients235 but these findings have not been replicated on a larger scale. 
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Insulin resistance as a driver of hypoglycinemia 
We found strong genetic evidence that low glycine levels are a consequence of insulin resistance, 
which suggests that the inverse association of glycine levels with incidence of T2D is at least partly 
driven by this early disease process which is often already present several years before T2D can be 
diagnosed236. Observational epidemiological research has previously described inverse associations 
between measures of insulin resistance and glycine levels179,180 and rodent experiments suggest that 
increased oxidative stress caused by insulin resistance leads to a higher rate of glutathione synthesis, 
for which glycine is one of the precursors, and thus lower glycine levels176. Another proposed 
mechanism that could link insulin resistance to lower levels of glycine is the increased demand for 
glycine to safely excrete fatty acyl-CoA esters which accumulate as the circulating levels of free 
fatty acids increase237. In an insulin resistant state, lipolysis in adipose tissue is incompletely 
suppressed by insulin, which leads to higher concentrations of free fatty acids in the circulation238. 
This leads to a build-up of beta oxidation intermediates, i.e., fatty acyl-CoA esters. Via a trans-
conjugation reaction with glycine catalysed by acyl-CoA:glycine-N-acyltransferase, fatty acyl-CoA 
esters are converted to fatty acyl-glycine, which can be excreted via the urine237,239. As lipolysis and 
free fatty acids are elevated as a consequence of insulin resistance, the demand for glycine to safely 
excrete beta oxidation intermediates increases, which could ultimately lead to a depletion in 
glycine237.  
Glycine has previously been suggested as a biomarker for insulin resistance180,240 and our findings 
suggesting that the inverse association of insulin resistance with glycine levels may represent a 
causal effect further strengthen this. Insulin resistance is not routinely screened for in primary 
health care settings, partly due to the high cost of measuring insulin. Using glycine as a biomarker 
for insulin resistance could be a financially more feasible approach to screening for insulin 
resistance, as glycine can be measured more cheaply than insulin, using fluorometric assays.   
Glycine reduces risk of CHD equally in men and women 
Based on genetic scores comprised of up to 24 SNPs, we demonstrate that low levels of glycine 
are genetically associated with higher risk of CHD, which supports a potential protective role of 
glycine against CHD. Hartiala et al. previously suggested that glycine metabolism may play a sex-
specific role in the aetiology of CHD in women, based on the association of the glycine-raising 
allele of rs715 at the CPS1 locus with lower risk of CHD in women only188. However, this sex-
specific association with CHD did not take into account the known strong sex difference in the 
effect size on glycine levels189, which we here estimated to be nearly three times stronger in women 
than in men. Besides its robust association with glycine levels, CPS1, which encodes the rate-
limiting enzyme of the urea cycle, influences a range of other metabolites. Thus, it is possible that 
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causal inferences based on this non-specific locus were driven by associations with other 
metabolites unrelated to glycine metabolism. We demonstrate using four genetic scores with 
different degrees of specificity to glycine that the inverse genetic association of glycine levels with 
CHD risk is likely to be specific to glycine. 
Based on sex-specific genetic scores for glycine that take into account sex differences in effect 
sizes, which we report for the first time for GLDC and TRIB1, we found no evidence that the 
effect on CHD per unit difference in glycine differed by sex. As the genetic score for glycine 
explains more than twice as much of the glycine variance in women than in men, the analyses in 
men were less powered, which caused the effect estimate of glycine on CHD risk for men to have 
wider confidence intervals.  
Blood pressure as a potential mediating factor of the cardio-protective effect of 
glycine 
We explored the underlying biological pathways through which glycine may protect against CHD 
by assessing the associations of genetically predicted glycine levels with CHD risk factors. Our 
findings suggested that glycine may reduce CHD risk by lowering blood pressure. High blood 
pressure is a major risk factor for cardiovascular diseases241 and has also been linked to low levels 
of glycine175,242. Glycine supplementation has been shown to lower blood pressure in several studies 
on rodents178,186,243 and in one small intervention study in participants with and without metabolic 
syndrome244. Our findings based on genetic associations with blood pressure in up to 445,360 
individuals corroborate the blood pressure-lowering effect of glycine for the first time in a large-
scale epidemiological setting. A potential mechanism through which glycine could lower blood 
pressure is through binding of glycine to the glycine-gated chloride channels expressed on the 
endothelium surface, which causes membrane hyperpolarisation. This results in the activation of 
the enzyme endothelial nitric oxide synthase which is responsible for the production of nitric oxide 
– a well-known vasodilator187. There was no evidence for a role of glycine in lipid metabolism or 
blood cell traits, despite previous studies suggesting that glycine may regulate lipid metabolism175 
and platelet245 and immune cell activation246. 
The potential of glycine supplementation as a preventative strategy for 
cardiometabolic diseases 
Our findings that higher glycine levels may be causally related to lower risk of cardiometabolic 
diseases raises the question if glycine supplementation should be evaluated as a preventative 
approach for CHD.  The modest genetic effect size of glycine levels on CHD suggests that the 
potential benefit of glycine supplementation on cardiometabolic disease risk will be relatively 
minor. As a first step in identifying the preventative potential of glycine supplementation for 
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cardiometabolic disease, the safety of such an intervention should be assessed. To our knowledge, 
no long-term toxicological studies of glycine supplementation have been conducted on human 
participants. One study was set up to study the metabolic benefits of glycine supplementation in 
60 participants, of which 30 received 15 mg of glycine per day for 3 months. This study did not 
report adverse effects associated with glycine supplementation and found that glycine 
supplementation reduced signs of oxidative stress, and lowered blood pressure in male participants 
only244. However, these findings have not been replicated in larger-scale studies with a longer 
intervention period. A potential concern of glycine supplementation is that this could lead to an 
increase in cancer risk. Research suggests that glycine and serine may promote oncogenesis by 
fuelling C1 and folate metabolism, thus increasing nucleotide biosynthesis and energy in the form 
of NADH and ATP247. This hypothesis is supported by findings from a systematic literature review 
on randomised controlled trials of folic acid supplements in human participants, which reported a 
suggestive increase in cancer incidence in individuals taking folic acid supplements248. Furthermore, 
in a recent study a glycine and serine-depleted diet was shown to improve survival in mouse models 
of colorectal cancer and lymphoma249. These findings indicate that a thorough assessment of the 
potential carcinogenicity of glycine should be conducted based on in vitro and in vivo animal-based 
experiments before further research on the cardiometabolic benefits of glycine supplementation is 
undertaken.   
Strengths and limitations 
Our investigation into the aetiological role of glycine metabolism on T2D on CHD has several 
strengths. The variance in glycine levels explained by the genetic score comprising 24 loci was 
more than 15%, which enabled us to conduct well-powered Mendelian randomisation 
experiments. The high proportion of explained variance can be attributed to the biological 
specificity of the exposure. As a comparison, the 751 loci identified for body mass index in the 
latest GWAS in up to 700,000 participants together explained approximately 6% of the variance 
in body mass index. Secondly, we conducted a thorough assessment of pleiotropic effects of the 
genetic score for glycine levels and generated a series of subsets of the full genetic score with 
increasing specificity to glycine metabolism, in order to reduce the likelihood of contributions of 
glycine-unrelated metabolic pathways to the causal effect estimate. We adopted multiple Mendelian 
randomisation approaches, including robust methods such as the weighted median method which 
are less sensitive to bias due to pleiotropic effects by a subset of genetic variants within the score, 
which further decreases the chance that the genetically determined effect estimate was driven by 
effects of the genetic scores of glycine on T2D and CHD through glycine-independent 
mechanisms.  
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We are aware of certain limitations to our study. First, some of the genetic loci we identified for 
glycine using a p value threshold of <5´10-8 may be false positives. It has recently been suggested 
that a lower p value cut-off, e.g., <5´10-9, is needed to account for the increased number of 
independent tests due to the higher density and increased coverage of rare variants by recent 
imputation reference panels250. Six of the 27 genetic loci for loci had p>5´10-9. Even if these 6 loci 
were not truly affecting glycine, this should not have had a substantial influence on the causal 
estimates from the MR analyses, as these loci were either not included in the genetic scores for 
glycine (KIF5B and TUBGCP4), or they had small effect sizes on glycine and were only included 
in the 24 SNP score (ARL15, ADGRV1, GLS2 and DAOA-AS1).  
Finally, despite undertaking sensitivity analyses, we cannot exclude the possibility that our findings 
may be driven by vertical pleiotropic effects of the genetic instruments. As the metabolome is 
comprised of thousands of metabolites connected through numerous reactions, some of which 
may be unknown, the distinction between horizontal and vertical pleiotropy is difficult to make in 
the context of metabolomics. The 2 SNP score, comprised of loci in genes of major enzymes of 
glycine catabolism, is the most specific score to the glycine pathway but still shows modest 
associations with some metabolites of which we cannot be sure that they are metabolically linked 
to glycine, e.g., the unknown metabolite X-16570, and with glycine-conjugated metabolites, which 
may have effects independent of glycine on cardio-metabolic disease risk. We can furthermore not 
exclude that the genetic scores for glycine were associated with metabolites not covered on the 
Metabolon platform or other aspects of the human “phenome” which were independently of 
glycine associated with cardio-metabolic disease risk. Therefore, we cannot fully exclude that 
glycine-independent mechanisms may have biased the genetically predicted association of glycine 
with disease risk. Moreover, as glycine is a metabolite on the intersection of many metabolic 
pathways, the genetic association of glycine with cardio-metabolic diseases may represent the 
causal effect of a metabolite to which glycine is metabolically close linked (e.g., tetrahydrofolate or 
serine).  
Independent of potential pleiotropic effects of the glycine score, the genetically determined effect 
size of glycine on cardiometabolic disease may be up- or downwardly biased. The Mendelian 
randomisation approach estimates the effect size of an exposure on a certain outcome, assuming 
that exposure levels remain constant throughout the life course. As glycine levels may decrease, 
increase or fluctuate during a person’s life, the estimated effect of glycine on CHD risk through 
genetics may be over- or underestimated. Furthermore, through a process called “canalization”56, 
i.e., the process of developmental compensation that reduce or negate the phenotypic effect of 
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certain genetic mutations, the effect of genetically lower glycine levels on T2D and CHD risk may 
be weaker than the effect size of low glycine levels developed during the life course.  
Finally, due to the relatively modest effect size of glycine levels on CHD risk, we had limited power 
to precisely quantify the extent to which the genetic association of glycine levels with CHD risk 
could be explained by blood pressure. There may also be other mechanisms underlying the genetic 
association between glycine levels and CHD risk, which we could not test here. For example, 
glycine may be linked to lower levels of oxidative stress, as it is a substrate for the biosynthesis of 
glutathione – a major antioxidant in human cells251,252.  
Conclusion 
I show that low glycine is associated with higher incidence of CHD and that a genetic instrument 
for glycine is compatible with this relationship being causal. We also show that the association 
between genetically lower glycine and genetically higher blood pressure may at least in part explain 
the inverse relationship between glycine levels and CHD risk. No conclusive evidence for a causal, 
protective role of glycine on risk of T2D was found, but our findings suggest that changes in 
glycine catabolism by the glycine cleavage system may have a causal relationship with T2D. Finally, 
strong, genetic evidence was found that insulin resistance is causally associated with 
hypoglycinemia. 
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Collaborations and contributions 
This chapter focuses on the genetic determinants of total body fat percentage (BF%) and fat-free 
mass index (FFMI). Most of the work described in this chapter was done as part of a consortium 
project led by Prof Ruth Loos (Charles R. Bronfman Institute of Personalized Medicine, Icahn 
School of Medicine at Mount Sinai), in which I played a leading role as one of the main analysts. 
We started this project by conducting exome chip meta-analyses for BF% and FFMI.  Study-level 
exome-wide association analyses were conducted by researchers at the research institutions 
running the studies. I ran exome chip analyses in the Ely and Fenland studies and conducted meta-
analyses of all study-level results. It is standard practice in large consortia that all analyses are run 
in parallel by two separate analysts. Therefore, all exome chip meta-analyses were replicated by Dr 
Michael Preuss (Icahn School of Medicine at Mount Sinai). As a next stage in this project, genome-
wide association studies for BF% and FFMI were conducted in UK Biobank. I conducted GWAS 
for BF% and FFMI on participants of European ancestry of UK Biobank. These analyses were 
done in parallel by Dr Hanieh Yaghootkar (University of Exeter). Meta-analyses of UK Biobank 
GWAS results with the exome chip results and published GWAS results were conducted by me 
for FFMI and Dr Kevin Lu (Vanderbilt University) for BF%. Significant independent variants for 
each trait were identified by me, Dr Hanieh Yaghootkar and Yingjie Ji (University of Exeter), and 
I conducted cross-trait LD clumping of the combined list of selected variants for BF% and FFMI. 
Collider bias tests for variants associated with FFMI were designed by Dr Zoltan Kutalik 
(University of Lausanne) and conducted by Dr Zoltan Kutalik and me. Annotations of the 
significant signals and LD score regression analyses were conducted by me and Dr Kevin Lu.  
Based on the genetic loci identified for BF% and FFMI, I also conducted the following analyses: 
I assessed the observational and genetic correlations between BF%, FFMI and related 
anthropometric traits, conducted conditional analyses for the rare and low-frequency variants to 
identify the coding variants that are likely to be the causal signal in the region, investigated cross-
trait associations of variants associated with BF% or FFMI, and identified BF%, FFMI and BMI 
loci with disproportionate effects on fat or lean mass.
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Abstract 
Background: The genetic determinants of overweight and obesity have thus far mostly been 
studied through large genetic discoveries for BMI, which has a low sensitivity to detect body 
fatness, as it does not distinguish fat from lean body mass. Evidence suggests that fat and lean 
mass may have discordant effects on metabolic health, but the distinct genetic determinants of fat 
and lean mass have not been studied at scale. Identifying genetic regions specific to body fat or 
lean mass can help us to assess their potential roles as aetiological factors for cardiometabolic 
diseases.  
 
Aims: This chapter aims to (1) conduct genetic discoveries for total body fat percentage (BF%) 
and fat-free mass index (FFMI), (2) assess pleiotropic effects of loci for BF% and FFMI on related 
anthropometric phenotypes, (3) identify subsets of loci which disproportionately affect lean 
and/or fat mass and (4) assess association patterns of low-frequency coding variants for BF% and 
FFMI with cardiometabolic disease risk and related phenotypes.  
 
Methods: (1) Genetic loci for BF% and FFMI were identified through exome chip meta-analyses 
including up to 112,443 participants and through GWAS on 443,391 UK Biobank participants of 
European ancestry. (2) Cross-anthropometric trait associations were assessed for the significant 
loci as well as across the entire genome using cross-trait LD score regression. (3) The 
proportionality of the effect sizes of loci for BF%, FFMI and BMI on fat versus lean mass was 
assessed based on genetic associations and observational correlations in UK Biobank. (4) For low-
frequency and rare coding variants for BF% and FFMI, associations with phenotypes related to 
body size and cardiometabolic health were assessed using publicly available exome chip association 
data.  
 
Results: (1) 673 novel genetic loci for BF% and 783 novel loci for FFMI were identified. Twenty 
low-frequency and rare coding variants for BF% and/or FFMI were identified as likely causal 
variants, including rare stop gained variants in PDE3B and GPR151 with strong effects on BF%. 
(2) Of the 1,216 independent genetic loci for BF% and FFMI, 173 were associated with both traits 
in the same direction, and 29 loci had opposite effects on BF% and FFMI. 447 and 567 loci were 
associated only with BF% and FFMI, respectively. Subsets of BF% and FFMI loci were strongly 
associated with WHR, WHRadjBMI and height. (3) Despite very strong correlations of BF% and 
FFMI with BMI, 16 of the 1,216 genetic loci had disproportionate effects on BF% beyond BMI, 
of which 11 loci also had disproportionately large, inverse effects on FFMI. The vast majority of 
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the reported BMI loci affected BF% and FFMI proportionately, with the exception of 4 loci mainly 
driven by BF% and 3 other loci which were disproportionately associated with FFMI. (4) 
Heterogeneous association patterns of the low-frequency coding variants for BF% and FFMI with 
cardiometabolic diseases and traits were observed.   
 
Conclusion: Through large-scale genetic discoveries for BF% and FFMI and systematic 
integration of genetic findings across anthropometric traits, genetic determinants of normal weight 
adiposity, i.e., high BF% in the absence of overweight, were identified. Furthermore, evidence was 
found that coding genetic factors associated with overall body fat and lean mass have a non-
uniform relationship with cardiometabolic health. This relationship may be partly mediated by 
body fat distribution.  
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Introduction 
The global health impact of overweight and obesity 
Numerous studies have demonstrated that overweight and obesity are leading causes of morbidity 
and mortality worldwide253. According to estimates by the WHO’s Global Health Observatory, 
39% of the global adult population is overweight (BMI ≥25 kg/m2) while 13% is obese (BMI ≥30 
kg/m2)254. In Europe alone, 59% and 23% of the population is overweight and obese, 
respectively254. 7% of all deaths worldwide in 2015 were attributed to overweight and obesity, of 
which 40% occurred among people with a BMI below the obese range253. The most common 
causes of death related to high BMI were cardiovascular disease (41% of all BMI-related deaths) 
and T2D (15%). Worldwide, nearly 5% of all disability-adjusted life years were lost due to high 
BMI253, with cardiovascular disease (34%), chronic kidney disease (18%) and T2D (5%) as the 
leading underlying causes253.  
Fat and lean mass have discordant associations with metabolic phenotypes and 
outcomes 
Most epidemiological and genetic research on adiposity thus far has focused on BMI217,255,256, as it 
is an easy-to-obtain measure which only requires scales and a height measure. However, BMI does 
not distinguish fat from lean body mass. Consequently, BMI has a low sensitivity to detect excess 
adiposity, as it underestimates fat mass in individuals with a high fat mass but low lean mass257,258. 
Total body fat percentage (BF%), defined as the ratio of total mass of body fat to total body mass, 
has been shown to be a more sensitive measure of adiposity than BMI257,258. Available evidence 
suggests that 50-60% of individuals with a BMI within the normal weight range may be classified 
as obese when applying the WHO’s cut-offs for BF% (men: BF% >25%, women: BF% >35%) 
to diagnose obesity258,259. In particular among men, elderly participants and among individuals with 
a BMI in the overweight range (25-29.9 kg/m2), BMI was found to be a poor predictor of BF%-
defined obesity258. Conversely, individuals with high lean but low fat mass, such as athletes, can, 
based on BMI, be misclassified as overweight260.  
Excess fat mass has been shown to be tightly associated with multiple pathophysiological 
processes, such as dyslipidaemia261, insulin resistance262,263 and hypertension264,265 and has been 
causally linked to higher risk of cardiometabolic diseases in genetic85,86 and intervention 
studies19,25,26. High BF% with a normal weight was found to be more strongly associated with 
abnormal blood glucose concentrations than overweight in the absence of elevated BF%259, which 
emphasises the strong relevance of BF% to metabolic risk. Conversely, lean mass266–268 and muscle 
density269 and strength270,271 have been associated with better cardiometabolic health. Muscles, 
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which make up around 50% of the total lean mass272,273, are the most important depots for post-
prandial glucose uptake274 and are therefore considered to play an essential in glucose regulation275. 
Reduced sensitivity to insulin at the level of the muscles has been proposed as a major risk factor 
for developing T2D later in life274, and maintenance of muscle mass and strength may play a role 
in the prevention of T2D275 and improving glucose control in T2D patients276. These discordant 
associations of fat and lean mass with cardiometabolic diseases and risk factors highlight the 
importance of studying the molecular mechanisms associated specifically with fat and lean mass, 
instead of with overall body mass and size only.  
 
Bio-impedance analysis is a cheap and non-invasive technique to estimate body fat 
and fat-free mass 
Bio-impedance analysis (BIA) is an anthropometric analysis technique that estimates total body fat 
and fat-free mass277, of which the latter includes the lean tissues, such as the muscles and internal 
organs, as well as total bone mass. Fat and fat-free mass are estimated by measuring the opposition, 
or electrical impedance, of the body to a small electrical current that is sent through the body, e.g. 
between the hands and the feet. Electrical impedance is inversely correlated with the total amount 
of water in the body and also with the total fat-free mass, as fat-free tissue contains a higher 
concentration of water than fat tissue. Using population and sex-specific equations which include 
age, height, sex and weight as covariates, fat and fat-free mass can be estimated from electrical 
impedance277. While BIA has most commonly been used to estimate total body fat and fat-free 
mass, so-called segmental BIA instruments can also measure impedance in the arms, legs and trunk 
separately and thus allow estimation of regional fat and fat-free mass. However, BIA has been 
shown to estimate overall and regional body fat and lean mass less accurately than imaging-based 
techniques such as dual-energy X-ray absorptiometry (DEXA) and magnetic resonance imaging 
(MRI). Despite relatively strong correlations between body fat measured by BIA and MRI (0.75 
for women and 0.81 for men)278, BIA tends to systematically underestimate total body fat mass by 
2 to 6% when compared to DEXA279 and by 5 kg when compared to MRI278, although this may 
vary by adiposity status. However, as BIA is a cheap, non-invasive and quick technique, it has over 
the past decade been used in many epidemiological studies and has enabled the first genetic 
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Genome-wide association studies on body mass index, BF% and lean mass 
Numerous genetic studies seeking to identify the genetic variation driving overweight and obesity 
have been conducted. In particular, the Genetic Investigation of Anthropometric Traits (GIANT) 
consortium has led multiple large-scale meta-analyses of GWAS and exome chip meta-analyses on 
adiposity based on BMI172,217,280. In the most recent and thus far largest genetic discovery for BMI 
which included nearly 700,000 individuals, 751 independent genetic variants, together explaining 
6% of the variance in BMI, reached genome-wide significance172. Through pathway enrichment 
analyses, the central nervous system has been identified as the most prominent site of action of 
genetic variation related to BMI217. Little evidence for sex-discordant effects of the identified 
genetic loci was found217.  
The strength of using BF%, measured through BIA or DEXA, as a proxy for adiposity was 
demonstrated in two genome-wide discovery efforts88,89. Twelve genetic loci in/near FTO, IRS1, 
MC4R, TMEM18, COBLL1, SPRY2, TOMM40, TUFM, IGF2BP1, SEC16B, PLA2G6 and 
CRTC1 for adiposity were identified, of which six loci (IRS1, COBLL1, SPRY2, IGF2BP1, 
PLA2G6 and CRTC1) were robustly associated with BF% in sample sizes up to 100,716 
individuals but were at the time not identified for BMI in sample sizes of up to 339,224 
participants. Studies on the genetic determinants of lean mass are scarcer. In 2017, Zillikens et al. 
published the first GWAS of total lean mass and lean mass in the limbs, which is also called 
appendicular lean mass and serves as a proxy for total muscle mass. This study included up to 
38,292 participants and identified the first 5 loci in/near FTO, VCAN, IRS1, HSD17B11 and 
ADAMTSL3 for lean mass. Other studies have focused on identifying genetic factors influencing 
muscle strength, by for example using hand grip strength as a proxy281,282, but associations of the 
identified loci with lean mass are uncertain, because muscle strength and lean mass tend to be only 
weakly associated283. No studies to date have attempted to identify low-frequency coding variants 
for fat or lean mass through exome chip analyses, despite the availability of body composition data 
generated using BIA and, to a lesser extent, DEXA imaging, and exome-wide genotyping in several 
epidemiological cohorts. Coding variants identified through exome chip studies are more likely to 
be associated with biological phenotypes than variants in non-coding regions, and hypotheses on 
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Opportunities and objectives 
The implementation of genome or exome-wide genotyping and of BIA-based body composition 
analysis in the baseline health assessment of half a million UK Biobank participants and several 
tens of thousands of participants of other epidemiological cohorts, provides the opportunity to 
identify the genetic determinants of body fat and lean mass at an unprecedented scale. Genetic loci 
specifically associated with higher BF% or FFMI can be utilised to construct genetic scores and 
assess the causality of body fat and lean mass as aetiological risk factors for cardiometabolic risk 
factors and diseases. The large group of individuals with a high BF% in the absence of elevated 
BMI and observational evidence suggesting that BF% is more strongly associated with metabolic 
risk than BMI highlight the importance of understanding the causality of normal weight adiposity, 
i.e., high BF% in the absence of BMI-defined overweight. Furthermore, genetic discoveries for 
BF% and FFMI can contribute to a refined characterisation of loci identified for more crude 
measures of adiposity, such as BMI, and for cardiometabolic phenotypes.  
This chapter aims to (1) identify the genetic determinants of BF% and FFMI through large-scale 
genome and exome-wide genetic discoveries, (2) assess the pleiotropy of loci identified for BF%, 
and FFMI across related anthropometric phenotypes, (3) identify subsets of genetic loci identified 
for BF% and FFMI and previously reported for BMI with disproportionately large effect sizes on 
BF% or FFMI and (4) assess associations of low-frequency coding variants affecting BF% or 
FFMI with cardiometabolic diseases and phenotypes. 




BF%, i.e., the ratio of total fat mass (kg) to total body weight (kg), and FFMI, which is total fat-
free mass (kg) divided by height squared (m2), were used as phenotypes representing fat and lean 
mass, respectively. These phenotypes were chosen because they are only moderately correlated 
(Pearson’s correlation coefficient based on BF% and FFMI in UK Biobank: R=0.47). Two 
strategies were used to identify the genetic determinants of BF% and FFMI (Figure 3.1). First, 
exome chip meta-analyses based on 28 studies were conducted to identify low-frequency coding 
mutations associated with BF% and FFMI. Exome chip meta-analyses were conducted for 
Europeans only and for all ancestries combined. Secondly, GWAS on UK Biobank participants of 
European ancestry were conducted to identify genome-wide genetic factors for BF% and FFMI. 
To maximise sample sizes and thus power to identify low-frequency coding variants for BF% 
(Figure 3.1 A) and FFMI (Figure 3.1 B), summary-level results of the exome chip meta-analyses 
were meta-analysed with the GWAS results. For BF%, an additional meta-analysis of the UK 
Biobank GWAS results with the largest publicly available summary-level GWAS results for BF%88 
was conducted.  





Figure 3.1: Flow chart of study design for genetic discoveries for BF% and FFMI. For both phenotypes, exome-chip meta-
analyses for European ancestry and all ancestries combined, and GWAS on UK Biobank participants of European ancestry were 
conducted. Meta-analyses of the UK Biobank GWAS results and the exome chip meta-analyses were conducted for both FFMI 
and BF%. A separate meta-analysis of the UK Biobank GWAS results with published GWAS results was conducted for BF%.  
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Exome-wide association analyses 
Study participants 
We conducted exome chip meta-analyses for BF% and FFMI, for participants of European 
ancestry only and for all ancestries combined. The analyses for participants of European ancestry 
included 107,902 adult individuals from 28 studies (32 datasets) for BF% and 93,494 individuals 
from 27 studies (31 datasets) for FFMI. All ancestry analyses included 5 additional datasets, of 
which two datasets included participants of South-East Asian ancestry (N ≤2,330) and three 
datasets included participants of Afro-American ancestry (N ≤2,213), leading to sample sizes of 
up to 112,443 and 98,035 participants for BF% and FFMI, respectively (Supplementary Table 3.1). 
All participating institutions and coordinating centres approved this project and informed consent 
was obtained from all study participants. 
Phenotypes 
BF% and FFMI were derived in each cohort based on either BIA or DEXA (see Supplementary 
Table 3.1). Within each study, BF% and FFMI were adjusted for age, age2, and genetic principal 
components (calculated from genome-wide genotyped data, all exome chip variants with minor 
allele frequency (MAF) >1%, or ancestry informative markers available on the exome chip) and 
additional study-specific covariates if applicable (e.g. recruitment centre) in linear regression 
models. The residuals of the linear regression model were then re-scaled based on the rank-based 
inverse normal transformation. For studies which included mostly unrelated participants, 
phenotypes were transformed for men and women separately, whereas for family-based studies 
sex was included as a covariate in the linear regression model. For case-control studies, phenotypes 
were transformed and analysed for cases and controls separately. The full analysis plan can be 
found in Supplementary Materials – Analysis plan 1. 
Genotype calling 
The majority of studies followed a standardized protocol and performed genotype calling using 
the designated manufacturer software, followed by zCall285. For studies participating in the Cohorts 
for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the raw 
intensity data for the samples were assembled into a single project for joint calling286 (see 
Supplementary Materials – Analysis plan 1 for further information).  
Study-level exome chip analyses 
Study-level analyses were conducted for both sexes combined as well as by sex, were based on 
additive and recessive genetic models and were run using either RAREMETALWORKER287 
(https://genome.sph.umich.edu/wiki/RAREMETALWORKER) or RVTEST288 
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(https://genome.sph.umich.edu/wiki/Rvtests) (see Supplementary Table 3.1). Both software 
packages estimate genetic associations based on linear mixed models and account for potential 
cryptic relatedness by generating a genetic kinship matrix. Both software tools are designed to 
perform rare variant association analyses and can analyse data from studies of both unrelated and 
related individuals. 
Centralised study-level quality control 
A centralised quality control (QC) procedure, implemented in the R package ‘EasyQC’289, was 
applied to individual cohort association summary statistics to identify cohort-specific problems, 
such as errors in the phenotype transformation by plotting the median standard error versus the 
square root of the sample size for all studies, strand issues by testing the alignment of the observed 
allele frequencies against 1000 Genomes Project phase 1 reference data, and inflation of the test 
statistics due to e.g. population stratification, cryptic relatedness or genotype biases based quantile-
quantile plots.  
Exome chip meta-analyses, QC and annotation 
Meta-analyses of the study-level exome-wide association results were carried out in parallel by two 
researchers using the R package ‘RareMETALS’287 
(https://genome.sph.umich.edu/wiki/RareMETALS). Variants were omitted if call rate <95% or 
if p-value for Hardy-Weinberg equilibrium <1×10-7. Only coding variants which reached exome-
wide significance (p<2.0×10-7) were considered. Variants were annotated based on the most severe 
annotation available from the Ensembl Variant Effect Predictor (VEP)290. Associations with height 
and BMI were obtained from publicly availably summary-level results from exome chip meta-
analyses280,291. Associations with waist-to-hip ratio (WHR) and WHR adjusted for BMI 
(WHRadjBMI) from a recent exome chip analysis project292 have only been released yet for variants 
reaching exome-wide significance for WHR or WHRadjBMI; therefore, associations of variants 
for BF% and FFMI with WHR and WHRadjBMI are only given for some of the identified variants.  
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Genome-wide association analyses in UK Biobank 
Phenotypes 
The UK Biobank study was introduced in the methods section of Chapter 2202. Participants 
underwent BIA using a Tanita BC418MA body composition analyser at baseline, from which BF% 
(UK Biobank data field 23099: http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=23099) and total 
fat-free mass (UK Biobank data field 23101: 
http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=23101) were derived. FFMI was calculated as 
total fat-free mass (kg)/standing height2 (m2). Standing height was measured using a SECA 240 
height measure. QC of the phenotypes was performed centrally by UK Biobank. BF% and FFMI 
were adjusted for age, age2, sex and assessment centre in linear regression models and the residuals 
of the linear regression models were rank-based inverse normally transformed. For the sex-specific 
analyses, phenotype transformations were conducted for men and women separately. 
Genome-wide genetic data and identification of participants of white European ancestry 
Genome-wide genotyping was conducted on 488,377 participants of UK Biobank using two 
different genotyping arrays, of which the probed genetic markers overlapped for 95%. 49,950 
participants were genotyped on the Affymetrix UK BiLEVE Axiom array and 438,427 participants 
on the Affymetrix UK Biobank Axiom array. Quality control of the genome-wide genetic data and 
imputation using a combined linkage disequilibrium (LD) reference panel of the Haplotype 
Reference Consortium192, the UK10K haplotype resource193 and 1000 Genomes Phase 3194 were 
performed centrally and have been described extensively elsewhere213. Genetic ancestry of the UK 
Biobank participants was determined using K-means clustering applied to the first four genetic 
principal components (PCs) anchored in the genetic PCs generated from the 1000 Genomes 
phase 3 reference panels for European (CEU), African (YRI) and Asian (CHB/JPT) ancestry 
populations194. Individuals who fell into the European cluster but who self-identified as being 
of any other ancestry than European were considered to be of non-European ancestry. 
GWAS and QC  
Phenotypes and genetic data were available for analyses on 442,278 (240,589 women and 201,689 
men) and 442,391 (240,552 women and 201,839 men) UK Biobank participants of European 
ancestry for BF% and FFMI, respectively. We performed sex-combined and sex-specific genome-
wide association analyses using BOLT-LMM293 (v2.3) for inverse normally transformed BF% and 
FFMI under an additive genetic model and with genotyping array as a covariate. The BOLT-LMM 
(v2.3) software203 was used as it fits linear mixed models, which can adjust for population structure 
and cryptic relatedness based on a genetic relatedness matrix. We used genotyped single nucleotide 
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polymorphisms (SNPs) present on both genotyping arrays, with MAF > 1% and which passed 
QC in all 106 genotyping batches, to estimate the parameters of the linear mixed model for the 
initial modelling step. The genome-wide association analyses were restricted to bi-allelic variants 
with INFO ≥0.4 if MAF ≥1%, and INFO ≥0.8 if MAF <1%. Variants in the human leukocyte 
antigen (HLA) region were excluded (variants on chromosome 6 with base-pair positions from 
28,477,797 to 33,448,354). 
Meta-analyses of the UK Biobank GWAS with exome chip meta-analyses and 
published GWAS data 
Summary statistics of the GWAS in UK Biobank were meta-analysed with the European ancestry 
exome chip meta-analysis results to maximise power to identify coding variants for BF% and FFMI 
(Figure 3.1). A separate meta-analysis of the UK Biobank GWAS for BF% with published 
summary statistics of the European ancestry GWAS on BF% published by Lu et al.88 was 
conducted (Figure 3.1). The published BF% GWAS included up to 89,297 individuals of European 
ancestry from 54 studies, of which 43 had genome-wide genetic data and 11 Metabochip data 
only88. Genotyped data in this previous study were imputed to the HapMap2 reference panel, 
which led to a total number of 2,516,560 testes variants, either directly genotyped or imputed. 
Meta-analyses were performed using the inverse variance-weighted fixed-effect method without 
adjustment for genomic control, as implemented in METAL205. Meta-analyses were conducted for 
the sex-combined and sex-specific analyses. The meta-analyses of the UK Biobank GWAS with 
the published GWAS for BF% and of the UK Biobank GWAS with the European ancestry exome 
chip data were used for all the following analyses, unless described otherwise.  
Assessment of genomic inflation and SNP-based heritability 
The linear mixed model-based GWAS method implemented in BOLT-LMM has been shown to 
sufficiently control for potential population stratification and cryptic relatedness in GWAS on UK 
Biobank participants293. To test if population stratification and cryptic relatedness caused inflation 
of the test statistics of our genetic discoveries for BF% and FFMI, we estimated genomic inflation 
using LD score regression (LDSC) based on the baseline LD model294,295. The LDSC intercept 
serves as an estimate for genomic inflation corrected for polygenicity, i.e., the inflation of the test 
statistics that is due to population stratification and cryptic relatedness. However, the LDSC 
intercept has been shown to increase with sample size and heritability due to attenuation bias203. 
The attenuation ratio (LDSC intercept - 1)/(mean χ2 - 1) has been proposed as an alternative to 
the LDSC intercept which is less biased by sample size and heritability293. We therefore made use 
of the attenuation ratio statistics to test for inflation of the test statistics due to residual population 
stratification and cryptic relatedness. LDSC was also used to estimate the SNP-based heritability 
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for BF% and FFMI. LDSC was conducted for the meta-GWAS results for BF% and the meta-
analysis of the UK Biobank GWAS with the exome chip data for FFMI. Variants with MAF <0.1% 
or INFO <0.4, multi-allelic variants and variants in the HLA region were excluded from the LDSC 
analyses. 
Identification of independent genetic loci for BF% and FFMI 
We combined three approaches to identify the independent common and rare genetic loci 
associated with BF% and FFMI, based on the meta-GWAS for BF% (Figure 3.2), and on the meta-
analysis of the UK Biobank GWAS and European exome chip data for FFMI (Figure 3.3). The 
genome-wide significance threshold was set at p≤5×10-9 to account for the increased number of 
tests that results from higher imputation density compared to earlier GWAS efforts250.  
For variants with MAF>1%, the independently associated lead variants that reached genome-wide 
significance were identified based on a combination of distance-based clumping and approximate 
conditional analyses conducted in GCTA-COJO206. Distance-based clumping of the common 
variants was conducted using 500 kb windows. In parallel, independent variant selection was 
conducted through a stepwise model selection procedure using the --cojo-slct function 
implemented in GCTA-COJO206. As LD reference panel for GCTA-COJO, we used SNPs with 
MAF >0.1% and INFO ≥0.3 from the approximately 343,000 UK Biobank participants who were 
unrelated and of British ancestry. Variants with a p≤5×10-9 in the joint model were considered to 
be conditionally independent. A combination of the variants selected through distance-based 
clumping (the “clumped variants”) and approximate conditional analyses (the “GCTA variants”) 
were used to generate the final list of common, independent loci. Starting from the list of GCTA 
variants, we replaced the GCTA variant by a clumped variant if the clumped variant was within 
500 kb of the GCTA variant. This was done because GCTA selected in several cases not the most 
significant variant in the region as the sentinel variant in the region. Clumped variants which were 
not within 500 kb of a GCTA variant were added to the list of independently associated variants, 
unless they were located in previously reported regions of long-range LD296 (see Supplementary 
Table 3.2). These clumped variants which were added in were mostly variants which had a marginal 
p-value near the significance threshold but for which the joint p-value dropped just below the 
significance threshold. Finally, GCTA variants were dropped if they were in LD (R2>0.05) with 
any of the other GCTA variants. These steps were done for the European sex-combined and sex-
specific analyses for BF% (Figure 3.2, Step A1 to 3) and FFMI (Figure 3.3, Step A1 to A3). Variants 
identified in the sex-specific analyses were only retained in the final list of independent variants if 
they were further than 500 kb from variants from selected in the sex-combined analysis (Figure 
3.2 and 3.3, Step B). 
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Next, we identified the rare variants that reached genome-wide significance and were conditionally 
independent of common variants selected in step A within 1 Mb of the rare variant(s) (Figure 3.2 
and 3.3, Step C). As GCTA-COJO is not optimised for identifying independently associated rare 
variants, we assessed the independence of the associations of rare variants using individual-level 
data-based conditional analyses. We first identified the “rare regions” by taking all genome-wide 
significant rare variants separated by less than 1 Mb, and added all common variants selected 
through the steps explained above. For each rare region, we fitted a joint model which included 
all rare and selected common variants in the subset of unrelated UK Biobank participants of British 
ancestry. Age, age2, the first 10 genetic principal components, sex, genotyping chip and assessment 
centre were included as covariates. Rare variants with p≤5×10-4 in the conditional models were 
considered to be associated with the phenotype independently of the common variants in the 
region.  
 
For lead variants identified in the sex-combined analyses, we tested for heterogeneity in the effect 
sizes for men and women based on the t statistic, which was calculated as follows: 
	"	 = 		 (%&'()*	–	%()*) -(./&'()*0 +	./()*0⁄  
Loci for which the t statistic reached Bonferroni significance (p≤ 0.05/total number of sex-
combined lead variants) were considered to have sex-dimorphic effects. 
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Figure 3.2: Overview of selection of common and rare independently associated lead variants for BF%, based on meta-
analysis of GWAS results in UK Biobank and published summary-level GWAS results. In step A, the common, independent 
loci were identified based on distance-based clumping and approximate conditional analyses in GCTA-COJO, for the sex-
combined and sex-specific analyses separately. In step B, sex-specific loci within 500 kb of a sex-combined locus were omitted, as 
they were likely to represent the same locus. In step C, rare variants which were associated independently of the common variants 
selected in step A, were identified based on individual-level data-based conditional analyses, and were added to the list of 
independently associated variants. This led to the identification of 685 independent loci for BF%.  
 
Figure 3.3: Overview of the selection of common and rare independent loci for FFMI, based on the meta-analyses of the 
GWAS in UK Biobank and the European exome chip meta-analyses. The same procedure as for BF% was followed, which 
led to the identification of 906 independent common and rare loci for FFMI.  
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Conditional analyses for rare and low-frequency coding variants based on 
individual-level data from the unrelated UK Biobank participants  
We had a specific interest in rare and low-frequency coding variants that reached genome-wide 
significance for BF% and/or FFMI and asked if they were (one of) the causal variant(s) in the 
region or, alternatively, were located in a region driven by another, non-coding variant, without 
the low-frequency coding variant itself being the causal variant. Although the approximate 
conditional analyses were conducted on all variants with MAF >1% and thus also included the 
low-frequency (but not the rare) coding variants, we conducted a separate series of conditional 
analyses based on individual-level data. This separate series of conditional analyses for all low-
frequency coding variants was conducted because, although GCTA-COJO has the advantage of 
identifying the statistically independent variants in an efficient manner and without the need of 
individual-level data, experience of the consortium members shows that GCTA-COJO may not 
always be reliable at identifying independently associated low-frequency and rare variants.  
We first tested in UK Biobank if the genotyped coding variant, if available, showed the same 
direction and strength of association as the imputed variant which was analysed by BOLT-LMM 
for the GWAS. We then conducted exact conditional analyses using the same strategy as for the 
selection of the rare (non-coding and coding) variants, including the rare and low-frequency coding 
variant(s) and all selected variants for BF% (Figure 3.2) or FFMI (Figure 3.3) within 1 Mb of the 
coding variant(s) in the model. Coding variants which reached a significance threshold of p≤5×10-
4 were considered to be independently associated with BF% or FFMI. Variants were annotated 
based on the most severe annotation found in VEP290. For the variants which were covered in 
previous exome chip projects, associations with related anthropometric phenotypes, including 
height291 and BMI280, and cardiometabolic risk factors and diseases, including blood lipids297, T2D40 
and CHD298, were extracted from publicly available summary-level results from European ancestry 
exome chip meta-analyses. 
Assessment of collider bias in the GWAS for FFMI due to adjustment for height  
Aschard et al. demonstrated that results of a GWAS for an outcome that is adjusted for a heritable 
covariate can be biased, and that this so-called collider bias increases with the strength of the 
correlation between the outcome and covariate299. In GWAS conducted on large sample sizes, 
collider bias can lead to significant associations that are solely driven by an association with the 
covariate without affecting the (unadjusted) outcome. As FFMI is calculated by the ratio of fat-
free mass to height squared, of which the latter is both highly heritable and strongly correlated 
with lean mass, some of the variants reaching genome-wide significance for FFMI may be driven 
by an inverse association with height only. Collider bias was therefore assessed for each of the 
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genetic variants selected for FFMI, using the approach described by Aschard et al.299.  The original 
approach to test for the presence of a collider bias was developed for linear covariates, while FFMI 
is adjusted for a quadratic covariate, i.e., height squared. Therefore, the original approach was 
adapted for quadratic covariates as follows: 
Let us define fat-free mass (FFM) as y, height as x and a genetic marker as g, measured in a 
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Based on x and y, we define a new trait z (i.e., FFMI) as their ratio z = y/x2. The new trait z can 
be written as 
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We can approximate z using the first order Taylor series expansion as follows: 
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We can now estimate the effect of variant g on z as follows: 
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with r(x,y) the correlation between x and y.  
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This enables us to estimate the effect of variant g on z, based on the effect estimates of g on x (α) 
and y (β). For variants which only have a non-zero effect on height but not on FFM, the estimated 
effect and variance of variant g on z become 










For variants with no apparent evidence for an association with FFM (p>0.05/number of 
independent FFMI variants) but with evidence for an association with height (p<0.05/number of 
independent FFMI variants), the observed effect size of the variant g on FFMI(Yj) was compared 
with the expected effect size of variant g on FFMI (YZ) if the association of variant g was solely 






Under the null hypothesis, the observed and expected effect sizes of variant g on FFMI are equal. 
The association of variant g is thus considered to be solely associated with FFMI through height. 
If the observed and expected effect sizes of variant g on FFMI are significantly different, then the 
null hypothesis is rejected and the association of variant g with FFMI is considered to be at least 
partially driven through an association with FFM. Variants for which the null hypothesis could not 
be rejected were omitted from the follow-up analyses. 
The effect sizes of the FFMI variants on FFM and height were assessed in GWAS on the European 
participants of UK Biobank, using the same phenotype adjustments and transformations and 
analytical strategies as for the GWAS for FFMI. The mean value and variance of BF% and FFMI 
and their correlation were assessed in European ancestry participants of UK Biobank and were 
based on untransformed phenotypes. 
Clumping of BF% and FFMI variants and associations with related anthropometric 
traits  
To obtain a list of unique, LD-independent loci associated with BF% and/or FFMI, we conducted 
LD clumping of the lead variants selected for BF% and FFMI in the sex-combined analyses. 
Genetic loci for BF% and FFMI were considered to represent the same locus if they were within 
500 kb and in LD (R2 ≥0.2). LD clumping was conducted in PLINK 2.0 alpha208 
(https://www.cog-genomics.org/plink/2.0/) and using an LD reference panel based on 10,000 
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randomly selected, unrelated UK Biobank participants of British ancestry. This same strategy was 
used to identify the number of loci identified for BF% and FFMI which were also reported for 
BMI in the latest, thus far largest genetic discovery for BMI, which was based on a meta-analyses 
of a GWAS in UK Biobank with the published GWAS published by the GIANT consortium (total 
N= 681,275)172.  
Effect sizes of variants associated with BF% or FFMI with height, BMI, waist-to-hip ratio (WHR) 
and WHR adjusted for BMI (WHRadjBMI) were tested based on GWAS on UK Biobank 
participants of European ancestry, using the same trait transformations and analytical strategy as 
for the GWAS for BF% and FFMI.  
Genetic and observational correlations with other anthropometric traits 
We assessed the genetic correlations between BF%, FFMI, BMI, height, WHR, WHRadjBMI, 
waist circumference (WC), WC adjusted for BMI (WCadjBMI), hip circumference (HC) and hip 
circumference adjusted for BMI (WCadjBMI) using cross-trait LD score regression294,300. Briefly, 
LD score regression allows estimation of the genetic correlation between two traits based on 
summary-level GWAS results for the two traits and an LD reference panel. The genetic covariance 
between the two traits is estimated based on the slope from the regression of the product of the z 
scores for the two respective traits versus the LD score, for all genetic variants. Analyses were 
based on sex-combined GWAS on European UK Biobank participants for inverse normally 
transformed phenotypes adjusted for age, age2 and sex. LD scores calculated for the 1000 Genomes 
phase 3 European population (downloaded from https://github.com/bulik/ldsc) were used. 
Variants with MAF<0.1% or INFO<0.4, multi-allelic variants and variants in the HLA region 
were omitted from the analyses. Observational correlations between the 10 anthropometric traits 
were assessed based on the Pearson’s correlation coefficients and using the same phenotype 
transformations as for the GWAS.  
Identification of BF%, FFMI and BMI loci with disproportionate effect sizes on fat 
and lean mass 
Loci identified for higher BF% and FFMI could purely reflect higher BMI or, alternatively, could 
be more strongly associated with BF% or FFMI, respectively, than expected for a BMI locus, given 
the observational correlations of BF% and FFMI with BMI and the genetic effect size of the 
variant on BMI. To test if the variants identified for BF% and FFMI disproportionately affected 
the respective phenotypes, the method for testing collider bias proposed by Aschard et al.299 was 
re-appropriated to estimate the expected effect size (%qr)*',)7q ) if the association with the 
phenotype (i.e., BF% or FFMI) was solely driven by BMI. The expected effect size and its variance 
were calculated as follows: 
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%qr)*',)7q = %stu ∙ vw_(xℎyzw, {|}) 
gh_~%qr)*',)7q = ./stu
0 ∙ vw_(xℎyzw, {|})0 
 
If the observed effect size (%qr)*','ÄÅ	) did not differ from the expected effect size %qr)*',)7q, 
then the association of the locus with the phenotype was only driven by BMI. If the observed 
effect size was significantly different from the expected effect size, then the association with the 
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If the null hypothesis is rejected and É%qr)*','ÄÅÉ > 	 É%qr)*',)7qÉ, then the locus is more strongly 
associated with the phenotype than a BMI locus would. If the null hypothesis is rejected and 
É%qr)*','ÄÅÉ < 	 É%qr)*',)7qÉ, then the effect on the phenotype is significantly less than would be 
expected for a locus driven by BMI only.  
The observed effect sizes on FFMI and BF% were taken from the meta-GWAS results and the 
effect on BMI was assessed in GWAS on the European participants of UK Biobank, using the 
same phenotype adjustments and transformations and analytical strategies as for the GWAS for 
FFMI and BMI%. The correlation between BF% and BMI and FFMI and BMI was assessed in 
European ancestry participants of UK Biobank and were based on the same phenotype 
transformations as the GWAS. 
The same approach was applied to identify reported BMI loci with disproportionate effect sizes 
on FFMI and/or BF%, based on the observational correlations of BMI with BF% and FFMI and 
the effect sizes of the BMI loci on BF% and FFMI. This was done for loci reported in the latest 
genetic discovery for BMI by Yengo et al.172, but analyses were restricted to loci for which the 
marginal p≤5×10-9. 
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Results 
Body fat percentage and fat-free mass index have a curvilinear relationship 
The observational relationships between BF%, FFMI, BMI and other anthropometric phenotypes 
were assessed in the UK Biobank population. Women had a higher BF% than men, for a given 
BMI and overall (mean BF% for women: mean±SE= 36.5±6.9%, for men: 25.3±5.8%, p for sex 
difference <2.2×10-16). A positive, curvilinear association of BF% with BMI was observed in the 
UK Biobank population, with a stronger increase in BF% per unit increase in BMI at the lower 
end of the observed BMI values (Figure 3.4 A). FFMI was higher in men than in women (women: 
mean±SE= 16.8±1.7 kg/m2, men: 20.6±1.9 kg/m2, p for sex difference <2.2×10-16) (Figure 3.4 
B). The curvilinear and linear relationships of BF% and FFMI, respectively, with BMI, resulted in 
a positive, curvilinear relationship between BF% and FFMI, with a stronger increase in BF% per 
unit increase in FFMI in the lower FFMI range (Figure 3.4 C).  
 
The plots in Figures 3.4 A-C indicate that for a small group of women with a BMI >40 kg/m2, the 
relationship of BMI with BF% and FFMI seems to follow a steeper and more linear slope. The 
vast majority of these outlying values came from participants from the assessment centre in 
Sheffield (Supplementary Figure 3.1 A-B). For around 160 of the 15,789 women who visited the 
centre in Sheffield, BF% follows a steeper relationship with BMI than for all other female 
participants from Sheffield (Supplementary Figure 3.1 D). The vast majority of the 160 women 
were of British ancestry and were between 50 and 60 years old, the latter of which made pregnancy 
an unlikely explanation for the outlying values. As this sub-group of women only represented 
0.0007% of the total number of women in the study, this small number of deviating values are 
unlikely to have any detectable influence on the results of the genetic analyses. Therefore, these 
values were not excluded from the analyses.  
 
The observational relationships of BF% and FFMI with related anthropometric traits was assessed 
based on observational correlations between the inverse normally transformed phenotypes 
adjusted for age, age2, sex and assessment centre (Figure 3.4 D). Strong correlations with BMI 
were observed for both BF% (Pearson’s correlation coefficient R=0.85) and FFMI (R=0.84), while 
the correlation between BF% and FFMI was less pronounced (R=0.47). BF% and FFMI also 
showed strong correlations with waist circumference (WC) (FFMI: R=0.80, BF%: R=0.83), hip 
circumference (HC) (BF%: R=0.69, FFMI: R=0.84) and waist-to-hip ratio (WHR) (BF%: R=0.62, 
FFMI: R=0.45), but these correlations became much weaker after adjustment for BMI. Weak 
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inverse correlations with height were observed for FFMI (R=-0.14) and BF% (R=-0.01). Because 
of the large sample sizes which were used to assess these correlations, all correlations were highly 




Figure 3.4: Scatter and correlation plots of total body fat percentage, fat-free mass index and related anthropometric 
phenotypes in UK Biobank. Plots are based on up to 207,585 male and 245,920 female participants of UK Biobank. A| Scatter 
plot of body mass index versus total body fat percentage (untransformed) B| Scatter plot of body mass index versus fat-free mass 
index (untransformed). C| Scatter plot of fat-free mass index versus total body fat percentage (untransformed). D| Plot of the 
Pearson’s correlation coefficients between body fat percentage, fat-free mass index and related anthropometric traits. All 
phenotypes were adjusted for age, age2, sex and assessment centre in linear regression models and the residuals were rank-based 
inverse normally transformed. BMI: body mass index, BF%: total body fat percentage, FFMI: fat-free mass index, WH: waist-to-
hip ratio, WHadj: WH adjusted for BMI, WC: waist circumference, WCadj: WC adjusted for BMI, HC: hip circumference, HCadj: 
HC adjusted for BMI. 
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Exome chip meta-analyses reveal a low-frequency coding variant in ZBTB7B 
influencing FFMI 
Five common coding variants associated with BF% 
Based on exome chip meta-analyses for European ancestry only (N=107,902) and all ancestries 
combined (N=112,443), 40 genetic variants were associated with BF% at exome-wide significance 
level (p≤2.0×10-7) (Figure 3.5 upper panel and Supplementary Table 3.3). Five of these were 
coding, missense variants, which were all common (EAF>5%) (Table 3.1). rs11057401 in CCDC92 
was the only coding variant which only reached significance in the all ancestries meta-analysis. The 
CCDC92 locus only reached significance for higher BF% in women and had a significantly lower 
effect on BF% in men (women: per-minor allele effect size on standard deviations (SDs) of BF%: 
beta=0.037, p=1.0×10-7; men: beta=0.005 , p=0.45, p for sex difference=9.8×10-4). For 4 of the 5 
significant coding variants, the association with BF% based on the additive model was most 
significant, while the association of rs2904880 in CD19 only reached significance based on the 
recessive genetic model. All five coding variants had exome-wide or nominally (nominal 
significance threshold: p≤1.25×10-3, CCDC92: pbmi=0.001) significant and directionally consistent 
effect sizes on BMI in published exome chip meta-analyses280 which included 718,734 participants. 
The BF%-raising allele at rs11057401 in CCDC92 is the only variant which has also been reported 
for body fat distribution in an exome chip study including 344,369 participants (sex-combined 
effect size on SDs on WHRadjBMI=-0.029, p=7.3×10-37)292. The sex-discordant effect of the 
CCDC92 locus was also observed for WHRadjBMI (women: beta=-0.045, p=7.3×10-51; men: 
beta=-0.014, p=4.7×10-5, p for heterogeneity between sexes=7.2×10-11)292. The BF%-raising allele 
at rs11676272 in ADCY3 was been reported for shorter height (p=1.6×10-32)291 but none of the 
other BF% coding variants were associated with height.  
  




Figure 3.5: Manhattan plots for exome chip meta-analyses for BF% and FFMI. –10log(p-value) and log(p-values) are plotted 
for the meta-analyses of all ancestries based on the additive genetic model, for BF% (top) and FFMI (bottom), respectively. Loci 
in black only contain non-coding variants, loci in orange contain at least one common non-synonymous coding variant and the 
locus in red contains a low-frequency non-synonymous coding variant. * This locus reaches significance in the recessive sex-
combined meta-analysis of the European ancestry only. ** This locus reaches significance in the meta-analysis of all ancestries for 
women, based on the additive model. 
 
One low-frequency and 7 common coding variants for FFMI 
Based on exome chip meta-analyses for FFMI including up to 98,035 participants, 40 genetic 
variants reached exome-wide significance (Figure 3.5, bottom panel and Supplementary Table 3.4). 
Eight of these were coding, of which all but one reached significance in the sex-combined, 
European ancestry meta-analysis based on the additive genetic model. Rs591120 in SEC16B only 
reached significance in the sex-combined meta-analysis of all ancestries (Table 3.1).  
Rs141845046 in Zinc Finger and BTB Domain Containing 7B (ZBTB7B) was the only low-
frequency coding variant that reached significance (c.670C>T, p.Pro224Ser, effect allele frequency 
(EAF)=3.1%, per-allele effect size on SDs of FFMI=0.074, p=3×10-8, p for heterogeneity between 
studies=0.70) (Table 3.1). The FFMI-raising allele at rs141845046 was not associated with BF% 
(per-allele effect size on SDs of BF%=0.018, p=0.16) and has previously been reported for higher 
BMI280 (per-allele effect size on SDs of BMI=0.047, p=4.2×10-13), taller height291 (per-allele effect 
size on SDs of height=0.058, p=7.3×10-17) and lower WHRadjBMI (per-allele effect size on SDs 
of WHRadjBMI=-0.037, p=3.8×10-8)292. This indicates that ZBTB7B increases BMI through lean 
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Seven common, coding variants in SEC16B, MST1R, BDNF, ADAMTSL3 (3 variants) and IQCK 
were also significantly associated with FFMI. Apart from the three coding variants in ADAMTSL3 
(pbmi>0.05), the common coding variants associated with FFMI also reached exome-wide 
significance for BMI280, and effect sizes were directionally consistent between BMI and FFMI. The 
FFMI-raising alleles at the three coding variants in ADAMTSL3 have previously been reported 
for shorter height (p-values ranging from 2.3×10-25 to 1.8×10-79), while the FFMI-raising allele in 
IQCK was nominally associated with shorter height (p=1.3×10-4), which indicates that the 
associations of these variants with FFMI is at least partly driven by the inverse associations with 
height.  
 
Table 3.2: Coding variants associated at exome-wide significance with BF% or FFMI. Chr; chromosome, pos: base-pair 
position, EA: effect allele, OA: other allele, EAF: effect allele frequency, sex-comb: sex-combined analyses, add: additive model, 
rec: recessive model.  
rsid chr pos Gene Amino acid change Analysis EA OA EAF Beta p-value 
BF% 
European ancestry only 
rs11676272 2 25,141,538 ADCY3 p.Ser107Pro sex-comb add G A 0.455 0.025 4.0E-08 
rs1801282 3 12,393,125 PPARG p.Pro12Ala sex-comb add G C 0.130 0.050 1.3E-13 
rs2904880 16 28,944,396 CD19 p.Leu174Val sex-comb rec G C 0.715 -0.053 1.3E-07 
rs1800437 19 46,181,392 GIPR p.Glu318Gln sex-comb add C G 0.210 -0.030 5.7E-08 
All ancestries combined 
rs11057401 12 124,427,306 CCDC92 p.Ser70Cys women add A T 0.314 0.037 1.0E-07 
FFMI 
          
European ancestry only 
rs141845046 1 154,987,704 ZBTB7B p.Pro224Ser sex-comb add T C 0.033 0.074 3.9E-08 
rs1062633 3 49,924,940 MST1R p.Arg1286Gly sex-comb add C T 0.484 0.026 1.9E-07 
rs6265 11 27,679,916 BDNF p.Val66Met sex-comb add T C 0.186 -0.041 1.1E-10 
rs4483821 15 84,488,636 ADAMTSL3 p.His146Arg sex-comb add G A 0.447 -0.028 7.2E-09 
rs4842838  15 84,582,124 ADAMTSL3 p.Val661Leu sex-comb add T G 0.516 -0.029 1.4E-08 
rs34047645 15 84,611,367 ADAMTSL3 p.Gly713Arg sex-comb add C G 0.183 0.041 7.0E-09 
rs7191155 16 19,800,213 IQCK p.Leu220Pro sex-comb add C T 0.162 -0.039 5.1E-09 
All ancestries combined 
rs591120 1 177,902,753 SEC16B p.Pro864Ala sex-comb add C G 0.435 0.025 2.0E-07 
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Genome-wide association analyses for BF% and FFMI  
685 conditionally independent genetic variants identified for BF% 
Based on meta-analyses of the UK Biobank GWAS with the published GWAS results, leading to 
a total sample size of up to 531,566 participants (286,110 women) of European ancestry, 685 
conditionally independent variants reached genome-wide significance for BF% (p≤5×10-9) (Figure 
3.6, bottom; Supplementary Table 3.5). The 5 most significant loci for BF% were located in FTO 
(p=9.9×10-189), SEC16B (p=2.8×10-59), ADCY3 (p=8.6×10-59), TUFM (p=3.3×10-56) and MC4R 
(p=1.0×10-54), and are all known as major loci for BMI. The variant with the largest effect size on 
BF% was the rare, stop gained variant (rs150090666, c.2347C>T, p.Arg783Ter) in 
Phosphodiesterase 3B (PDE3B), of which each minor allele (EAF=0.1%) was associated with 
0.150 SDs higher BF% (p=2.6×10-9). This association was based on the imputed variant in UK 
Biobank only, but the association of the genotyped variant in UK Biobank was very similar 
(beta=0.199, p=2.6×10-9). This variant had a scaled CADD score of 35, which indicates that it is 
predicted to be among the 0.03% most deleterious variants in the human genome301. 
Limited evidence was found for sex-discordant effects of the genetic loci identified for BF%. Of 
the 685 genetic loci identified for BF%, 10 and 14 loci only reached significance in the women-
only and men-only analyses, respectively (Supplementary Table 3.5). Of the 661 variants which 
reached significance in the sex-combined analyses, a significant sex difference (Bonferroni 
corrected p for 661 tests ≤7.6×10-5) in the effect sizes on BF% in men versus women was identified 
for three variants, which all had stronger effects in men than women and did not reach significance 
in women alone (Supplementary Table 3.5). The first variant was located near LOC646736 
(rs952227, women: beta±SE on SDs of BF% =0.011±0.003, men: beta±SE =-0.038±0.003, p for 
sex difference = 2.0×10-10). The two other variants were located in the non-pseudo-autosomal 
region of the X chromosome, near FAM9B (rs5934505, women: beta±SE on SDs of BF% 
=0.003±0.004, men: beta±SE =-0.024±0.003, p for sex difference = 2.7×10-5) and near EDA2R 
(X:66222744_CAA_C, women: beta±SE on SDs of BF% =0.003±0.003, men: beta±SE =-
0.023±0.002, p for sex difference = 2.9×10-8). I also found a strong correlation between the 
summary-level GWAS results for BF% in men and women based on LD score regression 
(R=0.89±0.01), which confirms that genetic effects on BF% are largely shared between men and 
women.  
The 12 previously reported loci for BF% also reached significance in the present study (p of lead 
variant at locus ≤5×10-9, lead variant within 500 kb of and in high LD (R2>0.5) with the published 
lead variant). Nearly a third (215 of the 685 independent variants, or 31.4%) of the genetic loci 
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which reached genome-wide significance for BF% have also been reported for BMI in up 681,275 
participants by Yengo et al.172.  
 
Figure 3.6: scatter plot of the minor alleles frequencies versus the effect sizes of the independent variants selected for 
FFMI and BF%. 685 independent variants reaching genome-wide significance in the meta-analysis of the GWAS in UK Biobank 
and the published GWAS results by Lu et al. were plotted for BF%. For FFMI, the 787 independent variants which reached genome-
wide significance in the meta-analysis of the GWAS in UK Biobank and the exome chip data and for which the association was 
not solely driven by height were plotted. The y axis represents the absolute effect sizes on standard deviations of FFMI (top) and 
BF% (bottom). Red dots indicate positive and blue dots negative effect sizes of the minor alleles. The diameter of the dots are 
scaled to the -10log(p-value).  
 
906 independent variants identified for FFMI 
Based on meta-analyses of the UK Biobank GWAS and the exome chip data, leading to a total 
sample size of up to 535,885 participants (287,956 women), 906 conditionally independent variants 
reaching genome-wide significance (p≤5×10-9) were identified for FFMI (Supplementary Table 
3.6). The five loci most significantly associated were located in/near FTO (p=2.1×10-346), MC4R 
(p=1.0×10-151), TMEM18 (p=2.2×10-126), LINC01874 (p=3.0×10-98) and ADAMTSL3 (p=1.1×10-
92), of which the first three are major BMI and the latter is a well-known locus for height. 
As for BF%, little evidence for sex-dimorphic genetic loci for FFMI was found. Of the 906 lead 
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3.6). Of the 892 variants identified in the sex-combined analyses, only 3 variants had significant 
sex differences in their effect sizes on FFMI (Bonferroni corrected p-value for 892 tests ≤5.6×10-
5). Two variants in close proximity had stronger effects in women (rs713586 near ADCY3 and 
DNAJC27 and 2:25365642_TAATA_T in ERF3B) while rs76895963 in CCND2-AS1 had a 
stronger effect on FFMI in men (Supplementary Table 3.6). A strong, positive correlation was 
found between the summary-level GWAS results for BF% in men and women based on LD score 
regression (R=0.90±0.01), which confirms the shared genetic architecture of FFMI between men 
and women.  
Four of the 5 genetic loci (FTO, IRS1, VCAN and ADAMTSL3) which were reported for total 
or appendicular lean mass, adjusted for age, age2, height and fat mass in the published GWAS by 
Zillikens et al.302 were replicated in the present GWAS for FFMI (p of lead variant at locus ≤5×10-
9, lead variant within 500 kb of and in high LD (R2>0.5) with the published lead variant). The 
reported locus in HSD17B11 (sentinel variant rs9991501) was not in LD with any of the loci in 
the region that reached genome-wide significance in the present analysis, nor was the sentinel 
variant itself associated with FFMI (rs9991501: p=0.21). The adjustment for different covariates, 
in particular total fat mass, or a false positive finding in the study by Zillikens et al.302 are possible 
reasons why this locus was not associated with FFMI in the present analysis. More than a third of 
the identified loci for FFMI (312 of the 906 or 34.5%) were also reported for BMI by Yengo et 
al.172.  
 
120 of the 906 genetic loci identified for FFMI are driven by collider bias due to height 
squared 
To test if the association of any of the genetic variants identified for FFMI were the result of 
collider bias due to the adjustment for height squared, we assessed the association of all 906 FFMI 
variants with height and fat-free mass (FFM). For the variants associated with height 
(pheight≤5.5×10-5) but not with FFM (pFFM>5.5×10-5), the observed effect size of the variant on 
FFMI was compared with the expected effect size if the association would by driven by height 
squared only. If the observed and expected effect size were not significantly different then the 
variant was associated solely through height and was omitted from further analyses. 
601 of the 906 genetic loci identified for FFMI were significantly associated with FFM (p for 906 
tests ≤5.5×10-5) (Figure 3.7, blue dots). 156 other variants were not associated with FFM nor with 
height (Figure 3.7, green dots). These variants were weakly associated with FFMI and may 
therefore not have reached significance for FFM. The remaining 228 loci did not reach significance 
for FFM (p>5.5×10-5) but were associated with height (p≤5.5×10-5, Figure 3.7, red and yellow 
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dots). For 108 of these 228 variants, the observed effect size on FFMI was significantly different 
from the predicted effect size if the association would only be driven by height squared (Figure 
3.7, yellow dots), which indicates that their associations with FFMI could not be fully explained 
by height. For the other 120 variants which reached significance for height only, the observed 
effect size on FFMI did not differ significantly from the expected effect size (Figure 3.7, red dots). 
The associations of these 120 variants with FFMI were therefore likely to be solely driven by the 
adjustment for height squared and they were therefore not considered for further analyses 
(Supplementary Table 3.7). In conclusion, we identified 787 independent genetic loci for FFMI 
which were not solely driven by height. 773 loci reached significance in the sex-combined analyses, 
while 6 were only associated in men and 8 only in women (Figure 3.6, top). This subset of FFMI 




Figure 3.7: Scatter plot of the observed effect size on FFMI versus the expected effect size on FFMI if the association is 
entirely driven by the adjustment for height squared. The plot includes the 906 variants identified for FFMI in sex-combined 
and sex-specific analyses. Variants in blue reached Bonferroni-corrected significance for FFM (p≤5.5×10-5), variants in green were 
not significant for FFM, nor for height (p>5.5×10-5). Variants in yellow and red reached significance for height but not for FFM. 
The expected and observed effect sizes on FFMI were significantly different (p≤5.5×10-5) for the yellow variants but not for the 
red variants. The red dashed line represents equal observed and expected effect sizes on FFMI. FFM: fat-free mass; FFMI: fat-free 





−0.05 0.00 0.05 0.10
















Expected vs observed not different, FFM non−sign, height sign
Expected differs from observed, FFM non−sign, height sign






−0.05 0.00 0.05 0.10
















Expected vs observed not different, FFM non−sign, height sign
Expected differs from observed, FFM non−sign, height sign
FFM non−sign and height non−sign
FFM sign
Chapter 3: The genetic determinants of BF% and FFMI 
 108 
Genomic inflation, polygenicity and SNP-based heritability 
Substantial genomic inflation was observed in the meta-GWAS of both BF% and FFMI (BF%: 
λGC = 2.456; FFMI: λGC = 2.6745). LDSC was conducted to assess to what extent this inflation was 
due to polygeneticy and population stratification or cryptic relatedness. The LDSC intercepts and 
attenuation ratios based on the Baseline LD model indicated that this inflation was due to 
polygenicity (BF%: LDSC intercept ±SE = 1.124±0.019, attenuation ratio ± SE =0.054±0.008; 
FFMI: LDSC intercept ±SE = 1.160±0.025, attenuation ratio ± SE =0.058±0.009). Similar and 
slightly higher attenuation ratios have been reported for GWAS for other phenotypes in UK 
Biobank293. The SNP-based heritability for BF% estimated using LDSC was h2±SE =23.3±0.6%, 
while for FFMI the SNP-based heritability was h2±SE =30.2±0.9%. 
 
Associations of BF% and FFMI loci with related anthropometric traits 
Substantial overlap in genetic loci identified for BF% and FFMI 
The genetic loci identified for BF% and FFMI overlapped substantially, with the majority of shared 
loci affecting both traits in the same direction. Of the 1,216 LD-independent loci associated with 
BF% (661 loci) and/or FFMI (787 loci) in the sex-combined analyses, 202 (16.6%) were genome-
wide significantly associated with both BF% and FFMI. 173 (86.5%) of the 202 shared loci had 
directionally consistent effects on BF% and FFMI (Figure 3.8, green dots), while 29 (14.3%) were 
associated with both phenotypes in opposite direction (Figure 3.8, blue dots). 447 of the 1,216 loci 
(36.8%) only reached genome-wide significance for BF% (Figures 3.8, pink dots) and 567 (46.6%) 
only for FFMI (Figure 3.8, yellow dots). However, of the variants only selected for BF%, 140 
(32.5%) also reached nominal significance (Bonferroni-corrected significance threshold for 1,216 
tests: p≤4.1×10-5) for FFMI, of which 14 had an opposite direction of effect on FFMI. 151 (26.6%) 
of the variants only selected for FFMI also reached nominal significance for BF%, of which 19 
had opposite effects on FFMI and BF%. Overall, around 60% of the 1,216 identified loci were 
specific to one of the two traits, with 307 only affecting BF% and 416 only affecting FFMI. The 
remaining 40% were at least nominally significant for both phenotypes, of which approximately 
half reached genome-wide significance for both traits.  
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Figure 3.8: Scatter plot of the effect sizes of the 1,216 LD-independent genetic loci on BF% versus FFMI. Effect sizes are 
aligned to the BF%-raising allele. Variants in red reached genome-wide significance for BF% only, variants in yellow for FFMI 
only, and variants in green and blue for both BF% and FFMI with the same (green) and opposite (blue) directions of effect on 
BF% and FFMI. Because of its large effect size on BF%, the locus in PDE3B was omitted from this plot. The effect size of PDE3B 
on FFMI was non-significant: beta=0.030, p=0.21. 
 
Association of BF% and FFMI loci with related anthropometric traits 
As evidence was found that a substantial proportion of the genetic determinants of BF%, FFMI 
and BMI are shared and that BF% and FFMI are observationally correlated with other 
anthropometric phenotypes, I next asked if genetic loci associated with BF% and FFMI also affect 
other phenotypes reflecting body size and composition. The genetic associations of the 1,216 loci 
for BF% or FFMI with related anthropometric traits, i.e., BMI, height, WHR and WHRadjBMI 
were assessed based on GWAS on the UK Biobank participants of European ancestry. For the 
vast majority of 649 BF%-raising loci, of which 202 were common with FFMI, a similar, positive 
association with BMI was found (Figure 3.9, upper left). 526 of the 649 BF% loci reached at least 
nominal significance for BMI (Bonferroni-corrected significance threshold for 1,216 tests: 
p≤4.1×10-5), of which all but two had the same directions of effect on both BMI and BF% (Figure 
3.9, upper left). The BF%-raising alleles at the common missense variant rs72755233 in 
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BMI (rs72755233: per-BF%-raising allele effect size on SDs of BMI = -0.016, p=5.7×10-8; 
rs61327788: beta= -0.010, p=9.3×10-8). Although no consistent pattern of association of the BF% 
loci with height was observed, 189 BF%-raising loci were also associated with height, of which 107 
loci were positively and 82 were negatively associated with height, including several well-
established height loci, such as ADAMTS10, ADAMTS17 and MAP3K3 (Figure 3.9, upper right). 
More than a third (255 of the 649 loci) of the BF%-raising loci also reached nominal significance 
for higher WHR, which may be due to the observational correlation of BF% with WHR (Figure 
3.9, bottom left). However, 27 of the BF%-raising genetic regions were associated with lower WHR. 
After adjusting WHR for BMI, only 27 BF%-raising loci remained associated with higher central-
to-lower body fat distribution; while 46 BF% loci were associated with lower WHRadjBMI (Figure 
3.9, bottom right). Among the genetic loci associated with higher BF% but lower WHR or 
WHRadjBMI were well-known loci for body fat distribution, including DNAH10, VEGFA and 
in particular the low-frequency variant rs72959041 in RSPO3 which has a particularly strong effect 
size on lower WHR (beta=-0.130, p=1.9×10-169) and WHRadjBMI (beta=-0.165, p=1.3×10-167) 
This indicates that these loci increase overall body fat mainly through allowing more fat 
accumulation in the lower body instead of in the waist area. 
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Figure 3.9: Scatter plots of the effect sizes of loci selected for BF% on BF% versus related anthropometric traits. Effect 
sizes are plotted for the 658 variants selected for BF% of which 202 were also selected for FFMI. All effect sizes are aligned to the 
BF% raising allele. Variants in red are significantly (Bonferroni corrected p-value ≤4.1×10-5) associated with the trait on the y axis. 
Effect sizes on BMI, height, WHR and WHRadjBMI were estimated through GWAS on inverse-normally transformed traits on 
the UK Biobank participants of European ancestry.  
 
The rare, stop gained variant rs150090666 in PDE3B with a large effect size on BF% (beta=0.150, 
p=2.6×10-9) but not on FFMI (beta=0.030, p=0.21) was strongly associated with taller height 
(beta=0.228, p=1.4×10-16) and lower WHRadjBMI (beta=-0.241, p=1.3×10-11). The variant also 
reached nominal significance for higher BMI (beta=0.132, p=2.0×10-5) but not for lower WHR 
(beta=-0.131, p=2.0×10-4) (Figure 3.10). Similar to RSPO3, this locus thus increases body fat by 
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Figure 3.10: Forest plot of the effect sizes of the stop-gained variant in PDE3B on BF%, FFMI and related 
anthropometric phenotypes. All effect sizes were from GWAS in UK Biobank only and are expressed as per-allele effect size on 
standard deviations of the phenotype. 
 
As for the loci identified for BF%, the vast majority of loci identified for higher FFMI showed 
similar and positive effect sizes on BMI (Figure 3.11, upper left). 611 out of the 769 loci associated 
with FFMI reached at least nominal significance (p≤4.1×10-5) for BMI. Rs11118310 near 
LYPLAL1 was the only FFMI-raising locus which was associated with lower BMI (beta for BMI 
per FFMI-raising allele=-0.009, p=1.6×10-5). Although these analyses excluded the FFMI loci for 
which the associations were entirely driven by inverse effects on height, 88 (11%) FFMI-raising 
variants were associated with shorter height, while 76 reached nominal significance for taller height 
(Figure 3.11, upper right). As expected given the positive correlation between FFMI and WHR, 
172 of the FFMI-raising loci were also associated with higher WHR, while 17 loci were associated 
with lower WHR (Figure 3.11, bottom left).  Conversely, of the 100 FFMI-raising loci which 
reached at least nominal significance for WHRadjBMI, 92 were associated with lower WHRadjBMI 
(Figure 3.11, bottom right). The locus near LYPLAL1 was one of the exceptions, as the FFMI-
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Figure 3.11: Scatter plots of effect sizes on FFMI versus related anthropometric traits for the loci selected for FFMI. 
Effect sizes are plotted for the 769 variants selected for FFMI of which 202 were also selected for BF%. All effect sizes are aligned 
to the FFMI raising allele. Variants in red are significantly (Bonferroni corrected p-value ≤4.1×10-5) associated with the trait on the 
y axis. Effect sizes on BMI, height, WHR and WHRadjBMI were estimated through GWAS on inverse normally transformed traits 
in UK Biobank participants of European ancestry.  
 
Genetic correlations of FFMI and BF% with other anthropometric traits mirror 
observational correlations 
As strong association patterns of the genetic loci reaching significance for BF% and FFMI with 
related anthropometric phenotypes were found, I next extended this exercise to the entire genome 
using cross-trait LD score regression analyses. Based on GWAS in UK Biobank, I assessed the 
genome-wide genetic correlations between BF%, FFMI and eight related anthropometric traits, 
i.e., BMI, height, WHR, WHRadjBMI, waist circumference (WC), WC adjusted for BMI 
(WCadjBMI), hip circumference (HC) and hip circumference adjusted for BMI (HCadjBMI) 
(Figure 3.12). BF% and FFMI were genetically moderately correlated (R=0.49, p=8×10-154) 
(Bonferroni corrected p-value threshold for 17 tests <0.003), and the strength of the genetic 
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correlation coefficient: R=0.47). The strongest genome-wide genetic correlations of BF% and 
FFMI were found with BMI (BF%: R±SE=0.849±0.006; FFMI: R±SE=0.879±0.005), WC (BF%: 
R±SE=0.878±0.006; FFMI: R±SE=0.68±0.01) and HC (BF%: R±SE=0.813±0.008; FFMI: 
R±SE=0.66±0.02). WHR was genetically more strongly associated with BF% (R±SE=0.62±0.02) 
than with FFMI (R±SE=0.44±0.02). However, after adjusting the fat distribution traits for BMI, 
their genetic correlations with BF% became weak (WCadjBMI: R±SE=0.14±0.02; HCadjBMI: 
R±SE=0.10±0.02, WHRadjBMI: R±SE=0.08±0.02). FFMI was weakly correlated with the BMI-
adjusted fat distribution traits (WCadjBMI: R±SE=-0.36±0.02; HCadjBMI: R±SE=-0.24±0.02, 
WHRadjBMI: R±SE=-0.18±0.02), which is likely to be caused by the strong genetic correlation 
of BMI with FFMI. Height was inversely correlated with FFMI (R±SE=-0.22±0.02) but was not 
associated with BF% (p=0.35). The genome-wide genetic correlations of BF% and FFMI with 
related anthropometric traits were very similar the observational correlations (Figure 3.12). 
 
 
Figure 3.12: Genetic and observational correlations of total body fat percentage and fat-free mass index with related 
anthropometric traits in UK Biobank. All traits were adjusted for age, age2 and assessment centre and residuals were inverse 
normally transformed. Correlations with body fat percentage are shown in yellow and with fat-free mass index in blue. Correlations 
between body fat percentage and fat-free mass index are shown in green. The confidence intervals of the genetic and observational 
correlations were too narrow to visualize on the plot. HC: hip circumference, HCadjBMI: HC adjusted for BMI, WC: waist 
circumference, WCadjBMI: WC adjusted for BMI. 
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16 loci act on BF% or FFMI beyond BMI 
Given the strong observational and genetic correlations of both BF% and FFMI with BMI, several 
of the identified loci associated with higher BF% or FFMI may purely reflect higher BMI. To 
identify the genetic loci which affect BF% or FFMI more strongly than a BMI locus would, given 
the correlations of both phenotypes with BMI, I calculated for each of the 1,216 BF% and FFMI 
loci the predicted effect size if the effect of that variant on BF% or FFMI were only due to an 
effect on BMI (Figure 3.13). Of 649 loci associated with higher BF%, 16 loci (ADAMTS3, 
LYPLAL1, MTMR11, ADAMTSL3, RIN3, UBE2Q2P1, ADAMTS14, LINC01184, PLCE1, 
TNP1, LIN28B, ACAN, VCAN, ADAMTS10, ADAMTS17 and LOC646736) had an effect size 
on BF% that was significantly larger (Bonferroni-corrected p for 1,216 tests ≤4.1×10-5) than the 
predicted effect size if the association with BF% had been due to BMI only. For 62 additional loci, 
the effect size on BF% was higher than the predicted effect size at nominal significance (p<0.05). 
Four BF% loci had a significantly lower effect size on BF% than expected if its association only 
reflected BMI (FTO, MC4R, SEMA3F-AS1, TMEM18 and LINC01874), while 36 other loci had 
a nominally lower than predicted effect on BF% (Figure 3.13, left panel). 
Of the 769 FFMI-raising loci, 11 had a significantly (p ≤4.1×10-5) stronger effect on FFMI than 
expected if the variant was associated through BMI only (ADAMTS3, LYPLAL1, MTMR11, 
ADAMTSL3, UBE2Q2P1, ADAMTS14, PLCE1, ACAN, VCAN, ADAMTS17 and 
LOC646736) and 71 loci had an observed effect size that was higher than the expected effect size 
at nominal significance. TUFM was the only FFMI-raising locus which had a significantly lower 
observed compared to predicted effect size on FFMI. 35 loci had a nominally lower observed 
effect size on FFMI than expected if was driven by BMI only (Figure 3.13, right panel).  
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Figure 3.13: Scatterplots of observed versus predicted effect sizes on FFMI and BF% of the genetic loci associated with 
BF% and/or FFMI. The predicted effect size on the y axis reflects the expected effect size on BF% (left) or FFMI (right) if the 
association is entirely due to the association of the variant with BMI and were calculated based on a GWAS for BMI in the European 
ancestry participants of UK Biobank and the correlation of BF% and FFMI with BMI. The observed effect sizes on BF% and 
FFMI come from the meta-GWAS results. For the variants in pink, the observed effect size was stronger than the predicted effect 
size (dark pink: Bonferroni-corrected significance: ≤4.1×10-5, light pink: nominal significance: p<0.05). The variants in green had 
a lower observed than predicted effect size (dark green: Bonferroni-corrected significance: ≤4.1×10-5, light green: nominal 
significance: p<0.05). For variants in grey, the predicted effect size did not differ from the observed effect size (p>0.05) The dashed 
blue line indicates equal observed and predicted effects. 
 
Overall, 16 loci had stronger effects on both BF% and FFMI than would be expected if the 
associations had only been driven by BMI (ADAMTS3, LYPLAL1, MTMR11, ADAMTSL3, 
UBE2Q2P1, ADAMTS14, PLCE1, ACAN, VCAN, LOC646736 and ADAMTS17) or on BF% 
only (RIN3, LINC01184, TNP1, LIN28B and ADAMTS10). After aligning the alleles to the BF%-
increasing allele, all 11 loci that were more strongly associated with both BF% and FFMI had an 
inverse effect on FFMI (Figure 3.14A, yellow variants). The 5 variants with disproportionate 
effects on higher BF% only also all had negative effects on FFMI (Figure 3.14A, red variants). 
None of the 16 variants reached genome-wide significance for BMI (p>5×10-9), but the BF%-
raising alleles at 6 loci reached nominal significance for lower BMI (rs10518106 near ADAMTS3, 
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rs2250127 in LINC01184, beta=-0.007, p=2.3×10-3; rs314274 in LIN28B, beta=-0.006, p=1.9×10-
3; rs3817428 in ACAN, beta=-0.008, p=1.7×10-4 and rs72755233 in ADAMTS17, beta=-0.016, 
p=5.7×10-8), while the BF%-raising allele near LYPLAL1 was nominally associated with higher 
BMI (rs11118310, beta for BMI =0.009, p=1.6×10-5) (Figure 3.14 B and C).  
 
 
Figure 3.14: scatter plots of effect sizes of the 16 genetic loci associated with BF% and FFMI beyond BMI, on BF%, 
FFMI and BMI. A| Effect sizes on BF% versus FFMI, B| Effect sizes on BF% versus BMI, C| Effect sizes on FFMI versus 
BMI. All effect sizes are aligned to the BF%-raising allele. Effect sizes on BMI were estimated in a GWAS including the European 
ancestry participants of UK Biobank. For variants in red, the observed effect was significantly higher than the predicted effect for 
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The majority of genetic loci for BMI have proportionate effects on fat and lean mass 
Given that a subset of the BF% and FFMI loci were associated with fat or lean mass beyond BMI, 
I next assessed if there are loci which have been reported with BMI with disproportionately strong 
effect sizes on either fat or lean body mass. Based on the GWAS results, I assessed the effect sizes 
of the 620 genetic loci reported for BMI with p≤5×10-9 reported by Yengo et al.172 on BF% and 
BMI. Of the 620 loci, 130 reached genome-wide significance for both BF% and FFMI, while 106 
and 193 reach genome-wide significance only for BF% and FFMI, respectively (Figure 3.15). The 
vast majority of the BMI loci had directionally consistent, nominally significant effects on BF% 
and FFMI (Bonferroni corrected p for 620 tests ≤8.1×10-5). However, 23 BMI variants were 
associated with FFMI (p for FFMI ≤8.1×10-5) but had no effect on BF% (p for BF% >0.05): 
JAZF1, BC021693, GAB2, DOCK3, MMP16, NEK6, L3MBTL3, ATP2B1, EIF4G1, LINC01286, 
TBX15, SMG6, ITIH1, MSL2, CEP120, CAST, NADK, ANAPC4, ZC3HAV1, KCNH2, 
CCNL1, SLC9B1 and VIL1. Seven other BMI loci were only associated with higher BF% (p for 
BF% ≤8.1×10-5) but not with FFMI (p for FFMI >0.05): LYPLAL1, DNAH10, ZNF664, PEPD, 
GFPT1, CDK5RAP3 and HOXA13. PPARG (sentinel variant rs1899951) was the only BMI locus 
which had significant effects on BF% and FFMI in opposite directions. The BMI raising allele at 
the PPARG locus was associated with higher BF% (beta±SE on SDs of BF% =0.028±0.002, 
p=1.2×10-36) but lower FFMI (beta±SE on SDs of FFMI =-0.009±0.002, p=3.1×10-5), which 
means that the BMI raising effect of this locus (beta±SE on SDs of BMI =0.017±0.002,  
p=3.1×10-12) is entirely driven by fat mass.  




Figure 3.15: Effect sizes of 620 genetic loci reported for BMI on fat-free mass index and body fat percentage. Per-allele 
effect sizes on standard deviations of BF% or FFMI are aligned to the BMI-raising alleles. Variants in green reached genome-wide 
significance (p≤5×10-9) for both BF% and FFMI, variants in yellow only reached genome-wide significance for BF%, variants in 
blue only reached genome-wide significance for FFMI and variants in black did not reach significance for either phenotypes.  
As a next step, I identified the BMI variants which disproportionately affected BF% and/or FFMI 
by comparing the observed effect size on BF% and FFMI with the predicted effect size based on 
the correlation of BMI with BF% and FFMI (Figure 3.16). For 10 of the 620 genetic variants for 
BMI, the observed effect size on BF% was significantly (p ≤8.1×10-5) lower than the predicted 
effect size (rs9816226 in JAZF1, rs10497807 near BOLL, rs905938 in ZBTB7B, rs13021737 near 
TMEM18, rs12446632 in LOC105371116, rs3751813 in FTO, rs8047395 in FTO, rs663129 near 
MC4R and rs9816226 near ETV5 and rs9922708 in FTO), which indicates that these BMI loci 
more strongly influence lean than fat mass (Figure 3.16, left panel). For 101 other BMI loci, the 
observed effect on BF% was weaker than the predicted effect at nominally significance (pdiff<0.05). 
No BMI variants had disproportionately large effect sizes on BF% at Bonferroni-corrected 
significance, but for 4 loci the observed effect size on BF% was disproportionately large at nominal 
significance (pdiff<0.05): rs10408013 in PEPD (pdiff=0.030), rs11118308 near LYPLAL1 
(pdiff=0.0011), rs1899951 in PPARG (pdiff=6.5×10-4) and rs7133378 in DNAH10 (pdiff=0.0056).  
5 of the 620 BMI loci had a significantly lower observed effect size on FFMI than predicted based 
on the observational correlation between BMI and FFMI and the effect size of the BMI variants 
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TUFM and rs9922708 in FTO (Figure 3.16 right panel). These 5 loci affect fat mass more strongly 
than lean mass, given the observational correlation between BMI and FFMI. For 54 of the 620 
BMI loci, the observed effect size on FFMI was lower than the expected effect size at nominal 
significance. None of the BMI loci were more strongly associated with FFMI than predicted at 
Bonferroni-corrected significance, but for 3 loci (rs9816226 in JAZF1, pdiff=0.013; rs905938 in 
ZBTB7B, pdiff=0.039; and rs10497807 near BOLL, pdiff=0.011) the observed effect size was larger 
than the expected effect size at nominal significance. Overall, evidence was found that 4 BMI loci 
were disproportionately associated with BMI through BF% (PPARG, DNAH10, CELF1 and 
TUFM) and that 8 BMI loci were disproportionately associated through FFMI (JAZF1, BOLL, 
ZBTB7B, TMEM18, LOC105371116, MC4R, ETV5 and FTO), while no strong evidence was 
found for disproportionate effects on fat or lean mass for all other 148 BMI loci. 
 
 
Figure 3.16: Scatter plots of observed versus expected effect sizes of the loci for BMI on BF% and FFMI. All effect sizes 
are aligned to the BMI-raising allele. The predicted effect size reflects the expected effect size on A| BF% or B| FFMI if the 
association with BF% or FFMI is proportionate to the effect size on BMI, given the observational correlations of BMI with BF% 
and FFMI, respectively. The observed effect sizes on BF% and FFMI come from the meta-GWAS results. For variants in dark 
and green, the observed effect size was smaller than the predicted effect size on Bonferroni-corrected significance (p≤8.1×10-5) 
and nominal significance, respectively. For variants in pink, the observed effect size was larger than the predicted effect size at 
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20 low-frequency coding variants identified as likely causal variant for association 
with BF% or FFMI 
Low-frequency coding variants associated with BF% 
31 low-frequency coding variants (MAF <5%) reached genome-wide significance for BF%, based 
on meta-analyses of the UK Biobank GWAS with the European exome chip data or the published 
GWAS results by Lu et al.88 (Supplementary Table 3.8). Three of the 31 coding variants were rare 
(MAF <1%) and had strong effect sizes on BF%: The missense variant rs148330006 in CYR61 
(MAF=0.8%, per-rare allele beta=0.055, p=4.1×10-12), the stop gained variant rs114285050 in 
GPR151 (MAF=0.8%, beta=-0.048, p=5.5×10-10) and the stop gained variant rs150090666 in 
PDE3B (MAF=0.1%, beta=0.151, p=2.6×10-9). The low-frequency missense variant rs74580294 
in MLXIP only reached significance in the women-only analyses (MAF=4.96%, per-rare allele 
effect on BF%=-0.039, p=5.4×10-11). 23 of the 31 coding variants were also genotyped in UK 
Biobank, and effect sizes of the genotyped variants correlated perfectly (Pearson’s correlation 
coefficient =0.9997) with those of the imputed variants (Supplementary Figure 3.2). For 8 of the 
31 coding variants, evidence was found that they were associated with BF% independently of 
common variants in the region, based on individual-level data-based conditional analyses (Table 
3.2). Among these 8 variants were the 2 rare stop gained variants in PDE3B and GPR151. Six of 
the 8 independently associated coding variants were themselves sentinel variants for BF%. Coding 
variants in ARHGAP17 and MC4R were not selected as sentinel variants in the GWAS but were 
independently associated with BF% in the exact conditional analyses.  
Low-frequency coding variants associated with FFMI 
44 low-frequency coding variants reached genome-wide significance for FFMI in the meta-analyses 
of the GWAS in Europeans of UK Biobank and the European ancestry exome chip meta-analyses 
(Supplementary Table 3.9). One missense variant only reached significance in the analyses in men 
(rs77169818 in GALR1, MAF=4.6%, beta per rare allele=-0.042, p=1.7×10-10) and 5 missense 
variants were rare (rs141374503 in ADAMTS3, MAF=0.4%, beta per rare allele=0.075, p=2.6×10-
12; rs61744853 in ZMYM6, MAF=0.9%, beta=0.044, p=4.1×10-10; rs78727187 in FBN2, 
MAF=0.6%, beta=-0.057, p=5.8×10-11; rs41290587 in SPARC, MAF=0.7%, beta=0.051, 
p=3.0×10-10; rs149615348 in CRISPLD2, MAF=0.7%, beta=0.049, p=5.6×10-10). For the 33 of the 
44 variants that were also genotyped in UK Biobank, the associations of the genotyped variants 
with FFMI correlated perfectly (Pearson’s correlation coefficient = 0.9999) with the associations 
of the imputed variants (Supplementary Figure 3.3). 14 low-frequency and 3 rare coding variants 
remained with FFMI associated after conditioning on the common sentinel variants within 1 Mb 
of the coding variant, of which one was specific for men (rs77169818 in GALR1) and 3 were rare 
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(rs61744853 in ZMYM6, rs141374503 in ADAMTS3 and rs78727187 in FBN2) (Table 3.2). 4 of 
the 17 independently associated coding variants were not among the selected sentinel variants for 
FFMI, i.e., the coding variants in ZBTB7B, NSD1, R3HDM2 and MC4R. Collider bias analyses 
showed that the associations of rs141374503 in ADAMTS3 and rs145878042 in RAPGEF3 with 
FFMI were solely driven by their associations with height and were therefore omitted from further 
analyses.  
 




EAF Gene Trait 
BF% FFMI 
Beta±-SE p Beta±-SE p 
Sex-combined analyses 
rs61744853 1:35,453,651 C/A 0.009 ZMYM6 FFMI 0.007±0.337 0.34 0.044±0.007 4.1E-10 
rs141845046 1:154,987,704 T/C 0.023 ZBTB7B FFMI -0.004±0.005 0.35 0.034±0.005 8.8E-14 
rs11722554 4:5,016,883 A/G 0.038 CYTL1 FFMI -0.009±0.004 0.012 0.026±0.004 1.4E-13 
rs1229984 4:100,239,319 T/C 0.025 ADH1B BF% -0.032±0.005 4.6E-11 0.021±0.005 4.5E-06 
rs61749613 5:82,815,170 G/A 0.041 VCAN BF%, FFMI -0.030±0.004 5.5E-17 0.038±0.003 8.4E-30 
rs78727187 5:127,668,685 T/G 0.006 FBN2 FFMI 0.043±0.009 3.3E-06 -0.057±0.009 5.8E-11 
rs114285050 5:145,895,394 A/G 0.008 GPR151 BF% -0.048±0.008 5.5E-10 -0.029±0.007 7.3E-05 
rs78247455 5:176,722,005 A/G 0.026 NSD1 FFMI 0.005±0.005 0.29 0.033±0.004 7.7E-15 
rs41271629 6:86,257,229 G/T 0.029 SNX14 FFMI -0.003±0.004 0.47 0.025±0.004 3.0E-10 
rs62621812 7:127,015,083 A/G 0.022 ZNF800 FFMI -0.008±0.005 0.13 0.046±0.005 5.5E-22 
rs150090666 11:14,865,399 T/C 0.001 PDE3B BF% 0.151±0.025 2.6E-09 0.030±0.024 0.21 
rs1126930 12:49,399,132 C/G 0.036 PRKAG1 FFMI 0.009±0.004 0.019 0.031±0.004 4.7E-18 
rs78607331 12:57,648,644 T/C 0.045 R3HDM2 FFMI 0.015±0.004 1.2E-05 0.020±0.003 7.5E-10 
rs61754230 12:72,179,446 T/C 0.02 RAB21 BF% 0.032±0.005 1.9E-10 0.023±0.005 2.9E-06 
rs28929474 14:94,844,947 T/C 0.02 SERPINA1 FFMI 0.015±0.005 0.0039 -0.042±0.005 3.9E-18 
rs12595158 15:62,316,035 T/C 0.025 VPS13C BF%, FFMI -0.030±0.005 3.8E-09 0.029±0.005 7.5E-10 
rs78457529 16:24,950,880 T/C 0.012 ARHGAP17 BF%, FFMI 0.039±0.006 1.5E-09 -0.046±0.006 3.3E-14 
rs2229616 18:58,039,276 T/C 0.02 MC4R BF%, FFMI -0.068±0.005 1.0E-40 -0.065±0.005 3.1E-39 
rs62621197 19:8,670,147 T/C 0.037 ADAMTS10 BF%, FFMI -0.025±0.004 1.7E-09 0.041±0.004 5.7E-27 
Men-only analyses 
rs77169818 18:74,980,601 T/A 0.046 GALR1 FFMI -0.005±0.007 0.55 -0.042±0.007 1.7E-10 
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Associations of coding variants for BF% and FFMI with related anthropometric and 
metabolic phenotypes. 
Evidence was found that 20 low-frequency and rare coding variants were the likely causal signals 
in the genomic region for BF% and/or FFMI. Of the 20 variants, 5 reached genome-wide 
significance for both BF% and FFMI: rs12595158 in VPS13C, rs2229616 in MC4R, rs78457529 
in ARHGAP17, rs62621197 in ADAMTS10, and rs61749613 in VCAN. The former two 
(VPS13C and MC4R) were associated with BF% and FFMI in the same direction, while the latter 
3 (ARHGAP17, ADAMTS10 and VCAN) affected the phenotypes in opposite directions. 
However, some uncertainty remains if the variants in VPS13C and VCAN are the causal variants 
in the region because conditional analyses for BF% and FFMI gave contradictory results. For 
VPS13C, conditional analyses for FFMI indicated that this association was not independent of 
common variants in the region, despite the independent association found for BF%. Similarly, the 
coding variant in VCAN was found to be independently associated with FFMI but not with BF%.  
4 of the 20 likely causal coding variants only reached genome-wide significance for BF%, including 
the rare stop gained variant in PDE3B, which was the only coding variant for BF% not also 
nominally associated with FFMI (p for BF%>2.1×10-3). Two of the coding variants for BF% were 
nominally associated with FFMI in the same direction (RAB21 and GRP151), while ADH1B had 
an opposite effect on FFMI. Of the 11 coding variants reaching genome-wide significance for 
FFMI only, 9 did not reach nominal significance for BF% (p>2.1×10-3) (ZMYM6, ZBTB7B, 
CYTL1, NSD1, SNX14, ZNF800, PRKAG1, SERPINA1 and GALR1), while R3HDM2 had a 
directionally consistent effect on BF% and FBN2 affected BF% in the opposite direction. 
 
To characterise the broader anthropometric and cardiometabolic implications of the coding 
variants for BF% and FFMI, cross-trait associations were assessed for the coding variants which 
were covered in previous exome chip projects on anthropometric and cardiometabolic risk factors 
and diseases. Look-ups were available for all but 3 (PDE3B, MC4R, ADAMTS10) of the 19 coding 
variants reaching significance in the sex-combined analyses (Figure 3.17).  
Cross-trait look-ups of the coding variants revealed heterogeneous association patterns of the 
BF% and FFM-altering variants with cardiometabolic risk factors and diseases (Figure 3.17). For 
a subset of the 16 loci, including ZBTB7B, VCAN, CYTL1, RAB21 and GPR151, the alleles 
associated with higher BF% and/or lower FFMI were associated with higher cardiometabolic risk 
factors or disease risk, or vice versa, which is in line with evidence from observational 
epidemiological research. The FFMI-raising, low-frequency variant in ZBTB7B (rs141845046, 
c.670C>T, p.Pro224Ser, beta=0.034, p=8.8×10-14) has previously been reported for higher BMI 
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(beta=0.047, p=4.2×10-13) and taller height (beta=0.058, p=7.3×10-17). However, the variant did 
not affect BF% (beta=-0.004, p=0.35), which indicates that the association of ZBTB7B with BMI 
is only due to higher lean mass. Suggestive, non-significant associations with lower LDL (beta=-
0.025, p=0.0026) and total cholesterol (beta=-0.020, p=0.013) suggest that the high lean mass 
associated with ZBTB7B may have a metabolically favourable effect. VCAN (rs61749613, 
c.1045A>G, p.Lys349Glu) was associated with lower BF% (beta=-0.030, p=5.5×10-17) and higher 
FFMI (beta=0.038, p=8.4×10-30) but not with BMI (beta=0.012, p=0.03), and was also nominally 
associated with a favourable lipid profile: higher HDL cholesterol (beta=0.030, p=7.1×10-6) and 
lower total triglycerides (beta=-0.028, p=3.4×10-5). The rare, stop gained variant in GPR151 
(rs114285050, c.283C>T, p.Arg95Ter) was more strongly associated with lower BF% than with 
lower FFMI and has also been reported for lower BMI. While no associations with cardiometabolic 
disease risk were identified in published exome chip studies, a recent study by Emdin et al. on 
associations of rare loss-of-function mutations with cardiometabolic phenotypes reported 
suggestive associations of the rare nonsense mutation in GPR151 with lower risk of T2D (per-
allele OR for T2D=0.86, p=0.006) and CHD (per-allele OR for CHD=0.91, p=0.01)303. Other 
examples include CYTL1, of which the FFMI-increasing variant was associated with lower total 
cholesterol, and RAB21, which increases BF% more strongly than FFMI and is associated with 
higher total and LDL cholesterol.  
However, for other coding variants, including ZNF800, PRKAG1, SERPINA1 and PDE3B, the 
BF%-increasing and/or FFMI-decreasing allele was inversely associated with cardiometabolic 
phenotypes or disease risk, or vice-versa. ZNF800 (rs62621812, c.307C>T, p.Pro103Ser) was 
associated with higher FFMI (beta=0.046, p=5.5×10-22) and was associated with BMI (beta=0.021 
, p=0.0012) through lean mass only (BF%: beta=-0.006, p=0.20). Positive associations with LDL 
(beta=0.032, p=3.3×10-4) and total cholesterol (beta=0.028, p=9.5×10-4) indicated that this lean 
mass locus may have a metabolically adverse effect. Similarly, PRKAG1 (rs1126930, c.293C>G, 
p.Thr98Ser) was associated with BMI (beta=0.039, p=2.6×10-11) through lean mass (FFMI: 
beta=0.031, p=5.5×10-22) but not through body fat (BF%: beta=0.009, p=0.016), and was 
associated with an metabolically unfavourable blood lipid profile, i.e., with higher triglycerides 
(beta=0.026 , p=7.7×10-4) and lower HDL cholesterol (beta=-0.038 , p=7.0×10-7). The rare, stop 
gained variant in PDE3B was strongly associated with higher BF% but not with FFMI. This variant 
was not covered in published exome chip data, but in the study by Emdin et al., a suggested inverse 
association with CHD risk was found (per-allele OR for CHD=0.65, p=0.03)303. The CHD-
protective effect of the BF%-raising, rare allele may be due to increased body fat storage in the hip 
region, as indicated by the strong, inverse association with WHR and WHRadjBMI (Figure 3.10). 
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Finally, the missense mutation in SERPINA1 (c.1096C>T, p.Glu366Lys), which was associated 
with lower FFMI (beta=-0.042, p=3.9×10-18), has been described as a causal mutation for a severe 
form of alpha-1-antitrypsin deficiency304 – a recessive, monogenetic condition which leads to high 
risk of lung emphysema and chronic liver disease305 and, in the more severe cases, shortened 
lifespan306. The minor, FFMI-lowering allele was also associated with taller height (beta=0.120, 
p=1.4×10-45) but not with BMI (beta=-0.014, p=0.09) or BF% (beta=0.013, p=0.023). Although 
the rare allele was associated with higher LDL (beta=0.081, p=4.3×10-14) and total cholesterol 
(beta=0.078, p=5.5×10-14), a nominal, inverse association with lower CHD risk (OR=0.889, 
p=0.0014) and a suggestive association with lower risk of T2D have been reported (OR=0.922, 
p=0.0026). This at first sight contradictory association pattern can be a consequence of the 
shortened lifespan or more intense clinical monitoring of the risk allele carriers.  
 
 
Figure 3.17: Heat plot of reported associations of independent low-frequency and rare coding variants for FFMI and 
BF% with related anthropometric and metabolic traits and diseases. Z scores are aligned to the rare allele. Associations 
highlighted with a yellow asterisk reach genome-wide significance (p<5×10-9) and associations highlighted with a green asterisk 
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Discussion 
In this chapter, I aimed to identify genetic factors specifically associated with overall body fatness 
and leanness, using BF% and FFMI as the respective phenotypes, in order to enable genetics-
based causal assessments of total body composition phenotypes as aetiological risk factors for 
cardiometabolic diseases. To this end, large-scale genetic discoveries through exome chip analyses 
and GWAS were conducted, and loci for BF%, FFMI or BMI with disproportionately strong effect 
sizes on total body fat or lean mass were identified through an approach that integrated genetic 
associations with BF%, FFMI and BMI and observational relationships between the 3 traits. I 
furthermore aimed to characterise association patterns of the low-frequency coding variants that 
were identified as the likely causal signals for FFMI and BF%, with related anthropometric and 
cardiometabolic phenotypes. 
 
BF% and FFMI are highly heritable traits with no strong evidence for sex-
dimorphic genetic control 
In the thus far largest genetic discoveries for BF% and FFMI, 673 novel genetic loci for BF% and 
783 loci for FFMI not previously reported for total lean body mass were identified. Despite the 
strong observational and genetic correlations of both BF% and FFMI with BMI, only around 30 
to 35% of the identified loci for BF% and FFMI were reported in the latest meta-GWAS for BMI 
in up to 700,000 participants172.  
Although we confirmed the salient sex differences in overall body composition, no strong evidence 
was found that BF% and FFMI are controlled by distinct genetic factors in men and women. This 
is in line with findings from GWAS on BMI, in which the vast majority of loci had similar effect 
sizes in women and men and very few sex-specific loci have been identified172,217. In contrast, 
GWAS on WHR and WHRadjBMI found that the difference in fat distribution between men and 
women307 was also reflected by the identified genetic loci, of which nearly half were found to have 
sex-dimorphic effects308,309. Sherman et al.310 recently identified 300 million base pairs, accounting 
for 10% of the estimated total size of the human genome, which do not map to the current 
reference sequence of the human genome. It is therefore possible that genetic signals driving the 
sex dimorphism in BF% and FFMI may be located on parts of the genome which are currently 
not yet queried because they are missing from the human genome reference sequence upon which 
array-based genome-wide genotyping and imputation are based. 
The estimated SNP-based heritability for BF% was very similar to the heritability for BMI, i.e., 
approximately 23% for BF% and 22% for BMI, while the heritability estimated for FFMI was 
higher (30%). However, the estimated heritability for FFMI was likely to be substantially increased 
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by loci which were only associated with FFMI through height, of which the latter is highly 
heritable, with a SNP-based heritability of around 48%172. Therefore, the higher estimated SNP-
based heritability for FFMI than for BF% is unlikely to reflect a true, higher heritability of lean 
than fat mass. Zillikens et al. reported a SNP-based heritability for total lean mass of around 43%, 
although the inclusion of different covariates and a different analytical approach302 does not allow 
direct comparison between the published and our heritability estimates.   
 
The importance of interpreting loci for BF% and FFMI in the context of 
associations with BMI and other standard anthropometric risk factors 
BF% and FFMI were chosen as the phenotypes representing fat and lean mass, respectively, 
because they are only moderately correlated, despite each having a strong but distinct relationship 
with BMI. While FFMI is linearly associated with BMI, the relationship of BF% with BMI was 
curvilinear, with stronger variation and increases per BMI unit in BF% at the lower end of the 
BMI scale than at the higher end. Individuals with a high BF% typically have a higher BMI and 
therefore also higher absolute levels of lean mass311, as higher total body weight due to higher BMI 
and/or taller height, acts as a chronic overload stimulus on the muscles, which leads to higher 
muscle mass and strength312. Overweight and obesity are therefore typically positively associated 
with both BF% and FFMI. However, the observational and genetic relationships between BF% 
and FFMI are weaker than their respective correlations with BMI are, because BF% represents 
total fat adjusted for total body weight while FFMI represents lean mass adjusted for height. As 
total body weight and height are weakly correlated at a population level, this results in a modest 
but curvilinear relationship between BF% and FFMI. However, for a given BF%, a large variation 
in FFMI was observed, especially among individuals with a high BF%.  
 
Because BF% and FFMI are strongly correlated with BMI and moderately with each other and 
other standard anthropometric risk factors, genetic loci identified for BF% or FFMI need to be 
interpreted in the context of their associations with the other trait as well as with standard 
anthropometric risk factors, in order to obtain a full overview of their effects on body size and 
composition. Despite the positive observational and genetic correlations between BF% and FFMI, 
only a third of the 1,216 loci identified for BF% and/or FFMI in the sex-combined analyses had 
directionally consistent effects on BF% and FFMI, while 307 and 416 genetic loci were specific to 
BF% and FFMI, respectively, and 92 loci had opposite effects on BF% and FFMI. In line with the 
strong observational and genetic correlations with BMI, 4 out of 5 of all loci identified for higher 
BF% or FFMI also reached at least nominal significance for BMI with concordant effect sizes, 
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with the exception of two BF%-raising loci in/near COQ10B and ADAMTS17 and the FFMI-
raising locus near LYPLAL1, which were nominally associated with lower BMI.  
 
A third of the BF% loci was also positively associated with WHR but most of these associations 
disappeared after adjusting for BMI, which mirrors the strong observational and genetic 
correlations of BF% with WHR but not with WHRadjBMI. However, loci in/near RSPO3, 
VEGFA and DNAH10 were associated with higher BF% and have been reported for lower WHR 
with and without adjustment for BMI308,309. This indicates that these loci drive higher body fat by 
an absolute increase in fat mass accumulation in the hip region. Although all three loci are 
associated with higher overall adiposity, each of these has been linked to lower metabolic risk factor 
levels, including lower fasting insulin94 and total triglycerides and higher HDL cholesterol76,214 
and/or lower risk of T2D16,37,46. The associations of the BF%-increasing loci with higher 
distribution of body fat to the hip region and lower cardiometabolic risk provide evidence that 
genetic loci for adiposity do not have uniformly detrimental effects on cardiometabolic health and 
that the inverse associations of adiposity-raising loci with cardiometabolic risk factors and diseases 
may be at least partly mediated by positive associations with fat accumulation in the hip region but 
not in the waist. These findings corroborate the hypothesis that having a high capacity to store fat 
in the gluteo-femoral region has a protective effect against cardiometabolic diseases, even in the 
context of high overall adiposity, as has been suggested in the literature79.  
 
The genetic determinants of “normal weight adiposity” 
The strong correlations of BF% and FFMI with BMI suggested that many loci reaching genome-
wide significance for BF% and FFMI may simply represent BMI, without disproportionately 
affecting fat or lean mass. In this chapter, I adopted a quantitative approach to identify genetic loci 
which affect fat or lean mass disproportionately, by re-appropriating the method proposed by 
Aschard et al. to test for collider bias299. The vast majority of the genetic loci identified for BF% or 
FFMI had proportionate effect sizes on fat and lean mass and thus represented BMI. However, 
strong evidence was found that 16 loci had disproportionately strong effects on BF%, of which 
11 were also disproportionately strong and inversely associated with FFMI. Only one of the 16 
loci (LYPLAL1) reached nominal significance for higher BMI and 6 others reached nominal 
significance for lower BMI; this indicates that the identified loci may represent the molecular 
determinants of a body composition pattern characterised by higher relative adiposity and lower 
relative lean mass in the absence of an elevated BMI259. To the best of our knowledge, these 16 
loci represent the first reported genetic determinants of “normal weight adiposity”, which has in 
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observational epidemiological research been proposed as an aetiological pathway to 
cardiometabolic diseases. Variants in lysophospholipase-like protein 1 gene (LYPLAL1) have 
previously been reported for higher insulin resistance and waist-to-hip ratio, but it is the first time 
that this locus has been reported for disproportionately high body fatness and low leanness, while 
only modestly affecting BMI.  
5 of the 16 loci with disproportionate effect on BF% were loci located near genes encoding 
enzymes of the A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) 
family: ADAMTS3, ADAMTS10, ADAMTS14, ADAMTS17 and ADAMTSL3. These secreted, 
matrix-associated metallo-endopeptidases play multiple roles in tissue morphogenesis and all exert 
their function by regulating the structure and function of the extracellular matrix313. Several 
members of the ADAMTS family have been linked to fat distribution308,309 (ADAMTS3, 
ADAMTS9, ADAMTSL3) and height172,314 (ADAMTS3, ADAMTS10, ADAMTS17, 
ADAMTSL3), but also to metabolic risk factors (ADAMTS3, ADAMTS10), cardiovascular 
disease (ADAMTS1, ADAMTS4, ADAMTS5) and cancers313.  
Further research is required to identify the molecular mechanisms through which loci in genes of 
the ADAMTS family and in other identified regions increase relative fatness and/or reduce relative 
lean body mass without increasing BMI. Conducting phenome-wide associations and targeted, 
more detailed cross-trait associations on refined anthropometric and cardiometabolic phenotypes 
will be the first step to characterise the identified loci. Through fine-mapping of the identified loci, 
hypotheses about the causal variant(s) in the regions can be generated, which can enable functional 
in vitro and in vivo studies, to elucidate the physiological and molecular mechanisms driving normal 
weight adiposity.   
 
BMI loci driven by fat but not lean mass have been reported for lower 
cardiometabolic risk 
The same strategy as for the BF% and FFMI was applied to investigate if there are loci reported 
for BMI for which the association is predominantly driven by either fat or lean mass. The vast 
majority of loci reported for BMI had proportionate effects on fat and lean mass, with the 
exception of 7 loci, which all had modest effect sizes on BMI. Compelling evidence was found 
that ZBTB7B, JAZF1 and BOLL were associated with higher BMI only through affecting lean 
mass, while loci in PPARG, DNAH10, PEPD and LYPLAL1 affected BMI only through fat mass. 
Despite their disproportionate effects on higher adiposity, PPARG, LYPLAL1, PEPD and 
DNAH10 have all been associated with lower insulin resistance79,94 and PPARG and PEPD have 
been reported for lower risk of T2D16,37,40. However, the BF%-increasing alleles at all 4 loci have 
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also been reported for higher fat distribution to the lower body, which has been proposed to have 
protective effects against cardiometabolic disease. Our findings corroborate this hypothesis that 
higher lower body fat could be a protective factor against cardiometabolic conditions, even in the 
context of overall higher adiposity, and emphasise the importance interpreting overall higher body 
fat in combination with body fat distribution, both in the context of clinical assessment and of 
genetic research on anthropometric risk factors.  
The major BMI loci in FTO, MC4R and TMEM18 were also identified as loci for both BF% and 
FFMI in the present study. Our analyses suggested that these BMI loci may have larger effects on 
lean than on fat percentage, although this disproportionately is minor in magnitude but did still 
reach statistical significance due to the large effect sizes of the three loci on BMI, BF% and FFMI.  
 
Implications of the collider bias affecting the genetic discovery for FFMI 
In a recent study, Aschard et al. provided evidence that collider bias may occur in a GWAS for an 
outcome adjusted for a heritable covariate which is correlated with the outcome299. Concretely, this 
means that false positive genetic associations for the outcome may be identified if the genetic 
variant is only associated with the covariate but not with the unadjusted outcome. As FFM and 
height are strongly correlated and both heritable172,302, we tested for collider bias in the GWAS 
results for FFMI. Using a novel adaptation for quadratic covariates to the approach proposed by 
Aschard et al., we found strong evidence for collider bias in the GWAS on FFMI, with associations 
of more than 13% of the FFMI loci that reached genome-wide significance being solely driven by 
associations with height. We have however not tested collider bias for variants which did not reach 
genome-wide significance. Testing for collider bias for larger groups of variants which met a lower 
significance threshold would have increased the multiple testing burden and would thus have 
further decreased the power of a statistical test that is already limited in its power due to the 
uncertainty on 3 phenotypes that needs to be taken into account. Therefore, look-ups of genetic 
variants in our summary-level GWAS results for FFMI, which we intend to make publicly 
available, always need to be carefully interpreted and in the context of associations with FFM and 
height. 
This finding also raises questions about the role of collider bias in other GWAS adjusted for height 
or height squared, in particular for BMI, in which collider bias has thus far not been systematically 
investigated. If collider bias affects GWAS on BMI similar to GWAS on FFMI, then several of 
the currently known BMI loci may not be truly associated with overweight or obesity. 
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Low-frequency coding mutations for BF% or FFMI  
In this chapter, I presented the first exome chip meta-analyses for BF% and FFMI, of which the 
results were meta-analysed with the GWAS in UK Biobank. This resulted in the identification of 
34 and 44 low-frequency coding variants reaching genome-wide significance for BF% and FFMI, 
respectively. Through exact conditional analyses conducted in UK Biobank, I found evidence that 
only 20 of all 67 low-frequency coding variants were the likely causal variant in the region. This 
emphasises the importance of interpreting low-frequency coding variants in the context of GWAS 
results, as has previously also been demonstrated for coding variants associated with T2D40. 5 of 
the 20 causal low-frequency variants were associated with both BF% and FFMI, 14 with FFMI 
only and one with BF% only. Heterogeneous association patterns of the BF%-increasing and/or 
FFMI-decreasing alleles with cardiometabolic risk factors were identified, with some showing 
associations with higher cardiometabolic risk factors (ZBTB7B, VCAN, CYTL1, RAB21 and 
GPR151), while the for other variant the fat-increasing or lean mass-decreasing alleles were 
associated with lower cardiometabolic risk (ZNF800, PRKAG1, SERPINA1 and PDE3B). 
Particularly interesting findings were the missense variant in ZBTB7 associated with FFMI only, 
the nonsense mutation in PDE3B which strongly affected BF% and the pathogenic mutation in 
SERPINA1.  
The low-frequency coding variant in Zinc finger and BTB domain-containing protein 7B 
(ZBTB7B) was identified as a likely causal variant for higher FFMI. Although this variant has 
recently been reported for BMI280, our findings indicate that the association with BMI was only 
driven by higher lean mass. ZBTB7B encodes a zinc finger-containing transcription factor, which 
was recently identified as one of the driving factors of the development of brown adipose tissue 
and cold-induced beige fat in murine models315. In humans, brown adipose tissue has been linked 
to lower overall fat mass316, but its association with lean mass is unknown. However, brown 
adipocytes have been shown to originate from the same cellular lineage as skeletal myocytes317, but 
it is unclear if ZBTB7 also promotes myocyte development.  ZBTB7 has also been reported to 
inhibit type 1 collagen gene expression in the skin318 and regulates T cell fate in the thymus319. The 
suggestive associations of the lean mass-increasing allele with lower blood lipids suggest that this 
lean mass-increasing locus may have a cardioprotective effect, although no associations with T2D 
or CHD were found. Further analyses are needed to investigate if ZBTB7B could be a potential 
drug target for treating sarcopenia and reducing cardio-metabolic disease risk. First, it needs to be 
determined which components of fat-free mass – skeletal muscle, bone and non-muscle lean mass 
– are directly affected by ZBTB7B. This can be done by assessing the genetic associations with the 
3 distinct components of fat-free mass, and through tissue-specific gene expression and eQTL 
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analyses. If these analyses suggest that ZBTB7B influences skeletal muscle mass, in vitro and in vivo 
experiments will be needed to investigate if ZBTB7B plays a role in skeletal muscle development, 
maintenance and/or function and how increasing the activity or expression of ZBTB7B alters 
cardio-metabolic phenotypes.   
The rare stop gained mutation in phosphodiesterase 3B (PDE3B) which was predicted to have 
deleterious effects on protein function and structure was recently described by Emdin et al. in a 
study of loss-of-function variants in UK Biobank303. Based on the identified inverse associations 
with CHD risk, physician-prescribed lipid-lowering medication and WHR, Emdin et al. proposed 
PDE3B as a novel potential target for the treatment of CHD. In this chapter, we link PDE3B for 
the first time to higher overall body fatness and BMI, but not to lean mass. Our findings in 
combination with previously published results indicate that loss of PDE3B leads to higher overall 
BMI and body fat but may decrease cardiovascular risk by promoting distribution of fat to the hip 
region over the central region. PDE3B encodes a phosphodiesterase that is expressed in several 
tissues involved in energy homeostasis, such as adipose tissue, the pancreas and liver320, and 
regulates metabolic processes by breaking down the second messengers cyclic AMP and cyclic 
GMP. PDE3B has been identified as a key intermediate through which insulin exerts its anti-
lipolytic action in adipocytes321 and  was found to enhance glucose-induced insulin secretion by 
pancreatic β cells322.  Furthermore, PDE3B knock-out mice were found to gain less weight on a 
high-fat diet, carry less fat tissue and developed more brown adipose tissue323. Although these in 
vitro and in vivo experiments clearly indicate a role for PDE3B in adiposity, our finding that the 
nonsense mutation in PDE3B causing a truncated, likely non-functional gene product is strongly 
associated with higher BF% seems to be opposite to the experimental findings which suggest that 
non-functional PDE3B increases lipolysis and reduce fat mass. Further research on the potential 
of PDE3B as a novel target of cardiometabolic diseases is needed and should seek to clarify the 
seemingly opposite findings from observational genetic research on humans  and functional 
studies on cell and rodent models.  
The low-frequency missense mutation in serpin family A member 1 (SERPINA1) reached 
genome-wide significance for lower FFMI, taller height and higher LDL and total cholesterol. 
SERPINA1 encodes alpha-1-antitrypsin, which is a member of the serine protease inhibitors, a 
class of proteins responsible for inhibiting the activity of certain enzymes.  Alpha-1-antitrypsin 
inhibits the activity of elastases secreted by neutrophils in lungs, which prevents damage to the 
connective tissue in the lungs305. The mutation that reached significance for lower FFMI is known 
to be a pathogenic mutation that causes a severe form of alpha-1-antitrypsin deficiency, a recessive 
condition characterised by lung emphysema and, in some cases, liver cirrhosis. Duckers et al. 
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reported lower lean mass in patients with alpha-1-antitrypsin deficiency compared to unaffected 
individuals324. Sarcopenia is likely to be a mere consequence of the reduced ability to engage in 
physical activity due to the restricted lung capacity. However, findings by Heinzelmann et al. 
showed that patients with alpha-1-antritrypsin deficiency showed less skeletal muscle adaptation 
to exercise as compared to patients with chronic obstructive pulmonary disease due to other 
causes325. Further research is needed to determine if SERPINA1 has a primary function in body 
composition and to clarify the role of sarcopenia in the pathophysiology of alpha-1-antitrypsin 
effect of pathogenic mutations in SERPINA1 on reduced lean mass.  
 
Strengths and limitations 
With a sample size of up to more than half a million participants, the unprecedented scale at which 
the genetic discoveries for BF% and FFMI were conducted and thus the power to identify genetic 
associations is one of the major strengths of the study presented in this chapter.  The 5- and 10-
times larger sample sizes compared to the previous GWAS for BF% and lean mass, respectively, 
led to the identification of 673 not previously reported for BF% and 783 not previously reported 
for FFMI. Secondly, I set out a framework for a systematic and quantitative assessment of the 
extent to which loci identified for fat and lean mass merely reflect BMI or, alternatively, 
disproportionately affect fat and lean mass, beyond BMI. Finally, exact conditional analyses were 
systematically conducted for all low-frequency coding variants reaching genome-wide significance, 
which allowed us to distinguish coding variants which were the likely causal variant in the region 
from coding variants hitchhiking on a GWAS locus without themselves being causal.  
While conducting a genetic study in one large biobank has the advantage that all data is collected 
and processed in a more uniform manner than is typically the case when data from multiple cohorts 
are meta-analysed, this also has the disadvantage that findings may be population or even study-
specific. As UK Biobank is unique in its scale and availability of genome-wide data imputed to 
three LD reference panels, we could not replicate our findings in an independent study. Secondly, 
BF% and FFMI were derived from a BIA-based body composition assessment. While BIA has the 
advantages of being a cheap, quick and non-invasive technique, which are attractive characteristics 
for any type of measurement that needs to be conducted on half a million participants, BIA is a 
less accurate technique for analysing body composition than certain imaging-based techniques 
such as dual-energy X-ray absorptiometry (DEXA) or magnetic resonance imaging (MRI), as it 
has been shown to systematically underestimate body fat. However, the systematic 
underestimation of body fat by BIA is unlikely to have influenced the findings, as BF% and FFMI 
were rank-based inverse normally transformed. A final limitation is that BIA does not allow to 
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distinguish fat-free muscle mass from the fat-free mass made up by the internal organs and bones. 
As muscle mass only represents about half of the total lean mass326, genetic loci identified for FFMI 
do not only reflect muscle mass but also represent variation in the mass of the internal organs and, 
to a much lesser extent, bone mass. FFMI loci of specific interest may therefore need to be 
replicated using gold-standard methods, i.e., MRI or computerised tomography (CT).   
Conclusion and future research directions 
The genetic determinants of BF% and FFMI were found to largely coincide with the genetic 
factors driving BMI. However, by systematically integrating genetic findings of multiple 
anthropometric phenotypes, subsets of genetic variants with disproportionately strong effects on 
fat and/or lean mass were identified, including 15 genetic loci associated with disproportionately 
high fat mass in the absence of overweight. Furthermore, evidence was found that the associations 
loci for high BF% with cardiometabolic risk factors is highly dependent on the pattern of fat 
distribution associated with the locus, as evidenced by the identification of multiple loci associated 
with higher BF% but with lower central-to-lower body fat distribution and lower cardiometabolic 
risk factors and/or disease risk.  
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Collaborations and contributions 
In this chapter, I describe an ongoing project that focuses on the genetic determinants of fat and 
lean mass compartments based on DEXA imaging. GWAS for 9 fat compartments and 7 lean 
mass were conducted in 5 cohorts, including the Fenland, EPIC-Norfolk, ORCADES, Oxford 
Biobank and UK Biobank studies. I conducted all analyses described in this chapter myself, with 
the exception of the study-level GWAS in the Oxford Biobank, which were conducted by Dr 
Matthew Neville (Oxford Centre for Diabetes, Endocrinology and Metabolism, University of 
Oxford) and the study-level GWAS in ORCADES, which were conducted by  Katherine 
Kentistou (Centre for Global Health Research, Usher Institute of Population Health Sciences and 
Informatics, University of Edinburgh).  
 
Publications related to this chapter 
§ M. J. Neville, L. B.L. Wittemans (co-first author), K. E. Pinnick, M. Todorčević, R. Kaksonen, 
K. H. Pietiläinen, J. Luan, R. A. Scott, N. J. Wareham, C. Langenberg, F. Karpe. Regional fat 
depot masses are influenced by protein-coding gene variants. Under review at PLoS ONE  
This project was conducted in collaboration with Prof Fredrik Karpe and Dr Matthew Neville 
(Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford) and 
focused on the identification and functional characterisation of protein-coding variants 
associated with 6 fat mass compartments adjusted for BF%. I designed the genetic analyses 
and conducted exome chip analyses in two cohorts, conducted exome chip meta-analyses, 
annotated the identified coding variants and interpreted the findings in the context of the 
existing literature on the genetic determinants of anthropometric and cardiometabolic 
phenotypes. As different decisions were made in terms of the included covariates, the findings 
from this paper cannot be directly compared to the GWAS results presented in this chapter. 
Therefore, the decision was made to exclude the exome chip from the thesis. 
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§ L. A. Lotta, L. B. L. Wittemans, [15 authors], C. Langenberg. Specific genetic determinants 
of gluteo-femoral and abdominal fat distribution and risk of type 2 diabetes and 
cardiovascular disease. JAMA 320(24), 2553-2563 (2018). 
This project sought to identify genetic factors specifically associated with abdominal and 
gluteo-femoral fat mass and to assess the independent unconfounded effect sizes of central 
and lower body fat on risk of cardiometabolic disease, based on the identified genetic 
instruments. I contributed to the genetic discovery for WHR and waist and hip circumference 
in UK Biobank by preparing the phenotypes for analysis, identifying the independent, 
significant loci and generating plots of the GWAS results. I furthermore assessed the 
associations of the loci for WHR, waist and hip with compartmental fat phenotypes based on 
DEXA imaging and contributed to the manuscript.  
 
§ C. Hilton, M. J. Neville, L. B. L. Wittemans, [12 authors], F. Karpe. MicroRNA-196a links 
human body fat distribution to adipose tissue extracellular matrix composition. Under 
review at EBioMedicine. 
This study sought to characterise the function of microRNA-196a in body fat distribution 
through a combination of in vitro functional studies and in silico genetic analyses. I contributed 
to this study by assessing the associations of eQTL signals for microRNA-196a with body fat 
compartments in the Fenland, EPIC-Norfolk and UK Biobank studies. 
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Abstract 
Background: Waist-to-hip ratio (WHR) is a prominent cardiometabolic risk factor that increases 
disease risk independently of BMI. However, the role of other patterns of fat distribution and of 
regional lean mass as cardiometabolic risk factors is largely unknown. Identifying the genetic 
determinants of regional fat and lean mass forms a first important step towards assessing the 
causality of refined patterns of fat and lean mass distribution on cardiometabolic disease risk. 
 
Aims: This chapter aims to (1) identify the genetic determinants of absolute and relative levels of 
fat and lean mass in different compartments of the body and (2) to assess fat and lean mass 
distribution patterns associated with the identified genetic loci. 
 
Methods: (1) Meta-analyses of GWAS were conducted for 9 fat and 7 lean mass compartments 
and included up to 25,452 participants from 5 cohorts. Analyses for absolute fat and lean mass 
compartments were adjusted for age, sex and genetic principal components only, while analyses 
for relative fat and lean mass compartments were additionally adjusted for total fat mass and height 
squared, respectively. (2) The heterogeneity of the effect sizes of genetic loci associated with 
absolute fat or lean mass compartments across all compartments was assessed based on the 
Cochran’s Q statistic. Fat and lean mass distribution patterns of the identified loci for relative and 
absolute fat and lean compartments were assessed based on hierarchical clustering applied to the 
associations across all compartments.  
 
Findings: (1) 34 and 13 independent genetic loci reached genome-wide significance for absolute 
and relative lean mass compartments, respectively, while 11 and 51 genetic loci were identified for 
absolute and relative fat compartments. FTO was the only locus associated with both fat and lean 
mass compartments. (2) 38 of the 51 loci reaching genome-wide significance for relative fat mass 
compartments were associated with a higher central-to-lower body fat distribution pattern that is 
highly similar to WHR. The 38 loci had consistent positive effects on all central fat compartments 
with the exception of subcutaneous android fat mass, and consistent, negative effects on the leg 
and gynoid fat compartments but not on arm fat mass. An inverse correlation between the effect 
sizes of the central fat-increasing alleles on visceral versus subcutaneous android fat adjusted for 
total fat mass was found. 7 loci were identified for higher arm fat adjusted for total fat, of which 
two loci (PPARG and SPATA20) were also associated with absolute fat mass in the arms but not 
in any of the other compartments. For lean mass, no heterogeneity in the effect sizes on the 7 
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different lean mass compartments was found for any of the 34 and 13 genetic loci reaching 
genome-wide significance for absolute or relative lean mass compartments, respectively.  
 
Conclusion: Although the majority of loci associated with relative regional fat mass represented 
WHR, a subset of the identified loci was associated with other patterns of fat distribution. Loci 
with strong effect sizes on arm but not on leg fat mass were identified, which indicates that 
peripheral fat mass in the upper and lower limbs is controlled by distinct genetic factors. Genetic 
loci identified for absolute levels of regional fat mass tend to have heterogeneous effects across 
different body fat compartments. Conversely, all loci identified for lean mass compartments had 
similar effects across all lean mass compartments, which suggests that lean mass in the different 
regions of the body is controlled by shared genetic factors. 
Chapter 4: The genetics of fat and lean mass compartments 
 143 
Introduction 
Fat distribution is a major independent risk factor for cardiometabolic disease 
Despite the well-established role of overall adiposity as an aetiological risk factor for T2D and 
cardiovascular diseases21,253, strong differences in cardiometabolic risk have been observed between 
individuals who are overweight or obese327,328.  Fat distribution, and central fat accumulation in 
particular, has been proposed as an important driver of differences in cardiometabolic risk among 
individuals with generalised adiposity327,329,330. Central fat accumulation, usually measured by waist-
to-hip ratio (WHR) or WHR adjusted for BMI (WHRadjBMI), has been shown to be a prominent 
risk factor of cardiometabolic diseases independently of overall adiposity85,331,332. Central fat is 
distributed over two compartments, i.e., so-called “visceral fat” that is stored in the abdominal 
cavity, and subcutaneous fat. The distribution over the visceral and subcutaneous compartments 
is highly variable between individuals and between men and women. Research suggests that it is 
mostly through the former that central fat accumulation deteriorates insulin sensitivity and 
increases cardiometabolic risk factor levels30,330,332, but simple indices of fat distribution, such as 
WHR or waist circumference, cannot distinguish visceral from subcutaneous fat.  
Gluteo-femoral fat as an independent, protective factor against T2D and CHD 
Studies on the cardiometabolic sequelae of high WHR have predominantly focused on the 
numerator of the ratio and considered the denominator, i.e., hip circumference, merely as a 
correction factor for overall body size. More recently, interest in the role of hip circumference 
independent of waist as an aetiological factor has grown, after observational epidemiological 
research associated higher hip circumference with lower risk of cardiometabolic disease30,327,333,334. 
In a few genetics-based studies,  higher hip circumference was suggested to be causally related to 
lower risk of cardiometabolic diseases79,335. Our recent causal investigation based on genetic 
instruments specific for waist and hip, corroborated this hypothesis and found a strong, protective 
effect of higher hip circumference and gluteo-femoral fat against CHD and T2D, independent of 
overall BMI and waist circumference336. These findings emphasise that both central and lower 
body fat play an aetiological role in cardiometabolic disease risk and raise the question about the 
metabolic relevance of fat accumulation in other regions of the body that are not represented by 
WHR.  
Lean mass distribution patterns and their metabolic sequelae are largely unknown 
The extensive research on fat distribution and its relationship with cardiometabolic disease risk 
has thus far not been mirrored by a similar research interest in the metabolic role of lean mass 
distribution patterns. Studies on lean mass distribution have mostly focused on sarcopenia in the 
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context of aging337,338, bone mineral density339 and rare neurological340 and musculoskeletal 
conditions341. Differences in absolute and relative lean mass and lean mass distribution have been 
described between men and women, with the strongest relative difference being found for muscle 
mass in the arms342. Evidence for pronounced differences in lean mass distribution between 
women of different ethnicities has been reported339. Few studies to date have attempted to identify 
metabolic risk profiles associated with different patterns of lean mass distribution. Hamasaki et al. 
reported that higher lean mass in the lower extremities relative to total body weight or lean mass 
in the upper extremities was associated with a better blood lipid profile in patients with T2D338. 
Overall, the variation in lean mass distribution and its role as a metabolic risk factor in the general 
population remains unclear.   
Imaging techniques for regional body composition assessment  
Imaging techniques such as dual-energy X-ray absorptiometry (DEXA), computerised 
tomography (CT) and magnetic resonance imaging (MRI), allow for accurate measurement of fat, 
lean and bone mass in specific regions of the body. MRI and CT are considered the “gold-
standard” techniques for measuring fat and lean mass compartments but are not routinely used 
for whole-body scans in large-scale epidemiological studies because of the lack of software tools 
to efficiently process whole-body images, the high cost and time investments and, for CT, concerns 
about radiation exposure.  
DEXA is a non-invasive, two-dimensional imaging technique which is considered the gold-
standard method for bone densitometry but has more recently also been used to measure overall 
and regional fat and lean mass. DEXA technology uses the differences in attenuation of X rays at 
two different energies as they pass through bone or lean versus fat tissue to estimate bone mineral, 
fat and lean mass, for the whole body and by region. Although DEXA does not allow direct 
measurement of visceral fat mass, software packages have been developed which allow estimation 
of visceral fat mass and volume, based on measured total android fat and estimated subcutaneous 
fat in the android region. In epidemiological studies, DEXA-based measures of body composition 
have been shown to correlate more strongly with metabolic risk factors than traditional 
anthropometric risk factors, such as BMI and waist and hip circumference30.  
In a recent validation study based on 4,753 participants of UK Biobank343, total fat and lean mass 
and visceral fat mass measured by DEXA were compared with estimates based on MRI. DEXA 
and MRI measurements correlated very well for total body fat (R=0.99, prediction error standard 
deviation relative to the mean (CV) = 4.5%) and lean tissue (R=0.97, CV=4.6%), but visceral fat 
measured by MRI diverged more substantially from visceral fat predicted by DEXA (R=0.94, 
CV=21%)343. The main advantages of DEXA over MRI and CT is that it is a relatively low-cost 
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and high-throughput technique which causes a much lower radiation exposure to the participants 
than CT imaging. Furthermore, image processing for DEXA has become efficient and 
straightforward with the software packages developed by the manufacturers of DEXA 
instruments, while constraints on processing the large numbers of images generated by MRI 
imaging have limited the use of MRI for whole-body composition analysis. An important limitation 
of DEXA imaging is that it does not have sufficient spatial and contrast resolution to detect ectopic 
fact, such as fat infiltration in the liver and muscles. 
Genome and exome-wide association studies on WHR and refined anthropometric 
phenotypes 
The genetic determinants of fat distribution have been extensively studied through GWAS308,309 
and exome chip analyses292 for WHR and WHRadjBMI. GWAS in up to 695,000 individuals, 
mostly of European ancestry, have led to the identification of more than 460 loci associated with 
WHR308,309. Strong evidence for distinct genetic factors controlling fat distribution in men and 
women was found, with nearly half of the loci identified for WHR having sex-discordant 
effects308,309, of which the majority had stronger effect sizes or only reached significance in women. 
WHR was also found to be more heritable in women (SNP-based heritability estimate of 26%) 
than in men (17%)309. Adipogenesis, angiogenesis and insulin resistance have been identified 
through genetic enrichment analyses as the prominent physiological processes linked to WHR308. 
To our knowledge, no previous studies aiming to systematically characterise the genetic 
determinants of all fat and lean mass compartments have been conducted. However, a series of 
genetic discoveries on highly refined adiposity phenotypes based on CT imaging have been 
conducted in up to 18,300 participants of multiple ancestries. The studied phenotypes included 
ectopic fat, such as pericardial fat, visceral and subcutaneous fat volume and fat attenuation –  an 
index for adipocyte size, lipid content and maturity – have been conducted344–346. Through GWAS, 
multiple genetic loci, including regions in/near ATXN, TRIB2, UBE2E2, EBF1, RREB1, 
GSDMB, GRAMD3 and ENSA, were identified for ectopic fat traits.  Interestingly, none of these 
loci reached significance in the at the time largest GWAS for BMI217 or WHR308, which indicates 
that ectopic fat may be controlled by genetic factors that are distinct from those controlling overall 
adiposity and fat distribution in the adipose tissues.  
 
Zillikens et al. conducted genome-wide association analyses for appendicular lean mass, i.e., the 
combined lean mass in the legs and arms, which serves as a proxy for total muscle mass302. Loci in 
IRS1, ADAMTSL3 and VCAN reached genome-wide significance for appendicular lean mass. 
However, all three loci had nearly identical effect sizes on total lean mass, for which a GWAS was 
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conducted in the same study. This suggests that the three identified loci were not specific to 
appendicular lean mass but instead act on overall lean mass.  
Opportunities, objectives and outline 
In recent years, DEXA-based body composition analysis has been adopted in several 
epidemiological cohort studies, and is currently being undertaken in 100,000 UK Biobank 
participants, as part of the UK Biobank imaging study343. However, large-scale genetic studies of 
regional body composition traits measured by DEXA have not yet been conducted. Through 
identifying the genetic factors that influence specific body fat and lean mass compartments, the 
molecular mechanisms driving fat and lean mass in specific regions of the body can be identified, 
genetic loci known for standard anthropometric phenotypes can be characterised in terms of the 
body compartments they affect the most, and genetic instruments for specific body fat and lean 
mass compartments can be constructed, which, in turn, can enable causal investigations of  
patterns of fat and lean distributions as aetiological factors for cardiometabolic diseases. 
In the final research chapter of this thesis, I aim to identify the genetic determinants of absolute 
and relative fat and lean mass in distinct compartments of the body and to assess fat and lean mass 
distribution patterns associated with the identified genetic loci. As an introduction, I investigate 
relationships between the fat and lean mass compartments and in relation to standard 
anthropometric phenotypes in a healthy middle-aged population of more than 10,000 individuals. 
I then describe the results of the first genome-wide genetic discoveries for 16 fat and lean mass 
compartments measured by DEXA, which were in the initial stage of this ongoing project 
conducted for the sexes combined only, as has traditionally been done in the initial genetic 
discoveries for novel phenotypes. 
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Methods 
DEXA-based assessment of whole-body and regional body composition 
All cohorts included in the genome-wide association studies made use of DEXA technology to 
assess overall and regional body composition. DEXA-based body composition analysis is based 
on whole-body X ray images of the bone and soft tissues. Seven body regions (android region, 
gynoid region, legs, arm , trunk, head and pelvis), some of which partially overlap, were 
automatically demarcated by the software developed by the manufacturers of the DEXA 
instruments79,347 and were manually checked and corrected if necessary. The head region is defined 
by the area above the horizontal line that touches the base of the skull. A line through the gleno-
humeral joint and the crease of the axilla demarcates the arm region. The pelvic region is defined 
by a horizontal line that touches the upper edge of the iliac crest and diagonal lines that cut through 
the acetabulofemoral joints. The trunk region includes the entire upper body and pelvic regions 
without the head and arms regions. The leg region includes the entire area below the pelvic region. 
The android region is defined as the area between horizontal line on top of the iliac crest and a 
second line at a distance equal to 20% of the total distance between the iliac crest and the base of 
the skull. The gynoid region partly overlaps with both the legs and trunk regions. Its upper 
horizontal edge is placed at a distance of 1.5 times the height of the android region from the iliac 
crest and its lower edge is at a distance of 2 times the height of the android region from the upper 
edge. Visceral fat mass was estimated by measuring the thickness of the subcutaneous fat in the 
android region and subtracting the estimated subcutaneous android fat mass from the total android 
fat mass.  
 
GWAS were conducted for fat mass in the arms, legs, trunk, gynoid region, android region, 
subcutaneous android region, visceral region and for total body and peripheral fat mass, and for 
lean mass in the arms, legs, trunk, gynoid region, android region and total body and appendicular 
lean mass. Peripheral fat and appendicular lean mass were calculated by adding up the arm and leg 











The participants and the design of the Fenland study and genome-wide genotyping and imputation 
procedures have been described in the methods section of Chapter 2. DEXA imaging was 
performed on 11,869 participants (6,396 women) of the Fenland study, using the Lunar Prodigy 
advanced fan beam scanner (GE Healthcare, Madison, Wisconsin, USA). The manufacturer’s 
enCORE software (version 14.10.022, GE Healthcare) was used to identify the regions and 
estimate overall and regional fat and lean masses. Scanning was performed by trained operators 
and the images were manually reviewed by a researcher, who discarded images of low quality due 
to movement artefacts or positioning errors and manually adjusted the boundaries defining the 
regions placed by the software where necessary. DEXA variables on 11,741 participants (6,334 
women) passed QC. Related individuals were identified on the basis of the identity-by-descent 
(IBD) statistic computed in PLINK208,349. Individuals with IBD > 10% were excluded from 
genome-wide analyses. In total, DEXA and genome-wide genetic data on 10,309 participants 




The study design, participants and genotyping and imputation procedures for the EPIC-Norfolk 
study have been described in Chapter 1. Whole-body DEXA scanning and processing and quality 
control of the images was conducted using the same instruments, software and protocols as for 
the Fenland study. DEXA imaging was conducted on 5,568 participants, of which 5,547 
participants (3,098 women) passed QC. Related individuals were excluded if IBD> 10%, which 
resulted in 4,440 participants (2,441 women) with DEXA and genome-wide data included in the 
genome-wide association analyses.  
Oxford Biobank 
The Oxford Biobank includes more than 8,000 participants living in Oxfordshire (United 
Kingdom)30. Participants were randomly invited to participate in the study based on all individuals 
on the UK National Health Service population registry who were between 29 and 55 years of age 
and free of any known chronic diseases. Whole-body DEXA imaging using the GE Lunar iDXA 
machine was performed as part of a health assessment, and images were processed using the 
enCORE software (version 14.0; GE Healthcare, Bucks, UK). Genome-wide genotyping was 
performed using the Affymetrix UK Biobank Axiom array and genome-wide genotyped data were 
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imputed to the HRC LD reference panel. Participants of non-European descent were identified 
based on a scatter plot of the first two genetic principal components of the Oxford Biobank 
participants, calculated in PLINK, versus those of the CEU, YRI and CHB/JPT reference panels 
from 1000 Genomes phase 3, and were omitted from the analyses. DEXA and genome-wide data 
were available for 4,572 participants, of which 2,603 were women.  
Orkney Complex Disease Study 
The Orkney Complex Disease Study (ORCADES) is set in the Orkney Isles of northern Scotland 
and is a cross-sectional, family-based epidemiological study focusing on the genetic determinants 
of complex diseases350. Ethical approval for this study was given by the local research ethics 
committee and all participants provided informed consent. The participants underwent whole-
body DEXA scans using the Hologic QDR4500 densitometer machine and images were processed 
using the manufacturer’s APEX4 software. During the image processing, images were excluded if 
the regions could not be correctly identified due to low quality of the scans. Fat and lean mass 
measures >5 SDs from the mean were omitted. Genome-wide genotyping was done in two phases. 
Panel A consisted of 890 participants and was genotyped using the Illumina HumanHap300v2. 
The Illumina OmniX or Omni1 were used to genotype panel B which was comprised of 1,300 
participants. Only variants represented on both the OmniX and Omni1 array were retained for 
analyses. SNPs were omitted if the call rate <98%, MAF <0.01 or Hardy-Weinberg equilibrium 
(HWE) p-value <10-6. Duplicate samples were removed, and individuals of non-European ancestry 
were identified and excluded based on a scatter plot of the first two genetic principal components 
anchored in the 1000G phase 3 CEU, YRI and CHB/JPT reference panels. Imputation to the 
HRC LD reference panel was done for panels A and B separately. Up to 1,194 women and 785 
men participating in ORCADES were included in the analyses.  
UK Biobank 
As part of the ongoing UK Biobank Imaging Study351, which has the aim to conduct detailed 
imaging on 100,000 participants of the UK Biobank study, whole-body DEXA scans using the 
GE-Lunar iDXA (GE Healthcare, Madison, Wisconsin, USA) are conducted343. DEXA images 
are processed using the GE enCORE software by the DEXA operator during or shortly after the 
imaging is completed. DEXA data on 5,170 participants (2,713 women), which passed QC 
conducted by UK Biobank, were available at the time the analyses were conducted. As an 
additional QC step, DEXA data were omitted if the total weight estimated by DEXA deviated 
more than 2.5% from the weight measured using scales on the day that DEXA imaging was 
conducted, as this suggests that the participant’s body was not entirely within the scanning area. 
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This led to a total number of 4,995 participants (2,604 women) who passed DEXA QC. Details 
on genotyping, imputation and quality control have been described in Chapter 2. Analyses in UK 
Biobank were restricted to participants of European ancestry, as current sample sizes for non-
European ancestries with available DEXA data are very low. DEXA and genome-wide data were 
available for 4,707 participants (2,463 women) of European ancestry. Genotyping, imputation, 






Genetic discovery for fat and lean mass compartments 
Phenotype transformations 
All DEXA traits were analysed with minimal adjustments and with adjustment for total fat mass 
for the fat compartments, and for height squared for the lean compartments. For the minimally 
adjusted analyses, the traits were first natural log-transformed and then adjusted for age and study-
specific covariates. Additional adjustment for total fat mass or height for the fat and lean mass 
compartments, respectively, were done for the fully adjusted models. The residuals of these linear 
regression models were rank-based inverse normally transformed. Transformations were done for 
men and women separately. 
Study-level genome-wide association analyses 
In the Fenland and EPIC-Norfolk studies, GWAS adjusted for the first four genetic principal 
components were conducted using BGENIE v1.2213. For the Fenland study, separate GWAS for 
the Genome-Wide Human SNP Array, the UK Biobank axiom array and the CoreExome array 
were run. In the Oxford Biobank, GWAS adjusted for the first four genetic principal components 
were conducted using SNPTEST352. As ORCADES is a family-based study, a genetic relatedness 
matrix based on identity-by-state inferred from the genotyping array was calculated and phenotypic 
residuals were calculated using GenABEL353. Genome-wide association analyses adjusted for 
genotyping array were run using RegScan354. GWAS in UK Biobank were adjusted for the first 10 
genetic principal components and genotyping chip and were conducted using BOLT-LMM203. 
Quality control of GWAS 
Variants were omitted if the minor allele count was less than 10, if the variant represented an 
insertion or deletion, if more than two alleles were present for the same chromosome number and 
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base pair position, if the p-value for HWE <10-8 or if the absolute value of the beta or standard 
error was larger than 5. Next, a second-stage quality control was conducted using the R package 
‘EasyQC’289, in which scatter plots of the observed allele frequencies versus the allele frequencies 
from CEU 1000G, scatter plots of the p-values versus the Z scores, quantile-quantile plots and 
λGC plots were generated to identify analytical errors.  
Meta-analyses of the genome-wide association studies 
Fixed-effect meta-analyses of the study-level GWAS results based on the effect sizes and standard 
errors were conducted using METAL205. Variants were dropped from the meta-analyses results if 
they were not available in at least 50% of the maximum sample size and at least half of the included 
datasets, if the maximum difference in effect allele frequency between the studies was larger than 
0.2, if the minor allele frequency <1% or if the absolute value of the effect size or standard error 
was larger than 5. 
Identification and clumping of genetic loci 
Loci and lead variants were first identified within traits, using distance-based clumping. Variants 
with p-value<5×10-8 more than 1 Mb apart were considered to represent independent, genome-
wide significant loci. Based on the significant lead variants for all traits, a second distance-based 
clumping was applied across traits and analyses, to identify the overall number of independent loci 
across traits. Variants which were less than 1 Mb apart were considered to represent the same 
locus. At each locus, the variant selected for the highest number of traits was selected as the 
sentinel variant at the locus. In case any of the other variants was in low linkage disequilibrium 
(R2<0.6 and D’<0.6) then this variant was retained as a secondary signal at the locus. 
 
Annotations, reported associations and cross-trait associations for loci reaching genome-
significance for fat and lean mass compartments 
Sentinel variants were annotated based on the most severe annotation of the variant in the 
Ensembl Variant Effect Predictor (VEP)290. Reported associations for the variants reaching 
genome-wide significance were identified through searches using the PhenoScanner355 and loci 
reported in the largest GWAS for standard anthropometric traits, including BMI172, height172, 
WHR309 and WHRadjBMI309. Associations with BF% and FFMI were based on the GWAS 
described in Chapter 3. Associations of variants not reported for BMI, height, WHR and 
WHRadjBMI but reaching nominal significance were based on GWAS conducted on the UK 
Biobank participants of European ancestry for the respective traits, as described in Chapter 3.  
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Fat and lean mass distribution patterns associated with the loci reaching genome-wide significance 
for fat and lean mass compartments were assessed by visualising and clustering the effect sizes of 
all significant loci across all fat and lean mass compartments using the R package ‘pheatmap’356 
v1.0.10. Hierarchical clustering of both the variants and the body compartments was based on the 
Euclidean distances between the variants and phenotypes.  
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Results 
Body composition by body region in a healthy middle-aged population 
The distribution of fat and lean mass across the different regions of the body was assessed among 
6,316 female and 5,295 male middle-aged, generally healthy participants of the Fenland study. 
Overall and regional fat and lean mass differed significantly between men and women, both on 
the absolute (kilograms (kg) fat, lean or bone mass) and relative scales (percentage of total body 
weight) (Figure 4.2, Table 4.1). In women, fat and lean body mass represent 37.4±6.9% (27.2±9.8 
kg) and 59.3±6.6% (41.3±5.3 kg) of the total body weight, respectively, while in men around 
28.9±5.9% (25.2±8.2 kg) of the total body weight is accounted for by body fat mass and 
67.4±6.9% (57.2±6.8 kg) by lean mass (Table 4.1). While women store half of their total body fat 
in the trunk (18.1±5.1%) and the other half in the peripheral compartments (18.1±2.9%), men 
tend to store a higher proportion in the trunk (16.5±4.4%) than peripherally (11.3±2.1%). The 
distribution of peripheral fat over the legs and arms was similar in men and women, with around 
77% of the total peripheral fat being stored in the legs and the remaining 23% in the arms. Despite 
men and women having similar relative amounts of android fat (men: 2.9±1.0% of total body 
weight, women: 2.8±1.1%), a larger relative proportion of women’s android fat is located 
subcutaneously (2.1±0.6%) than viscerally (0.78±0.60%), while men store approximately equal 
amounts of android fat in the subcutaneous (1.4±0.5%) and visceral (1.5±0.8%) compartments. 
Although men had higher lean mass than women on the absolute and relative scale, the distribution 
of lean mass over the central and appendicular compartments was similar in men and women, with 
appendicular lean mass representing about 45% of the total lean mass. 
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Table 4.1: Overall and regional fat, bone and lean mass for 5,395 men and 6,316 women of the Fenland study, expressed 





p for sex 
difference 
Men % of 
total 
weight±SD 
Women % of 
total 
weight±SD 
p for sex 
difference 
Age (years) 48.64±7.61 48.71±7.43 0.6 - - - 
Weight (kg) 85.54±13.24 70.75±13.76 <2.2E-16 - - - 
Height (cm) 177.43±6.62 163.99±6.31 <2.2E-16 - - - 
Total fat mass (kg) 25.22±8.16 27.16±9.76 <2.2E-16 28.9±5.9% 37.4±6.9% <2.2E-16 
Legs fat mass (kg) 7.45±2.30 10.16±3.39 <2.2E-16 8.6±1.7% 14.1±2.6% <2.2E-16 
Arms fat mass (kg) 2.36±0.71 2.90±0.93 <2.2E-16 2.7±0.5% 4.0±0.07% <2.2E-16 
Peripheral fat mass (kg) 9.81±2.92 13.05±4.17 <2.2E-16 11.3±2.1% 18.1±2.9% <2.2E-16 
Gynoid fat mass (kg) 3.71±1.19 4.96±1.60 <2.2E-16 4.3±0.9% 6.9±1.2% <2.2E-16 
Android fat mass (kg) 2.54±1.15 2.13±1.16 <2.2E-16 2.9±1.0% 2.8±1.1% 0.39 
Visceral fat mass (kg) 1.35±0.82 0.60±0.54 <2.2E-16 1.5±0.8% 0.78±0.60% <2.2E-16 
Subcutaneous fat mass (kg) 1.19±0.54 1.52±0.73 <2.2E-16 1.4±0.5% 2.1±0.6% <2.2E-16 
Trunk fat mass (kg) 14.51±5.50 13.32±5.98 <2.2E-16 16.5±4.4% 18.1±5.1% <2.2E-16 
Total lean mass (kg) 57.17±6.79 41.29±5.28 <2.2E-16 67.4±6.9% 59.3±6.6% <2.2E-16 
Legs lean mass (kg) 20.13±2.78 14.19±2.24 <2.2E-16 23.7±2.2% 20.3±2.2% <2.2E-16 
Arms lean mass (kg) 6.80±1.10 3.93±0.70 <2.2E-16 8.0±0.9% 5.6±0.7% <2.2E-16 
Appendicular lean mass (kg) 26.93±3.71 18.12±2.85 <2.2E-16 31.7±2.8% 25.9±2.7% <2.2E-16 
Gynoid lean mass (kg) 9.12±1.19 6.54±0.90 <2.2E-16 10.7±1.1% 9.4±1.1% <2.2E-16 
Android lean mass (kg) 4.25±0.55 3.14±0.44 <2.2E-16 5.0±0.5% 4.5±0.6% <2.2E-16 
Trunk lean mass (kg) 26.96±3.19 20.45±2.51 <2.2E-16 31.7±3.1% 29.4±3.8% <2.2E-16 
Total bone mass (kg) 3.15±0.38 2.39±0.31 <2.2E-16 3.7±0.4% 3.4±0.5% <2.2E-16 
Legs bone mass (kg) 1.21±0.17 0.85±0.12 <2.2E-16 1.42±0.20% 1.23±0.20% <2.2E-16 
Arms bone mass (kg) 0.45±0.06 0.30±0.039 <2.2E-16 0.53±0.08% 0.43±0.08% <2.2E-16 
Gynoid bone mass (kg) 0.32±0.05 0.23±0.037 <2.2E-16 0.38±0.06% 0.34±0.05% <2.2E-16 
Trunk bone mass (kg) 0.95±0.15 0.72±0.12 <2.2E-16 1.11±0.14% 1.03±0.16% <2.2E-16 
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Figure 4.2: Histograms of the body composition by anatomical region in men and women of the Fenland study. Based 
on DEXA measures of regional fat, lean and bone mass on 11,711 participants (6,316 women). 
 
To assess the extent to which fat and lean mass compartments measured by DEXA are captured 
by standard anthropometric traits, correlations of 6 standard anthropometric traits (weight, height, 
BMI, waist and hip circumference and WHR) with fat and lean mass compartments measured by 
DEXA were assessed in the Fenland study (Figure 4.3). Weight, BMI and waist and hip 
circumference were strongly correlated with all fat compartments (range of Pearson’s correlation 
coefficients for the correlations of total body weight with fat compartments: R = 0.82-0.92; BMI: 
R = 0.74-0.92; waist: R = 0.72-0.90; hip: R = 0.61-0.91), while correlations of WHR with fat 
compartments were moderate (R = 0.27-0.68). Height correlated very weakly with regional fat 
mass (R = 0.01-0.21). Strong positive correlations between all fat compartments were observed (R 
= 0.53-0.98) (Figure 4.3 A).  
The standard anthropometric trait most strongly correlated with lean mass compartments was total 
body weight (range of Pearson’s correlation coefficients of height with lean mass compartments: 
R = 0.74-0.82), and substantial correlations with lean mass were also found for height (R = 0.37-
0.56), BMI (R = 0.54-0.62), and waist (R = 0.51-0.60) and hip circumference (R = 0.55-0.67). Total 
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and regional lean mass were very strongly inter-correlated (R = 0.73-0.99) and also showed 




Figure 4.3: Plots of the correlations between standard and DEXA-based anthropometric traits. The Pearson’s correlation 
coefficients were calculated based on data from 11,711 participants (6,316 women) from the Fenland study for which measurements 
of all included anthropometric traits were available. A| Correlations between anthropometric traits which were only adjusted for 
age and sex. B| Correlations between anthropometric traits which were all adjusted for age and sex, and additionally for BMI 
(waist, hip and waist-to-hip ratio), total body fat mass (fat compartments) or height squared (lean compartments).  
After adjusting compartmental fat mass for total fat mass, no substantial correlations of weight 
(absolute value of R <0.02), height (absolute value of R <0.21) and BMI (absolute value of R 
<0.07) with adjusted fat compartments were found (Figure 4.3 B). Waist and WHR adjusted for 
BMI were positively correlated with relative fat mass in the android (waist adjusted for BMI: R 
=0.35; WHRadjBMI: R =0.52) and visceral compartments (waist adjusted for BMI: R =0.28; 
WHRadjBMI: R =0.46) and inversely with relative fat mass in leg (waist adjusted for BMI: R =-
0.33; WHRadjBMI: R =-0.55) and gynoid compartments (waist adjusted for BMI: R =-0.32; 
WHRadjBMI: R =-0.58), but no correlations of BMI-adjusted waist, hip or WHR with arm (waist: 
R =-0.05, hip: R =-0.13, WHR: R =0.04, p for correlations ranging between 0.56-0.88) and 
subcutaneous android fat adjusted for total fat mass (waist: R =0.02, hip: R =0.09, WHR: R =-
0.02, p for all 3 correlations >0.05) were found. Relative arm and subcutaneous android fat did 
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also not correlate with any of the other fat compartments (p for correlation between 0.62 and 0.95), 
with the exception of a suggestive inverse correlation of subcutaneous android fat with visceral 
android fat (R =-0.43, p=0.06). Total and visceral android fat were positively correlated (R =0.91), 
and were both inversely correlated with lower body fat compartments and total peripheral fat 
(Figure 4.3 B).  
Total body weight and BMI – but not waist, hip or WHR adjusted for BMI – were substantially 
correlated with lean mass compartments adjusted for height squared (total body weight: R =0.65-
76; BMI: R =0.67-0.79). Adjusted lean mass compartments remained strongly inter-correlated (R 
= 0.63-0.98) but did not correlate with adjusted fat compartments (p for correlations between 
adjusted fat and lean mass compartments >0.05) (Figure 4.3 B). 
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Genome-wide association analyses for absolute and relative fat and lean mass 
compartments 
46 independent genetic variants associated with absolute fat or lean mass compartments 
75 variants and 150 associations reaching genome-wide significance (p≤5×10-8) were identified for 
9 fat (legs, arms, trunk, gynoid, total android, subcutaneous android, visceral android, total 
peripheral and total fat) and 7 lean mass compartments (arms, legs, android, gynoid, trunk, 
appendicular and total lean mass) through meta-analyses of GWAS adjusted for age and genetic 
principal components in up to 25,430 participants from 5 cohorts. 45 loci and 46 independent 
variants were identified through cross-trait LD clumping of the 75 lead variants (Figure 4.4, 
Supplementary Table 4.1). 11 of the 46 independent variants were only associated with fat mass 
compartment and 34 were only associated with one or more lean mass compartments. The locus 
near FTO was the only locus associated with both fat and lean mass compartments. FTO reached 
genome-wide significance for higher fat mass in all 9 regions, and with higher total, leg and 
appendicular lean mass and nominal significance for higher lean mass in the other 4 regions 
(p≤1.1×10-3). No heterogeneity in the effect sizes of the FTO locus across the 16 fat and lean mass 
compartments was identified (p for Cochran’s Q statistic = 0.37).  
The genetic effect sizes of the 46 independent variants on lean mass compartments clustered 
separately from the effect sizes on fat compartments when hierarchical clustering was applied to 
the effect sizes of the 46 independent variants on all 16 compartments (Figure 4.4) Overall, effect 
sizes across the lean mass compartments were more similar than effects on the fat compartments. 
Total android, subcutaneous android, trunk and total fat mass clustered separately from leg, gynoid 
and peripheral fat mass. Visceral android and, to a lesser extent, arm fat, clustered less closely with 
the other fat compartments (Figure 4.4).  
 
64 independent variants identified for relative regional fat and lean mass  
64 independent variants across 61 loci and 157 associations reached genome-wide significance in 
meta-analyses of GWAS for 8 fat mass compartments adjusted for total fat mass and 7 lean mass 
compartments adjusted for height squared in up to 25,260 participants from 5 cohorts (Figure 4.5, 
Table 4.2). 13 of the 64 independent variants reached genome-wide significance for one of more 
lean mass compartments adjusted for height squared, while 51 variants were associated with at 
least one the 8 fat compartments adjusted for total fat mass. No variants reached significance for 
both relative fat and lean mass compartments. Hierarchical clustering applied to the effect sizes of 
the 64 variants on all lean and fat mass compartments revealed three main clusters: one for central 
fat compartments, including trunk and total and visceral android fat, one for lower body fat 
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compartments, including leg, gynoid and peripheral fat, and one large cluster which was comprised 
of all lean mass compartments. Subcutaneous android fat clustered more closely with lean 
compartments than with central fat compartments, and relative arm fat clustered separate from 
gynoid, leg and total peripheral fat (Figure 4.5). Of the 51 loci associated with relative regional fat, 
7 loci were only associated with arm fat mass (loci in/near RDH14, PPARG, HOXA10-HOXA9, 
FGFR2, HOXC-AS2, TBX5 and SPATA20), 38 signals showed opposite associations with central 
versus lower body fat, 3 loci reached significance for subcutaneous android fat only (LMX1A, 
WT1 and PIWIL3) and 3 other loci for gynoid fat only (CALCRL, TMCC1 and LY86). 
 
 
Figure 4.4: Heat plot and hierarchical clustering of the loci reaching genome-wide significance for absolute fat and lean 
mass compartments measured by DEXA. Associations of 46 independent variants at 45 loci reaching genome-wide significance 
(p≤5×10-8) for at least one of the 7 lean mass and/or 9 fat mass compartments are represented in this plot. The yellow asterisks 
indicate associations that reach genome-wide significance and colour coding indicates the per-allele effect sizes on SDs of the 
DEXA phenotype. Effect sizes are aligned to the allele with a positive effect size on BMI in the UK Biobank. Phenotypes were 
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Figure 4.5: Heat plot of 64 independent variants associated with fat or lean mass distribution at genome-wide 
significance. Models were adjusted for age, genetic principal components and study-specific covariates, and additionally for total 
fat mass for the fat compartments and for height squared for the lean mass compartments. The colour coding indicates the per-
allele effect size on standard deviations of the phenotypes. Effect sizes are aligned to the allele with a positive effect size on BMI 
in the UK Biobank. Associations reaching genome-wide significance are indicated by yellow asterisks.  
 
Seven genetic loci reach genome-wide significance for arm fat 
Seven genetic loci in/near RDH14, PPARG, HOXA10-HOXA9, FGFR2, HOXC-AS2, TBX5 
and SPATA20 reached genome-wide significance for arm fat mass adjusted for total fat, of which 
the loci in PPARG and SPATA20 also reached significance for absolute arm fat. None of the arm 
fat loci reached genome-wide significance for any other fat or lean mass compartments (Figures 
4.4 and 4.5).  
Three loci in PPARG, SPATA20 and TBX5 for arm fat adjusted for total fat mass were associated 
with a pattern of fat distribution characterised by higher relative fat mass in the arms and less 
relative fat mass in the central compartments, without affecting relative leg fat mass (Figure 4.6). 
The intronic variant rs13064760 (EAF=11.8%) in PPARG was strongly associated with higher 
relative arm fat mass (per-allele effect size on SDs of arm fat mass adjusted for total fat 
mass=0.117, p=2.2×10-17), and reached nominal significance for lower relative android (beta=-
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(beta=0.020, p=0.14) or gynoid fat mass (beta=-0.001, p=0.94). The arm fat-raising allele showed 
suggestive associations with lower android visceral (beta=-0.039, p=5.5×10-3) and subcutaneous 
fat mass (beta=-0.030, p=0.032). The PPARG locus also reached significance for higher absolute 
arm fat mass (sentinel variant rs13083375, EAF=11.8%, in perfect LD with the sentinel variant 
rs13064760 for relative arm fat mass), with a per-allele effect size of 0.086 SDs on arm fat. 
Heterogeneity among the effect sizes of the PPARG locus across all absolute fat compartments 
was identified (p for Cochran’s Q statistic=0.035), which corroborates the effect of PPARG on fat 
distribution. Nominally significant but weaker associations with absolute leg (beta=0.046, 
p=8.1×10-4) and peripheral fat mass (beta=0.059, p=2.1×10-5) were also found, while effect sizes 
on absolute central fat compartments did not reach nominal significance (trunk fat: beta=0.031, 
p=0.025, total android fat: beta=0.027, p=0.054, subcutaneous android fat: beta=0.035, p=0.012, 
visceral android fat: beta=0.020, p=0.14). The arm fat-raising allele at PPARG has been reported 
for higher BMI172 (beta=0.017, p=1.3×10-11) and is known to be associated with lower T2D risk46 
(BMI unadjusted: OR=0.878, p=1.4×10-12; BMI adjusted: OR=0.861, p=1.1×10-11). Variants 
in/near PPARG have been reported for WHRadjBMI308 but these were LD-independent 
(R2=0.03) of the sentinel variant for arm fat mass, which reached nominal significance for lower 
WHR (p=7.4×10-6) but not for WHRadjBMI (p=0.025) in UK Biobank, indicating that the 
association with WHR was mostly driven by its effect on BMI. 
 
The low-frequency, missense sentinel variant in SPATA20 (rs62621401, p.Lys406Arg, 
EAF=98.5%) had a per-allele effect size of 0.391 SDs on arm fat adjusted for total fat mass 
(p=1.4×10-26). Weaker effects on lower relative android (beta=-0.110, p=0.0029), trunk (beta=-
0.119, p=0.0012) and gynoid fat mass (beta=-0.0927, p=0.012) but not on relative leg fat (beta=-
0.007, p=0.85) were observed (Figure 4.6). The missense variant was also associated with higher 
absolute arm fat mass (per-allele effect size on SDs of arm fat mass=0.222, p=1.0×10-9), but did 
not reach significance for other compartments. Weaker, suggestive associations (p<0.05) were 
found with higher total fat (beta=0.076, p=0.036), leg fat (beta=0.073, p=0.045) and peripheral fat 
(beta=0.107, p=0.003), but evidence for heterogeneity in the effect sizes of rs62621401 across the 
absolute fat compartments was found (p for Cochran’s Q statistic=0.012). The variant was not 
associated with BMI (effect size on SDs of BMI per arm fat-raising allele=0.012, p=0.12), height 
(beta=0.010, p=0.24) in published exome chip meta-analyses280,291, nor did it reach significance in 
recently published GWAS309 and exome chip analyses292 for WHR or WHRadjBMI. The SPATA20 
locus was also not associated with BF% in the analyses presented in Chapter 3 of this thesis (beta=-
0.012, p=0.47). A suggestive (p<0.05) inverse association of the arm fat-increasing allele with 
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higher T2D risk (BMI unadjusted: OR=1.03, p=0.031; BMI adjusted: OR=1.02, p=0.14)40 but not 
with CHD risk (OR=1.05, p=0.12)298 has been reported.  
The intronic variant rs2551377 in TBX5 (EAF=16.8%) was associated with higher relative arm fat 
mass (per-allele effect size on SDs of arm fat adjusted for total fat mass=0.132, p=3.4×10-28), had 
suggestive associations with lower relative android (beta=-0.039, p=0.0011), trunk (beta=-0.029, 
p=0.017) and gynoid fat (beta=-0.035, p=0.0039) but was not associated with relative leg (beta=-
0.017, p=0.16), visceral (beta=-0.012, p=0.33) or subcutaneous android fat (beta=-0.021, p=0.085) 
(Figure 4.6). The TBX5 locus has not been reported for BMI, WHR or WHRadjBMI. 
 
HOXA10-HOXA9, RDH14, HOXC-AS2 and FGFR2 were also significantly associated with 
relative arm fat mass but had no effect on total android fat mass (p>0.05) (Figures 4.5 and 4.6). 
None of these 4 loci have been reported for BMI, WHR or WHRadjBMI. HOXA10-HOXA9 
(rs1859164, EAF=53.8%) was associated with higher arm fat mass (beta=0.080, p=7.1×10-19), 
showed weak associations with lower trunk fat (beta=-0.028, p=0.0016) and higher leg fat 
(beta=0.021, p=0.019) but did not affect android (p=0.084), gynoid (p=0.66), visceral (p=0.99) and 
subcutaneous fat (p=0.05). RDH14 (rs11096542, EAF=59.2%) was associated with higher arm fat 
mass (beta=0.050, p=4.0×10-8), reached nominal significance for lower subcutaneous android fat 
(beta=-0.042, p=5.3×10-6) and showed suggestive associations with higher visceral android fat 
(beta=0.023, p=0.011) and lower trunk fat (beta=-0.026, p=0.0049), but not with leg (p=0.59), 
gynoid (p=0.12) or total android fat (p=0.22). HOXC-AS2 (rs1109391, EAF=56.6%) increased 
arm fat (beta=0.050, p=2.5×10-8) while suggestively decreasing subcutaneous android fat (beta=-
0.030, p=0.0010) and increasing visceral android fat (beta=0.018, p=0.042), but not android 
(p=0.30), trunk (p=0.21), leg (p=0.05), or gynoid fat (p=0.33). Rs11199849 at FGFR2 
(EAF=74.8%) reached genome-wide significance for higher arm fat (beta=0.073, p=1.2×10-12), 
nominal significance for lower visceral fat (beta=-0.037, p=3.7×10-4) and showed suggestive 
associations with lower trunk (beta=-0.028, p=0.0063) and gynoid fat (beta=-0.028, p=0.0062) and 
higher subcutaneous android fat (beta=0.022, p=0.033). FGFR2 was not associated with leg 
(p=0.61) or total android fat mass (p=0.062). 
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Figure 4.6: Forest plots of associations of 7 arm fat loci with all 8 fat compartments adjusted for total fat mass. The 7 
presented loci reached genome-wide significance for arm fat only (p≤5×10-8) in GWAS adjusted for age, genetic principal 
components, study-specific covariates and total fat mass. Effect sizes ± 95% confidence intervals are expressed as per-allele betas 
on SDs of fat compartments. 
 
No uniform association pattern of the 7 relative arm fat-raising loci with T2D risk was found, 
based on published T2D GWAS38,219 and exome chip40 summary-level results (Figure 4.7). The arm 
fat-raising allele at rs13064760 (PPARG) reached genome-wide significance for lower T2D risk 
(OR=0.90, p=5.9×10-23), while rs11096542 at RDH14 reached nominal significance (OR=0.97, 
p=3.6×10-4). Suggestive associations of the arm fat-raising alleles at SPATA20 with lower T2D 
risk (OR=0.97, p=0.031) and at HOXC-AS2 (OR=1.02, p=0.040) with higher T2D risk were 





































































−0.050−0.025 0.000 0.025 0.050
HOXC−AS2
Chapter 4: The genetics of fat and lean mass compartments 
 164 
 
Figure 4.7: Scatter plot of effect sizes of 7 arm fat loci on SDs of arm fat adjusted for total fat mass versus log odds for 
T2D. Effect sizes on arm fat mass were adjusted for total fat mass, age, genetic PCs and study-specific covariates. Look-ups for 
T2D came from the summary-level GWAS results by Xue et al.38, except for HOXC-AS2 (Scott et al.46) and SPATA20 (Mahajan et 
al.40). Alleles were aligned to the arm fat-raising allele.  
 
Majority of loci for relative regional fat mass associated with central-to-lower body 
fat distribution 
Loci associated with central-to-lower body fat distribution are captured by WHR 
38 of the 51 loci reaching genome-wide significance for fat compartments adjusted for total fat 
mass were associated with a pattern of higher central-to-lower body fat distribution (Figures 4.5 
and 4.8). Loci were considered to be associated with higher central-to-lower body fat distribution 
if they were associated with at least one relative central fat mass compartment (android or trunk) 
or one relative lower body fat compartment (legs or gynoid region) at genome-wide significance, 
and showed nominally significant associations (Bonferroni corrected significance threshold for 64 
loci associated with relative fat or lean mass compartments: p≤7.8×10-4) in the opposite direction 
with lower or central body fat, respectively. Central-to-lower body fat distribution is also captured 
by WHR and WHRadjBMI, as evidenced by the fact that all but 3 (LINC01134, EMC2 and 
PLA2G6) of the 38 loci have previously been reported for WHR and/or WHRadjBMI308,309. The 
central fat-increasing allele at LINC01134 (rs4073647) reached nominal significance for 
WHRadjBMI (beta=0.012, p=1.7×10-4) but not for WHR (beta=0.0084, p=0.0049) (p≤7.8×10-4 in 
GWAS for WHR and WHRadjBMI in UK Biobank) and was not associated with BF% (beta=-
0.0030, p=0.22) or BMI (beta=-0.0022, p=0.36). The central fat-increasing allele at rs13264315 
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(beta=0.0027, p=0.23) or WHRadjBMI (beta=0.0016, p=0.43). The leg fat-lowering allele at 
PLA2G6 (rs4380, EAF=52.8%) reached genome-wide significance for lower BF% (beta=-0.019, 
p=2.0×10-22) and nominal significance for lower BMI (beta=-0.0066, p=6.5×10-4), but was not 
associated with WHR (beta=-0.0001, p=0.98) or WHRadjBMI (beta=0.0044, p=0.033). 
Five loci for central-to-lower body fat distribution affect absolute leg fat mass only 
5 of the 38 loci (DNAH10, RSPO3, FAM13A, VEGFA and COBLL1) associated with central-
to-lower body fat distribution also reached genome-wide significance for absolute leg fat mass, but 
none of these loci affected central fat mass (p>0.05) (DNAH10: ptrunk=0.13, pandroid=0.24; RSPO3: 
ptrunk=0.97, pandroid=0.64; COBLL1: ptrunk=0.13, pandroid=0.23; FAM13A: ptrunk=0.15, pandroid=0.11; 
VEGFA: ptrunk=0.14, pandroid=0.06). Significant heterogeneity between the effect sizes on the 9 fat 
compartments was observed for all five loci (DNAH10: p for Cochran’s Q statistic=5.9×10-15, 
RSPO3: p=3.1×10-14, FAM13A: p=4.9×10-3, COBLL1: p=1.1×10-3, VEGFA: p=9.6×10-11). These 
findings indicate that the associations of DNAH10, RSPO3, FAM13A, VEGFA and COBLL1 
with relative central-to-lower body fat distribution and WHR is solely driven by leg fat mass, 
without substantial effects on central fat mass.  
 
The effects of WHR loci on visceral versus subcutaneous android fat are inversely 
correlated 
The effect sizes of the 38 loci associated with central-to-lower body fat across all 8 fat 
compartments were assessed and hierarchical clustering was applied (Figure 4.8 A). As expected, 
the effect sizes on lower relative gynoid, leg and peripheral fat mass and the effect sizes on higher 
relative trunk and total and visceral android fat mass clustered together. However, associations 
with relative arm and subcutaneous android fat were generally weaker, followed different patterns 
and formed a separate, third cluster (Figure 4.8 A).  
To further investigate the effects of loci for higher central-to-lower body fat distribution on relative 
visceral and subcutaneous fat mass, I compared the effect sizes on the two separate android 
compartments (Figure 4.8 B). 36 of the 38 loci associated with higher central-to-lower body fat 
distribution were at least suggestively associated with higher relative visceral fat mass (p values 
ranging from 0.037 for HERC1 to 1.4×10-16 for DNAH10). Conversely, 14 of the 38 loci, which 
were all positively associated with visceral fat (p-values between 1.2×10-3 and 2.2×10-10), had no 
effect (LOC646736, ADAMTS9-AS2, CPEB4, HMGA1, MLXIPL, CDCA2, SPON1, AHNAK, 
MACROD1, HCAR2, LINC02210, LINC00310) (p>0.05) or a negative effect (PRKAG3: beta for 
relative subcutaneous fat=-0.064 , p=0.005) on relative subcutaneous android fat. LINC00880 and 
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C5orf67 were the only two loci which did not affect relative visceral fat mass (LINC00880: beta=-
0.0019, p=0.84; C5orf67: beta=0.0102, p=0.36). However, both loci were significantly associated 
with higher relative subcutaneous android fat (LINC00880: beta=0.068, p=6.6×10-13; C5orf67: 
beta=0.094, p=3.5×10-15), which suggests that these two known loci for WHR increase waist 
circumference by acting on the subcutaneous android compartment but not on the visceral 
compartment.  
A weak inverse correlation between the effect sizes of the central-to-lower fat distribution-
increasing alleles on relative visceral and subcutaneous android fat was observed (R = -0.359, 
p=0.027) (Figure 4.8 B). This suggests that WHR loci do not tend to affect visceral and 
subcutaneous android fat similarly. An important exception to this was the intronic variant 
rs577721086 in RSPO3, which had strong positive effect sizes on both relative visceral and 
subcutaneous android fat (visceral: beta=0.147, p=9.9×10-13; subcutaneous: beta=0.059, p=0.005). 
 
 
Figure 4.8: Cross-compartment associations for the 38 loci associated with central-to-lower body fat distribution. A| 
Heat plot and hierarchical clustering of the effect sizes on 8 body fat compartments adjusted for total fat mass for the 38 loci 
associated with higher central-to-lower body fat distribution. The colour coding represents the per-allele effect size on SDs of fat 
compartments adjusted for total fat mass, age, genetic PCs and study-specific covariates. B| Scatter plot of the effect sizes (±95% 
confidence intervals) of the 38 central-to-lower body fat-increasing alleles on subcutaneous versus visceral android fat adjusted for 
total fat mass. The blue line and grey shadow represent the best line of fit ± standard error. 
 
Central-to-lower body fat distribution and risk of type 2 diabetes 
10 of the 38 loci for higher central-to-lower body fat distribution were associated with higher T2D 
risk38,46 (p≤7.8×10-4). All 10 loci were positively associated with relative visceral fat mass (p<0.05), 
of which 5 reached nominal significance (ITPR2, COBLL1, LOC646736, ADAMTS9-AS2, 
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also associated with higher subcutaneous fat (C5orf67, HERC1, COBLL1, ITPR2 and LINC01184) 
while the five other loci (LOC102723886, MACROD1, DNAH10, LOC646736 and ADAMTS9-
AS2) were not associated with subcutaneous android fat (p>0.05). Positive but non-significant 
correlations were observed between the effect sizes of the 38 variants on total android fat and 
T2D risk (R = 0.198, p=0.24) and on visceral android fat and T2D risk (R=0.281, p=0.092), while 
the effect sizes on subcutaneous android fat and T2D risk were negatively but non-significantly 
correlated (R=-0.111, p=0.51) (Figure 4.9). Overall, these findings indicate that loci for central-to-
lower body fat distribution are more likely to increase T2D risk if they are associated with visceral 
fat mass.  
 
 
Figure 4.9: Scatter plots of effect sizes of 38 loci for higher central-to-lower body fat distribution on total, visceral and 
subcutaneous android fat versus T2D risk. All alleles are aligned to the android fat-increasing allele and effect sizes on fat 
compartments are adjusted for total fat mass, age, genetic PCs and study-specific covariates. Associations with T2D risk came from 
Xue et al.38, if available, and from Scott et al.46 when not available in the results by Xue et al. The blue line and grey shadow represent 
the best line of fit ± standard error. Loci in red reached nominal significance for subcutaneous fat only but were not associated 
with visceral fat, loci in yellow reached nominal significance for visceral fat but were not associated with subcutaneous fat and loci 
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6 loci associated with gynoid or subcutaneous android fat 
Finally, 3 loci only reached genome-wide significance for relative gynoid fat mass (rs7586854 near 
CALCRL, rs72628505 in TMCC1 and rs744056 in LY86) and three genetic signals were identified 
for relative android subcutaneous fat only (rs1553607 in LMX1A, rs11031749 near WT1 and 
rs9612738 near PIWIL3). Despite the fact that all 3 loci associated with higher gynoid fat have 
been reported for lower WHR and/or WHRadjBMI, they did not reach nominal significance for 
lower relative android or trunk fat (p>7.8×10-4) (Figure 4.10 upper row). However, all 3 loci did 
reach nominal significance for higher leg fat mass (p≤7.8×10-4), and TMCC1 and LY86 also 
reached nominal significance for lower arm fat mass.  
The subcutaneous android fat-raising loci at LMX1A and WT1 have been reported for 
WHRadjBMI309 but not for BMI (p for BMI in UK Biobank GWAS =0.46 and 0.003, respectively) 
and were also not associated with BF% (p for BF% in UK Biobank GWAS=0.78 and 0.67, 
respectively). The nominally significant effect of LMX1A on total android fat (beta=0.037, 
p=4.0×10-5) was only due to subcutaneous fat, as no association with visceral fat mass (beta=-
0.002, p=0.82) was found. The subcutaneous android fat-raising allele at WT1 had a suggestive 
inverse association with visceral fat mass (beta=-0.028, p=0.010) and a positive association with 
arm fat mass (beta=0.027, p=0.010). Finally, PIWIL3 has not been reported for any of the 
traditional anthropometric traits (pbmi=0.66, pBF%=0.76, pWHR=0.65, pWHRadjBMI=0.85, based on 
GWAS in UK Biobank) and the allele associated with higher subcutaneous android fat did not 
affect visceral fat mass (beta=-0.001, p=0.94) (Figure 4.10, bottom row).  
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Figure 4.10: Forest plots of effect sizes 3 loci for gynoid fat and 3 loci for subcutaneous android fat on fat compartments 
adjusted for total fat mass. The 3 loci on the first row reached genome-wide significance for gynoid fat only and the three loci 
on the second row reached genome-wide significance for subcutaneous android fat only. Results are based on GWAS adjusted for 
age, genetic principal components, study-specific covariates and total fat mass. Effect sizes ± 95% confidence intervals are 
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No evidence for distinct genetic factors driving lean mass in different body 
compartments 
No heterogeneity between the effect sizes on the 7 lean mass compartments was observed for any 
of the 34 loci identified for absolute lean mass compartments (p for Cochran’s Q statistic ranging 
from p=0.18 for GDF5 to p=0.99 for BDNF). 4 of the 34 loci were associated with all 7 lean mass 
compartments (MC4R, ATAD5, CCND2, L3MBTL3) and 7 loci were associated with all 
compartments except lean mass in the arms (GDF5, GH1, LCORL1, TMEM18, CDK6, GHSR, 
MIR588). 5 of the 34 lean mass loci were only significantly associated with trunk lean mass 
(CAVIN4, SDR16C5, EFCAB12, SHC2, E2F1), and OTUD4, LOC644145, FAIM2 and SCMH1 
only reached significance for gynoid, appendicular, leg and arm lean mass, respectively. The 
remaining 14 loci were associated with between 2 and 5 lean mass compartments. Of the 34 lean 
mass loci, 16 have been reported for height172,314 and 8 loci have been reported for BMI172,217, all 
with directionally consistent effects on lean mass and height or BMI. The remaining 5 lean mass 
loci (STAB2, CAVIN4, EFCAB12, PPFIA3 and LOC644145) have not been reported for height 
or BMI. 11 and 7 of the 34 lean mass loci reached genome-wide and nominal significance, 
respectively, for FFMI in the GWAS presented in Chapter 3. 16 loci were not associated with 
FFMI (p>1.1×10-3), of which all but two (CAVIN4: pheight in GWAS UK Biobank=0.67, 
LOC644145: pheight=1.1×10-3) reached genome-wide significance for height in the same direction 
as with lean mass, which suggests that their association with absolute regional lean mass could 
have been driven mostly be height. 
 
Of the 13 loci identified for lean mass compartments adjusted for height squared (SLC2A1, 
SEC16B, LOC105373352, IRS1, LINC00992, PPARD, L3MBTL3, TUBA1C, STAB2, 
ADAMTSL3, GPR139, FTO and MC4R), 6 loci also reached genome-wide significance for 
unadjusted lean mass compartments (TMEM18, IRS1, L3MBTL3, STAB2, FTO and MC4R). 
Although none of the 13 loci reached genome-wide significance for all lean mass compartments, 
all lean loci had directionally consistent effects and reached nominal significance (Bonferroni 
corrected p-value for 64 tests ≤7.8×10-4) across all lean mass compartments, with the exception 
of TUBA1C for arm lean mass (p=0.002) and PPARD for leg lean mass (p=0.0009) (Figure 4.11). 
For none of the 13 lean mass loci heterogeneity was found among the effect sizes on the 7 lean 
mass compartments (Cochran’s Q statistic’s p-value>0.05) (Figure 4.11). 
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Figure 4.11: Forest plots of 13 loci reaching genome-wide significance for at least one lean mass compartment adjusted 
for height squared. Effect sizes are expressed as per-allele beta ± upper and lower 95% confidence intervals on standard deviations 
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8 of the 13 loci for relative lean mass (SEC16B, LOC105373352, LINC00992, PPARD, 
L3MBTL3, ADAMTSL3, GPR139, FTO and MC4R) also reached genome-wide significance for 
FFMI (p≤5×10-9) in the GWAS in UK Biobank presented in Chapter 3, with the same directions 
of effect for lean mass compartments and FFMI. Loci at IRS1 (pFFMI=3.3×10-6) and TUBA1C 
(pFFMI=6.4×10-5) reached nominally significant (p≤7.8×10-4), directionally consistent associations 
with FFMI, but LINC00992 (pFFMI=0.0011), STAB2 (pFFMI=0.017) and SLC2A1 (pFFMI=0.22) were 
not associated with FFMI. 5 of the 13 relative lean mass loci (IRS1, MC4R, L3MBTL3, 
ADAMTSL3 and GPR139) have been reported for height172,314. The lean mass-increasing alleles at 
IRS1 (rs4675093, EAF=93.0%) and MC4R (rs538656, EAF=23.4%) have been reported for taller 
height, while the other three loci had opposite effects on lean mass and height (L3MBTL3, 
ADAMTSL3, GPR139), which suggests their associations with lean mass compartments may have 
partly been driven by the adjustment for height squared. However, collider bias analyses in Chapter 
3 indicated that associations of these 3 loci with FFMI were not solely driven by the adjustment 
for height. 8 of the 13 lean mass loci have been reported for BMI172,217 with directionally consistent 
effect sizes on lean mass and BMI (SEC16B, LOC105373352, PPARD, L3MBTL3, ADAMTSL3, 
GPR139, FTO and MC4R). The lean mass-raising alleles at IRS1 (pbmi=4.5×10-5) and LINC00992 
(pbmi=7.7×10-4) reached nominal significance for higher BMI (p in GWAS for BMI in UK Biobank 
≤7.7×10-4), while loci at SLC2A1 (pbmi=0.19), TUBA1C (pbmi=0.27) and STAB2 (pbmi=0.049) were 
not associated with BMI (p in GWAS for BMI in UK Biobank >7.7×10-4).  
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Table 3.2: 61 loci and 64 variants reaching genome-wide significance for DEXA fat and lean mass compartments adjusted for total fat and height squared, respectively. 
Locus Chr Position 
Sentinel 
variant 
EA OA EAF Nearest genes Phenotype Beta±SE p-value hetpval N 
Lead variant for 
trait (if other than 
sentinel variant)  
1 1 3,830,619 rs4073647 c a 0.860 LINC01134 
Leg fat 0.0729±0.0129 1.6E-08 7.4E-01 25,259  
Peripheral fat 0.0746±0.0129 7.3E-09 8.8E-01 25,260   
2 1 43,443,005 rs7534178 g a 0.836 SLC2A1-AS1 Arm lean 0.0682±0.0121 1.9E-08 2.0E-01 25,256   
3 1 165,221,696 rs1553607 a c 0.528 LMX1A 
Subcutaneous 
android fat 
0.0501±0.009 2.5E-08 8.7E-01 25,177   
4 1 177,843,479 rs2094510 t c 0.208 
LINC01741, 
SEC16B 
Leg lean 0.0603±0.0111 4.9E-08 6.9E-01 25,252   
5 1 219,721,283 rs11118336 c t 0.419 LOC102723886 
Trunk fat -0.05±0.009 3.3E-08 5.7E-01 25,256 rs77962041 
Leg fat 0.0631±0.009 2.8E-12 9.1E-01 25,259  
Peripheral fat 0.0625±0.009 4.7E-12 8.6E-01 25,260  
Gynoid fat 0.0547±0.009 1.5E-09 7.9E-01 25,252 rs4846565 
6 2 610,603 rs2867131 c t 0.832 
LOC105373352, 
TMEM18 
Android lean 0.0687±0.0119 7.6E-09 2.0E-02 25,244  
Appendicular 
lean 
0.0759±0.0119 1.7E-10 2.2E-04 25,252  
Leg lean 0.0801±0.0119 1.5E-11 5.4E-05 25,252  
Total lean 0.0771±0.0119 8.9E-11 8.1E-04 25,254  
Trunk lean 0.0707±0.0119 2.8E-09 2.6E-02 25,252  
Gynoid lean 0.069±0.0119 6.5E-09 1.7E-04 25,248 rs2867115 
7 2 18,707,873 rs11096542 a g 0.592 KCNS3, RDH14 Arm fat -0.05±0.0091 4.0E-08 3.5E-01 25,254   
8 2 165,539,661 rs6717858 c t 0.406 COBLL1 
Gynoid fat 0.0619±0.0091 8.3E-12 5.4E-01 25,252 rs10184004 
Android fat -0.0589±0.0091 7.7E-11 8.7E-01 25,247 rs10195252 
Leg fat 0.063±0.0091 3.5E-12 9.1E-01 25,259  
Peripheral fat 0.0558±0.0091 7.4E-10 8.9E-01 25,260  
Trunk fat -0.0622±0.0091 6.4E-12 7.8E-01 25,256   
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Locus Chr Position 
Sentinel 
variant 
EA OA EAF Nearest genes Phenotype Beta±SE p-value hetpval N 
Lead variant for 
trait (if other than 
sentinel variant)  
9 2 188,075,837 rs7586854 c t 0.500 
ZSWIM2, 
CALCRL 
Gynoid fat -0.0485±0.0089 4.9E-08 9.7E-01 25,252  
Leg fat -0.0405±0.0089 5.4E-06 7.0E-01 25,259 rs7592188 
10 2 219,699,999 rs78058190 g a 0.947 PRKAG3, WNT6 
Leg fat 0.155±0.0227 8.0E-12 6.5E-01 25,259  
Peripheral fat 0.1377±0.0227 1.3E-09 9.2E-01 25,260  
Trunk fat -0.1271±0.0227 2.1E-08 8.6E-01 25,256   
11 2 
227,100,698 rs2972146 g t 0.356 
LOC646736, 
MIR5702 
Trunk fat -0.0515±0.0092 2.4E-08 2.9E-01 25,256  
227,637,763 rs4675093 a t 0.930 IRS1 
Android lean 0.0979±0.0176 2.5E-08 7.7E-01 25,244   
Total lean 0.0977±0.0175 2.6E-08 7.1E-01 25,254  
Trunk lean 0.1025±0.0175 5.1E-09 8.1E-01 25,252  
Gynoid lean 0.0974±0.0176 2.9E-08 5.4E-01 25,248 rs111851950 
12 3 12,369,401 rs13064760 t c 0.118 PPARG Arm fat 0.1174±0.0138 2.2E-17 5.8E-01 25,254   
13 3 64,718,258 rs2371767 c g 0.275 ADAMTS9-AS2 
Gynoid fat 0.0477±0.0099 1.6E-06 1.1E-01 25,252 rs574435140 
Leg fat 0.0583±0.0099 4.5E-09 1.9E-01 25,259   
14 3 129,398,165 rs72628505 t g 0.935 TMCC1 Gynoid fat 0.1021±0.0186 3.8E-08 2.5E-01 25,252   
15 3 156,795,408 rs56406311 c t 0.609 
LEKR1, 
LINC00880 
Leg fat -0.0532±0.0094 1.3E-08 2.2E-01 25,259  
Subcutaneous 
android fat 
0.0675±0.0094 6.6E-13 5.7E-02 25,177 rs900400 
16 4 89,741,269 rs3822072 g a 0.547 FAM13A 
Peripheral fat 0.0481±0.0089 7.4E-08 3.0E-01 25,260 rs4544678 
Leg fat 0.0552±0.0089 6.8E-10 4.6E-01 25,259  
Trunk fat -0.0536±0.0089 2.1E-09 6.8E-01 25,256   
17 5 55,860,866 rs3936510 g t 0.802 C5orf67 
Android fat -0.0758±0.0111 8.1E-12 8.5E-01 25,247  
Leg fat 0.0822±0.0111 1.2E-13 9.2E-01 25,259  
Peripheral fat 0.0868±0.0111 4.8E-15 7.4E-01 25,260  
Subcutaneous 
android fat 
-0.0936±0.0111 3.5E-17 1.5E-01 25,177  
Trunk fat -0.0862±0.0111 7.2E-15 6.4E-01 25,256   
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Locus Chr Position 
Sentinel 
variant 
EA OA EAF Nearest genes Phenotype Beta±SE p-value hetpval N 
Lead variant for 
trait (if other than 
sentinel variant)  
18 5 116,895,323 rs187859 t c 0.641 LINC00992 Leg lean 0.0511±0.0092 3.2E-08 4.6E-01 25,252   
19 5 127,357,526 rs17764730 t c 0.249 LINC01184 Leg fat 0.0617±0.0103 2.1E-09 8.3E-02 25,259   
20 5 173,334,219 rs75049939 t g 0.693 CPEB4 
Leg fat 0.048±0.0096 5.7E-07 1.2E-01 25,259 rs56364564 
Peripheral fat 0.0498±0.0096 2.2E-07 8.1E-02 25,260 rs56364564 
Android fat -0.0587±0.0096 1.0E-09 4.2E-01 25,247  
Trunk fat -0.0633±0.0096 4.6E-11 5.6E-01 25,256   
21 6 6,733,540 rs744056 a g 0.413 LY86, RREB1 Gynoid fat 0.0682±0.0091 6.6E-14 5.1E-01 25,252   
22 6 34,190,449 rs10214450 c t 0.955 GRM4, HMGA1 
Leg fat 0.1307±0.0217 1.6E-09 8.3E-01 25,259  
Peripheral fat 0.1467±0.0217 1.4E-11 6.4E-01 25,260  
Trunk fat -0.1338±0.0217 6.8E-10 4.3E-01 25,256   
23 6 35,373,877 rs6942357 a g 0.055 PPARD Android lean 0.1155±0.0197 4.6E-09 9.7E-01 25,244   
24 6 43,757,896 rs998584 c a 0.517 
VEGFA, 
LINC01512 
Android fat -0.0809±0.009 2.1E-19 1.6E-01 25,247  
Gynoid fat 0.075±0.009 6.6E-17 9.7E-01 25,252  
Leg fat 0.0983±0.009 6.0E-28 6.5E-01 25,259  
Peripheral fat 0.0945±0.009 6.5E-26 5.2E-01 25,260  
Trunk fat -0.0857±0.009 1.3E-21 8.1E-02 25,256   
25 6 127,440,047 rs577721086 t c 0.948 RSPO3 
Android fat -0.1835±0.0205 4.0E-19 6.5E-01 25,247  
Gynoid fat 0.201±0.0205 1.1E-22 4.2E-01 25,252  
Leg fat 0.211±0.0205 7.9E-25 9.5E-01 25,259  
Trunk fat -0.1947±0.0205 2.4E-21 8.8E-01 25,256  
Visceral 
android fat 
-0.1468±0.0206 9.9E-13 2.3E-01 25,180 rs1936807 
Peripheral fat 0.2081±0.0205 3.7E-24 8.3E-01 25,260 rs72959041 
26 6 130,379,160 rs12661232 t c 0.311 L3MBTL3 Arm lean 0.0611±0.0109 2.4E-08 7.0E-01 19,438   
27 6 139,831,180 rs679582 a g 0.628 Android fat -0.0607±0.0092 5.0E-11 7.1E-01 25,247  
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Locus Chr Position 
Sentinel 
variant 
EA OA EAF Nearest genes Phenotype Beta±SE p-value hetpval N 
Lead variant for 
trait (if other than 
sentinel variant)  
LINC01625, 
LOC100132735 
Leg fat 0.0634±0.0092 6.1E-12 5.6E-01 25,259  
Peripheral fat 0.0681±0.0092 1.6E-13 6.4E-01 25,260  
Visceral 
android fat 
-0.0561±0.0093 1.4E-09 5.8E-01 25,180  
Trunk fat -0.0741±0.0092 9.4E-16 8.1E-01 25,256 rs632057 
28 7 27,218,419 rs1859164 t c 0.538 
HOXA10-
HOXA9 
Arm fat 0.0796±0.009 7.1E-19 3.7E-01 25,254   
29 7 73,042,085 rs62466318 t c 0.198 
MLXIPL, 
VPS37D 
Gynoid fat 0.073±0.0112 7.9E-11 7.2E-01 25,252   
30 8 25,464,690 rs11992444 g t 0.488 CDCA2, EBF2 
Visceral 
android fat 
-0.0576±0.0091 2.2E-10 8.3E-01 25,180 rs73221948 
Android fat -0.0554±0.0091 9.7E-10 2.7E-01 25,247   
31 8 72,469,742 rs4738141 g a 0.251 EYA1, MSC 
Trunk fat 0.061±0.0102 2.5E-09 1.5E-01 25,256 rs13260920 
Android fat 0.0773±0.0102 4.2E-14 3.2E-01 25,247  
Gynoid fat -0.0652±0.0102 1.9E-10 5.8E-01 25,252  
Leg fat -0.0583±0.0102 1.2E-08 3.3E-01 25,259  
Peripheral fat -0.0589±0.0102 8.6E-09 1.7E-01 25,260   
32 8 109,432,178 rs13264315 t a 0.341 EIF3E, EMC2 Leg fat -0.0607±0.011 3.2E-08 5.1E-01 19,438   
33 8 126,506,694 rs112875651 g a 0.605 
TRIB1, 
LINC00861 
Android fat 0.0605±0.0092 5.6E-11 5.8E-01 25,247  
Gynoid fat -0.052±0.0092 1.7E-08 1.3E-01 25,252  
Leg fat -0.0585±0.0092 2.2E-10 7.4E-01 25,259  
Trunk fat 0.0611±0.0092 3.5E-11 5.8E-01 25,256  
Peripheral fat -0.0556±0.0092 1.7E-09 7.5E-01 25,260 rs6470361 
34 9 107,722,705 rs1962883 t c 0.459 
ABCA1, 
SLC44A1 
Leg fat -0.0684±0.0104 5.5E-11 3.1E-02 19,438  
Peripheral fat -0.0684±0.0104 5.7E-11 3.9E-02 19,438  
Trunk fat 0.0628±0.0104 1.8E-09 4.8E-02 19,438  
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Locus Chr Position 
Sentinel 
variant 
EA OA EAF Nearest genes Phenotype Beta±SE p-value hetpval N 
Lead variant for 
trait (if other than 
sentinel variant)  
107,869,756 rs41396353 t g 0.042 
ABCA1, 
SLC44A1 
Android fat -0.1275±0.0223 1.1E-08 5.7E-01 25,247   
35 10 122,995,312 rs11199849 c t 0.252 WDR11, FGFR2 Arm fat -0.073±0.0103 1.2E-12 2.7E-01 25,254   
36 11 14,258,655 rs4757244 g a 0.694 SPON1 Leg fat 0.0538±0.0097 2.5E-08 8.2E-02 25,259   
37 11 32,387,562 rs11031749 t g 0.205 SNORA88, WT1 
Subcutaneous 
android fat 
0.0606±0.0111 4.3E-08 9.0E-01 25,177  
Visceral 
android fat 
-0.0284±0.0111 1.0E-02 7.6E-01 25,180 rs11031796 
38 11 62,316,195 rs11231138 g c 0.372 AHNAK, EEF1G 
Peripheral fat -0.0525±0.0092 1.4E-08 7.1E-01 25,260  
Gynoid fat -0.0534±0.0092 7.5E-09 9.0E-01 25,252 rs11231156 
39 11 63,929,215 rs11231711 a g 0.059 MACROD1 
Peripheral fat -0.1051±0.019 3.1E-08 7.6E-01 25,260  
Gynoid fat -0.1161±0.019 9.9E-10 9.4E-01 25,252 rs56271783 
40 12 26,457,650 rs2129869 t a 0.217 SSPN, ITPR2 
Gynoid fat -0.0668±0.0108 7.2E-10 3.0E-02 25,252 rs10842703 
Android fat 0.0739±0.0108 9.1E-12 8.2E-01 25,247  
Peripheral fat -0.0625±0.0108 8.0E-09 2.9E-01 25,260  
Trunk fat 0.0739±0.0108 9.0E-12 9.1E-01 25,256  
Leg fat -0.0682±0.0108 3.0E-10 2.4E-01 25,259 rs2175723 
41 12 49,609,808 rs11168921 a g 0.185 
TUBA1A, 
TUBA1C 
Leg lean 0.0673±0.0115 4.8E-09 7.9E-01 25,252   





-0.0297±0.009 1.0E-03 6.3E-01 25,177 rs11614913 
Arm fat 0.0503±0.009 2.5E-08 9.6E-01 25,254   
43 12 66,411,692 rs1871675 g a 0.366 
HMGA2, 
MIR6074 
Leg fat 0.0597±0.0093 1.3E-10 8.3E-01 25,259 rs7979129 
Peripheral fat 0.0657±0.0093 1.4E-12 7.6E-01 25,260 rs7979129 
Android fat -0.0558±0.0093 2.0E-09 6.5E-01 25,247  
Trunk fat -0.0582±0.0093 3.9E-10 5.7E-01 25,256   
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Locus Chr Position 
Sentinel 
variant 
EA OA EAF Nearest genes Phenotype Beta±SE p-value hetpval N 
Lead variant for 
trait (if other than 
sentinel variant)  
44 12 104,001,177 rs11111676 a t 0.868 STAB2 
Total lean 0.1114±0.0196 1.3E-08 5.5E-01 19,438  
Trunk lean 0.1169±0.0196 2.5E-09 6.5E-01 19,438   
45 12 114,877,400 rs2551377 t g 0.168 TBX5-AS1, TBX3 Arm fat 0.1318±0.012 3.4E-28 2.5E-02 25,254   
46 12 
123,024,476 rs147730268 g t 0.914 KNTC1 Trunk fat -0.0991±0.0166 2.1E-09 9.2E-01 25,256  
123,192,599 rs11059476 c t 0.942 HCAR2, HCAR3 
Leg fat 0.1257±0.0201 4.1E-10 3.7E-01 25,259   
Peripheral fat 0.1234±0.0201 8.4E-10 5.3E-01 25,260   
47 12 124,409,502 rs7133378 g a 0.672 DNAH10 
Android fat 0.091±0.0095 9.3E-22 8.6E-01 25,247  
Gynoid fat -0.0845±0.0095 5.6E-19 6.1E-01 25,252  
Leg fat -0.1132±0.0095 7.6E-33 9.2E-01 25,259  
Peripheral fat -0.105±0.0095 1.9E-28 8.4E-01 25,260  
Trunk fat 0.0996±0.0095 9.2E-26 5.7E-01 25,256  
Visceral 
android fat 
0.0787±0.0095 1.4E-16 9.7E-01 25,180   
48 15 63,922,474 rs11071759 t c 0.397 HERC1 
Leg fat -0.0537±0.0091 3.4E-09 8.9E-01 25,259  
Peripheral fat -0.0509±0.0091 2.2E-08 8.6E-01 25,260   
49 15 84,542,945 rs56100529 t a 0.282 ADAMTSL3 Leg lean 0.0612±0.0112 4.3E-08 7.9E-01 19,438   
50 16 19,980,931 rs7199285 c t 0.819 GPRC5B, GPR139 Total lean 0.0657±0.0118 2.5E-08 7.5E-01 25,254   
51 16 53,809,123 rs55872725 t c 0.405 FTO 
Appendicular 
lean 
0.0605±0.009 2.1E-11 2.2E-01 25,252  
Leg lean 0.0626±0.009 4.2E-12 2.5E-01 25,252  
Total lean 0.0567±0.009 3.4E-10 2.3E-01 25,254 rs11642841 
52 17 17,988,591 rs12952818 a g 0.606 GID4, DRG2 
Gynoid fat 0.062±0.0104 2.3E-09 8.5E-01 19,438 rs2955382 
Leg fat 0.0649±0.0104 3.9E-10 9.5E-01 19,438 rs2955382 
Android fat -0.0671±0.0104 1.0E-10 6.0E-01 19,438  
Peripheral fat 0.0652±0.0104 3.3E-10 9.3E-01 19,438  
Trunk fat -0.0658±0.0104 2.3E-10 9.4E-01 19,438   
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Locus Chr Position 
Sentinel 
variant 
EA OA EAF Nearest genes Phenotype Beta±SE p-value hetpval N 
Lead variant for 
trait (if other than 
sentinel variant)  
53 17 43,691,377 rs382362 c t 0.206 
MAPK8IP1P2, 
LINC02210 
Gynoid fat -0.0638±0.0116 3.7E-08 9.1E-01 25,252   
54 17 48,628,160 rs62621401 a g 0.985 SPATA20 Arm fat 0.3913±0.0367 1.4E-26 3.5E-01 25,254   
55 18 2,846,812 rs11664106 t a 0.371 EMILIN2 
Leg fat 0.0655±0.0096 1.0E-11 3.4E-01 25,259  
Peripheral fat 0.0625±0.0096 8.7E-11 3.2E-01 25,260  
Trunk fat -0.0659±0.0096 8.4E-12 6.1E-01 25,256   
56 18 57,850,422 rs538656 t g 0.234 PMAIP1, MC4R 
Android lean 0.0507±0.0105 1.3E-06 9.0E-01 25,244 rs8084834 
Trunk lean 0.0635±0.0105 1.3E-09 9.6E-01 25,252 rs7235626 
Gynoid lean 0.0608±0.0106 9.4E-09 7.2E-01 25,248 rs7240682 
Appendicular 
lean 
0.0702±0.0105 2.0E-11 7.7E-01 25,252  
Leg lean 0.0705±0.0105 1.7E-11 6.4E-01 25,252  
Total lean 0.0727±0.0105 3.8E-12 8.6E-01 25,254  
Arm lean 0.0593±0.0105 1.5E-08 8.4E-01 25,256 rs35693910 
57 19 33,925,588 rs11084734 t c 0.305 PEPD 
Leg fat 0.054±0.0097 2.8E-08 1.2E-01 25,259  
Trunk fat -0.0558±0.0097 9.9E-09 2.6E-01 25,256  
Gynoid fat 0.0363±0.0097 1.9E-04 4.1E-02 25,252 rs60497719 
Android fat -0.053±0.0097 5.3E-08 4.6E-01 25,247 rs35968262 
Peripheral fat 0.0527±0.0097 6.1E-08 8.3E-02 25,260 rs182863881 
58 21 35,593,827 rs28451064 a g 0.132 
LINC00310, 
KCNE2 
Peripheral fat -0.0788±0.0135 4.9E-09 6.4E-02 25,260   





-0.059±0.0108 4.8E-08 9.7E-01 25,177   
60 22 29,142,286 rs6005856 a g 0.035 HSCB Leg fat -0.1328±0.0243 4.4E-08 5.2E-01 25,259   
61 22 38,569,529 rs4380 c t 0.472 PLA2G6 Leg fat 0.0577±0.0101 1.3E-08 9.3E-02 19,438   
 

Chapter 4: The genetics of fat and lean mass compartments 
 181 
Discussion 
In this chapter, I have sought to fill a gap in current knowledge of genetic factors driving regional 
adiposity between large-scale GWAS on WHR (a crude measure of one pattern of fat distribution) 
and smaller-scale genetic discoveries of highly refined but selective adiposity traits based on CT 
imaging. I furthermore aimed to conduct the first systematic genetic investigation of regional 
absolute and relative lean mass.  
GWAS of DEXA phenotypes allows refined characterisation of WHR loci 
I aimed to identify genetic loci associated with patterns of fat distribution by conducting GWAS 
for absolute fat mass in different regions of the body and regional fat mass adjusted for total fat 
mass. 38 of the 51 loci identified for relative regional fat mass were associated with a WHR-like 
fat distribution pattern, which suggests that differences in WHR are the most common source of 
variation in body fat distribution. However, it cannot be excluded that this finding may be due to 
greater power to identify loci for central and leg fat, which are by far the largest fat depots in the 
human body and are, after transformation to the standard distribution, measured with greater 
precision than arm fat mass, which among the Fenland participants only account for approximately 
9 to 10% of the total body fat. Variations in central-to-lower body fat distribution are largely 
captured by WHR based on simple tape measures, as evidenced by the at least nominally significant 
associations of all but two of the 38 loci with WHRadjBMI.  
However, genetic associations with refined absolute and relative fat compartments allowed us to 
conduct a detailed characterisation of the effects of the WHR-like loci across all fat compartments, 
and to distinguish their effects on visceral and subcutaneous central fat mass. I provide evidence 
that loci increasing central-to-lower body fat distribution do not have consistent effects on arm fat 
nor on subcutaneous android fat. Neither of these two relative fat compartments showed 
substantial observational correlations with WHRadjBMI, which further corroborates the 
independence of relative arm and subcutaneous android fat from WHR. However, similar to the 
moderate inverse observational association between visceral and subcutaneous fat mass adjusted 
for total fat, a weak inverse correlation between the genetic effect sizes of the 38 WHR-like loci 
on visceral and subcutaneous android fat was observed. This finding suggests that visceral and 
subcutaneous central fat are to some extent regulated by distinct genetic factors.  
An exception to this observation was the locus in R-spondin 3 (RSPO3), which encodes the 
activator of the canonical Wnt signalling pathway and had strong positive effects on both visceral 
and subcutaneous android fat mass adjusted for total fat mass. Variants in RSPO3 have been 
reported for higher WHRadjBMI308, higher fasting insulin94, lower HDL cholesterol and higher 
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triglycerides214. The allele for higher central-to-lower fat distribution was also identified for lower 
BF% in Chapter 3 and without adjustment for total fat mass, RSPO3 was only associated with 
lower leg and gynoid fat mass. Altogether, this indicates that the RSPO3 locus decreases overall 
BF% by decreasing only absolute fat mass in the legs and hip and that the relative increase in 
central-to-lower body fat distribution affects both the visceral and the subcutaneous android 
compartment in the same direction.  
 
The upper peripheral fat compartments are observationally and genetically distinct 
from the lower peripheral compartments and standard anthropometric traits 
In the extant literature, peripheral fat mass is a frequently used term that refers to the combined 
fat mass in the legs and arms. While multiple studies have focused on the genetic determinants 
and cardiometabolic correlates of lower body fat, based on indirect measures such as hip 
circumference, very few studies have explicitly focused on arm fat mass. The results presented in 
this chapter indicate that arm fat may not simply be the “upper body equivalent” of lower body 
peripheral fat mass. Firstly, after adjusting for total fat mass, arm fat mass did not correlate with 
leg fat mass or any other fat compartments, nor with standard anthropometric phenotypes, 
including WHRadjBMI and BMI. The latter observation indicates that relative fat distribution to 
the arms is not captured by the commonly used anthropometric risk factors. Furthermore, 
evidence was found that arm fat may be controlled by genetic factors that are distinct from those 
controlling leg fat mass, as indicated by the two genetic loci in PPARG and SPATA20 reaching 
genome-wide significance for absolute arm fat mass but not (SPATA20) or only weakly (PPARG) 
affecting leg fat mass, and the 7 loci associated for proportionately higher arm fat mass but not 
(PPARG, SPATA20, TBX5, RDH14, FGFR2, HOXC-AS2) or to a lesser extent (HOXA10-
HOXA9) with relative leg fat mass.  
 
These findings raise the question of whether the peripheral fat compartments in the upper versus 
the lower extremities may also differ in terms of their relationships to cardiometabolic disease risk. 
Although the trunk and legs provide a larger storage capacity for adipose tissue than any of the 
other compartments, this does not preclude arm fat from having a metabolically relevant function. 
For instance, only a small fraction of the total fat mass is stored in the visceral compartment, and 
yet visceral fat is highly relevant in the aetiology of cardiometabolic diseases330,332. As a first step to 
identifying the aetiological role of arm fat in T2D, genetic associations of the arm fat loci with 
T2D risk were investigated. The absolute arm fat-raising alleles at PPARG and SPATA20 were 
genome-wide significantly and suggestively associated with lower risk of T2D, which suggests that 
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having a larger capacity to store fat in the arms may have a similar protective effect against 
cardiometabolic disease risk as does leg fat mass. However, associations of the other 5 loci for 
relative arm fat mass with T2D risk did not follow a clear trend. Further investigations of 
observational associations of absolute and relative arm fat mass with detailed cardiometabolic risk 
factors and disease outcomes, as well as a further expansion of the genetic discovery for arm fat 
mass, which will allow us to generate larger and more powered genetic instruments for arm fat 
mass, are needed to understand the metabolic relevance of the arm fat compartment.  
 
The T2D risk-reducing locus at PPARG is most strongly associated with absolute 
and relative higher arm fat mass 
The locus in PPARG was associated with higher absolute levels of arm fat mass and with arm fat 
distribution. The peroxisome proliferator-activated receptor-γ gene (PPARG) encodes a nuclear 
fatty acid receptor that is highly expressed in adipose tissue and which, upon binding of a fatty 
acid, regulates gene expression by binding to the peroxisome proliferator-response element. 
PPAR-γ has been identified as a key regulator of adipocyte differentiation, lipid metabolism and 
uptake of fatty acids and glucose in adipose and muscle tissue357. Coding mutations in PPARG 
have been identified as a cause of familial partial lipodystrophy358 while the arm fat-increasing allele 
of the common locus in PPARG has been reported for lower risk of T2D16,359, lower fasting insulin 
levels94, higher WHR308 and more recently with higher BMI172. In the previous chapter of this 
thesis, I found that the association of PPARG with BMI was entirely driven by fat mass and that 
a significantly inverse association with lean mass was observed. In this chapter, I show that PPARG 
has heterogeneous effects on fat mass in different areas of the body, with an effect nearly twice as 
strong on SDs of arm fat mass than on leg fat mass and only weak effects on central fat mass. 
After adjustment for total fat mass, PPARG remained most strongly associated with higher arm 
fat mass and was nominally associated with lower central fat mass but not with leg fat mass. These 
findings suggest that PPARG is more strongly associated with a higher arm-to-central fat 
distribution than with central-to-lower fat distribution, as suggested by the previously reported 
association with WHR.  
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No evidence for distinct genetic determinants for different lean mass 
compartments 
In contrast to the analyses of regional fat mass, GWAS for lean mass compartments with or 
without adjustment for height squared did not lead to the identification of any loci which affected 
lean mass more strongly in some compartments than in others. For none of the identified lean 
mass loci was evidence found for heterogeneity in the effect sizes across the absolute lean mass 
compartments, while for the majority of loci identified for absolute fat compartments at least 
suggestive evidence for heterogeneity was found. These findings are in line with the strong 
observational correlations between the lean mass compartments, with and without adjustment for 
height squared. Larger sample sizes and analyses adjusted for total lean mass may be required to 
identify loci associated with lean mass distribution patterns, and epidemiological research to 
identify lean mass compartments and distribution patterns associated with cardiometabolic risk 
factors and outcomes are needed. 
 
Strengths and limitations 
I conducted the first large-scale genome-wide association analyses of fat and lean mass distribution 
based on direct, DEXA-based measures in up to 25,000 participants. The analyses were not 
restricted to certain fat compartments for which there was a prior interest, as was the case for the 
previously published CT-based GWAS of specific fat traits330,344. Instead, I analysed fat and lean 
mass in all regions of the body and was therefore able to characterise for all the identified loci the 
patterns of association with all fat and lean mass compartments in the body. This enabled a 
complete overview of the anthropometric effects of the identified loci. Finally, the analyses were 
based on meta-analyses of 5 cohorts and heterogeneity of the effect sizes between the studies was 
assessed. Therefore, the findings are unlikely to be study-specific.  
However, the presented analyses also suffer from certain limitations. Firstly, this ongoing project 
started off by conducting analyses for the sexes combined and may therefore not have been able 
to identify loci that are specific to men or women and were not able to assess sex differences in 
the effect sizes of the identified loci. The high number of sex-specific loci and loci with sex-
discordant effects for WHR and WHRadjBMI309 suggest that also for other patterns of fat 
distribution sex-dimorphic associations may be identified. Secondly, no conditional analyses to 
identify the independent variants at each locus were performed. The reasons for this are that our 
main focus was on refined characterisation of known loci rather than on identifying novel loci, 
and because current tools designed to conduct such analyses based on summary-level data cannot 
identify independent variants across multiple traits. Instead, a pragmatic, distance-based clumping 
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approach was adopted to identify the cross-trait lead variant at each locus. The vast majority of 
the loci identified in this chapter have previously been reported in large discovery projects for 
BMI, WHR, BF% and FFMI led by GIANT and others, and the refined structure of these loci has 
in most cases already been described. Furthermore, collider bias due to the adjustment for height, 
which is heritable and correlated with regional and overall lean mass, was not systematically 
assessed. Therefore, some of the loci identified in the adjusted analyses, in particular for lean mass 
compartments adjusted for height squared, may be false positives, as was the case for the GWAS 
findings for FFMI in Chapter 3. Moreover, the analyses are restricted to common and low-
frequency variants, as the current sample size was relatively modest and does not allow me to 
reliably assess the effects of rare loci on regional fat and lean mass. Finally, certain limitations are 
associated with DEXA-based body composition analysis279,343. DEXA is known to modestly 
underestimate fat mass in very large individuals279. Furthermore, visceral fat mass estimates based 
on DEXA imaging have been shown to be less accurate than for the other compartments, when 
compared to MRI, which is the “gold standard”343. These DEXA-related limitations may have led 
to inaccurate measurements for some participants and thus lower power.  
 
Conclusion and future directions  
In this chapter, loci associated with patterns of fat distribution not captured by standard 
anthropometric risk factors, such as relative arm and subcutaneous android fat, were identified 
based on GWAS for refined fat and lean traits measured by DEXA imaging. The majority of loci 
associated with regional fat mass represented variation in WHR, but by assessing the cross-
compartment associations of these loci, a refined characterisation of their effects on body size and 
composition was obtained. While strong evidence was found for genetic factors influencing fat 
distribution, the presented findings did not provide evidence for the existence of genetic factors 
which affect lean mass in distinct compartments differently.   
The results presented in this chapter are preliminary findings of an ongoing project. We are 
currently in the process of expanding this discovery further with approximately 3,000 individuals 
from the Avon Longitudinal Study of Parents and Children (ALSPAC) study (GWAS ongoing) 
and around 10,000 participants from the Canadian Longitudinal Study on Aging (phenotype QC 
ongoing). Furthermore, DEXA variables for at least 5,000 additional UK Biobank participants are 
expected within the next 6 months, which we intend to include in the following round of GWAS 

















Summary of the findings 
This PhD thesis set out to identify aetiological pathways to cardiometabolic diseases by integrating 
genome-wide data with refined metabolic traits, based on high-throughput metabolic profiling 
(Chapter 2) and body composition measurement techniques (Chapters 3 and 4) in large-scale 
population-based and disease-specific cohort studies. 
 
While metabolic disruption lies at the heart of the aetiology of cardiometabolic diseases, the role 
of metabolic pathways has not been studied systematically. In this thesis, I developed a strategy 
based on the Mendelian randomisation framework to assess the aetiological role of metabolic 
pathways on cardiometabolic diseases and to characterise the underlying mechanisms through 
which a metabolic pathway acts on disease risk. By integrating high-throughput untargeted 
metabolomics with large-scale genome-wide data, I identified glycine metabolism as a potential 
aetiological pathway to CHD and found evidence that low glycine levels may increase the risk of 
CHD by elevating blood pressure. Evidence for glycine as a potential causal factor for T2D risk 
was weaker and may depend on the biological mechanism through which glycine levels are 
reduced. The strong association of genetically predicted insulin resistance with lower genetically 
predicted glycine suggests that the observational, inverse glycine-to-T2D association may at least 
partly be due to confounding by insulin resistance. My findings indicate that glycine 
supplementation may be beneficial for individuals diagnosed with, or at high risk of developing 
cardiometabolic diseases but potential negative side effects, in particular on cancer risk, must be 
assessed prior to setting up trials.  
 
Secondly, this thesis focused on the genetic characterisation of overall and regional body size and 
composition, with the aim to generate genetic risk scores for specific patterns of overall body 
composition and fat and lean mass distribution that are not, or not fully, captured by standard 
indices of obesity, such as BMI and WHR. Through genetic discoveries for BF% and FFMI, I 
identified genetic loci associated with high relative body fat in the absence of overweight or obesity. 
Observational epidemiological research has proposed normal weight adiposity as a risk factor for 
cardiometabolic and other complex diseases. The genetic loci identified in this thesis for normal 
weight adiposity allow for causal assessment and molecular characterisation of this emerging 
anthropometric risk factor, which may lead to the identification of novel targets for treatment. 
Furthermore, I identified genetic loci associated with fat compartments, such as arm and 
subcutaneous android fat mass, that are largely independent of BMI and WHR, based on GWAS 
for regional body composition phenotypes measured by DEXA imaging. Genetic loci associated 
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with arm fat mass did not or only weakly affect leg fat mass, which indicates that fat mass in the 
upper and lower peripheral compartments are controlled by distinct genetic factors. Whether arm 
fat has a similar, protective role on cardiometabolic disease risk as leg fat mass remains unclear, 
but the identified genetic loci for arm fat mass can enable future investigations that seek to clarify 
the metabolic function of arm fat mass. While the majority of the loci identified for regional fat 
had heterogeneous effect sizes across the different compartments, genetic evidence suggested that 
lean mass in different regions of the body is controlled by the same genetic factors.  
 
In this concluding chapter, I will first discuss the limitations of the research described in this thesis 
and discuss how these may have had an impact on the findings. I will then continue with a 
discussion of the implications of the presented findings and an outline of new research avenues to 




Limitations of using genetics to identify causal risk factors 
The presented research into the aetiological factors of cardiometabolic diseases relied on the 
assumption that genetic effects represent unconfounded estimates for risk factor-to-disease 
associations. This assumption is made most explicitly in the Mendelian randomisation analyses on 
glycine presented in Chapter 2, but it is also relevant to the genetic loci identified for refined 
anthropometric phenotypes (Chapters 3 and 4), if these were used as genetic instruments to study 
causal associations of body size and composition with cardiometabolic diseases and traits in the 
future. The 3 main reasons why a genetically predicted effect size of a risk factor with a disease 
outcome may not reflect a causal effect are the following: (1) Some of the genetic loci reaching 
statistical significance may not be truly associated with the risk factor, (2) genetic loci often violate 
the instrumental variable assumptions and may thus lead to biased causal estimates and (3) even 
genetic associations based on valid genetic instruments may under- or overestimate the causal 
effect size. I will outline these three reasons and discuss how each of them may have affected the 
research presented in the thesis. 
 
Statistical associations of genetic loci with the risk factor may be false positive, study-
specific or biased 
Genetic loci that reach genome-wide significance in a GWAS for a risk factor may not be truly 
associated with the risk factor, for reasons of chance, study-specific effects and collider bias. For 
many years, the GWAS community has adopted a p-value threshold of 5×10-8, based on the 
assumption that conducting genome-wide tests for associations with a phenotype represents 1 
million independent statistical tests and that therefore, to limit the chance of false positive findings 
to 5%, the significance threshold for GWAS should be set at p<5×10-8. However, with the 
emergence of new and denser LD reference panels, some argue that the number of independent 
statistical tests has increased and that therefore stricter p-value thresholds should be used, in 
particular when studying rare variants360. Despite the stringent Bonferroni-corrected significance 
threshold used throughout this thesis to limit type I errors, 5% of the loci may have reached 
significance due to chance, without being truly associated with the phenotype. In the meta-analyses 
of GWAS presented in Chapter 2 (glycine) and Chapter 4 (regional fat and lean mass) in which the 
effects were replicated across multiple studies, the likelihood of such false positive associations 
was less likely than for loci identified for BF% and FFMI (Chapter 3), which were mostly based 
on the GWAS in UK Biobank only. As no studies with a sufficiently large sample size were 
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immediately available to us in which we could attempt to replicate loci identified for BF% and 
FFMI in UK Biobank, it is likely that a subset of the identified loci were statistically associated 
with the phenotypes by chance only.  
 
The external validity of genetic loci identified in UK Biobank only was not tested. Therefore, some 
of the identified loci in UK Biobank may be study-specific, e.g. due to technical issues related to 
the genotyping array, genotype calling or imputation. Furthermore, participants of UK Biobank 
do not represent a cross-section of the British population, as the cohort is strongly enriched for 
individuals of European ancestry who are in good health, follow lifestyle recommendations and 
have a higher than average socio-economic status361.  Therefore, some of the genetic findings based 
on UK Biobank only may not be generalisable to the entire UK and other populations.   
 
Finally, work by Aschard et al.299 and Day et al.362 highlighted that genetic loci reaching genome-
wide significance for a phenotype adjusted for another heritable and correlated trait, such as WHR 
adjusted for BMI, may be associated through the covariate (i.e., BMI) only, without having any 
effect on the phenotype (WHR) itself. Loci for which the association in the GWAS is entirely 
driven by this so-called collider bias have no effect on the intended phenotype. In this thesis I 
undertook genetic discoveries for several adjusted anthropometric phenotypes, either by taking 
the ratio of two traits (e.g., FFM to height squared) or by adjusting the anthropometric phenotype 
(e.g., arm lean mass adjusted for height squared). Even if collider bias is formally assessed for each 
identified locus, as was done for all loci reaching genome-wide significance for FFMI, false positive 
findings due to collider bias can still remain due to the limited power of such assessments. Collider 
bias was not tested for in the other genetic discoveries presented in this thesis. Therefore, the 
identified loci presented in this thesis may require replication in an independent study. 
 
Pleiotropic genetic instruments 
Pleiotropy is the phenomenon in which a gene or genetic locus is associated with two or more 
apparently unrelated traits363. One of the conditions which must be met by a genetic locus for it to 
be a valid genetic instrument is that it cannot influence the outcome through any other pathway 
than through the risk factor for which it was identified. The challenge of this no-pleiotropy 
condition is that it is not fully empirically testable. Potential bias of the causal estimates due to 
pleiotropic genetic instruments is therefore one of the most commonly raised limitations of the 
Mendelian randomisation framework363–366. It is generally assumed that the chance of bias due to 
pleiotropy decreases with increasing numbers of genetic instruments included in the MR analysis363, 
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as the biases introduced by the individual loci, which each have a unique set of pleiotropic effects, 
may cancel out each other363.  However, in a recent study by Verbanck et al.60, 48% of the significant 
causal estimates based on the MR framework were estimated to be biased due to pleiotropy of the 
genetic instruments. So-called robust MR methods which are less sensitive to bias caused by 
pleiotropic instruments have been developed58–60. The MR analyses presented in Chapter 2 of the 
thesis were based on such robust methods, but bias due to known and unknown pleiotropic effects 
can never be fully excluded. Therefore, a significant MR-based association of a risk factor with an 
outcome based on multiple, robust MR methods is highly indicative but not final, conclusive 
evidence for a causal relationship between a risk factor and a disease.  
 
The Mendelian randomisation framework is based on a simple model of causality 
Even if a significant genetic risk factor-to-disease association is identified based on genetic variants 
which meet the instrumental variable assumptions, the genetic effect size may differ from the 
causal effect size366. A significant MR-based genetic association of the risk factor with disease risk 
represents a linear causal effect of lifelong higher (or lower) exposure levels to the risk factor on 
disease risk. In reality, however, causal relationships may be non-linear and could vary over time, 
or so-called “legacy effects”367 of the risk factor on disease risk may exist. Furthermore, there may 
be non-random time trends in exposure levels of certain risk factors. The current MR framework 
is limited in its ability to model these more complex and time-varying causal relationships. Applying 
MR in situations where the causal relationship between a risk factor and outcome is non-linear 
and/or differs over time can lead to inaccurate conclusions. For example, evidence suggests that 
the association of BMI with breast cancer risk may be non-linear and could be different for pre 
and post-menopausal breast cancer and disease sub-types368. The possible non-linear and time-
varying causal relationship of BMI with breast cancer could be the reason why MR studies on BMI 
and breast cancer have thus far led to contradicting findings369,370.  
Finally, the genetic effect may in some cases underestimate the causal effect due to “canalisation”. 
This developmental phenomenon occurs if the phenotypic consequences of low or high risk factor 
levels driven by a certain genetic mutation are weakened by compensatory mechanisms that act to 
negate part of the potentially detrimental effects caused by the mutation and its direct phenotypic 
consequences. A genetic association of the risk factor with the exposure based on such a genetic 
locus will underestimate the effect of the risk factor.  
These general limitations of causal inference based on the MR framework indicate that evidence 
from observational epidemiological research on the nature of the relationship between a risk factor 
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and disease should be taken into account and that findings from MR should be primarily 
interpreted as the likelihood for causality, without over-interpretation of the estimated effect size.   
 
Eurocentric bias  
A strong Eurocentric bias dominates the field of human genomic research and of biomedical 
research in general371,372. The systematic under-representation of participants of non-European 
ancestries in genetic research is not only problematic for ethical reasons, but also forms an 
important limitation to scientific progress373. In the context of genetic research, a higher availability 
of genome-wide data from individuals of non-European ancestry would increase the overall 
sample size and thus the power to conduct genetic discoveries. Moreover, certain genetic variants 
for which the allele frequencies are very low in Europeans, may only be discovered in non-
European ancestries. Trans-ethnic genetic discoveries are also crucial for the fine-mapping of 
known loci and may thus facilitate the identification of the causal variants and genes373.  
Eurocentric bias also forms an important limitation in research on the aetiological risk factors of 
cardiometabolic diseases. While the major risk factors of cardiometabolic diseases are well 
understood for individuals of European ancestry living in high-income countries, this is less the 
case for individuals of e.g. South-Asian and African ancestries living in low or middle-income 
settings, despite the fact that the latter groups carry a disproportionately share of the T2D burden1. 
Differences in body composition have been suggested as one of the factors that could explain 
ethnic differences in susceptibility to cardiometabolic illnesses at a given BMI98,99,374. Expanding 
the work in this thesis on body composition patterns and their genetic determinants to participants 
of African, Latin-American and south and east Asian ancestries may therefore be in important step 
towards understanding ethnic differences in susceptibility to cardiometabolic diseases and 
improving risk stratification among individuals of non-European ancestries.  
 
General limitations of using the biomedical paradigm to study the aetiological 
pathways to cardiometabolic diseases 
This thesis focuses on identifying aetiological pathways to cardiometabolic diseases through the 
lens of biomedical science. The biomedical paradigm of studying the aetiology of cardiometabolic 
diseases mostly focuses on the proximal causes of disease that are located at the level of the 
individual375. However, a vast body of evidence indicates that these proximal causes of disease are 
under the influence of powerful, upstream determinants of health that lie outside the individual, 
including the build environment, socio-economic deprivation and other macro-institutional 
factors375–377. While biomedical research is essential for the development of treatments for 
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individuals who are already sick or are at high risk of developing a disease, the vast scale of the 
current metabolic disease epidemic also requires a societal approach to population health. In the 
words of Sir Michael Marmot: “Why treat people and send them back to the conditions that made 
them sick?”378. The need for such an approach is increasingly being recognised in the medical 





Implications and directions for future research 
Assessing metabolic pathways as aetiological factors for complex diseases 
Expanding the approach to other metabolic pathways and “non-metabolic” complex 
diseases 
The approach developed in this thesis to assess the role of metabolic pathways as aetiological risk 
factors for disease can be expanded to a broader systematic causal investigation of associations 
between the metabolome and a range of disease outcomes. Conducting such genetics-based causal 
investigations of metabolic pathways is being increasingly facilitated for research teams worldwide 
by the publicly available summary-level results of several published metabolome-wide GWAS 
efforts169–171,184, with results of several larger-scale ongoing efforts expected to become publicly 
available in the near future.  
The most obvious diseases to which metabolic pathways could be causally related are 
cardiometabolic diseases, as dysregulation of metabolic processes are key elements in their 
aetiology. Further research on the aetiological role of the many other metabolic pathways which 
have been associated with T2D and CHD, but which were not addressed in this thesis will 
therefore likely lead to the identification of other causal, metabolic pathways to cardiometabolic 
diseases, of which some may be good candidates for pharmacological intervention.   
In recent years, metabolic risk factors have been linked to higher incidence of complex diseases 
which are not traditionally considered to have a metabolic aetiology, such as cancers368,380, 
autoimmune conditions381 and neurodegenerative diseases382,383. Furthermore, associations 
between the metabolome and disease incidence have been identified for several of these “non-
metabolic” complex diseases384–386. These findings highlight that a causal role of metabolic 
pathways may not be restricted to the traditional metabolic diseases, and that the approach adopted 
in this thesis to study the causality of metabolic pathways may also lead to the identification of 
novel aetiological pathways to other complex diseases and thus novel treatment strategies. 
Attention also needs to be given to the aetiological role of metabolic pathways across diseases, as 
this may not only reveal causal effects of a potential modifiable pathway on multiple disease 
outcomes, but also predict potential adverse effects. This was evidenced by the work in this thesis 
which indicated a causal link between low glycine levels and high cardiometabolic disease risk, 
while glycine may potentially increase cancer risk. Another recent example is the subtle increase in 
T2D risk by statins – the major class of LDL cholesterol-lowering drugs that are commonly 
prescribed for primary and secondary CHD prevention63,75. These findings emphasise the 
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importance of a cross-disease approach, which can be conducted efficiently based on genetics, 
provided that disease-specific summary-level GWAS results are made publicly available.  
Two strategies for prioritising metabolic pathways for causal assessment 
Two main strategies can be adopted to prioritise metabolic pathways for causal assessment. Firstly, 
metabolic pathways can be prioritised based on those most strongly and consistently associated 
with disease risk in published and novel observational association analyses. This strategy was used 
in this thesis and led to prioritising the glycine pathway, which, together with the branched-chain 
amino acid pathway, is one of the most frequently reported pathways for T2D in longitudinal 
observational studies. With large-scale metabolite profiling being increasingly adopted in 
epidemiological cohorts and plans to conduct metabolite profiling for very large groups of 
participants, such as those of UK Biobank, the scale and thus power of such observational studies 
will drastically increase over the next decade, which will facilitate observational studies on links 
between the metabolome and diseases. However, as shown for the glycine pathway, strong and 
consistent observational evidence will not necessarily translate into strong causal evidence. 
Conversely, a metabolic pathway that is causal for disease risk is highly likely to be also 
observationally associated with disease incidence.  
An alternative strategy is to prioritise metabolic pathways for causal assessment based on the 
availability of good candidate genetic instruments for the pathway. Genetic loci are strong 
candidate instruments for a metabolic pathway if the locus is specifically associated with the 
metabolites of the pathway and if there is a plausible biological mechanism through which the 
genetic region influences metabolite levels. Loci which are most likely to fulfil these criteria are 
located in genes encoding enzymes that catalyse a reaction in the metabolic pathway of interest. 
Based on the identified loci for metabolites through metabolome-wide GWAS, such instruments 
can be found and tested for cross-metabolome associations, while phenome-wide association 
studies for such instruments in e.g. UK Biobank can give a first indication of potential causal 
effects on disease outcomes.  
In reality, a combination of both strategies will be most efficient, because specific genetic 
instruments may not be available for certain metabolic pathways prioritised through observational 
research, which may be particularly the case for lipid pathways. Furthermore, even if a powerful 
and specific instrument is found for a particular metabolic pathway, causal investigations may not 





The genetic determinants of refined anthropometric phenotypes: implications and 
future research avenues 
The metabolic sequelae of overall body fatness may be highly dependent on fat 
distribution 
This thesis aimed to identify the genetic determinants of refined anthropometric phenotypes which 
have a less heterogeneous relationship with cardiometabolic risk than the currently used 
anthropometric risk factors, such as BMI. The large heterogeneity in cardiometabolic risk among 
people with a similar BMI, especially among those with a BMI in the overweight but not obese 
range, has partly been attributed to differences in overall body composition, and partly to 
differences in fat distribution.  
This PhD thesis provides several lines of evidence that fat distribution is a more important factor 
for cardiometabolic risk than BF%. First, several of the loci which were identified for higher BF% 
have elsewhere been reported for lower cardiometabolic risk. The protective effects of these loci 
on cardiometabolic risk are likely to be driven by the positive effects of these loci on body fat in 
the hip or leg region but not on central body fat, as evidenced by the positive associations of these 
loci with higher leg fat mass only and the reported inverse associations with WHR. Secondly, 
known BMI loci for which findings from this thesis indicate that they only increase BMI through 
fat but not through lean mass, including PPARG, PEPD and DNAH10 have previously been 
reported for lower cardiometabolic risk, which may again be explained by the associations of these 
loci with fat distribution to the lower body.  
Loci associated for higher body fat and lower cardiometabolic risk were located in/near PDE3B, 
RSPO3, VEGFA, DNAH10, PPARG, ZNF664 and LYPLAL1, for the majority of which a 
functional role in adipogenesis has been described79,357,387,388. These findings highlight that the 
capacity to generate and expand subcutaneous adipose tissue plays a key role in protection against 
cardiometabolic conditions100.  
The use of pharmacological agonists of PPARγ, the so-called thiazolidinediones (TZD), for the 
treatment of T2D is based on the principle that insulin resistance and other pathophysiological 
processes driven by a long-term positive energy balance can be ameliorated by increasing the 
capacity to safely store excess energy in the form of lipids in the peripheral fat compartments357,389. 
Rosiglitazone, a thiazolidinedione (TZD) developed for T2D treatment, was found to improve 
glycaemic control and increase fat accumulation in individuals with T2D, but, due to concerns 
about side effects, including oedema, congestive heart failure and increased risk for bladder cancer, 
and fractures in women390, its use was discontinued in most countries. However, other loci which 
were here reported for higher BF% but lower cardiometabolic risk may point to novel potential 
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targets through which the capacity to safely store excess energy can be increased. Functional 
characterisation of these loci and experiments based on animal models of cardiometabolic diseases 
are needed to identify the potential of these gene products as targets for pharmacological 
intervention. Increased risk of congestive heart failure, potentially driven by water retention, was 
one of the major reasons the use of rosiglitazone was discontinued, but it is unclear if this side 
effect is a general consequence of increasing fat depots beyond their “natural” limits, or a TZD-
specific effect. Effects on fluid balance, which can be measured using BIA, should therefore be a 
primary focus in the early phases of novel studies on identifying targets to reduce cardio-metabolic 
risk by increasing peripheral fat storage.  
 
A shift in focus from expanding discoveries to in-depth characterisation of genetic loci 
In the past decade of genome-wide studies on body size and other complex traits, the main focus 
has been on accumulating data on ever increasing numbers of individuals in order to enhance 
power and thus increase the number of associated loci that reach genome-wide significance. The 
number of identified genetic loci for each standard anthropometric trait has now reached a 
thousand or more but for most of these loci the biological mechanisms through which they 
influence the anthropometric risk factor are entirely unknown. Therefore, the point has been 
reached at which further efforts into expanding discoveries for simple measures of obesity will 
only lead to limited further gains in biological understanding. Instead, a shift in focus to in-depth 
characterisation of the already known loci is more likely to lead to significant improvements in 
understanding of the pathophysiology of cardiometabolic diseases and to the identification of 
novel targets for prevention or treatment. The systematic integration of genetic, refined phenotypic 
and clinical data to create detailed biological pictures of already known loci may become the 
dominant approach in the next decade of genetic research on body composition and on complex 
traits in general.  
The findings presented in Chapters 3 and 4 regarding the genetic characterisation of overall and 
regional body fat and lean mass highlight that testable hypotheses on the biological functions of 
genetic loci for an anthropometric trait can be formulated by integrating knowledge on 
observational and genetic associations with a range of other anthropometric and metabolic 
phenotypes. Further enrichment of this integrative approach with molecular phenotypes based on 
-omics techniques and even more detailed imaging-based anthropometric data, which is facilitated 
by the increasing scale and the granularity at which phenotypic and clinical data are becoming 
available for research, is expected to accelerate the discovery of novel molecular targets for 
treatment. For instance, data generated by the UK Biobank Imaging Study, which aims to obtain 
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MRI imaging of the brain, heart and abdomen, ultrasound imaging of the carotid arteries and 
DEXA imaging for body composition and bone density analysis on 100,000 participants202,351, is 
of particular relevance to the anthropometric and metabolic research community and will help to 




While BMI predicts cardiometabolic risk well for those at the lower and higher ends of the BMI 
scale, there is a large variation in incidence of cardiometabolic disease risk among the large group 
of individuals who are mildly overweight. Based on the findings from this thesis which suggest 
that fat distribution is more relevant than overall body composition for cardiometabolic risk, risk 
stratification for those in the overweight category is more likely to improve by measuring fat 
distribution than by focussing on overall body composition. Therefore, central and hip fat 
accumulation should be routinely assessed by waist and hip circumference measurement and 
should be interpreted separately instead of as their ratio. Secondly, an estimation of the proportion 
of total central fat accounted for by subcutaneous fat, based on skinfold thicknesses in the waist 
region, could further improve risk stratification. Finally, once the metabolic role of the arm fat 
compartment is corroborated, this could be assessed by circumference and skinfold thickness 
measures. These simple and low-cost measures can easily be done in general practices, pharmacies 
or even at home, and an easy-to-use scoring system that also takes overall BMI and potentially 
total fat and lean mass based on BIA into account, could help to identify those individuals who 
are at highest risk and should undergo tests to measure a panel of blood-based cardiometabolic 
risk factors.   
 
Conclusion 
This PhD thesis develops and demonstrates an integrative approach, drawing on genome-wide 
genetic data and detailed metabolic phenotypes based on metabolomics and refined 
anthropometric assessment techniques, to identifying and characterising novel aetiological 
pathways to cardiometabolic diseases. By combining large-scale genetic, metabolomic and clinical 
data, I develop a strategy to assess metabolic pathways as aetiological factors of cardiometabolic 
diseases. Based on this strategy, I identify a novel causal metabolic pathway to cardiometabolic 
diseases and formulate testable hypotheses about its mechanisms of action. Furthermore, I set out 
a new framework for genetics-based causal investigations into the role of refined anthropometric 
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traits, such as normal weight adiposity and emerging patterns of body fat distribution, on 
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Supplementary Figure 2.1: Sex-combined and sex-specific per-allele effect sizes of rs715 
(CPS1) on metabolite levels. 
 
 
Analyses based on 5,706 women and 5,086 men of the EPIC-Norfolk study. Metabolites were 
included in the plot if they were associated with rs715 at p<5.6×10-4 in men or women, i.e., 69 out 
of 894 metabolites measured in both batches and at least 50% of the total sample size. 
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Supplementary Figure 2.2: Dosage plots of the effect sizes of genetic variants for glycine 
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A| Score comprising all common loci 
identified for glycine levels
B| Score including 6 loci near glycine 
enzymes
D| Score including 2 loci near 
enzymes of glycine cleavag  system
C| Score including 5 loci near glycine 







Supplementary Figure 2.3: Dosage plots of the effect sizes of genetic variants for glycine 









0.0 0.1 0.2 0.3

























0.05 0.10 0.15 0.20














0.05 0.10 0.15 0.20












0.0 0.1 0.2 0.3

























0.05 0.10 0.15 0.20














0.05 0.10 0.15 0.20













0.0 0.1 0.2 0.3 0.4














A| Score comprising all common loci 
identified for glycine levels
B| Score including 6 loci near glycine 
enzymes
D| Score including 2 loci near 
enzym s of glycine cleavag  system
C| Score including 5 loci near glycine 







Supplementary Figure 2.4: Dosage plots of the effect sizes of genetic variants for glycine 







Supplementary Figure 2.5: Dosage plots of the effect sizes of genetic variants for glycine 







Supplementary Figure 2.6: Forest plots showing the effect sizes of genetically predicted 








Supplementary Figure 3.1: Scatterplots of BMI versus BF% based on all assessment 













Supplementary Figure 3.2: Effect sizes of the low-frequency coding variants reaching 
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Supplementary Figure 3.3: Effect sizes of the low-frequency coding variants reaching 
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Supplementary Table 1.1: Search terms for systematic literature search on metabolite 
patterns associated with T2D 
 
 Search Terms  
Number 




studies #1  
“Case-Control Studies”[MeSH] OR Case-Control Study OR Case-Control 
Studies OR Case-control Study OR Case-control Studies OR Studies, Case-
Control OR Study, Case-Control OR Case-Comparison Studies OR Case 
Comparison Studies OR Case-Comparison Study OR Studies, Case-
Comparison OR Study, Case- Comparison OR Case-Referent Studies OR 
Case Referent Studies OR Case- Referent Study OR Studies, Case-Referent 
OR Study, Case-Referent OR Case- Referent Studies OR Case Referent 
Studies OR Case-Referent Study OR Studies, Case-Referent OR Study, Case-
Referent OR Case Control Studies OR Case Control Study OR Studies, Case 
Control OR Study, Case Control OR Matched Case-Control Studies OR 
Case-Control Studies, Matched OR Case-Control Study, Matched OR 
Matched Case Control Studies OR Matched Case-Control Study OR Studies, 
Matched Case-Control OR Study, Matched Case-Control OR Nested Case-
Control Studies OR Case-Control Studies, Nested OR Case-Control Study, 
Nested OR Nested Case Control Studies OR Nested Case-Control Study OR 
Studies, Nested Case-Control OR Study, Nested Case-Control OR “Cross-
Sectional Studies”[MeSH] OR Cross-sectional Studies OR Cross Sectional 
Studies OR Cross Sectional Study OR Cross-Sectional Study OR Studies, 
Cross-Sectional OR Study, Cross-Sectional OR Cross Sectional Analysis OR 
Analyses, Cross Sectional OR Cross Sectional Analyses OR Disease 
Frequency Surveys OR Surveys, Disease Frequency OR Disease Frequency 
Survey OR Survey, Disease Frequency OR Analysis, Cross- Sectional OR 
Analyses, Cross-Sectional OR Analysis, Cross Sectional OR Cross- Sectional 
Analyses OR Cross-Sectional Analysis OR Cross-Sectional Survey OR Cross 
Sectional Survey OR Cross-Sectional Surveys OR Survey, Cross-Sectional OR 
Surveys, Cross-Sectional OR Prevalence Studies OR Prevalence Study OR 
Studies, Prevalence OR Study, Prevalence OR "Cohort Studies"[Mesh] OR 
Cohort Study OR Studies, Cohort OR Study, Cohort OR Studies, Historical 
Cohort OR Cohort Studies, Historical Cohort Study, Historical OR Historical 






 Search Terms  
Number 
of Titles  
 
Cohort OR Cohort Analyses OR Cohort Analysis OR Incidence Studies OR 
Incidence Study OR Studies, Incidence OR Study, Incidence OR 
"Incidence"[Mesh] OR "Cohort Studies"[Mesh] OR Case- cohort study OR 
Nested case-control study OR Survey OR cross-sectional OR case- control  
Type 2 Diabetes #2  
“Diabetes mellitus, Type 2”[Mesh] OR NIDDM OR Maturity-Onset 
Diabetes OR Diabetes Mellitus, Noninsulin-Dependent OR Diabetes 
Mellitus, Adult-Onset OR Adult-Onset Diabetes Mellitus OR Diabetes 
Mellitus, Adult Onset OR Diabetes Mellitus, Maturity-Onset OR Diabetes 
Mellitus, Maturity Onset OR Diabetes Mellitus, Non-Insulin Dependent OR 
Diabetes Mellitus, Non-Insulin-Dependent OR Non-Insulin-Dependent 
Diabetes Mellitus OR Diabetes Mellitus, Noninsulin Dependent OR Diabetes 
Mellitus, Slow-Onset OR Diabetes Mellitus, Slow Onset OR Slow-Onset 
Diabetes Mellitus OR Diabetes Mellitus, Stable OR Stable Diabetes Mellitus 
OR Diabetes Mellitus, Type II OR Maturity-Onset Diabetes Mellitus OR 
Maturity Onset Diabetes Mellitus OR MODY OR Type 2 Diabetes Mellitus 
OR Noninsulin-Dependent Diabetes Mellitus OR “Type 2 Diabetes”[tiab] 
OR “Diabetes”[ti]  
 
289,004  
Metabolomics #3  
metabolomics OR metabolome OR metabonomics OR metabolic profiling 
OR metabolite profiling OR metabolites OR metabolome OR lipid profiling 
OR amino acid profiling OR lipidomics OR metabolite profiles OR 
metabolite profile OR “mass spectrometry” [MeSH] OR mass spectrometry 
OR NMR OR nuclear magnetic resonance OR “NMR spectroscopy” [MeSH] 










Supplementary Table 2.1: Results of approximate conditional analyses: stepwise selection 
model to identify additional independent signals for glycine levels 
 






pmarginal Zjoint Pjoint 
1 rs4646961 1:76217169 A G 0.297 ACADM intronic 8.854 8.4E-19 8.854 9.1E-19 
2 rs561931 1:120254506 G A 0.593 PHGDH UTR5 7.478 7.6E-14 7.478 7.9E-14 
3 rs10184004 2:165508389 T C 0.400 COBLL1 intergenic 6.041 1.5E-09 6.041 1.6E-09 
4 rs1861072 2:210851634 T C 0.591 UNC80 intronic 3.932 8.4E-05 7.250 2.8E-12 





13.236 5.4E-40 6.496 6.4E-10 
4 rs1509820 2:211386484 A G 0.530 CPS1 intronic 11.194 4.4E-29 29.075 2.1E-52 
4 rs715 2:211543055 C T 0.313 CPS1 UTR3 86.626 ###### 36.940 1.9E-105 
4 rs62177991 2:211884231 G A 0.517 CPS1 intergenic 8.318 9.0E-17 7.506 6.9E-14 
4 rs115683961 2:212385920 A G 0.938 ERBB4 intronic 3.89 1.0E-04 5.571 2.8E-08 
5 rs141015398 3:125618725 A G 0.989 
LOC1019270
56 
intergenic 5.558 2.7E-08 5.530 3.2E-08 
5 rs2276724 3:125854409 T C 0.841 ALDH1L1 exonic 6.554 5.6E-11 7.162 1.6E-11 
5 rs4646705 3:125875831 A G 0.497 ALDH1L1 intronic 6.187 6.1E-10 5.920 2.3E-08 





11.514 1.1E-30 13.317 6.3E-38 
5 rs79064296 3:125985069 T G 0.045 
ALDH1L1-
AS2 
intergenic 8.236 1.8E-16 6.448 1.6E-10 
6 rs148685782 4:155533035 G C 0.996 FGG exonic 
Rare variant: not included in conditional 
analyses 
7 rs1912826 4:187149540 A G 0.522 KLKB1 intronic 6.175 6.6E-10 6.175 6.8E-10 
8 rs156380 5:53378450 C T 0.807 ARL15 intronic 5.47 4.5E-08 5.470 4.5E-08 
9 rs3105793 5:90226061 A G 0.273 ADGRV1 intronic 5.489 4.0E-08 5.489 4.1E-08 
10 rs10900807 5:131757480 G C 0.805 C5orf56 
ncRNA 
intronic 
6.073 1.3E-09 6.073 1.3E-09 
11 rs2545801 5:176841339 C T 0.747 F12 intergenic 7.484 7.2E-14 7.484 7.5E-14 
12 rs543159 6:160776017 A C 0.482 SLC22A3 intronic 6.246 4.2E-10 6.246 4.3E-10 
13 rs4689 7:56067016 T G 0.771 NIPSNAP2 UTR3 11.743 7.7E-32 8.236 3.2E-12 
13 rs62457261 7:56080426 G C 0.570 PSPH intronic 10.98 4.8E-28 6.604 2.3E-08 
14 rs7012637 8:9173209 G A 0.525 LOC157273 intergenic 10.387 2.9E-25 8.088 1.8E-15 
14 rs9987289 8:9183358 A G 0.100 LOC157273 
ncRNA 
intronic 
14.788 1.7E-49 13.402 1.0E-39 
15 rs55748921 8:126492927 C A 0.693 TRIB1 intergenic 6.542 6.1E-11 6.646 3.1E-11 
15 rs28601761 8:126500031 G C 0.416 TRIB1 intergenic 11.338 8.5E-30 11.399 5.4E-30 
16 rs13299380 9:6078779 T C 0.053 RANBP6 intergenic 8.276 1.3E-16 6.662 3.6E-11 
16 rs113626350 9:6490491 A G 0.046 UHRF2 intronic 9.359 8.1E-21 6.976 5.4E-12 
16 rs17591030 9:6550024 C T 0.715 GLDC intronic 13.316 1.9E-40 11.612 2.7E-30 
16 rs143119940 9:6554781 A C 0.011 GLDC exonic 10.537 5.8E-26 9.140 1.4E-19 
16 rs67506027 9:6657690 A C 0.607 GLDC intergenic 8.571 1.0E-17 6.792 1.9E-11 
17 rs676996 9:136146077 T G 0.668 ABO intronic 7.843 4.4E-15 7.843 4.6E-15 
18 rs190595610  10:32274880 A G 0.997 KIF5B intergenic 
Rare variant: not included in conditional 
analyses 












pmarginal Zjoint Pjoint 
19 rs10740134 10:65315433 T C 0.515 REEP3 intronic 7.108 1.2E-12 20.257 4.0E-19 
20 rs12297321 12:47109387 T C 0.152 SLC38A4 intergenic 7.172 7.4E-13 7.238 4.6E-13 
21 rs2638314 12:56866334 A T 0.182 GLS2 intronic 5.659 1.5E-08 5.743 9.4E-09 
22 rs9514191 13:104520138 C G 0.312 LINC01309 intergenic 5.536 3.1E-08 5.536 3.1E-08 
23 rs201393666  15:43677979 A C 0.029 TUBGCP4 intronic 
Did not reach significance in conditional 
analyses 
24 rs2280195 15:58467095 A G 0.441 AQP9 intronic 5.923 3.2E-09 5.923 3.2E-09 
25 rs9923732 16:81110903 A G 0.914 C16orf46 upstream 13.518 1.2E-41 11.615 2.3E-28 
25 rs4520846 16:81142358 A C 0.353 PKD1L2 intronic 2.586 9.7E-03 8.070 2.6E-08 
25 rs11647428 16:81150559 G A 0.490 PKD1L2 intronic 8.398 4.5E-17 22.827 1.5E-28 




25 rs16954688 16:81156808 G A 0.953 PKD1L2 intronic 8.602 7.8E-18 7.724 4.7E-14 
26 rs8078686 17:45735706 C T 0.509 KPNB1 intronic 6.617 3.7E-11 6.617 3.8E-11 
27 rs273510 19:18223350 A G 0.708 MAST3 intronic 5.903 3.6E-09 5.903 3.6E-09 
EA: effect allele, OA: other allele, EAF: effect allele frequency, chr:pos: chromosome and base pair position according to genome 
build GRCh37, Zmarginal: Z score from p-value-based meta-analysis of 5 studies, pmarginal: p-value from p-value-based meta-analyses 
of 5 studies, Zjoint: Z from the joint model fitted by GCTA-COJO, pjoint: p-value from the joint model fitted by GCTA-COJO.  
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Supplementary Table 2.2: Reported associations of glycine loci with other traits and metabolites 
 
Locus rsid 
Traits associated with 
variant 
Traits associated 
with variants in 
high LD (R2>0.6) 
Reported metabolite associations 
for lead variant 
Reported metabolite associations for 
variants in high LD (R2>0.8) 
Reported metabolite associations for variants 
within 1 MB of lead variant 
1 rs4646961   
hexanoylcarnitine [24816252]; 
octanoylcarnitine[24816252]; cis-4-
decenoyl carnitine [24816252]; 
decanoylcarnitine [24816252];  X-
23293[28263315]; X-12824 
[28263315]; X-12855 [24816252] 
hexanoylcarnitine [24816252]; 
octanoylcarnitine [24816252];  cis-4-
decenoyl carnitine [24816252];  
decanoylcarnitine  [24816252];  
Decenoylcarnitine  [26068415]; 
Acylcarnitine levels  [26068415]; X-23293  
[28263315];  C6(C4:1-DC)  [20037589]; C8  
[20037589]; C10 [20037589]; X-12824  
[28263315];  hexanoylglycine  [28263315]; 
caprylate (8:0)  [28263315]; X-12855  
[24816252]; X-17327  [28263315];  X-
12101  [28263315] ; X-12472 [28263315]; 
hexanoylcarnitine  [24816252]; octanoylcarnitine 
[24816252]; cis-4-decenoyl carnitine [24816252];  
Decenoylcarnitine  [26068415]; Decanoylcarnitine  
[26068415]; Acylcarnitine levels [26068415];  X-
23293 [28263315]; C6(C4:1-DC)  [20037589]; Serum 
concentration of decanoylcarnitine  [21886157]; C8  
[20037589]; C10 [20037589]; X-12824  [28263315]; 
hexanoylglycine  [28263315];  C10:1  [20037589]; 
LDL cholesterol  [23063622]; caprylate (8:0)  
[28263315]; X-12855 [24816252]; X-17327  
[28263315]; X-12101  [28263315]; malonate  
[28263315]; 
2 rs561931   Serine[26068415] serine [24816252] 
serine[24816252]; alpha-hydroxyisovalerate 
[24816252]; 2-hydroxy-3-methylvalerate [28263315] 
3 rs10184004 
Type II diabetes (-) [ 
26551672]; hip (+) [ 
25673412]; waist/hip (-
) [ 25673412]; 
triglycerides (-) [ 
24097068]; 
HDL (+) [ 
24097068]; LDL (-) [ 
24097068]; fasting 




HDL cholesterol lipoprotein fraction concentration 
[19936222] 
4 rs715 
eGFR creatinine (-) 
[26831199], fibrinogen 
(-) [23969696], serum 
creatinine [20383146], 
HDL (-) [24097068] 




[28263315];   X-08988 [24816252]; 
glycine  [24816252]; N-acetylglycine 
[28263315]; propionylglycine  [28263315]; 
X-16570  [28263315];  N-palmitoylglycine 
[28263315]; Serum glycine (females) 
[21852955]; 3-methylglutaconate  
glycine  [24816252]; nonanoylcarnitine  [24816252]; 
Nonaylcarnitine  [26068415]; N-acetylglycine  
[28263315]; propionylglycine  [28263315]; X-16570 
[28263315]; N-palmitoylglycine  [28263315];  3-




Traits associated with 
variant 
Traits associated 
with variants in 
high LD (R2>0.6) 
Reported metabolite associations 
for lead variant 
Reported metabolite associations for 
variants in high LD (R2>0.8) 
Reported metabolite associations for variants 
within 1 MB of lead variant 







creatine [24816252]; serine 
[24816252];  betaine [24816252]; 
gamma-glutamylglycine [28263315]; 
creatine (urine) [26352407]; 







[28263315]; hexanoylglycine  [28263315]; 
X-08988  [24816252]; 3-
methylglutarylcarnitine (2)  [28263315]; 
homoarginine  [28263315]; 
cinnamoylglycine  [28263315]; creatine 
[24816252]; serine  [24816252]; glycine 
(urine) [26352407]; betaine [24816252]; 
gamma-glutamylglycine  [28263315]; 
creatine (urine) [26352407]; pyroglutamine 
[24816252]; glutaroyl carnitine  
[24816252]; guanidinosuccinate 
[28263315]; Serum creatinine  [20383146]; 
HDL cholesterol [24097068]; Serum 
glycine (males) [21852955];  gamma-
glutamylthreonine  [28263315];  
glutarylcarnitine (C5)  [28263315) 
[28263315]; X-08988  [24816252]; 3-
methylglutarylcarnitine (2)  [28263315]; 
homoarginine  [28263315]; cinnamoylglycine  
[28263315];  Serum 2,6-dimethylheptanoylcarnitine 
[23281178]; serine  [24816252]; glycine (urine) 
[26352407]; betaine [24816252];  gamma-
glutamylglycine  [28263315]; creatine (urine) 
26352407]; pyroglutamine [24816252]; glutaroyl 
carnitine  [24816252]; Serine  [26068415]; Serum 
creatinine [20383146]; HDL cholesterol [24097068]; 
pyroglutamine  [28263315]; gamma-
glutamylthreonine  [28263315]; Serum concentration 
of creatine [21886157]; citrulline  [24816252]; 
glutarylcarnitine (C5)  [28263315] 




 X-21628  [28263315] X-21628  [28263315] 







prolylproline  [28263315]; 
glycylphenylalanine  [28263315]; X-11792 
[24816252]; isoleucylvaline  [28263315]; 
Serum His  [22286219]; HWESASXX  
[28263315]; X-24071 [28263315) 
prolylproline  [28263315]; glycylphenylalanine  
[28263315];  X-11792  [24816252]; isoleucylvaline  
[28263315]; ADSGEGDFXAEGGGVR 
[24816252];Serum His [22286219]; HWESASXX  
[28263315]; X-24071  [28263315] 
8 rs156380     citrulline  [24816252] 




Traits associated with 
variant 
Traits associated 
with variants in 
high LD (R2>0.6) 
Reported metabolite associations 
for lead variant 
Reported metabolite associations for 
variants in high LD (R2>0.8) 
Reported metabolite associations for variants 
within 1 MB of lead variant 
10 rs10900807 











Octadecenoylcarnitine  [26068415]; 
glutaroyl carnitine  [24816252]; 
palmitoylcarnitine  [24816252) 
isovalerylcarnitine  [24816252];  tryptophan betaine  
[24816252]; 3-dehydrocarnitine [24816252]; 
Octadecadienylcarnitine  [26068415]; carnitine  
[24816252]; Acylcarnitine levels  [26068415]; 
propionylcarnitine  [24816252]; Serum 
concentration of Isovalerylcarnitine [21886157]; 
Octadecenoylcarnitine  [26068415];  Acetylcarnitine  
[26068415]; Serum concentration of 3-
dehydrocarnitine [21886157];  tryptophan betaine  
[28263315]; hexanoylcarnitine  [24816252]; 
oleoylcarnitine [24816252];  homostachydrine 
[24816252]; myristoylcarnitine  [28263315]; 
stearoylcarnitine  [24816252]; X-21365  [28263315]; 
palmitoylcarnitine  [24816252]; serum concentration 
of propionylcarnitine [21886157]; 2-tetradecenoyl 
carnitine  [24816252]; hydroxyisovaleroyl carnitine  
[24816252]; glutaroyl carnitine  [24816252]; 




thromboplastin time (-) 
[22703881],  C-terminal 






prolylproline  [28263315]; 
glycylphenylalanine  [28263315]; X-
24071  [28263315]; isoleucylvaline  




[28263315]; prolylproline  [28263315]; 
glycylphenylalanine [28263315]; X-24071  
[28263315]; isoleucylvaline  [28263315];  
ADSGEGDFXAEGGGVR [24816252]; 
Serum Phe  [22286219];  X-11792  
[24816252) 
leucylphenylalanine/isoleucylphenylalanine  
[28263315]; prolylproline [28263315]; 
glycylphenylalanine [28263315];  X-24071  
[28263315]; isoleucylvaline [28263315]; Serum 
creatinine [20383146]; ADSGEGDFXAEGGGVR 
[24816252]; 3-methylhistidine [28263315];  Serum 





Traits associated with 
variant 
Traits associated 
with variants in 
high LD (R2>0.6) 
Reported metabolite associations 
for lead variant 
Reported metabolite associations for 
variants in high LD (R2>0.8) 
Reported metabolite associations for variants 
within 1 MB of lead variant 
12 rs543159  
total cholesterol (-) [24097068], total triglycerides (-) 
[24097068] 
X-12798  [24816252] 
isobutyrylcarnitine  [24816252]; X-11261  
[24816252]; Octenoylcarnitine  [26068415]; 
propionylcarnitine  [24816252];  Serum creatinine 
[20383146]; 3-methylglutarylcarnitine (2)  
[28263315]; beta-hydroxyisovalerate  [24816252]; 
N1-methyladenosine [24816252]; 3-
dehydrocarnitine*  [24816252]; 2-
methylbutyroylcarnitine  [24816252];  3-
phenylpropionate (hydrocinnamate)  [21886157) 
13 rs4947534   Serine  [26068415] Serine  [26068415] 
Serine  [26068415];  Metabolites in glutathione and 
glycine biosynthesis pathways [23378610];  
erythronate [24816252]; X-11317  [24816252] 
14 rs9987289 
HDL (-) [24097068], 
LDL (-) [24097068], 
total cholesterol (-) 
[24097068], fasting 
glucose (+) [22885924], 
fasting insulin (+) 
[22885924], CRP (+) 
[21300955] 
fatty liver (+)[21423719], liver enzymes (+) [22001757]  
VLDL cholesterol mean particle size lipoprotein 
fraction concentration in fasting sample [19936222]; 
HDL Cholesterol - Triglycerides (HDLC-TG) 
[21386085] 
15 rs28601761  
HDL (-) [24097068], 
LDL (+) [24097068], 
total cholesterol (+) 
[24097068], total 
triglycerides (+) 
[24097068], CAD (+) 
[28530674] 
  
LDL cholesterol small lipoprotein fraction 
concentration [19936222]; LDL cholesterol total 
lipoprotein fraction concentration [19936222]; 
Triglycerides by NMR lipoprotein fraction 
[19936222]; LDL cholesterol mean size lipoprotein 
fraction concentration [19936222]; X-16946  
[28263315) 
16 rs17591030     
3-methylglutaconate  [28263315]; 3-




Traits associated with 
variant 
Traits associated 
with variants in 
high LD (R2>0.6) 
Reported metabolite associations 
for lead variant 
Reported metabolite associations for 
variants in high LD (R2>0.8) 
Reported metabolite associations for variants 
within 1 MB of lead variant 
17 rs676996  
MI (-) [26343387], 
venous thrombosis (-







Factor  VIII antigen 
(-) [23381943], von 
Willebrand factor (-) 
[23381943] 
 
Circulating galectin-3 levels [23056639]; 
Serum concentration of 
ADpSGEGDFXAEGGGVR* 
[21886157]; Serum phytosterol 
(campesterol)  [20529992]; leucylalanine  
[28263315] 
Circulating galectin-3 levels [23056639];  
ADpSGEGDFXAEGGGVR*  [24816252];Serum 
phytosterol (campesterol)  [20529992];  X-17178  
[28263315]; leucylalanine  [28263315];  O-sulfo-L-
tyrosine  [24816252]; Serum phytosterol  
[20529992]; glycylglycine  [28263315];alpha-
glutamylglycine [28263315] 
18 rs190595610     
19 rs10740134 
triglycerides (+) 
[24097068], HDL (-) 
[24097068] 
  
VLDL cholesterol total lipoprotein 
fraction concentration [19936222]; VLDL 
cholesterol medium lipoprotein fraction 
concentration [19936222] 
VLDL cholesterol medium lipoprotein fraction 
concentration  [19936222] 
20 rs12297321     
alanine  [24816252]; ibuprofen [24816252]; carnitine  
[24816252] 
21 rs2638314  
fasting blood glucose 
(+) [22885924] 
glutamine  [28263315]; gamma-
glutamylglutamine  [28263315) 
gamma-glutamylglutamine  [24816252]; 
glutamine [24816252] 
Serum Gln [22286219]; Urate levels [23263486]; 
gamma-glutamylglutamine  [24816252];  1,7-
dimethylurate [28263315]; caffeine [28263315] 
22 rs9514191     
X-12850 [24816252];  taurolithocholate 3-sulfate  
[28263315] 




Traits associated with 
variant 
Traits associated 
with variants in 
high LD (R2>0.6) 
Reported metabolite associations 
for lead variant 
Reported metabolite associations for 
variants in high LD (R2>0.8) 
Reported metabolite associations for variants 
within 1 MB of lead variant 
24 rs2280195     
HDL cholesterol large lipoprotein fraction 
concentration [19936222]; Serum XL-HDL-TG 
[22286219]; HDL cholesterol mean size lipoprotein 
fraction concentration [19936222]; LDL cholesterol 
large lipoprotein fraction concentration  [19936222]; 
HDL cholesterol large lipoprotein fraction 
concentration in fasting sample [19936222]; PE 36:4   
[22359512]; Serum HDL-D  [22286219]; HDL 
cholesterol mean size lipoprotein fraction 
concentration in fasting sample [19936222]; Serum 
LDL-D [22286219]; HDL cholesterol lipoprotein 
fraction concentration by NMR [19936222]; Serum 
XL-HDL-PL [22286219]; LDL cholesterol large 
lipoprotein fraction concentration in fasting sample 
[19936222]; Serum XL-HDL-P [22286219]; LDL 
cholesterol mean size lipoprotein fraction 
concentration  [19936222];  Serum L-HDL-P  
[22286219]; HDL cholesterol (female)  [23063622]; 
Serum L-HDL-L  [22286219]; Serum XL-HDL-L  
[22286219]; etc. 
25 rs9923732   Glycine  [26068415] Glycine  [26068415] 
Beta-carotene plasma levels  [19185284]; Carotenoid 
and tocopherol levels  [19185284]; Lutein plasma 
levels [19185284];  caprylate (8:0)  [24816252]; 
caprate (10:0)  [24816252) 
26 rs8078686 
height (+) [25282103],  
LDL (-) [24097068], 
total cholesterol (-) 
[24097068] 
optic cup area (-) 
[25631615] 
 carnitine  [24816252] carnitine  [24816252] 
27 rs273510     myo-inositol  [24816252] 
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Supplementary Table 2.3: Sex-specific effect sizes of the 27 glycine loci on log-
transformed-only levels of glycine in the EPIC-Norfolk study 
 
  
Men Women P-value for sex 
difference Locus SNP Beta SE P Beta SE P 
1 rs4646961 0.009 0.003 2.30E-03 0.015 0.004 1.01E-04 0.214 
2 rs561931 0.016 0.003 4.28E-09 0.003 0.004 3.72E-01 0.004 
3 rs10184004 0.004 0.003 1.03E-01 0.015 0.004 3.49E-05 0.021 
4 rs715 0.076 0.003 4.59E-159 0.194 0.003 0.00E+00 3.184E-158 
5 rs9862438 0.017 0.003 1.97E-10 0.031 0.004 9.21E-18 0.003 
6 rs148685782 0.026 0.024 2.89E-01 0.057 0.031 6.68E-02 0.436 
7 rs71640034 0.000 0.003 8.84E-01 0.008 0.004 3.45E-02 0.110 
8 rs156380 0.002 0.003 5.85E-01 0.010 0.004 2.72E-02 0.151 
9 rs3105793 0.007 0.003 2.66E-02 0.006 0.004 1.44E-01 0.877 
10 rs10900807 0.009 0.003 7.66E-03 0.006 0.005 2.17E-01 0.554 
11 rs2545801 0.003 0.003 3.24E-01 0.001 0.004 8.96E-01 0.628 
12 rs543159 0.005 0.003 8.37E-02 0.002 0.004 6.00E-01 0.528 
13 rs4947534 0.020 0.003 2.34E-10 0.014 0.004 5.37E-04 0.305 
14 rs9987289 0.033 0.005 1.16E-12 0.021 0.006 7.43E-04 0.123 
15 rs28601761 0.024 0.003 3.67E-19 0.015 0.004 7.30E-05 0.030 
16 rs17591030 0.014 0.003 2.64E-06 0.032 0.004 6.39E-16 0.000 
17 rs676996 0.003 0.003 3.44E-01 0.008 0.004 4.51E-02 0.307 
18 rs190595610 0.030 0.025 2.30E-01 0.027 0.036 4.54E-01 0.939 
19 rs10740134 0.002 0.003 3.58E-01 0.010 0.004 6.43E-03 0.104 
20 rs12297321 0.008 0.004 3.09E-02 0.021 0.005 9.77E-06 0.026 
21 rs2638314 0.004 0.003 2.47E-01 0.015 0.005 9.90E-04 0.057 
22 rs9514191 0.003 0.003 3.33E-01 0.005 0.004 1.72E-01 0.616 
23 rs201393666 0.036 0.008 3.08E-06 -0.004 0.011 7.25E-01 0.003 
24 rs2280195 0.010 0.003 1.35E-04 0.001 0.004 7.34E-01 0.044 
25 rs9923732 0.042 0.005 1.22E-16 0.016 0.007 1.72E-02 0.002 
26 rs8078686 0.010 0.003 1.33E-04 0.006 0.004 8.36E-02 0.354 





Supplementary Table 2.4: Associations of the 4 glycine scores and rs715 with the 84 





Full score (24 
SNPs) 
Glycine-related 
score (6 SNPs) 
Glycine-related 
score without 
CPS1 (5 SNPS) 
Glycine-specific 
score (2 SNPs) rs715 
Beta p Beta p Beta p Beta p Beta p 
glycine 1.000 1.203 <1E-320 1.260 
<1E-
320 1.156 1.7E-32 1.112 3.4E-16 0.564 1E-320 
gamma-glutamylglycine 0.903 1.056 2.22E-317 1.117 
3.7E-
308 0.991 2.1E-23 0.968 3.4E-12 0.501 4.6E-284 
N-acetylglycine 0.477 0.831 1.4E-197 0.913 
3.4E-
208 0.879 3.5E-19 0.869 2.4E-10 0.407 3.0E-189 
propionylglycine 0.451 0.796 5.4E-145 0.871 
4.7E-
152 0.663 1.8E-09 0.736 1.8E-06 0.395 4.9E-144 
X - 16570 0.404 0.679 1.5E-114 0.753 
1.6E-
122 0.618 4.1E-09 0.663 6.7E-06 0.340 9.1E-115 
3-methylglutaconate 0.180 0.611 2.4E-96 0.681 
2.2E-
104 0.319 2.0E-03 0.652 5.9E-06 0.319 3.8E-105 
3-
methylglutarylcarnitine 0.247 0.564 7.5E-85 0.642 2.3E-95 0.354 4.9E-04 0.751 1.2E-07 0.298 1.2E-94 
homoarginine -0.306 -0.544 5.2E-82 -0.605 4.5E-88 -0.255 1.0E-02 -0.286 3.9E-02 -0.285 1.2E-89 
N-palmitoyl glycine 0.235 0.512 2.7E-68 0.554 1.2E-69 0.530 2.5E-07 0.531 2.2E-04 0.247 1.0E-63 
X - 17367 0.286 0.540 1.8E-63 0.585 6.0E-65 0.252 2.6E-02 0.129 4.2E-01 0.275 6.1E-66 
X - 13722 0.300 0.526 6.4E-58 0.539 5.9E-53 0.564 8.2E-07 0.590 2.4E-04 0.237 2.4E-47 
isovalerylglycine 0.373 0.521 3.0E-54 0.537 1.8E-50 0.507 1.8E-05 0.709 1.8E-05 0.240 2.0E-46 
serine 0.560 0.427 6.2E-50 0.418 6.6E-42 0.978 1.6E-22 0.488 5.0E-04 0.159 1.8E-28 
cinnamoylglycine 0.268 0.420 3.5E-47 0.448 9.6E-47 0.448 1.0E-05 0.488 6.0E-04 0.199 2.3E-42 
X - 16564 0.227 0.411 3.9E-44 0.452 2.8E-46 0.252 1.5E-02 0.327 2.3E-02 0.210 6.1E-46 
isobutyrylglycine 0.275 0.469 1.3E-43 0.504 5.9E-44 0.435 2.3E-04 0.490 3.0E-03 0.227 5.1E-41 
creatine 0.253 0.353 1.0E-42 0.376 4.3E-42 0.370 4.0E-05 0.348 5.7E-03 0.167 2.5E-38 
hexanoylglycine 0.221 0.523 1.1E-41 0.610 2.6E-49 0.548 5.8E-05 0.661 6.4E-04 0.273 1.2E-45 
pyroglutamine* -0.165 -0.279 8.9E-34 -0.308 8.9E-36 -0.384 1.7E-06 -0.372 9.2E-04 -0.133 6.6E-31 
betaine 0.030 -0.312 8.2E-29 -0.378 2.1E-36 -0.301 2.1E-03 -0.200 1.4E-01 -0.171 1.9E-34 
X - 21467 0.165 0.324 1.1E-25 0.367 1.6E-28 0.274 1.1E-02 0.304 4.3E-02 0.167 2.6E-27 
X - 23637 0.468 0.250 9.8E-18 0.250 1.2E-15 0.691 8.8E-12 0.438 2.0E-03 0.090 5.8E-10 
X - 24542 0.159 0.205 4.7E-11 0.211 2.3E-10 0.259 1.7E-02 0.297 5.0E-02 0.092 3.9E-09 
5-methylthioadenosine 
(MTA) -0.142 -0.189 3.4E-10 -0.201 3.9E-10 -0.391 1.7E-04 -0.251 8.4E-02 -0.080 8.9E-08 
X - 11261 -0.047 -0.182 5.7E-10 -0.199 2.5E-10 -0.312 2.3E-03 -0.433 2.5E-03 -0.083 1.5E-08 
X - 11564 -0.133 -0.172 1.5E-09 -0.205 1.5E-11 -0.402 4.9E-05 -0.306 2.7E-02 -0.082 7.9E-09 
glutarylcarnitine (C5) -0.088 -0.172 2.9E-09 -0.205 4.0E-11 -0.038 7.0E-01 0.043 7.6E-01 -0.099 9.2E-12 
X - 17351 -0.045 -0.181 4.9E-09 -0.182 3.9E-08 -0.243 2.4E-02 0.088 5.6E-01 -0.078 4.4E-07 
taurocholenate sulfate -0.154 -0.171 5.9E-09 -0.169 8.8E-08 -0.176 8.6E-02 -0.123 3.9E-01 -0.075 4.1E-07 
1-stearoyl-2-
docosapentaenoyl-GPC 
(18:0/22:5n6)* -0.134 -0.171 6.6E-09 -0.153 1.3E-06 -0.217 3.5E-02 -0.270 6.0E-02 -0.065 1.1E-05 
gamma-
glutamylthreonine* 0.196 -0.172 6.7E-09 -0.225 1.7E-12 -0.147 1.6E-01 -0.084 5.6E-01 -0.103 3.4E-12 










Full score (24 
SNPs) 
Glycine-related 
score (6 SNPs) 
Glycine-related 
score without 
CPS1 (5 SNPS) 
Glycine-specific 
score (2 SNPs) rs715 
Beta p Beta p Beta p Beta p Beta p 
1-stearoyl-2-
docosahexaenoyl-GPC 
(18:0/22:6) -0.074 -0.161 4.0E-08 -0.130 3.6E-05 -0.180 7.8E-02 -0.272 5.7E-02 -0.055 1.6E-04 
1-methylurate -0.014 -0.164 4.9E-08 -0.184 1.2E-08 -0.048 6.5E-01 0.057 6.9E-01 -0.088 5.2E-09 
1-docosapentaenoyl-
GPC (22:5n6)* -0.088 -0.170 5.0E-08 -0.159 2.0E-06 -0.163 1.4E-01 -0.186 2.2E-01 -0.070 6.7E-06 
arginine 0.092 -0.157 1.0E-07 -0.194 9.2E-10 -0.037 7.2E-01 -0.144 3.2E-01 -0.093 2.6E-10 
aspartate -0.091 -0.150 3.3E-07 -0.153 1.2E-06 -0.284 5.4E-03 -0.256 7.3E-02 -0.062 2.6E-05 
glycocholenate sulfate* 0.035 0.146 3.8E-07 0.180 5.4E-09 0.143 1.5E-01 0.048 7.3E-01 0.082 1.4E-08 
deoxycarnitine 0.032 -0.134 4.1E-07 -0.152 8.2E-08 -0.173 6.0E-02 -0.196 1.3E-01 -0.066 5.0E-07 
taurolithocholate 3-
sulfate -0.028 -0.146 7.7E-07 -0.157 7.1E-07 -0.122 2.3E-01 -0.108 4.5E-01 -0.071 1.4E-06 
X - 21821 -0.050 -0.154 9.3E-07 -0.157 3.5E-06 -0.250 2.3E-02 0.076 6.2E-01 -0.065 3.6E-05 
X - 13431 -0.042 -0.143 9.3E-07 -0.143 4.7E-06 0.011 9.2E-01 -0.108 4.5E-01 -0.071 1.3E-06 
1-stearoyl-2-
docosapentaenoyl-GPC 
(18:0/22:5n3)* -0.032 -0.144 1.1E-06 -0.122 1.2E-04 -0.210 4.0E-02 -0.356 1.3E-02 -0.050 7.1E-04 
1-oleoyl-2-
docosahexaenoyl-GPC 
(18:1/22:6)* 0.098 -0.139 1.3E-06 -0.130 2.5E-05 -0.106 2.9E-01 -0.126 3.7E-01 -0.059 4.3E-05 
choline 0.022 -0.140 1.5E-06 -0.179 1.0E-08 -0.126 2.1E-01 -0.106 4.6E-01 -0.082 2.0E-08 
sphingomyelin 
(d18:1/20:1, 
d18:2/20:0)* 0.241 0.132 2.0E-06 0.135 5.8E-06 0.168 8.3E-02 0.162 2.3E-01 0.059 2.6E-05 
X - 12283 -0.047 -0.160 2.3E-06 -0.162 8.2E-06 -0.223 5.8E-02 -0.082 6.2E-01 -0.069 4.7E-05 
kynurenate -0.045 -0.136 2.9E-06 -0.172 3.4E-08 -0.128 2.1E-01 -0.050 7.2E-01 -0.078 7.1E-08 
adenine -0.104 -0.137 3.3E-06 -0.144 4.7E-06 -0.270 8.3E-03 -0.076 5.9E-01 -0.058 7.7E-05 
octanoylcarnitine -0.103 -0.138 3.4E-06 -0.068 3.2E-02 -0.103 3.2E-01 -0.117 4.2E-01 -0.029 5.3E-02 
dimethylglycine -0.084 -0.133 3.7E-06 -0.145 2.6E-06 -0.232 2.0E-02 -0.319 2.2E-02 -0.060 2.8E-05 
N-acetylthreonine -0.021 -0.135 3.9E-06 -0.139 9.3E-06 -0.142 1.6E-01 -0.107 4.5E-01 -0.061 2.6E-05 
X - 16944 0.015 -0.137 4.3E-06 -0.143 7.7E-06 -0.126 2.2E-01 -0.129 3.7E-01 -0.064 1.7E-05 
docosahexaenoylcholine 0.021 -0.133 5.5E-06 -0.113 3.3E-04 -0.030 7.7E-01 -0.064 6.5E-01 -0.054 2.4E-04 
biliverdin -0.021 0.131 5.9E-06 0.122 8.2E-05 0.180 7.4E-02 0.147 3.0E-01 0.052 3.7E-04 
4-hydroxycoumarin -0.057 -0.146 7.1E-06 -0.155 8.8E-06 -0.274 1.5E-02 -0.234 1.4E-01 -0.063 1.0E-04 
homostachydrine* 0.060 -0.132 8.8E-06 -0.136 1.8E-05 -0.165 1.1E-01 0.049 7.3E-01 -0.059 6.5E-05 
X - 16071 -0.087 -0.128 9.0E-06 -0.113 2.6E-04 -0.123 2.2E-01 -0.012 9.3E-01 -0.050 5.7E-04 
decanoylcarnitine -0.105 -0.132 9.0E-06 -0.079 1.3E-02 -0.074 4.7E-01 -0.061 6.7E-01 -0.035 1.7E-02 
1-adrenoyl-GPC (22:4)* -0.059 -0.131 9.5E-06 -0.112 3.9E-04 -0.106 3.0E-01 -0.023 8.7E-01 -0.050 7.0E-04 
bilirubin (Z,Z) 0.075 0.127 9.9E-06 0.122 6.7E-05 0.138 1.7E-01 0.063 6.5E-01 0.054 1.8E-04 
1-arachidonoyl-GPI 
(20:4)* -0.048 -0.128 1.2E-05 -0.108 5.8E-04 -0.138 1.7E-01 -0.230 1.1E-01 -0.047 1.5E-03 
histidine 0.186 -0.126 1.6E-05 -0.166 1.1E-07 -0.006 9.5E-01 -0.091 5.2E-01 -0.081 2.6E-08 
imidazole propionate -0.080 -0.130 1.7E-05 -0.137 2.2E-05 -0.091 3.9E-01 0.049 7.3E-01 -0.063 2.9E-05 
1-stearoyl-2-dihomo-
linolenoyl-GPC 
(18:0/20:3n3 or 6)* -0.135 -0.125 2.1E-05 -0.093 3.1E-03 -0.289 4.5E-03 -0.343 1.6E-02 -0.032 2.9E-02 
1-docosahexaenoyl-
GPC (22:6)* 0.002 -0.124 2.3E-05 -0.094 2.7E-03 0.011 9.1E-01 0.089 5.3E-01 -0.047 1.4E-03 
hexanoylcarnitine -0.121 -0.125 2.3E-05 -0.031 3.3E-01 -0.108 3.0E-01 -0.073 6.1E-01 -0.010 5.0E-01 






Full score (24 
SNPs) 
Glycine-related 
score (6 SNPs) 
Glycine-related 
score without 
CPS1 (5 SNPS) 
Glycine-specific 
score (2 SNPs) rs715 
Beta p Beta p Beta p Beta p Beta p 
gamma-
glutamylhistidine 0.120 -0.122 3.0E-05 -0.138 1.0E-05 -0.150 1.4E-01 -0.184 1.9E-01 -0.061 3.2E-05 
X - 23739 0.187 -0.120 4.2E-05 -0.142 6.9E-06 -0.104 3.1E-01 -0.160 2.6E-01 -0.065 1.1E-05 
X - 24452 0.090 0.117 4.5E-05 0.111 2.8E-04 -0.044 6.6E-01 -0.164 2.4E-01 0.057 7.4E-05 
X - 14939 -0.019 -0.120 4.6E-05 -0.121 1.3E-04 -0.056 5.9E-01 -0.094 5.1E-01 -0.057 1.2E-04 
N-acetyltryptophan 0.071 0.122 5.5E-05 0.184 1.2E-08 -0.066 5.3E-01 0.024 8.7E-01 0.093 6.0E-10 
pipecolate -0.048 -0.119 5.8E-05 -0.145 5.4E-06 -0.057 5.8E-01 -0.108 4.6E-01 -0.068 4.1E-06 
threonine 0.276 -0.117 6.8E-05 -0.185 4.3E-09 0.026 8.0E-01 -0.095 5.1E-01 -0.092 4.0E-10 
indoleacetylglutamine -0.029 -0.134 1.0E-04 -0.150 5.5E-05 -0.154 2.0E-01 -0.192 2.5E-01 -0.066 1.3E-04 
O-methylcatechol 
sulfate -0.006 -0.114 1.2E-04 -0.130 4.0E-05 -0.333 1.2E-03 -0.256 7.4E-02 -0.048 1.1E-03 
hypotaurine 0.074 -0.103 3.7E-04 -0.146 2.5E-06 -0.072 4.7E-01 -0.135 3.3E-01 -0.068 2.4E-06 
X - 12739 -0.001 -0.114 4.0E-04 -0.161 2.9E-06 -0.115 3.0E-01 -0.146 3.5E-01 -0.074 4.5E-06 
X - 24527 0.006 -0.103 8.1E-04 -0.139 2.3E-05 -0.096 3.6E-01 -0.084 5.7E-01 -0.064 3.4E-05 
asparagine 0.292 -0.098 8.8E-04 -0.131 3.4E-05 0.120 2.4E-01 0.065 6.5E-01 -0.070 2.2E-06 
X - 12101 0.052 -0.092 2.0E-03 -0.155 1.2E-06 -0.167 1.1E-01 -0.211 1.4E-01 -0.068 4.8E-06 









Supplementary Table 2.5: Results of Mendelian randomisation analyses for glycine to T2D 
Results of MR analyses based on 4 different genetic instruments for glycine and 4 different 
methods are shown: inverse-variance-weighted (IVW), EGGER, weighted median (WM) and 
penalized weighted median (PWM). OR: odds ratio, LCI: lower confidence interval, UCI: upper 
confidence interval, CochQ p: p for Cochran’s Q statistic, interEGGER: intercept of MR EGGER, 
EGGER p: p for EGGER intercept. 
 
Full Score 
Sex-combined Women Men 
IVW EGGER WM PWM IVW EGGER WM PWM IVW EGGER WM PWM 
OR 0.972 1.054 1.004 1.005 0.994 1.032 1.007 1.007 1.009 1.135 1.058 1.063 
LCI 0.877 0.934 0.969 0.967 0.928 0.960 0.969 0.969 0.875 0.954 0.970 0.973 
UCI 1.078 1.189 1.040 1.044 1.065 1.109 1.046 1.046 1.163 1.349 1.154 1.162 
p 0.594 0.397 0.840 0.808 0.871 0.391 0.731 0.729 0.902 0.152 0.203 0.178 
CochQ p 0.020 
   
0.139    
2.0E-





 -0.014    -0.015   
EGGER p  0.032 
  
 0.026    0.038   
             
6 SNP score 
Sex-combined Women Men 
IVW EGGER WM PWM IVW EGGER WM PWM IVW EGGER WM PWM 
OR 0.990 1.021 1.001 1.003 1.005 1.025 1.008 1.008 1.022 1.051 1.042 1.049 
LCI 0.935 0.948 0.964 0.966 0.968 0.978 0.971 0.972 0.894 0.823 0.957 0.963 
UCI 1.049 1.099 1.039 1.041 1.043 1.074 1.046 1.045 1.169 1.342 1.134 1.142 
p 0.743 0.588 0.966 0.887 0.801 0.310 0.683 0.675 0.752 0.689 0.342 0.271 
CochQ p 0.929 
   





 -0.011    -0.005   
EGGER p  0.228 
  
 0.084    0.776   
             
5 SNP score 
Sex-combined Women Men 
IVW EGGER WM PWM IVW EGGER WM PWM IVW EGGER WM PWM 
OR 0.869 0.758 0.868 0.868 0.919 1.054 0.928 0.928 0.918 0.708 0.908 0.831 
LCI 0.755 0.489 0.757 0.756 0.778 0.735 0.767 0.763 0.704 0.338 0.730 0.675 
UCI 1.001 1.173 0.996 0.997 1.085 1.511 1.123 1.130 1.197 1.483 1.129 1.024 
p 0.052 0.214 0.044 0.046 0.318 0.775 0.445 0.460 0.527 0.360 0.385 0.082 
CochQ p 0.93 
   
0.792 
   
0.724 




   
-0.014 
   
0.023 
  
EGGER p  0.510 
   
0.354 
   
0.458 
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2 SNP score 
Sex-combined Women Men 
IVW EGGER WM PWM IVW EGGER WM PWM IVW EGGER WM PWM 
OR 0.792 NA 0.792 0.792 0.919 NA 0.855 0.855 0.774 NA 0.774 0.774 
LCI 0.671 NA 0.682 0.680 0.778 NA 0.661 0.664 0.623 NA 0.620 0.613 
UCI 0.933 NA 0.919 0.921 1.085 NA 1.106 1.100 0.960 NA 0.966 0.976 
p 0.005 NA 0.002 0.003 0.318 NA 0.233 0.223 0.020 NA 0.024 0.031 
CochQ p 0.713 








   
NA 
   
NA 
  
EGGER p  NA 
   
NA 







Supplementary Table 2.6: reverse Mendelian randomisation analyses to assess the 
causality of T2D risk factors on glycine levels 
These are the results of the MR analyses with T2D risk factors as the exposure and glycine levels 
as the outcome. Analyses were conducted for body mass index (BMI), fasting insulin adjusted for 
BMI as a marker for insulin resistance (IR) and insulin levels at 30 minutes during an oral glucose 
tolerance test, as a marker for early-phase insulin secretion (IS). Results of 4 different methods are 
shown: inverse-variance-weighted (IVW), EGGER, weighted median (WM) and penalized 
weighted median (PWM). OR: odds ratio, LCI: lower confidence interval, UCI: upper confidence 
interval, CochQ p: p for Cochran’s Q statistic, interEGGER: intercept of MR EGGER, EGGER 
p: p for EGGER intercept. 
 
BMI IVW MR-Egger WM PWM 
Beta -0.041 -0.041 -0.009 -0.007 
SE 0.030 0.074 0.041 0.040 
pvalue 0.169 0.581 0.825 0.870 
CochQp 1.000 










     
IR IVW EGGER WM PWM 
beta -0.960 -1.179 -0.863 -0.822 
SE 0.212 1.253 0.211 0.211 
p 5.98E-06 3.47E-01 4.29E-05 9.56E-05 
CochQ p 0.393 










     
IS IVW EGGER MW PMW 
Beta 0.022 -0.030 -0.011 -0.010 
SE 0.033 0.087 0.038 0.037 
pvalue 0.516 0.733 0.762 0.786 
CochQ p 0.999 












Supplementary Table 2.7: Results of Mendelian randomisation analyses for glycine to 
CHD 
Results of MR analyses based on 4 different genetic instruments for glycine and 4 different 
methods are shown: inverse-variance-weighted (IVW), EGGER, weighted median (WM) and 
penalized weighted median (PWM). OR: odds ratio, LCI: lower confidence interval, UCI: upper 
confidence interval, CochQ p: p for Cochran’s Q statistic, interEGGER: intercept of MR 
EGGER, EGGER p: p for EGGER intercept. 
 
Full Score 
Sex-combined Women Men 
IVW EGGER WM PWM IVW EGGER WM PWM IVW EGGER WM PWM 
OR 0.904 0.977 0.948 0.881 0.928 0.957 0.953 0.954 0.817 0.954 0.926 0.937 
LCI 0.836 0.897 0.919 0.793 0.848 0.864 0.910 0.912 0.692 0.763 0.842 0.816 
UCI 0.978 1.064 0.978 0.979 1.014 1.060 0.997 0.998 0.964 1.193 1.019 1.076 
p 0.012 0.587 0.001 0.019 0.100 0.401 0.039 0.041 0.017 0.677 0.118 0.360 
CochQ p 0.507    0.174    0.092   
 
interEGGER  -0.013    -0.010    0.007  
 
EGGER p  0.003    0.226    0.057  
 
             
6 SNP score 
Sex-combined Women Men 
IVW EGGER WM PWM IVW EGGER WM PWM IVW EGGER WM PWM 
OR 0.945 0.967 0.953 0.958 0.942 0.975 0.954 0.954 0.926 0.972 0.941 0.942 
LCI 0.887 0.885 0.924 0.929 0.826 0.816 0.911 0.913 0.814 0.777 0.860 0.857 
UCI 1.006 1.056 0.984 0.988 1.075 1.165 0.998 0.998 1.054 1.216 1.029 1.036 
p 0.076 0.452 0.003 0.006 0.375 0.779 0.039 0.040 0.245 0.804 0.181 0.218 
CochQ p 0.845    0.127    0.800    
interEGGER  -0.007    -0.017    -0.007   
EGGER p  0.441    0.540    0.585   
             
             
5 SNP score 
Sex-combined Women Men 
IVW EGGER WM PWM IVW EGGER WM PWM IVW EGGER WM PWM 
OR 0.836 0.657 0.803 0.767 0.735 0.590 0.827 0.840 0.885 1.043 0.924 0.957 
LCI 0.699 0.389 0.710 0.677 0.424 0.128 0.649 0.658 0.663 0.432 0.736 0.756 
UCI 0.999 1.110 0.908 0.870 1.273 2.727 1.054 1.072 1.182 2.518 1.161 1.212 




5 0.272 0.500 0.124 0.162 0.408 0.926 0.498 0.716 
CochQ p 0.789    0.104    0.686    
interEGGER  0.018    0.019    -0.011   
EGGER p  0.338    0.759    0.695   
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2 SNP score 
Sex-combined Women Men 
IVW EGGER WM PWM IVW EGGER WM PWM IVW EGGER WM PWM 
OR 0.798 NA 0.798 0.798 0.832 NA 0.832 0.832 0.769 NA 0.769 0.798 
LCI 0.670 NA 0.693 0.701 0.656 NA 0.655 0.652 0.413 NA 0.595 0.615 
UCI 0.950 NA 0.919 0.908 1.055 NA 1.056 1.062 1.433 NA 0.993 1.036 
p 0.011 NA 0.002 0.001 0.130 
 
0.131 0.139 0.408 NA 0.044 0.091 
CochQ p 0.677 
   
0.784 
   
0.269 




   
NA 
   
NA 
  
EGGER p  NA 
   
NA 







Supplementary Table 2.8: Results of Cox proportional hazards models for the association 
of glycine levels with CHD, myocardial infarction and stroke, including stroke sub-types 
 
1. Coronary heart disease sex-combined women men 
  HR [95% CI] p HR [95% CI] p HR [95% CI] p 
Standardized glycine levels 0.92 [0.87,0.96] 4.7E-4 0.94 [0.88,1.01] 0.083 0.88 [0.82,0.95] 7.2E-4 
Log-transformed glycine 
levels 0.71 [0.58,0.86] 4.8E-4 0.79 [0.61,1.03] 0.086 0.60 [0.45,0.81] 7.1E-4 
2. Myocardial infarction sex-combined women men 
  HR [95% CI] p HR [95% CI] p HR [95% CI] p 
Standardized glycine levels 0.89 [0.82,0.97] 5.50E-3 0.95 [0.85,1.07] 0.39 0.82 [0.73,0.93] 1.6E-3 
Log-transformed glycine 
levels 0.62 [0.45,0.87] 5.80E-3 0.82 [0.51,1.31] 0.4 0.46 [0.28,0.75] 1.7E-3 
3. Stroke (all types) sex-combined women men 
  HR [95% CI] p HR [95% CI] p HR [95% CI] p 
Standardized glycine levels 0.99 [0.93,1.05] 0.70 0.98 [0.91,1.06] 0.68 1.00 [0.90,1.10] 0.92 
Log-transformed glycine 
levels 0.95 [0.75,1.21] 0.70 0.94 [0.70,1.26] 0.68 0.98 [0.65,1.49] 0.93 
4. Haemorrhagic stroke sex-combined women men 
  HR [95% CI] p HR [95% CI] p HR [95% CI] p 
Standardized glycine levels 1.11 [0.96,1.29] 0.15 1.07 [0.89,1.28] 0.49 1.20 [0.94,1.53] 0.13 
Log-transformed glycine 
levels 1.54 [0.86,2.75] 0.15 1.30 [0.63,2.69] 0.48 2.11 [0.80,5.59] 0.13 
5. Ischemic stroke sex-combined women men 
  HR [95% CI] p HR [95% CI] p HR [95% CI] p 
Standardized glycine levels 1.00 [0.92,1.10] 0.95 1.02 [0.91,1.14] 0.74 0.97 [0.84, 1.13] 0.73 
Log-transformed glycine 





Supplementary table 2.9: Associations of 4 genetic scores for glycine with blood pressure, lipid and blood cell phenotypes 
 
CHD risk factors 
Full glycine score (24 SNPs) Glycine-related score (6 SNPs) 
Glycine-related score without 
CPS1 (5 SNP score) 
Glycine-specific score (2 SNPs) 
beta SE p-value beta SE p-value beta SE p-value beta SE p-value 
Systolic blood pressure -0.028 0.007 1.49E-05 -0.029 0.006 2.56E-06 -0.050 0.021 1.93E-02 -0.042 0.022 5.71E-02 
Diastolic blood pressure -0.019 0.009 3.87E-02 -0.024 0.004 4.32E-11 -0.038 0.013 3.09E-03 -0.030 0.020 1.28E-01 
HDL cholesterol -0.058 0.034 8.89E-02 -0.056 0.010 7.37E-09 -0.006 0.039 8.76E-01 -0.061 0.049 2.16E-01 
LDL cholesterol -0.035 0.043 4.11E-01 0.015 0.013 2.53E-01 -0.034 0.057 5.53E-01 -0.012 0.053 8.23E-01 
Total cholesterol -0.061 0.044 1.65E-01 -0.011 0.013 4.18E-01 -0.019 0.065 7.68E-01 -0.018 0.052 7.30E-01 
Triglycerides -0.020 0.043 6.48E-01 -0.002 0.010 8.69E-01 -0.032 0.048 4.98E-01 0.017 0.048 7.31E-01 
Basophil -0.004 0.012 7.52E-01 -0.006 0.008 4.25E-01 0.010 0.026 7.11E-01 -0.007 0.036 8.56E-01 
Eosinophil 0.047 0.021 2.75E-02 0.046 0.020 2.52E-02 0.125 0.061 4.12E-02 0.213 0.103 3.92E-02 
Hematocrit 0.023 0.023 3.14E-01 0.004 0.014 7.96E-01 0.030 0.049 5.49E-01 0.006 0.036 8.76E-01 
Platelet count  -0.078 0.030 9.94E-03 -0.072 0.011 3.16E-10 -0.020 0.031 5.16E-01 -0.008 0.077 9.17E-01 
Platelet distribution width 0.042 0.026 1.06E-01 0.035 0.010 2.88E-04 -0.017 0.027 5.25E-01 0.009 0.037 8.15E-01 
Mean platelet volume 0.086 0.051 9.25E-02 0.061 0.008 5.35E-13 0.028 0.027 3.04E-01 0.031 0.037 4.06E-01 
Red cell distribution width 0.049 0.023 3.15E-02 0.023 0.008 4.37E-03 0.052 0.027 5.29E-02 0.038 0.037 3.04E-01 
Mean corpuscular hemoglobin 0.040 0.021 5.63E-02 0.057 0.021 7.78E-03 0.088 0.076 2.45E-01 0.146 0.071 4.00E-02 
Reticulocyte -0.001 0.022 9.80E-01 0.006 0.012 6.48E-01 -0.003 0.045 9.52E-01 -0.074 0.052 1.56E-01 
Immature reticulocyte fraction 0.024 0.014 7.83E-02 0.021 0.008 9.42E-03 0.049 0.027 6.93E-02 0.072 0.037 4.79E-02 
Neutrophil -0.032 0.024 1.80E-01 -0.045 0.014 1.03E-03 -0.095 0.042 2.26E-02 -0.066 0.037 7.52E-02 
Monocyte -0.018 0.020 3.73E-01 -0.029 0.013 2.24E-02 0.040 0.028 1.52E-01 0.091 0.037 1.35E-02 






Supplementary Table 3.1: Overview of cohorts included in the exome chip meta-analyses for BF% and FFMI 
 









Technique Instrument Reference 
AGES Population-based European 3988 (2234) 3988 (2234) 
Illumina HumanExome v1.0 
and v1.2 
RareMetalWorker 234,708 BIA 
A Xitron HYDRA 
ECF/ICF, Model 4200 
391Harris 2007 
Airwave Population-based European 14,3477 (5390) -- 
Illumina Infinium 
HumanExome12 v1.1 
RareMetalWorker 233,034 BIA 
Tanita BC-418MA body 
composition analyser 
392Elliott 2014 








Diogenes Population-based European 2159 (1068) 2159 (1068) Illumina ExomeChip RareMetalWorker 224,702 DEXA/BIA 
GE Lunar 
Prodigy/Tanita  body 
composition analyser 
394Larsen 2010 
Ely Population-based European 1432 (772) 1432 (772) Illumina HumanCoreExome RareMetalWorker 231,367 BIA BODY STAT 1500 395Forouhi 2007 
EPIC-Norfolk Population-based European 13554 (7426) 13542 (7417) UK Biobank Axiom Array RareMetalWorker 57,858 BIA Tanita TBF300 191Day 1999 




Family-based European 1144 (608) 1144 (608) 
Illumina Exome BeadChip 
array v1.0 
RVTest 240,035 DEXA GE Lunar Prodigy 397Henneman 2008 




Fenland-CE Population-based European 1006 (549) 1006 (549) Illumina HumanCoreExome RareMetalWorker 234,201 DEXA GE Lunar Prodigy 79Lotta 2017 
Fenland-EC Population-based European 1315 (706) 1314 (706) Illumina ExomeChip v1.0 RareMetalWorker 240,881 DEXA GE Lunar Prodigy 79Lotta 2017 
Fenland-
OMICS 
Population-based European 7363 (3867) 7363 (3867) UK Biobank Axiom Array RareMetalWorker 58,262 DEXA GE Lunar Prodigy 79Lotta 2017  
FHS Population-based European 5674 (3281) 5671 (3278) Illumina ExomeChip v1.0 RareMetalWorker 246,691 DEXA GE Lunar DPX-L 399Visser 1998 
Supplementary materials 
 260 









Technique Instrument Reference 












Afro-American 1060 (603) 1060 (603) Illumina ExomeChip v1.0 RVTest 228,571 DEXA Hologic QDR-4500 401Harris 2000 










KORA-F4 Population-based European 2881 (1477) 2881 (1477) Illumina ExomeChip v1.0 RVTest 245,163 BIA GmbH BIA 2000-S 403Wichmann 2005 
Leipzig adults Population-based European 608 (395) 608 (395) 
Illumina HumanExome 
12v1A 
RareMetalWorker 230,972 BIA 
BIA-Nutriguard-MS 







Indian Asian 1466 (421) 1466 (421) 
Illumina Human Exome 
BeadChip 






Indian Asian 864 (417) 864 (417) 
Illumina OmniExpressExome 
BeadChip 
RareMetalWorker 240,137 BIA Tanita TBF-401 405Kooner 2008 
METSIM Population-based European 10019 (0) 10019 (0) HumanExome 12v1A RVTest 241,780 BIA 
Bioimpedance Analyzer 
Model BIA101 (Akern 
Srl, Florence Italy) 
406Stancakova 2009 




RVTest 209,892 DEXA 
Hologic Discovery A, 
Tromp Medical BV, 
Castricum, The 
Netherlands 
407de Mutsert 2013 
PIVUS Population-based European 824 (419) 824 (419) 
Illumina HumanExome-
12v1_A 
RareMetalWorker 233,166 DEXA GE Lunar Prodigy 408Lind 2005 
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Technique Instrument Reference 
RAINE Population-based European 995 (475) 995 (475) 
Illuminia HumanExome 12 
v1A 




RISC Population-based European 313 (157) 313 (157) 
Illumina Human Exome 
Beadchip v1 
RareMetalWorker 236,893 BIA 





Population-based European 1213 (560) 1198 (555) Illumina ExomeChip v1.1 RVTest 237,783 DEXA GE Lunar Prodigy 411Hofman 2013 
SHIP Population-based European 6309 (3295) 6309 (3295) Illumina ExomeChip v1.0 RVTest 237,442 BIA 
BIA-Nutriguard-MS 
with the software Nutri3 
412Völzke 2011 
SORBS Population-based European 997 (595) 997 (595) 
Illumina HumanExome 12 
v1A 
RareMetalWorker 230,972 BIA 




TwinsUK Twins study European 1864 (1864) 1864 (1864) 
Illumina HumanExome 12 
v1A 
RareMetalWorker 221,836 DEXA 
Hologic Discovery W’ - 
QDR software version 
12.6 
414Moayyeri 2013 
Vejle cases Case-control European 1971 (757) 1971 (757) Illumina HumanExome 12 v1 RareMetalWorker 227,684 BIA 
Tanita Body 
Composition Analyzer 
418, IL, USA 
415Pedersen 2016 
Vejle controls Case-control European 430 (286) 430 (286) Illumina HumanExome 12 v1 RareMetalWorker 227,684 BIA 
Tanita Body 
Composition Analyzer 




Population-based European 4109 (4109) 4093 (4093) Illumina ExomeChip v1.0 RVTest 246,321 DEXA 
DXA; QDR2000, 






Population-based Afro-American 387 (387) 385 (385) Illumina ExomeChip v1.0 RVTest 246,321 DEXA 
DXA; QDR2000, 




YFS Population-based European 288 (145) 288 (145) Illumina CoreExome v1.0b RVTest 237,099 BIA 







Supplementary Table 3.2: Regions of long-range linkage disequilibrium 
Regions of long-range LD reported by Koch et al.296 
Chr Start position (bp) End position (bp) 
1 48,000,000 52,000,000 
2 86,000,000 100,500,000 
2 134,500,000 138,000,000 
2 183,000,000 190,000,000 
3 47,500,000 50,000,000 
3 83,500,000 87,000,000 
3 89,000,000 97,500,000 
5 44,000,000 51,500,000 
5 98,000,000 100,500,000 
5 129,000,000 132,000,000 
5 135,500,000 138,500,000 
6 25,000,000 33,500,000 
6 57,000,000 64,000,000 
6 140,000,000 142,500,000 
7 55,000,000 66,000,000 
8 8,000,000 12,000,000 
8 43,000,000 50,000,000 
10 37,000,000 43,000,000 
11 45,000,000 57,000,000 
11 87,500,000 90,500,000 
12 33,000,000 40,000,000 
12 109,500,000 112,000,000 





Supplementary Table 3.3: Variants reaching exome-wide significance for BF% in European and all ancestry exome chip meta-analyses 
 
rsid Chr Pos Gene Consequence OA EA EAF Most significant analysis beta p N Other significant analyses 
rs1384588816 1 72,765,116 NEGR1 intronic A G 0.612 Eur sex-comb add 0.025 3.7E-08 107,902 All anc sex-comb add 
rs1308970187 1 72,812,440 NEGR1 intergenic A G 0.611 Eur sex-comb add 0.025 7.4E-08 102,633 All anc sex-comb add 
rs1423754764 1 72,954,611 NEGR1 intergenic C A 0.358 Eur sex-comb add -0.027 1.5E-07 86,985 All anc sex-comb add 
rs1003699594 1 177,889,480 SEC16B intergenic G A 0.194 All anc sex-comb add 0.033 2.9E-09 109,524 Eur sex-comb add 
rs2947411 2 614,168 TMEM18 intergenic G A 0.830 Eur sex-comb add 0.035 5.6E-09 104,983 All anc sex-comb add, all anc women add 
rs2867125 2 622,827 TMEM18 intergenic C T 0.832 Eur sex-comb add 0.035 1.3E-08 104,983 All anc sex-comb add 
rs6548238 2 634,905 TMEM18 intergnic C T 0.833 Eur sex-comb add 0.034 1.5E-08 107,902 All anc sex-comb add 
rs11676272 2 25,141,538 ADCY3 missense G A 0.455 Eur sex-comb add 0.025 4.4E-08 103,105 All anc sex-comb add 
rs713586 2 25,158,008 DNAJC27 intergenic C T 0.472 Eur sex-comb add 0.025 1.3E-08 107,902 
All anc sex-comb add, All anc sex-comb rec, Eur sex-comb rec, All anc women rec, 
Eur women add, Eur women rec 
rs4665736 2 25,187,599 DNAJC27 intronic T C 0.533 Eur sex-comb add -0.026 7.6E-09 107,902 All anc sex-comb add, Eur women add 
rs10179126 2 165,511,794 COBLL1 intergenic G C 0.371 All anc sex-comb add 0.034 8.3E-11 83,438 Eur sex-comb add 
rs10195252 2 165,513,091 COBLL1 intergenic C T 0.399 All anc sex-comb add 0.036 1.1E-11 81,987 Eur sex-comb add, All anc men add, Eur men add 
rs13389219 2 165,528,876 COBLL1 intergenic T C 0.399 All anc sex-comb add 0.033 2.7E-11 91,526 Eur sex-comb add, All anc men add, Eur men add 
rs7578326 2 227,020,653 LOC646736 intronic G A 0.351 All anc sex-comb add 0.031 8.6E-12 112,443 
All anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, All anc men add, Eur 
men add 
rs2943634 2 227,068,080 LOC646736 intergenic C A 0.659 All anc sex-comb add -0.031 9.7E-12 112,443 
All anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, All anc men add, All anc 
men rec, Eur men add, Eur men rec 
rs2943641 2 227,093,745 LOC646736 intergenic C T 0.640 All anc sex-comb add -0.032 3.6E-12 112,443 
All anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, All anc men add, All anc 
men rec, Eur men add, Eur men rec 
rs2972146 2 227,100,698 LOC646736 intergenc T G 0.639 All anc men add -0.045 2.5E-12 56,037 
All anc sex-comb add, All anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, 
All anc men rec, Eur men add, Eur men rec 
rs17036101 3 12,277,845 PPARG intergenic A G 0.068 All anc sex-comb add 0.048 2.0E-07 98,889  
rs1801282 3 12,393,125 PPARG missense G C 0.128 All anc sex-comb add 0.050 5.3E-14 106,347 Eur sex-comb add, All anc men add, Eur men add 
rs10938397 4 45,182,527 GNPDA2 intergenic G A 0.438 All anc sex-comb add 0.028 1.4E-08 90,937 Eur sex-comb add, All anc men add 
rs459193 5 55,806,751 C5orf67 downstream G A 0.735 All anc sex-comb add -0.026 1.2E-07 109,137  
rs10968576 9 28,414,339 LINGO2 intronic G A 0.316 All anc sex-comb add 0.030 1.7E-10 112,443 Eur sex-comb add, Eur men add 
rs11057401 12 124,427,306 CCDC92 missense A T 0.314 all anc women add 0.037 1.2E-07 50,082  
rs2904880 16 28,944,396 CD19 missense G C 0.720 All anc sex-comb rec -0.053 6.5E-08 51,224 Eur sex-comb rec 
rs9930333 16 53,799,977 FTO intronic G T 0.432 Eur sex-comb add 0.052 1.6E-23 86,985 
All anc sex-comb add,  All anc sex-comb rec, Eur sex-comb rec, All anc men add, All 
anc men rec, Eur men add, Eur men rec, all anc women add, All anc women rec, Eur 
women add, Eur women rec 
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rsid Chr Pos Gene Consequence OA EA EAF Most significant analysis beta p N Other significant analyses 
rs1421085 16 53,800,954 FTO intronic C T 0.406 All anc sex-comb add 0.055 2.9E-32 112,443 
All anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, All anc men add, All anc 
men rec, Eur men add, Eur men rec, all anc women add, All anc women rec, Eur 
women add, Eur women rec 
rs1558902 16 53,803,574 FTO intronic A T 0.405 All anc sex-comb add 0.053 8.7E-24 85,430 
All anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, All anc men add, All anc 
men rec, Eur men add, Eur men rec, all anc women add, All anc women rec, Eur 
women add 
rs1121980 16 53,809,247 FTO intronic A G 0.431 Eur sex-comb add 0.052 3.3E-29 107,902 
All anc sex-comb add, All anc sex-comb rec, Eur sex-comb rec, All anc men add, All 
anc men rec, Eur men add, Eur men rec, all anc women add, All anc women rec, Eur 
women add, Eur women rec 
rs17817449 16 53,813,367 FTO intronic G T 0.400 All anc sex-comb add 0.052 2.9E-29 112,443 
All anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, All anc men add, All anc 
men rec, Eur men add, Eur men rec, all anc women add, All anc women rec, Eur 
women add, Eur women rec 
rs11075987 16 53,815,161 FTO intronic G T 0.499 Eur sex-comb add 0.042 7.3E-17 86,985 
All anc sex-comb add, All anc sex-comb rec, Eur sex-comb rec, All anc men add, All 
anc men rec, Eur men add, Eur men rec, Eur women add 
rs8050136 16 53,816,275 FTO intronic A C 0.400 All anc sex-comb add 0.052 3.7E-29 112,443 
All anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, All anc men add, All anc 
men rec, Eur men add, Eur men rec, all anc women add, All anc women rec, Eur 
women add, Eur women rec 
rs9939609 16 53,820,527 FTO intronic A T 0.401 All anc sex-comb add 0.051 1.6E-27 106,347 
All anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, All anc men add, All anc 
men rec, Eur men add, Eur men rec, all anc women add, Eur women add 
rs9941349 16 53,825,488 FTO intronic T C 0.417 Eur sex-comb add 0.051 1.8E-27 107,902 
All anc sex-comb add, All anc sex-comb rec, Eur sex-comb rec, All anc men add, All 
anc men rec, Eur men add, Eur men rec, all anc women add, All anc women rec, Eur 
women add, Eur women rec 
rs9930506 16 53,830,465 FTO intronic G A 0.435 Eur sex-comb add 0.048 1.4E-22 97,726 
All anc sex-comb add, All anc sex-comb rec, Eur sex-comb rec, All anc men add, All 
anc men rec, Eur men add, Eur men rec, all anc women add, Eur women add 
rs571312 18 57,839,769 MC4R intergenic A C 0.235 All anc sex-comb add 0.028 5.2E-08 112,443  
rs17782313 18 57,851,097 MC4R intergenic C T 0.235 All anc sex-comb add 0.028 1.5E-07 109,524  
rs10871777 18 57,851,763 MC4R intergenic G A 0.236 All anc sex-comb add 0.027 1.8E-07 112,443  
rs1800437 19 46,181,392 GIPR downstream C G 0.207 All anc sex-comb add -0.032 4.1E-09 104,742 Eur sex-comb add 
rs2284063 22 38,544,298 PLA2G6 intronic G A 0.354 All anc sex-comb add 0.029 2.1E-10 112,443 All anc sex-comb rec, Eur sex-comb add 
rs738322 22 38,569,006 PLA2G6 intronic G A 0.469 All anc sex-comb add 0.035 1.6E-15 112,443 
All anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, All anc men add, all anc 





Supplementary Table 3.4: Variants reaching exome-wide significance for FFMI in European or all ancestry exome chip meta-analyses 
 
rsid Chr Pos Gene Type OA EA EAF Most significant analysis beta p N Other significant analyses 
rs141845046 1 154,987,704 ZBTB7B missense C T 0.031 all anc sex-comb add 0.074 3.0E-08 98,035 Eur sex-comb add 
rs2282301 1 155,868,625 RIT1 3' UTR G A 0.247 Eur sex-comb add -0.037 3.5E-09 72,589 all anc sex-comb add 
rs633715 1 177,852,580 SEC16B intergenic T C 0.200 all anc sex-comb add 0.045 5.5E-12 76,740 Eur sex-comb add, all anc women  add, Eur women  add 
rs543874 1 177,889,480 SEC16B intergenic A G 0.193 all anc sex-comb add 0.050 4.9E-17 95,116 
all anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, all anc women  add, all anc 
women  rec, Eur women  add, Eur women  rec 
rs591120 1 177,902,753 SEC16B missense G C 0.435 all anc sex-comb add 0.025 2.0E-07 91,939  
rs10913469 1 177,913,519 SEC16B intronic T C 0.194 Eur women  add 0.056 1.1E-11 47,404 all anc sex-comb add, Eur sex-comb add, all anc women  add 
rs2947411 2 614,168 TMEM18 intergenic A G 0.830 Eur sex-comb add 0.050 1.6E-14 90,575 
all anc sex-comb add, all anc sex-comb rec, Eur sex-comb rec, all anc men add, all anc 
women  add, all anc women  rec, Eur women  add, Eur women  rec 
rs2867125 2 622,827 TMEM18 intergenic T C 0.832 Eur sex-comb add 0.051 5.6E-15 90,575 
all anc sex-comb add, all anc sex-comb rec, Eur sex-comb rec, all anc men add, Eur men 
add, all anc women  add, all anc women  rec, Eur women  add, Eur women  rec 
rs6548238 2 634,905 TMEM18 intergenic T C 0.833 Eur sex-comb add 0.053 2.7E-16 93,494 
all anc sex-comb add, all anc sex-comb rec, Eur sex-comb rec, all anc men add, all anc men 
rec, Eur men add, all anc women  add, all anc women  rec, Eur women  add, Eur women  
rec 
rs7561317 2 644,953 TMEM18 intergenic A G 0.839 Eur sex-comb add 0.050 5.9E-12 78,996 all anc sex-comb add, all anc sex-comb rec, Eur sex-comb rec 
rs1062633 3 49,924,940 MST1R missense T C 0.484 Eur sex-comb add 0.026 1.9E-07 93,494  
rs206936 6 34,302,869 NUDT3 intronic A G 0.212 all anc sex-comb add 0.030 1.2E-07 98,035  
rs2206277 6 50,798,526 TFAP2B intronic C T 0.184 all anc sex-comb add 0.039 1.2E-10 96,171 Eur sex-comb add, all anc men add, Eur men add 
rs987237 6 50,803,050 TFAP2B intronic A G 0.183 all anc sex-comb add 0.036 1.3E-09 98,035 Eur sex-comb add, all anc men add, Eur men add 
rs1167796 7 75,173,180 HIP1 intronic A G 0.567 Eur sex-comb add 0.029 5.8E-09 90,575 all anc sex-comb add 
rs1167800 7 75,176,196 HIP1 intronic G A 0.569 all anc sex-comb add 0.026 3.7E-08 98,035 Eur sex-comb add 
rs925946 11 27,667,202 BDNF intronic T G 0.691 all anc sex-comb add -0.029 2.0E-08 93,662 all anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec 
rs6265 11 27,679,916 BDNF missense C T 0.183 all anc sex-comb add -0.042 1.4E-11 93,252 Eur sex-comb add, all anc men add, Eur men add 
rs4483821 15 84,488,636 ADAMTSL3 missense A G 0.447 Eur sex-comb add -0.028 7.2E-09 93,494 all anc sex-comb add 
rs7183263 15 84,573,041 ADAMTSL3 intronic T G 0.515 Eur sex-comb add -0.031 5.0E-10 93,494 all anc sex-comb add, all anc sex-comb rec, Eur sex-comb rec 
rs11259936 15 84,580,582 ADAMTSL3 intronic A C 0.515 Eur sex-comb add -0.031 4.3E-10 93,494 all anc sex-comb add, all anc sex-comb rec, Eur sex-comb rec 
rs4842838 15 84,582,124 ADAMTSL3 missense G T 0.516 Eur sex-comb add -0.029 1.4E-08 88,225 all anc sex-comb add, all anc sex-comb rec, Eur sex-comb rec 
rs34047645 15 84,611,367 ADAMTSL3 missense G C 0.183 Eur sex-comb add 0.041 7.0E-09 72,284 all anc sex-comb add 
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rs7191155 16 19,800,213 IQCK missense T C 0.162 Eur sex-comb add -0.039 5.1E-09 88,225 all anc sex-comb add 
rs12444979 16 19,933,600 GPRC5B upstream C T 0.134 Eur sex-comb add -0.048 3.7E-12 93,494 all anc sex-comb add, Eur women  add 
rs9930333 16 53,799,977 FTO intronic T G 0.435 Eur sex-comb add 0.061 4.5E-27 72,589 
all anc sex-comb add, all anc sex-comb rec, Eur sex-comb rec, all anc men add, all anc men 
rec, Eur men add, Eur men rec, all anc women  add, all anc women  rec, Eur women  add, 
Eur women  rec 
rs1421085 16 53,800,954 FTO intronic T C 0.406 all anc sex-comb add 0.060 3.2E-34 98,035 
all anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, all anc men add, all anc men rec, 
Eur men add, Eur men rec, all anc women  add, all anc women  rec, Eur women  add, Eur 
women  rec 
rs1558902 16 53,803,574 FTO intronic T A 0.407 all anc sex-comb add 0.064 6.1E-29 71,034 
all anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, all anc men add, all anc men rec, 
Eur men add, Eur men rec, all anc women  add, all anc women  rec, Eur women  add, Eur 
women  rec 
rs1121980 16 53,809,247 FTO intronic G A 0.433 Eur sex-comb add 0.057 2.0E-30 93,494 
all anc sex-comb add, all anc sex-comb rec, Eur sex-comb rec, all anc men add, all anc men 
rec, Eur men add, Eur men rec, all anc women  add, all anc women  rec, Eur women  add, 
Eur women  rec 
rs17817449 16 53,813,367 FTO intronic T G 0.401 all anc sex-comb add 0.058 5.5E-32 98,035 
all anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, all anc men add, all anc men rec, 
Eur men add, Eur men rec, all anc women  add, all anc women  rec, Eur women  add, Eur 
women  rec 
rs11075987 16 53,815,161 FTO intronic T G 0.501 Eur sex-comb add 0.051 2.2E-20 72,589 
all anc sex-comb add, all anc sex-comb rec, Eur sex-comb rec, all anc men add, all anc men 
rec, Eur men add, all anc women  add, Eur women  add, Eur women  rec, ,  
rs8050136 16 53,816,275 FTO intronic C A 0.401 all anc sex-comb add 0.059 2.3E-32 98,035 
all anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, all anc men add, all anc men rec, 
Eur men add, Eur men rec, all anc women  add, all anc women  rec, Eur women  add, Eur 
women  rec 
rs9939609 16 53,820,527 FTO intronic T A 0.403 all anc sex-comb add 0.059 9.4E-31 91,939 
all anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, all anc men add, all anc men rec, 
Eur men add, Eur men rec, all anc women  add, all anc women  rec, Eur women  add, Eur 
women  rec 
rs9941349 16 53,825,488 FTO intronic C T 0.413 all anc sex-comb add 0.055 2.1E-29 98,035 
all anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, all anc men add, all anc men rec, 
Eur men add, Eur men rec, all anc women  add, all anc women  rec, Eur women  add, Eur 
women  rec 
rs9930506 16 53,830,465 FTO intronic A G 0.430 all anc sex-comb add 0.051 8.4E-23 87,875 
all anc sex-comb rec, Eur sex-comb add, Eur sex-comb rec, all anc men add, all anc men rec, 
Eur men add, Eur men rec, all anc women  add, all anc women  rec, Eur women  add, Eur 
women  rec 
rs571312 18 57,839,769 MC4R intergenic C A 0.235 all anc sex-comb add 0.042 3.8E-14 98,035 Eur sex-comb add, all anc men add, Eur men add 
rs17782313 18 57,851,097 MC4R intergenic T C 0.235 all anc sex-comb add 0.042 1.8E-13 95,116 all anc sex-comb rec, Eur sex-comb add, all anc men add, Eur men add 
rs10871777 18 57,851,763 MC4R intergenic A G 0.237 all anc sex-comb add 0.042 5.8E-14 98,035 all anc sex-comb rec, Eur sex-comb add, all anc men add, Eur men add 
rs489693 18 57,882,787 MC4R intergenic C A 0.312 all anc sex-comb add 0.032 3.3E-10 98,035 all anc sex-comb rec, Eur sex-comb add, all anc men add, Eur men add, Eur men rec 
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rs12970134 18 57,884,750 MC4R intergenic G A 0.260 all anc sex-comb add 0.035 3.8E-10 92,766 Eur sex-comb add, all anc men add, Eur men add 
Supplementary materials 
 268 
Supplementary Table 3.5: Independent variants associated with BF% at genome-wide 
significance in a European meta-GWAS 
 
rsid Chr Pos 
Nearest 
gene 
Type EA OA EAF Beta±SE p N 
Sex-combined 
rs72634814 1 1,538,046 C1orf233 intergenic A G 0.35 -0.013±0.0016 1.1E-15 442,278 
rs3762444 1 2,427,712 PLCH2 intronic T C 0.46 -0.0084±0.0014 7.1E-09 506,306 
rs12124126 1 6,660,349 KLHL21 intronic A G 0.67 0.0113±0.0016 6.9E-13 442,278 
rs4908676 1 7,737,099 CAMTA1 intronic A G 0.54 -0.0101±0.0014 2.3E-12 507,570 





A G 0.66 -0.0106±0.0015 2.1E-12 506,306 
rs1318408 1 11,925,781 NPPB intergenic A G 0.88 -0.0139±0.0022 2.1E-10 530,194 
rs7540681 1 16,832,446 CROCCP3 intergenic T C 0.52 -0.0104±0.0015 1.5E-12 492,344 
rs779765342 1 23,353,906 KDM1A intronic I D 0.83 -0.0138±0.002 4.2E-12 442,278 
rs747686078 1 29,453,545 TMEM200B intergenic I D 0.11 -0.0154±0.0024 2.4E-10 442,278 
rs909001 1 32,196,647 ADGRB2 exonic C G 0.83 -0.0124±0.002 2.8E-10 442,278 
rs12022461 1 33,232,525 KIAA1522 intronic A G 0.17 -0.0111±0.0019 4.8E-09 508,103 
rs9426003 1 34,602,870 CSMD2 intronic A G 0.30 -0.0106±0.0016 1.4E-11 506,310 
rs4660590 1 42,441,288 HIVEP3 intergenic A G 0.46 0.0114±0.0014 1.5E-15 508,070 
rs56158851 1 42,784,893 FOXJ3 intronic I D 0.69 0.008±0.0016 7.2E-07 442,278 
rs115092994 1 46,185,726 IPP intronic A G 0.96 0.0284±0.0038 4.4E-14 442,278 
rs11211481 1 47,694,167 TAL1 intronic A G 0.41 0.0116±0.0014 1.4E-15 508,101 
rs7531656 1 49,828,663 AGBL4 intronic A G 0.32 0.0134±0.0015 4.9E-19 529,754 
rs630602 1 54,728,864 SSBP3 intronic C G 0.61 0.0091±0.0015 8.0E-10 505,839 
rs10493217 1 57,820,637 DAB1 intronic T C 0.09 0.015±0.0025 2.0E-09 531,556 
rs41313250 1 62,483,623 INADL intronic A G 0.88 0.0215±0.0023 3.7E-20 442,278 
rs1013293 1 62,570,321 INADL intronic A G 0.43 -0.0143±0.0014 5.2E-23 508,072 
rs7519259 1 66,434,743 PDE4B intronic A G 0.53 0.0102±0.0014 1.3E-12 500,064 
rs1993709 1 72,838,529 NEGR1 intergenic A G 0.20 -0.02±0.0018 2.1E-29 531,385 




intronic T C 0.40 0.0084±0.0014 4.8E-09 530,219 
rs71658797 1 77,967,507 AK5 intronic A T 0.12 0.0237±0.0023 1.2E-25 442,278 
rs17391694 1 78,623,626 GIPC2 intergenic T C 0.14 0.0204±0.0021 4.3E-23 529,785 
rs6688826 1 80,812,329 
LOC1019274
12 
intergenic T C 0.70 -0.01±0.0016 1.4E-10 508,105 
rs2642183 1 84,603,487 PRKACB intronic A G 0.24 -0.01±0.0017 1.9E-09 508,099 
rs11165643 1 96,924,097 
LOC1019282
41 
intergenic T C 0.59 0.015±0.0014 1.3E-25 531,517 
rs12072739 1 98,315,893 DPYD intronic A G 0.77 -0.0141±0.0018 1.9E-15 442,278 
rs2077569 1 103,350,876 COL11A1 intronic A G 0.61 -0.0093±0.0015 8.5E-10 442,278 
rs11434203 1 107,623,489 PRMT6 intergenic D I 0.34 0.0104±0.0016 3.8E-11 442,278 
rs7550711 1 110,082,886 GPR61 intronic T C 0.03 0.0458±0.0044 1.7E-25 525,851 
rs3768486 1 110,123,971 GNAI3 intronic A G 0.82 -0.0114±0.0018 5.2E-10 529,292 
rs12120956 1 113,202,571 CAPZA1 intronic A G 0.20 -0.0147±0.0018 7.4E-17 508,065 
rs11205303 1 149,906,413 MTMR11 missense T C 0.59 -0.0182±0.0014 3.2E-36 526,146 
rs114529840 1 150,457,517 TARS2 intergenic T G 0.94 0.0293±0.0032 1.7E-20 442,278 
rs2305813 1 150,981,267 PRUNE intronic C G 0.12 -0.016±0.0022 1.2E-12 442,278 
rs79100766 1 151,690,804 CELF3 intergenic I D 0.48 -0.0094±0.0015 3.0E-10 442,278 
rs35154152 1 155,172,725 THBS3 missense T C 0.89 0.0195±0.0024 4.2E-16 442,278 
rs76102184 1 156,171,486 SLC25A44 intronic T C 0.02 0.0368±0.005 1.3E-13 442,278 
rs12046534 1 170,709,593 PRRX1 intergenic T G 0.45 -0.0091±0.0015 1.8E-09 442,278 
rs77779886 1 173,740,028 KLHL20 intronic A G 0.02 -0.0311±0.005 3.4E-10 442,278 
rs189194497 1 174,347,661 RABGAP1L intronic T C 0.99 0.0568±0.0082 3.7E-12 442,278 
rs77560793 1 175,001,179 MRPS14 intergenic A G 0.03 -0.0298±0.0043 5.8E-12 442,278 
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rs543874 1 177,889,480 SEC16B intergenic A G 0.80 -0.0283±0.0017 2.8E-59 531,565 
rs746336168 1 184,706,212 EDEM3 intronic D I 0.48 0.0099±0.0015 4.5E-11 442,278 
rs491055 1 190,308,834 BRINP3 intronic A G 0.44 0.0088±0.0015 3.2E-09 442,278 
1:195029618_
C_CT 
1 195,029,618 KCNT2 intergenic I D 0.31 -0.0116±0.0017 3.7E-12 442,278 
rs2820295 1 201,800,868 IPO9 intronic A G 0.34 0.0134±0.0015 6.5E-19 508,032 
rs16849710 1 202,106,797 ARL8A intronic A G 0.47 0.0081±0.0014 1.9E-08 505,010 
rs2802774 1 203,527,812 OPTC intergenic A C 0.55 0.0108±0.0015 7.2E-13 442,278 
rs2356722 1 209,524,734 MIR205HG intergenic A G 0.71 -0.0093±0.0016 3.9E-09 508,063 
rs17015701 1 210,337,691 SYT14 downstream A G 0.19 0.0114±0.0018 2.0E-10 531,566 
rs528296052 1 213,287,698 RPS6KC1 intronic I D 0.66 -0.0098±0.0016 6.7E-10 442,278 
rs1377184 1 215,246,432 KCNK2 intronic A T 0.25 -0.0125±0.0017 2.8E-13 442,278 
rs11118310 1 219,637,671 LYPLAL1 intergenic A T 0.41 0.0206±0.0015 1.5E-45 508,106 
rs11118893 1 222,085,672 
LOC1019297
71 
intergenic A G 0.70 0.0104±0.0016 2.7E-11 505,804 
rs10915840 1 225,668,524 ENAH intergenic A G 0.27 -0.0096±0.0016 2.2E-09 507,936 
rs11122450 1 230,301,811 GALNT2 intronic T G 0.39 0.0095±0.0015 2.2E-10 465,732 
rs12042959 1 243,533,273 SDCCAG8 intronic A G 0.85 0.0133±0.002 5.9E-11 508,044 
rs7549780 1 243,712,455 AKT3 intronic A C 0.32 0.0071±0.0015 4.4E-06 507,190 
rs62106258 2 417,167 FAM150B intergenic T C 0.95 0.0504±0.0034 1.7E-48 442,278 
rs13415094 2 653,093 TMEM18 intergenic T C 0.83 0.0291±0.0019 1.7E-54 530,246 
rs4669869 2 12,898,460 TRIB2 intergenic T C 0.55 -0.0092±0.0014 1.4E-10 508,027 
rs78265103 2 24,468,191 ITSN2 intronic A T 0.95 0.0205±0.0034 9.5E-10 442,278 
rs6752378 2 25,150,116 ADCY3 intergenic A C 0.48 0.0228±0.0014 8.6E-59 530,088 
rs934778 2 25,389,224 POMC intronic A G 0.68 -0.0188±0.0015 2.0E-35 531,497 
rs1627854 2 26,953,540 KCNK3 UTR3 A G 0.53 -0.0115±0.0014 6.9E-16 505,091 
rs3770799 2 36,788,616 FEZ2 intronic A G 0.63 -0.0122±0.0015 1.6E-16 506,313 
rs7580551 2 41,718,026 LOC388942 intergenic A G 0.64 -0.0123±0.0015 1.2E-16 508,081 
rs786420 2 44,719,893 CAMKMT intronic T C 0.76 0.0099±0.0017 3.3E-09 507,160 
rs58569862 2 46,896,921 SOCS5 intergenic T C 0.79 0.0144±0.0018 3.4E-15 442,278 
rs58120873 2 47,313,562 C2orf61 downstream A G 0.09 -0.0163±0.0026 6.3E-10 442,278 
rs555219016 2 50,215,757 NRXN1 intronic D I 0.60 -0.0105±0.0015 1.4E-11 442,278 
2:50759450_
AT_A 
2 50,759,450 NRXN1 intronic D I 0.45 0.0098±0.0016 3.7E-10 442,278 
rs10176888 2 50,861,049 NRXN1 intronic A T 0.75 -0.0098±0.0016 2.7E-09 508,000 
rs7601895 2 55,281,901 RTN4 intergenic C G 0.69 0.0101±0.0016 9.2E-11 503,609 
rs13432055 2 56,603,985 CCDC85A intronic T C 0.71 -0.0096±0.0016 9.8E-10 531,000 
rs6754296 2 58,002,882 VRK2 intergenic T G 0.92 -0.0161±0.0027 1.8E-09 505,116 
rs10197655 2 58,791,420 LINC01122 
ncRNA 
intronic 
A G 0.43 -0.0114±0.0015 2.2E-14 442,278 
rs6545714 2 59,307,725 LINC01122 intergenic A G 0.60 -0.0143±0.0014 2.6E-23 531,512 
rs6545966 2 62,861,353 EHBP1 intergenic A G 0.52 0.0089±0.0015 1.8E-09 442,278 
rs12477088 2 67,841,326 
LOC1019277
01 
intergenic T C 0.59 0.0111±0.0014 2.0E-14 508,083 
rs4453725 2 69,659,126 NFU1 missense A T 0.59 0.0127±0.0014 2.3E-18 508,101 
rs396354 2 86,850,022 RNF103 UTR5 T C 0.28 0.01±0.0016 2.5E-10 507,230 
rs2871344 2 100,839,430 LINC01104 
ncRNA 
intronic 
A G 0.60 0.0129±0.0014 2.7E-19 531,486 
rs6707445 2 104,420,858 
LOC1002870
10 
intergenic A G 0.45 0.0092±0.0014 1.9E-10 506,310 
rs445077 2 105,404,701 LINC01158 intergenic A T 0.48 0.0113±0.0015 2.9E-14 442,278 
rs4676084 2 110,010,962 SH3RF3 intronic A G 0.42 0.009±0.0014 4.3E-10 507,511 
rs4848281 2 112,945,188 FBLN7 UTR3 A T 0.74 -0.0106±0.0016 1.1E-10 507,196 
rs10204422 2 133,528,953 NCKAP5 intronic C G 0.73 -0.0107±0.0017 1.9E-10 442,278 
rs10496731 2 135,597,628 ACMSD intronic T G 0.63 0.0108±0.0015 3.6E-13 508,084 
rs4988235 2 136,608,646 MCM6 intronic A G 0.74 0.0097±0.0016 2.1E-09 529,763 
rs4662318 2 144,016,529 ARHGAP15 intronic T C 0.16 -0.0117±0.002 2.6E-09 508,036 
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rs453520 2 147,907,202 PABPC1P2 intergenic T C 0.58 -0.0115±0.0014 1.4E-15 507,146 
rs62169721 2 151,471,941 
LOC1019292
82 
intergenic T G 0.03 0.0298±0.0047 2.3E-10 442,278 
rs3771653 2 159,483,811 PKP4 intronic T C 0.63 0.0088±0.0015 7.2E-09 442,278 
rs6711375 2 161,090,873 
LOC1005059
84 
intergenic A G 0.68 0.0103±0.0015 1.8E-11 508,038 
rs939643 2 165,387,977 GRB14 intronic T G 0.43 0.0097±0.0014 2.1E-11 508,068 
rs1128249 2 165,528,624 COBLL1 intergenic T G 0.39 0.0176±0.0014 3.3E-34 531,493 
rs3754963 2 166,185,707 SCN2A intronic A T 0.74 0.0105±0.0016 1.2E-10 508,073 
rs17694506 2 171,632,225 ERICH2 intronic T C 0.61 -0.0098±0.0015 3.6E-11 496,879 
rs12997093 2 172,564,438 DYNC1I2 intronic T C 0.41 -0.0094±0.0014 7.2E-11 507,624 
rs34234296 2 175,166,636 LINC01305 intergenic A G 0.39 -0.0117±0.0015 2.5E-14 442,278 
rs374500261 2 175,521,358 WIPF1 intronic A G 0.99 0.050±0.009 4.48E-09 442,278 
rs4972476 2 176,426,297 KIAA1715 intergenic A G 0.11 -0.017±0.0023 2.8E-13 508,078 
rs11679338 2 181,606,895 SCHLAP1 
ncRNA 
intronic 
T C 0.66 0.0117±0.0015 9.2E-15 495,637 
rs12478299 2 193,811,641 PCGEM1 intergenic T C 0.75 0.0109±0.0016 4.1E-11 508,020 





T C 0.38 0.0104±0.0015 1.7E-12 506,311 
rs12997625 2 202,970,250 KIAA2012 intronic T C 0.53 0.0098±0.0014 6.4E-12 508,096 
rs11693128 2 204,115,901 CYP20A1 intronic A G 0.45 -0.0092±0.0014 9.1E-11 530,216 
rs4482463 2 205,375,909 PARD3B intergenic A C 0.92 -0.0224±0.0027 1.7E-16 494,260 
rs7569010 2 206,084,518 PARD3B intronic C G 0.43 0.01±0.0014 4.1E-12 507,146 
rs16846136 2 212,291,371 ERBB4 intronic A C 0.27 0.0107±0.0016 3.6E-11 508,094 
rs7599312 2 213,413,231 ERBB4 intergenic A G 0.27 -0.0097±0.0016 1.2E-09 531,505 
rs2712169 2 217,671,349 TNP1 intergenic A G 0.58 -0.0108±0.0015 1.2E-13 508,046 
rs952227 2 227,062,080 LOC646736 intergenic A G 0.33 0.0171±0.0015 2.2E-30 530,620 
rs200882902 2 228,996,202 SPHKAP intronic I D 0.33 0.0133±0.0016 1.2E-16 442,278 
rs3791837 2 230,681,905 TRIP12 intronic A G 0.67 -0.0141±0.0015 2.0E-20 508,090 
rs71036299 2 236,819,547 AGAP1 intronic D I 0.28 0.0106±0.0018 3.4E-09 442,278 
rs3085964 2 242,021,008 SNED1 intronic D I 0.86 -0.0132±0.0022 2.9E-09 442,278 
rs11542009 3 9,517,369 SETD5 missense T C 0.10 0.0152±0.0024 4.5E-10 442,278 
rs7649970 3 12,392,272 PPARG intronic T C 0.12 0.0289±0.0022 3.6E-41 530,258 
rs6809832 3 12,414,420 PPARG intronic T C 0.85 0.019±0.002 1.3E-21 531,557 
rs17819328 3 12,489,342 PPARG intergenic T G 0.57 0.0068±0.0014 1.8E-06 529,267 
rs2600224 3 12,933,866 IQSEC1 intergenic T C 0.68 -0.0083±0.0015 7.3E-08 506,310 
rs4619804 3 18,674,644 SATB1-AS1 intergenic A C 0.26 -0.0131±0.0016 1.1E-15 506,312 
rs17016133 3 25,313,167 RARB intronic T C 0.87 0.0125±0.0021 3.9E-09 508,101 
rs602543 3 27,547,083 SLC4A7 intergenic T C 0.40 0.0095±0.0015 6.4E-11 507,190 
rs10490871 3 35,667,761 ARPP21 intergenic A G 0.63 -0.0102±0.0015 5.0E-12 508,098 
rs9816029 3 41,311,362 ULK4 intronic C G 0.34 0.0102±0.0015 1.3E-11 508,041 
rs33485 3 42,417,982 LYZL4 intergenic T C 0.74 -0.0112±0.0016 5.8E-12 508,062 
rs7637852 3 44,041,777 MIR138-1 intergenic A G 0.30 0.0123±0.0016 3.0E-15 507,567 
rs33807 3 45,334,692 TMEM158 intergenic A G 0.12 0.0134±0.0022 1.9E-09 502,248 
rs62259939 3 49,386,047 USP4 intergenic A G 0.44 0.0131±0.0015 1.3E-18 442,278 
rs2681780 3 49,897,830 CAMKV intronic T C 0.51 0.0155±0.0014 3.5E-27 508,075 
rs2612012 3 53,745,625 CACNA1D intronic A C 0.75 0.0105±0.0017 2.3E-10 505,829 
rs1916801 3 61,187,046 FHIT intronic A T 0.59 0.0108±0.0014 5.4E-14 531,322 
rs9968060 3 62,471,282 CADPS intronic T C 0.64 0.0112±0.0015 1.5E-13 505,028 





T C 0.70 -0.0118±0.0015 2.5E-14 530,071 
rs3856595 3 66,492,604 LRIG1 intronic T G 0.45 -0.0091±0.0015 1.0E-09 442,278 
rs1491592 3 70,654,244 FOXP1 intergenic T C 0.55 0.0088±0.0015 3.6E-09 442,278 
rs17007949 3 70,920,041 FOXP1 intergenic C G 0.31 0.0091±0.0016 5.2E-09 506,312 
rs9866090 3 71,585,144 FOXP1 intronic A G 0.23 0.0123±0.0017 6.2E-13 507,576 
rs13080520 3 81,850,742 GBE1 intergenic T C 0.64 -0.0105±0.0015 1.6E-12 507,604 
rs76345589 3 84,185,140 LINC00971 intergenic C G 0.93 0.0201±0.003 1.2E-11 442,278 
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rs12495178 3 85,886,077 CADM2 intronic T C 0.64 0.0116±0.0015 3.9E-15 529,741 
rs9826925 3 88,206,392 C3orf38 UTR3 T G 0.88 0.016±0.0022 9.1E-13 506,312 
rs1495824 3 88,733,658 EPHA3 intergenic A G 0.50 -0.0105±0.0014 2.0E-13 508,063 
rs4857329 3 94,036,952 NSUN3 intergenic A G 0.48 0.013±0.0014 9.6E-20 508,060 
rs4577503 3 99,657,922 MIR548G 
ncRNA 
intronic 
A G 0.59 -0.0088±0.0015 1.6E-09 508,095 
rs2141180 3 101,179,057 SENP7 intronic T C 0.38 -0.0095±0.0015 6.0E-11 531,559 
rs1436348 3 104,612,668 ALCAM intergenic A G 0.42 -0.0117±0.0014 6.8E-16 508,076 
rs1078455 3 108,129,348 MYH15 intronic T C 0.69 -0.0105±0.0016 1.4E-11 506,313 
rs2124499 3 123,093,541 ADCY5 intronic C G 0.37 -0.0131±0.0015 4.8E-19 517,754 
rs9820766 3 123,264,017 HACD2 intronic T C 0.69 -0.0103±0.0015 3.0E-11 508,085 
rs9847672 3 131,618,541 CPNE4 intronic T C 0.28 0.0141±0.0016 1.0E-18 508,079 
rs10935143 3 134,665,159 EPHB1 intronic A G 0.45 -0.0083±0.0014 8.5E-09 507,618 
rs2293251 3 138,124,114 MRAS UTR3 T G 0.84 0.0132±0.002 2.1E-11 508,104 
rs11917587 3 141,207,575 RASA2 intronic A G 0.43 0.0121±0.0014 3.2E-17 530,992 
rs62271373 3 150,066,540 LINC01214 intergenic A T 0.06 -0.024±0.0032 4.5E-14 442,278 
rs7652639 3 153,183,198 C3orf79 intergenic T C 0.55 0.0091±0.0014 2.6E-10 508,102 
rs1568488 3 153,657,951 
ARHGEF26-
AS1 
intergenic C G 0.60 0.0115±0.0015 6.3E-15 506,312 
rs9289970 3 156,301,324 SSR3 intergenic A C 0.85 0.0124±0.002 8.1E-10 497,414 
rs6802443 3 157,888,438 RSRC1 intronic A G 0.44 0.0098±0.0014 1.4E-11 496,946 
rs8192675 3 170,724,883 SLC2A2 intronic T C 0.71 -0.0095±0.0016 1.1E-09 531,548 
rs4894808 3 171,833,266 FNDC3B intronic C G 0.40 -0.0093±0.0015 5.1E-10 506,739 
rs488029 3 173,119,378 NLGN1 intronic A G 0.53 0.0103±0.0014 8.5E-13 503,321 




3 183,513,243 YEATS2 intronic D I 0.53 -0.0099±0.0015 6.0E-11 442,278 
rs1516725 3 185,824,004 ETV5 intronic T C 0.14 -0.0142±0.0021 5.1E-12 530,218 
rs200915692 3 196,115,344 UBXN7 intronic D I 0.64 -0.0099±0.0016 2.2E-10 442,278 
rs6782581 3 196,979,106 DLG1 intronic C G 0.56 0.0102±0.0014 1.6E-12 496,887 
rs2279178 4 906,647 GAK intronic A G 0.18 0.0132±0.0019 2.8E-12 502,923 
rs2798297 4 3,064,004 HTT-AS downstream A G 0.37 0.0102±0.0016 5.1E-11 442,278 
rs2192527 4 18,329,824 LCORL intergenic A G 0.54 -0.0139±0.0015 7.9E-21 442,278 
rs1485554 4 20,120,863 SLIT2 intergenic A G 0.12 0.0167±0.0023 1.8E-13 442,278 
rs7664617 4 21,862,428 KCNIP4 intronic C G 0.49 0.0083±0.0014 6.4E-09 508,106 
4:25355782_
AAAG_A 
4 25,355,782 ZCCHC4 intronic D I 0.22 -0.0126±0.0018 4.3E-12 442,278 
rs17644283 4 26,308,792 RBPJ intergenic A G 0.37 0.0089±0.0015 1.5E-09 529,134 
4:28526950_
AAAAC_A 
4 28,526,950 MIR4275 intergenic D I 0.17 -0.0153±0.002 2.2E-14 442,278 
rs13137372 4 34,928,521 
LOC1019286
22 
intergenic T C 0.70 -0.0111±0.0016 6.8E-12 442,278 
rs10938397 4 45,182,527 GNPDA2 intergenic A G 0.57 -0.0204±0.0014 2.3E-46 531,498 
rs411261 4 48,354,057 SLAIN2 intronic T C 0.62 0.0088±0.0015 1.6E-09 530,595 
rs62645069 4 49,125,019 CWH43 intergenic A T 0.69 -0.0098±0.0017 4.3E-09 442,278 
rs3113509 4 52,932,825 SPATA18 intronic T C 0.73 -0.01±0.0017 2.3E-09 442,278 
rs11943456 4 56,276,334 TMEM165 intronic T C 0.54 -0.0114±0.0014 2.3E-15 508,064 
rs4694127 4 73,552,093 ADAMTS3 intergenic T C 0.06 0.022±0.003 1.0E-13 508,102 
rs7692075 4 78,808,669 MRPL1 intronic T G 0.85 -0.0133±0.0021 8.0E-11 486,266 
rs72649373 4 80,609,966 LINC00989 intergenic T C 0.86 -0.0153±0.0022 1.3E-12 442,278 
rs564988630 4 83,192,564 HNRNPD intergenic I D 0.50 -0.0096±0.0015 1.5E-10 442,278 
rs2276936 4 89,726,283 FAM13A intronic A C 0.53 0.0127±0.0014 2.2E-19 530,402 
rs2865384 4 96,145,120 UNC5C intronic A G 0.63 -0.0102±0.0015 5.9E-12 506,303 
rs1229984 4 100,239,319 ADH1B missense T C 0.02 -0.0324±0.0048 1.9E-11 442,278 
rs546865674 4 102,197,018 PPP3CA intronic D I 0.85 -0.0153±0.0021 5.8E-13 442,278 
rs13107325 4 103,188,709 SLC39A8 missense T C 0.07 0.0304±0.0027 5.9E-29 528,344 
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T C 0.12 0.0129±0.0022 2.7E-09 507,580 
rs4864201 4 130,731,284 
LOC1019272
82 
intergenic T C 0.35 0.0094±0.0015 2.3E-10 529,748 
rs1296328 4 137,083,193 LINC00613 intergenic A C 0.44 0.0115±0.0015 2.3E-15 506,308 
rs57800857 4 140,863,365 MAML3 intronic A C 0.63 0.0135±0.0015 3.8E-18 442,278 
rs113079574 4 147,354,089 SLC10A7 intronic T C 0.19 -0.0114±0.0019 1.8E-09 442,278 
rs112323962 5 284,768 PDCD6 intronic D I 0.91 -0.017±0.0027 4.7E-10 442,278 
rs13177679 5 42,915,470 FLJ32255 intergenic T C 0.34 -0.0105±0.0015 5.0E-12 528,730 
rs17820010 5 50,384,662 
LOC1002875
92 
intergenic T G 0.70 -0.0109±0.0016 4.3E-12 505,722 
rs12189178 5 50,914,726 ISL1 intergenic T C 0.03 0.0279±0.004 2.3E-12 531,323 
rs256108 5 52,874,253 NDUFS4 intronic T C 0.77 -0.0126±0.0017 5.6E-14 531,496 
rs11744289 5 53,283,329 ARL15 intronic A G 0.94 0.0195±0.0032 1.0E-09 504,520 
rs40271 5 55,796,319 C5orf67 intergenic T C 0.74 -0.0125±0.0016 1.1E-14 531,434 
rs13173241 5 55,861,359 C5orf67 intronic A G 0.21 -0.0103±0.0017 3.8E-09 531,510 
rs10805383 5 63,034,606 HTR1A intergenic A G 0.48 0.0119±0.0014 4.9E-17 530,112 
5:63940500_
CA_C 
5 63,940,500 RGS7BP intergenic I D 0.47 -0.0102±0.0015 6.5E-12 442,278 
rs6893495 5 64,409,378 ADAMTS6 intergenic T C 0.21 0.0117±0.0018 1.2E-10 442,278 
rs27218 5 66,207,261 MAST4 intronic T C 0.28 -0.0103±0.0016 1.2E-10 508,077 
rs4976033 5 67,714,246 PIK3R1 intergenic A G 0.60 0.012±0.0015 3.7E-16 529,123 
rs11954242 5 74,411,629 ANKRD31 intronic C G 0.66 0.0142±0.0016 1.9E-19 442,278 
rs2112347 5 75,015,242 POC5 intergenic T G 0.64 0.0175±0.0015 1.2E-32 531,525 
5:80811501_
AT_A 
5 80,811,501 SSBP2 intronic D I 0.23 -0.0108±0.0018 7.7E-10 442,278 
rs115912456 5 82,815,158 VCAN intronic A G 0.96 0.0278±0.0037 9.6E-14 442,278 
rs11951885 5 86,727,566 CCNH intergenic T C 0.98 -0.0321±0.0049 5.0E-11 501,024 





T C 0.21 -0.0148±0.0017 1.2E-17 531,532 
rs7733438 5 87,986,284 LINC00461 intergenic T G 0.86 -0.0244±0.0021 3.7E-31 508,058 
rs618741 5 88,064,012 MEF2C intronic T C 0.58 -0.0104±0.0014 6.9E-13 508,079 
rs4869417 5 92,544,460 NR2F1-AS1 intergenic T C 0.27 -0.0103±0.0016 8.7E-11 531,526 
rs159032 5 94,206,202 MCTP1 intronic T C 0.25 0.0102±0.0017 1.0E-09 506,312 





T C 0.67 0.011±0.0015 5.7E-13 507,146 
rs28119 5 96,131,733 ERAP1 intronic A G 0.79 0.0109±0.0018 5.7E-10 508,042 
rs10059133 5 103,901,424 RAB9BP1 intergenic T C 0.54 -0.0101±0.0014 2.2E-12 508,092 
rs11742930 5 105,774,098 
LOC1024672
13 
intergenic T C 0.57 0.0086±0.0014 3.2E-09 508,049 
rs10623997 5 107,478,679 FBXL17 intronic D I 0.76 0.0148±0.0018 1.8E-16 442,278 
rs11953203 5 112,446,930 MCC intronic T G 0.57 -0.0089±0.0014 7.0E-10 507,583 
rs3203922 5 118,728,953 TNFAIP8 synonymous C G 0.27 0.0102±0.0016 2.6E-10 508,091 
rs1948325 5 119,374,787 FAM170A intergenic C G 0.53 -0.0091±0.0014 1.9E-10 518,858 
rs6860245 5 127,367,998 LINC01184 
ncRNA 
intronic 
C G 0.25 -0.0116±0.0017 1.4E-11 442,278 
rs34912177 5 127,932,957 FBN2 intergenic A C 0.86 0.0104±0.0021 9.6E-07 442,278 
rs17768640 5 128,769,387 
ADAMTS19-
AS1 
intergenic A G 0.91 -0.0156±0.0026 2.0E-09 502,772 
rs329120 5 133,861,756 JADE2 intronic T C 0.42 -0.0086±0.0015 4.4E-09 496,529 
rs13174863 5 139,080,745 CXXC5 intergenic A G 0.85 -0.0135±0.002 1.9E-11 528,061 
rs2190788 5 144,484,261 KCTD16 intergenic T G 0.32 0.0101±0.0015 4.5E-11 508,064 
rs114285050 5 145,895,394 GPR151 stopgain A G 0.008 -0.050±0.008 5.52E-10 550,180 
rs1438945 5 152,510,937 LINC01470 intergenic A T 0.71 -0.0095±0.0016 9.1E-09 442,278 
rs2126165 5 153,167,595 GRIA1 intronic A G 0.49 0.0101±0.0015 1.1E-11 442,278 
rs6580054 5 153,548,134 MFAP3 intergenic T C 0.35 0.0113±0.0015 3.6E-14 508,082 
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rs10044492 5 157,931,500 
LOC1019276
97 
intergenic T C 0.27 0.0137±0.0016 9.2E-18 529,986 
rs1122080 5 158,015,903 EBF1 intergenic A G 0.19 -0.0149±0.0018 4.6E-16 531,494 
rs7730898 5 170,459,675 RANBP17 intronic A G 0.73 0.0136±0.0016 7.6E-18 531,558 
rs758654273 5 170,694,204 RANBP17 intronic D I 0.09 -0.0152±0.0028 8.2E-08 442,278 
rs7733087 5 176,164,941 LINC01574 intergenic A G 0.38 -0.009±0.0015 2.0E-09 489,496 
rs6899218 5 178,988,608 RUFY1 intronic A T 0.51 0.0098±0.0015 4.0E-11 442,278 
rs369386134 5 179,134,664 CANX intronic D I 0.20 0.0112±0.0019 3.6E-09 442,278 
rs4959613 6 1,835,403 GMDS intronic A C 0.59 0.0097±0.0016 5.5E-10 442,278 
rs2228213 6 12,124,855 HIVEP1 missense A G 0.35 -0.0118±0.0015 2.2E-15 531,538 
rs10807323 6 12,795,031 PHACTR1 intronic A G 0.43 -0.0079±0.0014 4.1E-08 531,536 
rs796970069 6 13,177,596 PHACTR1 intronic D I 0.68 0.0106±0.0016 5.6E-11 442,278 
rs1322842 6 20,488,897 E2F3 intronic A G 0.39 0.0117±0.0015 9.9E-15 463,355 
rs9366627 6 25,686,405 SCGN intronic T C 0.29 -0.0094±0.0016 2.1E-09 531,478 
rs10946808 6 26,233,387 HIST1H1D intergenic A G 0.72 0.0209±0.0016 9.6E-40 529,743 
rs2130655 6 26,789,628 GUSBP2 intergenic T C 0.75 0.0157±0.0017 1.8E-19 442,278 
rs147930667 6 31,676,702 LY6G6F intronic D I 0.87 0.0187±0.0022 2.4E-17 442,278 
rs368213214 6 32,378,647 BTNL2 intergenic D I 0.43 -0.0118±0.0015 2.0E-14 442,278 
6:33249617_
CCTTTT_C 
6 33,249,617 WDR46 intronic I D 0.65 0.0092±0.0016 3.3E-09 442,278 
rs2281819 6 33,771,673 MLN intronic A T 0.23 -0.0137±0.0017 9.8E-16 507,155 
rs2815005 6 34,638,847 C6orf106 intronic A G 0.14 0.0245±0.002 1.2E-33 531,534 
rs11755266 6 35,162,141 SCUBE3 intergenic T C 0.10 0.0256±0.0024 3.5E-26 527,708 
rs2766535 6 35,691,782 FKBP5 intronic A G 0.47 0.0112±0.0014 5.3E-15 505,821 
rs9471333 6 40,362,023 LRFN2 intronic T C 0.55 -0.0143±0.0015 9.3E-22 442,278 
rs998584 6 43,757,896 VEGFA intergenic A C 0.48 -0.0095±0.0014 2.8E-11 527,142 





T G 0.48 -0.0091±0.0014 1.9E-10 508,077 
rs4391262 6 50,378,717 TFAP2D intergenic T C 0.05 0.0234±0.0032 3.1E-13 507,243 
rs4715213 6 50,911,091 PKHD1 intergenic T C 0.17 0.0229±0.0019 5.2E-34 530,185 
rs2474896 6 51,760,527 PKHD1 intronic T C 0.55 0.0121±0.0015 7.8E-16 442,278 
rs796663884 6 52,426,285 TRAM2 intronic I D 0.42 0.0094±0.0015 7.6E-10 442,278 
rs7452651 6 55,135,513 HCRTR2 intronic A G 0.25 -0.0101±0.0017 9.9E-10 508,094 
rs6910590 6 70,359,738 LMBRD1 intergenic A G 0.21 -0.0114±0.0018 1.1E-10 506,309 
rs9294260 6 83,433,228 UBE3D intergenic A G 0.48 0.0089±0.0014 4.2E-10 531,042 





T C 0.29 -0.0108±0.0016 8.7E-12 508,087 
rs1487441 6 98,553,894 MIR2113 intergenic A G 0.48 -0.0152±0.0014 2.8E-26 508,076 
rs57989773 6 100,629,078 MCHR2-AS1 intergenic T C 0.76 -0.0123±0.0018 4.8E-12 442,278 
rs314288 6 105,434,078 LIN28B intronic T C 0.11 0.0157±0.0023 1.5E-11 442,278 
rs768023 6 108,876,002 FOXO3 intergenic A G 0.63 0.0112±0.0015 2.1E-14 531,523 
rs77043842 6 111,647,203 REV3L intronic D I 0.91 -0.0178±0.0027 6.4E-11 442,278 
rs13218383 6 120,173,501 MIR3144 intergenic C G 0.66 0.0093±0.0015 6.8E-10 508,094 
rs1361108 6 126,767,600 MIR588 intergenic T C 0.46 -0.0113±0.0014 4.1E-15 507,187 
rs72959041 6 127,454,893 RSPO3 intronic A G 0.05 -0.0223±0.0034 6.4E-11 461,206 
rs9321191 6 130,165,691 TMEM244 intronic T C 0.80 0.011±0.0018 8.2E-10 507,576 
rs1970341 6 141,361,290 MIR4465 intergenic A G 0.05 0.0195±0.0033 4.4E-09 442,278 
6:143187255_
CA_C 
6 143,187,255 HIVEP2 intronic I D 0.51 0.0096±0.0015 8.5E-11 442,278 
rs9390370 6 146,357,569 GRM1 intronic T C 0.31 0.0088±0.0015 1.6E-08 508,052 
rs2063347 6 160,882,029 LPAL2 intergenic A G 0.39 -0.0084±0.0014 7.5E-09 531,529 
rs6461115 7 2,103,668 MAD1L1 intronic A G 0.77 0.0121±0.0017 8.2E-13 531,563 
rs1182197 7 2,863,289 GNA12 intronic A C 0.62 0.0091±0.0015 2.0E-09 465,729 
rs4722398 7 3,125,220 CARD11 intergenic T C 0.14 0.0137±0.0021 5.4E-11 508,076 
rs11408091 7 6,387,863 FAM220A intronic D I 0.87 -0.0132±0.0022 2.5E-09 442,278 
rs4307239 7 24,354,300 NPY intergenic A G 0.54 -0.0084±0.0014 4.5E-09 508,062 
rs6967749 7 26,713,194 SKAP2 intronic T C 0.91 -0.0163±0.0026 2.3E-10 505,064 
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rs4722672 7 27,231,762 HOXA11-AS intergenic T C 0.82 -0.0156±0.0019 4.3E-17 529,277 
rs215634 7 32,369,148 PDE1C intergenic A G 0.39 0.0121±0.0015 3.8E-16 497,301 
rs4549685 7 39,326,478 POU6F2 intronic T C 0.33 -0.0114±0.0016 6.0E-13 442,278 
rs2289379 7 44,804,225 ZMIZ2 intronic T C 0.40 -0.0089±0.0015 1.3E-09 507,136 
rs17172722 7 46,620,312 IGFBP3 intergenic T C 0.42 -0.0098±0.0015 1.7E-11 508,044 
rs10259490 7 49,616,420 VWC2 intergenic A G 0.62 -0.0088±0.0015 2.4E-09 506,312 
rs17449259 7 50,733,714 GRB10 intronic T G 0.07 0.0188±0.003 2.0E-10 506,722 
rs10263467 7 69,179,509 AUTS2 intronic A G 0.05 0.0191±0.0032 2.4E-09 496,510 
rs10237317 7 70,045,941 AUTS2 intronic A G 0.58 -0.0114±0.0014 3.4E-15 529,753 
rs10950290 7 71,439,590 CALN1 intronic A T 0.74 0.0111±0.0016 1.2E-11 495,636 
rs116903188 7 74,347,183 PMS2P5 intergenic T G 0.87 0.0194±0.0027 1.3E-12 442,278 
rs236660 7 75,050,086 POM121C intronic T C 0.43 -0.0141±0.0016 1.8E-19 442,278 
rs6970595 7 77,426,482 TMEM60 intronic T C 0.60 -0.0106±0.0015 4.0E-13 508,104 
rs3840590 7 77,827,064 MAGI2 intronic D I 0.65 0.0113±0.0016 5.6E-13 442,278 
rs17704028 7 95,140,031 ASB4 intronic T C 0.15 -0.0131±0.002 9.7E-11 503,677 
rs73232637 7 96,613,246 DLX6-AS1 
ncRNA 
intronic 
A G 0.96 -0.0248±0.004 7.5E-10 442,278 
rs1011024 7 99,197,401 
GS1-
259H13.2 
intronic A G 0.85 0.0149±0.002 6.0E-14 508,039 




7 104,885,481 SRPK2 intronic D I 0.38 0.0093±0.0015 1.4E-09 442,278 
rs7788008 7 112,972,483 LINC00998 intergenic A G 0.44 -0.0109±0.0014 3.2E-14 508,074 
rs6944092 7 113,483,569 PPP1R3A intergenic A G 0.63 -0.0092±0.0015 6.0E-10 508,022 
rs1530680 7 114,407,396 FOXP2 intergenic T G 0.20 -0.0109±0.0018 1.3E-09 508,070 
rs7777351 7 121,962,953 CADPS2 intronic A C 0.37 0.0094±0.0015 9.4E-10 442,278 
rs2283093 7 126,721,231 GRM8 intronic T C 0.20 0.0107±0.0018 1.5E-09 508,077 
rs972283 7 130,466,854 KLF14 intergenic A G 0.49 0.0148±0.0014 1.0E-25 531,549 
rs6977081 7 150,542,515 AOC1 intergenic T G 0.33 -0.0113±0.0015 9.6E-14 530,577 
rs11782341 8 4,813,459 CSMD1 intronic A G 0.81 -0.0107±0.0018 6.4E-09 508,039 
rs4841218 8 9,653,902 TNKS intergenic T C 0.38 0.0098±0.0015 2.7E-11 506,310 
rs775959252 8 14,190,443 SGCZ intronic I D 0.26 0.0107±0.0018 1.5E-09 442,278 
rs11786089 8 21,975,521 HR intronic A G 0.54 -0.0104±0.0015 3.7E-12 442,278 
rs11781222 8 23,389,571 SLC25A37 intronic T C 0.86 0.0154±0.0021 9.3E-14 531,549 
rs117176448 8 27,261,138 PTK2B intronic C G 0.90 -0.017±0.0025 1.5E-11 442,278 
rs11775287 8 30,864,339 PURG intronic T C 0.48 -0.0102±0.0014 1.3E-12 508,085 
rs12681990 8 36,859,186 KCNU1 intergenic T C 0.84 0.0124±0.0019 1.2E-10 531,492 
rs1808629 8 73,435,964 KCNB2 intergenic A G 0.69 -0.0167±0.0016 2.9E-25 442,278 
rs1992974 8 76,653,245 HNF4G intergenic C G 0.41 -0.0145±0.0015 3.3E-23 508,101 
rs1594447 8 77,227,907 LINC01111 intergenic A G 0.43 -0.0148±0.0014 3.4E-25 531,553 
rs17481178 8 78,882,007 
LOC1027248
74 
intergenic A G 0.37 0.0086±0.0015 4.6E-09 529,759 
rs111884404 8 87,342,875 WWP1 intergenic A G 0.64 -0.0104±0.0017 6.8E-10 442,278 
rs2957446 8 106,355,864 ZFPM2 intronic A G 0.47 -0.0087±0.0014 7.2E-10 531,408 
rs4433183 8 112,501,602 LINC01609 intergenic T C 0.27 -0.0103±0.0016 2.8E-10 508,043 
rs3808477 8 116,670,347 TRPS1 intronic T C 0.28 -0.0176±0.0016 2.0E-28 507,945 




8 126,504,383 TRIB1 intergenic I D 0.40 -0.0126±0.0016 1.2E-14 442,278 
rs1106761 8 142,619,234 MROH5 intergenic A G 0.39 0.0103±0.0015 2.9E-11 442,278 
rs4072917 8 143,300,279 TSNARE1 intronic A G 0.48 0.0086±0.0014 2.8E-09 505,828 
rs2717609 8 143,769,252 PSCA intergenic A T 0.53 0.0098±0.0015 5.8E-11 442,278 
8:144505206_
ACCT_A 
8 144,505,206 MAFA-AS1 intergenic D I 0.21 0.0115±0.0019 6.2E-10 442,278 
rs10124645 9 11,321,119 PTPRD-AS2 intergenic A G 0.59 0.0092±0.0015 3.3E-10 507,608 
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rs1948080 9 11,852,043 TYRP1 intergenic T G 0.63 0.0102±0.0015 4.7E-12 508,073 
rs424539 9 14,442,595 NFIB intergenic C G 0.62 -0.0104±0.0015 2.3E-12 506,668 
rs7046483 9 14,777,395 FREM1 intronic A G 0.61 -0.0098±0.0015 1.4E-10 442,278 
rs16933350 9 15,515,940 PSIP1 intergenic T G 0.96 0.0327±0.0035 1.0E-20 504,263 
rs10756713 9 15,880,555 CCDC171 intronic A G 0.56 0.0193±0.0015 9.7E-38 442,278 
rs10116857 9 16,595,649 BNC2 intronic A C 0.06 -0.0237±0.003 3.2E-15 508,077 
rs10756798 9 16,739,763 BNC2 intronic T C 0.65 -0.0138±0.0016 6.6E-19 442,278 
rs10968577 9 28,415,512 LINGO2 intronic T C 0.32 0.0158±0.0015 2.4E-25 521,832 
rs13292491 9 29,688,257 LINGO2 intergenic T C 0.76 0.0108±0.0018 7.4E-10 442,278 
rs16916303 9 30,823,761 LINC01242 intergenic A G 0.88 0.015±0.0023 3.1E-11 493,875 
rs10973160 9 36,994,969 PAX5 intronic T C 0.32 -0.0101±0.0016 2.7E-10 442,278 
rs725959 9 81,349,608 
LOC1019274
50 
intergenic T G 0.41 -0.0091±0.0015 4.3E-10 508,096 
rs12349699 9 86,640,377 RMI1 intergenic T C 0.52 0.0087±0.0014 1.8E-09 506,156 
rs7030895 9 92,189,513 GADD45G intergenic A C 0.46 -0.0107±0.0014 1.0E-13 508,057 
rs7024028 9 96,395,022 PHF2 intronic T C 0.32 0.0091±0.0015 3.5E-09 508,097 
9:103113656_
AC_A 
9 103,113,656 TEX10 intronic D I 0.38 0.0107±0.0016 5.8E-12 442,278 
rs41307479 9 116,082,647 WDR31 missense C G 0.78 -0.0121±0.0018 1.3E-11 442,278 
rs10982576 9 117,920,248 01-Dec intronic T C 0.76 0.0112±0.0017 2.7E-11 506,313 
rs10982884 9 118,462,904 
LOC1019287
75 
intergenic T C 0.09 0.0152±0.0025 9.0E-10 505,068 
rs1928295 9 120,378,483 
LOC1019287
97 
intergenic T C 0.57 0.0085±0.0014 2.1E-09 531,540 
rs7863807 9 124,625,886 TTLL11 intronic A G 0.68 -0.0091±0.0015 3.2E-09 508,067 
rs3829849 9 129,390,800 LMX1B intronic T C 0.37 0.0113±0.0015 1.0E-14 531,538 
rs11790436 9 129,929,189 RALGPS1 intronic T G 0.40 -0.01±0.0015 1.1E-11 506,313 
rs1147345 9 132,212,511 LINC00963 intergenic A T 0.47 0.0088±0.0015 6.0E-09 442,278 
rs4740383 9 133,783,566 FIBCD1 intronic A G 0.41 0.0089±0.0015 1.4E-09 496,638 
rs674302 9 136,146,664 ABO intronic A T 0.32 0.0088±0.0015 9.0E-09 508,086 
rs10993907 9 136,928,644 BRD3 intronic T C 0.67 0.0098±0.0015 1.0E-10 508,058 
rs35475612 10 16,750,948 RSU1 intronic I D 0.69 0.0108±0.0016 2.0E-11 442,278 
rs7084454 10 21,821,274 MLLT10 intergenic A G 0.32 0.0159±0.0015 4.2E-25 503,323 
rs12762056 10 33,969,962 LINC00838 intergenic T C 0.84 -0.0129±0.002 5.4E-11 508,043 
rs10998304 10 70,342,775 TET1 intronic T C 0.55 -0.0098±0.0014 4.9E-12 531,499 
rs12359330 10 72,414,845 ADAMTS14 intergenic T C 0.27 0.0159±0.0017 3.6E-21 442,278 
rs3088142 10 76,854,564 DUSP13 missense T C 0.41 0.0091±0.0015 3.7E-10 508,041 
rs200800095 10 77,630,139 C10orf11 intronic I D 0.73 0.0109±0.0017 8.5E-11 442,278 
rs2114824 10 88,119,015 GRID1 intronic A G 0.50 -0.0094±0.0014 6.8E-11 500,061 
rs2274224 10 96,039,597 PLCE1 missense C G 0.43 -0.0163±0.0014 3.6E-30 531,015 
rs4110517 10 96,650,328 CYP2C19 intergenic A G 0.21 -0.0123±0.0018 4.2E-12 508,088 
rs522110 10 99,772,885 CRTAC1 intronic A G 0.44 -0.0129±0.0014 3.0E-19 508,096 
rs41310284 10 102,447,647 PAX2 intergenic A C 0.10 -0.0209±0.0025 2.5E-17 442,278 
rs11191017 10 103,213,564 BTRC intronic A G 0.19 -0.0106±0.0018 3.2E-09 531,513 





A C 0.49 0.0082±0.0014 1.1E-08 507,145 
rs7903146 10 114,758,349 TCF7L2 intronic T C 0.29 -0.0111±0.0016 1.2E-12 531,494 
rs10886017 10 118,672,531 SHTN1 intronic A C 0.25 0.0119±0.0016 6.0E-13 531,405 
rs11199266 10 122,061,612 PLPP4 intergenic A G 0.64 -0.009±0.0015 1.6E-09 506,309 
rs2172071 10 122,968,030 MIR5694 intergenic T C 0.68 0.009±0.0015 4.7E-09 508,093 
rs72828935 10 126,587,488 ZRANB1 intergenic C G 0.28 0.0116±0.0017 2.8E-12 442,278 
rs374873119 10 128,836,112 DOCK1 intronic I D 0.54 -0.0097±0.0016 8.8E-10 442,278 
rs11017772 10 132,954,247 TCERG1L intronic T C 0.21 -0.0117±0.0018 3.5E-11 508,098 
rs4880341 10 133,992,689 JAKMIP3 intronic T C 0.58 -0.0106±0.0014 2.9E-13 507,959 
rs6578412 11 1,482,582 BRSK2 UTR3 T C 0.06 0.019±0.0032 4.2E-09 442,278 
rs10128597 11 8,694,830 RPL27A intergenic A G 0.27 -0.0137±0.0016 1.3E-17 529,114 
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rs2923093 11 10,360,934 CAND1.11 
ncRNA 
intronic 
A T 0.59 -0.0104±0.0014 6.0E-13 528,445 
rs6416051 11 10,409,041 CAND1.11 
ncRNA 
intronic 
T C 0.50 0.0108±0.0014 6.3E-14 494,258 
rs4757144 11 13,331,226 ARNTL intronic A G 0.59 0.0116±0.0015 2.1E-15 508,048 
rs7938266 11 14,709,324 PDE3B intronic A G 0.59 0.0078±0.0014 6.3E-08 531,485 
rs150090666 11 14,865,399 PDE3B stop gain T C 0.001 0.150±0.025 2.56E-09 442,278 
rs6265 11 27,679,916 BDNF missense T C 0.19 -0.0212±0.0018 6.1E-32 531,552 
rs962369 11 27,734,420 BDNF intronic T C 0.69 -0.0173±0.0015 1.9E-29 529,352 
rs6484478 11 30,306,440 ARL14EP intergenic A G 0.23 -0.0105±0.0017 7.2E-10 506,313 
rs10838123 11 43,551,572 MIR670 intergenic C G 0.49 -0.0094±0.0014 8.4E-11 507,930 
rs2862996 11 43,653,833 HSD17B12 intergenic T G 0.69 -0.0177±0.0015 5.0E-31 531,483 
rs71474196 11 46,977,160 C11orf49 intronic T C 0.11 -0.0158±0.0024 6.0E-11 442,278 
rs7124681 11 47,529,947 CELF1 intronic A C 0.41 0.0222±0.0014 4.1E-54 531,501 
rs2081361 11 57,411,742 YPEL4 downstream T C 0.28 0.0095±0.0016 3.2E-09 505,841 
rs71458418 11 62,318,081 AHNAK intergenic D I 0.64 0.0088±0.0016 2.3E-08 442,278 
rs2516633 11 62,371,773 EML3 intronic A C 0.31 -0.0114±0.0016 3.4E-13 506,308 
rs7947143 11 64,090,422 PRDX5 intergenic A G 0.16 -0.0161±0.0019 1.6E-16 506,312 
rs3200401 11 65,271,832 MALAT1 
ncRNA 
exonic 
T C 0.22 0.0111±0.0017 1.9E-10 506,155 
rs801738 11 65,924,217 PACS1 intronic C G 0.64 0.0133±0.0015 9.5E-18 442,278 
rs35099456 11 66,649,527 PC intronic C G 0.06 -0.0213±0.0031 5.1E-12 442,278 
rs4930427 11 67,200,819 RPS6KB2 synonymous T C 0.44 -0.0095±0.0014 4.5E-11 519,452 
rs7102705 11 69,143,284 MYEOV intergenic A G 0.20 -0.0113±0.0018 3.8E-10 496,218 
rs112326082 11 76,479,391 TSKU intergenic D I 0.79 0.0112±0.0019 3.2E-09 442,278 
rs393308 11 85,135,100 DLG2 intronic T C 0.16 -0.0127±0.002 3.3E-10 442,278 
rs61903695 11 89,922,417 NAALAD2 intronic A G 0.74 -0.0109±0.0017 1.9E-10 442,278 
rs2155645 11 112,912,947 NCAM1 intronic T C 0.25 -0.0102±0.0016 3.9E-10 529,755 
rs719802 11 113,234,679 TTC12 intronic T C 0.39 0.0102±0.0015 4.5E-12 506,308 
rs2046149 11 117,054,709 SIDT2 intronic C G 0.94 -0.0185±0.0031 2.0E-09 508,103 
rs583893 11 118,904,233 SLC37A4 intergenic T G 0.43 -0.0103±0.0015 1.1E-11 442,278 
rs607824 11 119,754,895 
LOC1027243
01 
intergenic A G 0.47 -0.0087±0.0014 1.3E-09 531,037 
rs12419776 11 122,528,863 UBASH3B intronic A T 0.37 0.0093±0.0015 1.7E-09 442,278 
rs11603783 11 122,752,954 C11orf63 upstream T C 0.75 -0.0115±0.0017 3.7E-11 442,278 
rs3829271 11 130,753,912 SNX19 intronic A T 0.41 0.0117±0.0015 1.0E-15 508,102 
rs12788343 11 131,452,912 NTM intronic T C 0.59 -0.011±0.0015 3.9E-13 442,278 
rs11533200 11 131,955,594 NTM intronic A G 0.31 -0.0092±0.0016 3.1E-09 508,048 
rs4936175 11 132,641,959 OPCML intronic T C 0.56 -0.0087±0.0014 1.7E-09 508,088 
rs329651 11 133,767,622 MIR4697HG 
ncRNA 
exonic 
T G 0.81 0.0105±0.0018 6.1E-09 528,019 
rs61910767 11 134,515,899 LOC283177 intergenic T C 0.17 -0.0147±0.002 2.1E-13 442,278 
rs55726687 12 991,306 WNK1 intronic A G 0.21 0.0132±0.0018 3.5E-13 442,278 
rs2108635 12 2,159,556 
CACNA1C-
IT2 
downstream A G 0.66 -0.0093±0.0016 3.1E-09 442,278 
rs3782800 12 3,350,276 TSPAN9 intronic A G 0.09 -0.0191±0.0025 3.0E-14 508,035 
rs7980313 12 3,353,862 TSPAN9 intronic T C 0.94 0.016±0.003 1.4E-07 500,676 
rs1526573 12 18,202,053 RERGL intergenic A C 0.31 0.01±0.0016 5.8E-10 442,278 
rs883528 12 19,241,157 PLEKHA5 intergenic T C 0.30 -0.0091±0.0016 2.6E-08 442,278 
rs11045172 12 20,470,221 PDE3A intergenic A C 0.80 -0.0109±0.0018 2.0E-09 505,685 
rs12811752 12 20,577,805 PDE3A intronic T C 0.59 0.0087±0.0015 4.2E-09 505,682 
rs1350429 12 41,819,131 PDZRN4 intronic A G 0.52 -0.0109±0.0014 2.8E-14 508,087 
rs3730071 12 49,168,798 ADCY6 missense A C 0.03 -0.0266±0.0042 3.7E-10 493,910 
rs7138803 12 50,247,468 BCDIN3D intergenic A G 0.37 0.0184±0.0015 2.3E-36 531,530 
rs10876528 12 54,421,476 
HOXC4,HO
XC6 
intronic A C 0.37 0.0102±0.0015 4.1E-12 518,947 
rs4759276 12 57,526,646 LRP1 intronic A G 0.39 0.0098±0.0015 1.0E-10 442,278 
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rs11173522 12 60,953,472 SLC16A7 intergenic A C 0.21 0.011±0.0018 4.0E-10 508,068 
rs1031580 12 62,263,995 FAM19A2 intronic T C 0.76 0.01±0.0017 1.2E-08 442,278 
rs12819035 12 64,236,002 SRGAP1 intergenic A T 0.08 -0.017±0.0029 5.3E-09 442,278 
rs650198 12 69,674,595 CPSF6 intergenic T C 0.72 -0.0094±0.0016 5.4E-09 495,637 
rs61754230 12 72,179,446 RAB21 missense T C 0.02 0.0319±0.0053 2.3E-09 442,278 
rs10506971 12 89,757,937 DUSP6 intergenic A G 0.55 -0.015±0.0014 1.7E-25 508,090 
rs1054807 12 89,913,419 GALNT4 UTR3 T C 0.24 0.0134±0.0017 1.0E-15 531,388 
rs12426970 12 90,436,372 LINC00936 intergenic A C 0.95 0.0282±0.0033 2.2E-17 504,634 
rs11105846 12 91,257,268 LINC00615 intergenic T G 0.37 -0.0104±0.0015 4.3E-12 508,056 
rs10745785 12 97,586,257 RMST intergenic T C 0.66 -0.009±0.0015 3.2E-09 508,090 
rs7137989 12 103,689,076 C12orf42 intergenic T C 0.34 -0.0102±0.0015 1.4E-11 507,612 
rs2287214 12 108,090,518 PWP1 intronic A G 0.60 -0.0131±0.0015 4.0E-19 508,084 
rs11609659 12 108,296,260 LOC728739 downstream T C 0.75 0.0134±0.0017 1.5E-15 505,745 
rs3764002 12 108,618,630 WSCD2 missense T C 0.26 -0.0179±0.0016 1.4E-28 518,172 
rs12300276 12 110,697,965 ATP2A2 intergenic A G 0.24 0.011±0.0018 3.3E-10 442,278 
rs10492021 12 113,197,315 RPH3A intergenic T C 0.87 -0.0131±0.0021 7.4E-10 508,069 
rs7963783 12 118,409,363 KSR2 intergenic T G 0.71 0.0094±0.0016 2.8E-09 508,077 
rs61945796 12 120,384,155 CCDC64 intergenic T G 0.03 -0.0255±0.0041 4.1E-10 442,278 
rs145350287 12 120,907,309 SRSF9 missense A T 0.04 -0.0307±0.0038 5.1E-16 442,278 
rs75412871 12 121,709,430 CAMKK2 intronic T C 0.05 -0.0208±0.0033 4.5E-10 442,278 
rs371575888 12 122,293,634 HPD intronic A C 0.04 -0.0341±0.0041 3.5E-17 442,278 
rs12369179 12 122,963,550 ZCCHC8 intronic T C 0.09 -0.0286±0.0025 4.7E-30 504,173 
rs147530811 12 123,817,477 SBNO1 intronic A C 0.04 -0.0288±0.0039 2.1E-13 442,278 
rs7133378 12 124,409,502 DNAH10 intronic A G 0.32 0.0196±0.0015 7.3E-38 529,731 
rs863750 12 124,505,444 
ZNF664-
FAM101A 
intronic T C 0.60 -0.0152±0.0014 1.1E-25 531,553 
rs1023229 13 20,270,925 PSPC1 intergenic A G 0.86 -0.0145±0.002 1.0E-12 508,076 
rs9579775 13 20,616,557 ZMYM2 intronic A C 0.86 -0.0141±0.0023 3.9E-10 442,278 
rs9512696 13 28,012,527 MTIF3 intronic A G 0.34 -0.0121±0.0016 1.7E-14 442,278 
rs2026752 13 31,012,459 LINC01058 intergenic T G 0.75 0.0117±0.0017 1.2E-11 442,278 
rs7328213 13 33,377,830 LINC00423 intergenic T C 0.55 0.0116±0.0015 7.6E-15 442,278 
rs75983170 13 40,788,838 LINC00548 
ncRNA 
intronic 
T G 0.66 -0.0097±0.0016 1.6E-09 442,278 
rs12429545 13 54,102,206 LINC00558 intergenic A G 0.13 0.0198±0.0021 1.9E-20 527,719 
rs2446169 13 54,520,877 LINC00558 intergenic A G 0.15 0.013±0.002 2.1E-10 505,832 
rs7995015 13 54,828,961 MIR1297 intergenic T G 0.32 0.0104±0.0015 1.6E-11 508,087 
rs6561937 13 58,257,667 PCDH17 intronic A T 0.75 -0.0112±0.0017 2.5E-11 502,695 
rs4055791 13 59,266,053 LINC00374 intergenic T C 0.42 -0.009±0.0015 2.1E-09 442,278 
rs9527958 13 59,841,918 DIAPH3 intergenic A G 0.66 -0.0094±0.0015 4.4E-10 508,054 
rs629443 13 76,386,075 LMO7 intronic T G 0.24 0.0109±0.0017 7.1E-11 530,424 
rs1441264 13 79,580,919 LINC00331 intergenic A G 0.59 0.0117±0.0015 1.9E-15 526,774 
rs693839 13 80,958,288 SPRY2 intergenic T C 0.70 -0.0112±0.0015 4.5E-13 531,051 
rs112108364 13 86,490,590 SLITRK6 intergenic T G 0.72 -0.0122±0.0017 2.3E-13 442,278 
rs9634490 13 97,049,100 HS6ST3 intronic A G 0.46 0.0082±0.0014 1.1E-08 506,313 
rs4294654 13 99,119,607 STK24 intronic A G 0.29 -0.0134±0.0016 2.6E-17 508,092 
rs7992207 13 104,090,183 LINC01309 intergenic C G 0.15 -0.0119±0.002 3.1E-09 505,111 
rs9522183 13 111,977,280 TEX29 intronic T G 0.56 -0.0106±0.0015 1.7E-12 442,278 
rs1183668 13 112,191,837 TEX29 intergenic C G 0.63 0.011±0.0015 1.2E-12 442,278 
rs17256211 14 23,754,580 HOMEZ intronic A G 0.35 -0.0092±0.0015 1.6E-09 505,106 
rs9788550 14 29,681,138 MIR548AI intergenic C G 0.25 -0.0154±0.0017 4.0E-19 442,278 
rs1959430 14 30,184,162 PRKD1 intronic T C 0.59 -0.0092±0.0015 1.0E-09 442,278 
rs61979560 14 30,727,033 G2E3 intergenic A C 0.29 0.0107±0.0017 1.6E-10 442,278 
rs17522122 14 33,302,882 AKAP6 downstream T G 0.47 0.0123±0.0014 7.6E-18 525,539 
rs796950072 14 33,403,525 NPAS3 intergenic I D 0.46 -0.0083±0.0015 6.4E-08 442,278 
rs1451963 14 41,350,367 LOC644919 intergenic T G 0.08 0.0161±0.0026 8.9E-10 505,075 
rs34688745 14 47,298,299 MDGA2 intergenic D I 0.50 0.0098±0.0015 9.9E-11 442,278 
rs72681869 14 50,655,357 SOS2 missense C G 0.01 -0.0573±0.0071 8.4E-16 442,278 
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rs72681698 14 51,207,741 NIN intronic T C 0.99 0.0541±0.0072 4.8E-14 442,278 
rs2481899 14 56,460,686 PELI2 intergenic A G 0.45 -0.0089±0.0015 3.0E-09 442,278 
rs7154973 14 59,408,754 LINC01500 
ncRNA 
intronic 
A T 0.83 0.0134±0.0019 3.1E-12 508,092 
rs217672 14 62,361,021 SNAPC1 intergenic A C 0.73 -0.0132±0.0017 2.8E-15 442,278 
rs4430672 14 63,094,407 KCNH5 intergenic T C 0.20 0.0112±0.0018 5.6E-10 506,309 
rs8003790 14 64,947,181 ZBTB25 intronic T C 0.52 -0.0088±0.0015 3.9E-09 442,278 
rs12890931 14 69,753,369 GALNT16 intronic T G 0.64 -0.01±0.0015 2.1E-11 507,151 
rs10138360 14 75,293,386 YLPM1 intronic A G 0.54 0.0094±0.0014 2.9E-11 529,754 
rs745614299 14 79,563,356 NRXN3 intronic D I 0.63 0.0085±0.0015 3.4E-08 442,278 
rs2370901 14 79,572,031 NRXN3 intronic T C 0.63 0.0087±0.0015 5.3E-09 508,055 
rs7144011 14 79,940,383 NRXN3 intronic T G 0.22 0.0192±0.0017 2.1E-29 531,469 
rs11624512 14 93,111,120 RIN3 intronic T C 0.19 -0.0147±0.0018 1.6E-15 505,934 
rs12434217 14 94,014,337 UNC79 intronic A G 0.37 -0.0131±0.0015 2.2E-17 442,278 
rs12885251 14 99,670,791 BCL11B intronic A G 0.46 -0.0095±0.0015 3.0E-10 442,278 
rs7161194 14 101,529,005 MIR377 downstream A G 0.34 0.0107±0.0016 1.7E-11 524,667 
rs10431745 14 102,302,372 PPP2R5C intronic A G 0.93 0.0182±0.0028 3.5E-11 508,098 
rs3803286 14 103,246,470 TRAF3 intronic A G 0.33 0.0124±0.0015 2.6E-16 507,941 
rs2010281 14 103,862,322 MARK3 intronic A G 0.34 -0.0096±0.0015 1.3E-10 529,377 
rs12441543 15 31,689,543 KLF13 intronic A G 0.29 0.0119±0.0016 6.2E-14 506,309 
rs316611 15 41,751,678 RTF1 intronic T C 0.25 0.0111±0.0017 2.4E-11 505,093 
rs1559677 15 47,738,063 SEMA6D intronic A G 0.60 -0.0098±0.0014 1.5E-11 531,502 
rs199764228 15 48,745,490 FBN1 intronic D I 0.81 0.0117±0.002 2.7E-09 442,278 
rs8031903 15 51,838,161 DMXL2 intronic T C 0.52 -0.0105±0.0014 4.1E-13 497,425 
rs35697691 15 52,353,498 MAPK6 missense C G 0.91 -0.0212±0.0026 1.1E-15 442,278 
rs2440315 15 53,084,353 ONECUT1 intergenic T G 0.74 -0.0114±0.0016 3.0E-12 508,088 
rs7169205 15 59,080,203 FAM63B intronic A G 0.85 -0.0124±0.002 4.7E-10 508,077 
rs340025 15 60,908,307 RORA-AS1 
ncRNA 
intronic 
T C 0.42 -0.0089±0.0014 7.5E-10 529,735 
rs12595158 15 62,316,035 VPS13C missense T C 0.02 -0.0295±0.005 3.8E-09 525,103 
rs2245586 15 66,878,900 LINC01169 
ncRNA 
intronic 
A G 0.35 -0.0102±0.0015 6.0E-12 531,467 
rs2119261 15 67,011,980 SMAD6 intronic T C 0.35 0.0104±0.0015 4.7E-12 508,078 
rs8038652 15 67,552,064 IQCH intronic A G 0.23 -0.0158±0.0017 2.1E-20 508,083 
rs16951304 15 68,089,618 MAP2K5 intronic T C 0.79 0.0206±0.0018 2.6E-31 508,074 
rs7168991 15 68,605,612 ITGA11 intronic T C 0.08 -0.0162±0.0027 2.0E-09 507,169 
rs7164727 15 73,093,991 ADPGK-AS1 intergenic T C 0.67 0.0146±0.0015 5.2E-22 531,550 
rs3826043 15 73,618,238 HCN4 intronic T C 0.43 -0.0135±0.0015 5.8E-19 442,278 
rs5742915 15 74,336,633 PML missense T C 0.54 0.0087±0.0014 9.7E-10 529,126 
rs936227 15 75,131,959 ULK3 synonymous A G 0.37 -0.0091±0.0015 5.0E-10 530,166 
rs139469059 15 75,922,603 SNUPN intergenic A G 0.009 0.050±0.008 3.36E-09 442,278 
rs11856579 15 78,012,688 LINGO1 intronic A G 0.27 -0.0101±0.0016 5.7E-10 495,634 
rs12914623 15 80,993,570 ABHD17C intronic C G 0.27 -0.0104±0.0016 1.6E-10 506,153 
rs11853949 15 84,516,904 ADAMTSL3 intronic A G 0.29 -0.0224±0.0016 3.9E-43 463,363 
rs11631096 15 85,100,929 UBE2Q2P1 
ncRNA 
intronic 
C G 0.28 0.0155±0.0016 6.3E-22 503,325 
rs3817428 15 89,415,247 ACAN missense C G 0.73 0.0148±0.0016 7.7E-20 508,098 
rs16946314 15 92,572,682 SLCO3A1 intronic A G 0.22 -0.0107±0.0018 8.5E-10 508,054 
rs11073382 15 95,274,277 LOC440311 intergenic A G 0.49 -0.0082±0.0014 1.1E-08 508,048 
rs12908437 15 99,287,375 IGF1R intronic T C 0.37 0.011±0.0015 8.0E-14 531,509 
rs2581348 15 100,514,063 ADAMTS17 UTR3 T C 0.65 0.0088±0.0016 1.6E-08 442,278 
rs72755233 15 100,692,953 ADAMTS17 missense A G 0.11 -0.0156±0.0023 3.2E-11 442,278 
rs412243 16 339,672 AXIN1 intronic T C 0.62 0.0104±0.0015 1.3E-11 442,278 
rs7203729 16 2,140,010 PKD1 synonymous A G 0.81 0.0129±0.0019 1.8E-11 442,278 
rs188242066 16 2,803,298 SRRM2 intronic T C 0.01 0.0515±0.0075 5.2E-12 442,278 
rs879620 16 4,015,729 ADCY9 UTR3 T C 0.61 0.0138±0.0015 9.8E-21 508,053 
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rs79431809 16 4,299,089 LINC01569 
ncRNA 
intronic 
A G 0.22 0.0125±0.0018 2.7E-12 442,278 
rs2456779 16 4,925,817 UBN1 intronic C G 0.35 0.0108±0.0015 5.7E-13 508,060 
rs2534760 16 6,509,009 RBFOX1 intronic A T 0.70 -0.0093±0.0016 3.8E-09 508,015 
rs4780837 16 20,047,093 GPR139 intronic A G 0.78 -0.0095±0.0017 6.3E-08 508,086 
rs4238585 16 20,255,097 GP2 intergenic T C 0.87 0.015±0.0021 1.7E-12 528,579 
rs4483850 16 20,375,776 PDILT intronic A T 0.50 0.0103±0.0014 5.3E-13 507,581 
rs2343606 16 24,793,741 TNRC6A intronic T C 0.27 -0.0134±0.0016 1.2E-16 508,055 
rs2466826 16 28,348,344 NPIPB6 intergenic A G 0.40 0.0213±0.0015 3.0E-44 442,278 
rs7187776 16 28,857,645 TUFM UTR5 A G 0.60 -0.0228±0.0014 3.3E-56 531,482 
rs72798148 16 29,926,552 KCTD13 intronic T C 0.78 0.0156±0.0018 1.0E-17 442,278 
rs111739641 16 30,510,984 ITGAL intronic D I 0.50 0.0088±0.0015 3.6E-09 442,278 
rs4889606 16 31,011,183 STX1B intronic A G 0.62 0.0145±0.0015 2.9E-23 531,410 
rs9923167 16 51,817,229 LINC01571 intergenic C G 0.91 0.0167±0.0027 3.3E-10 442,278 
rs16951015 16 52,317,810 TOX3 intergenic A G 0.17 -0.0114±0.0019 1.6E-09 508,079 
rs1558902 16 53,803,574 FTO intronic A T 0.40 0.0422±0.0014 9.9E-189 530,202 
rs12927987 16 66,720,206 CMTM4 intronic A T 0.48 -0.0088±0.0015 4.5E-09 442,278 
rs192042440 16 69,285,510 SNTB2 intronic T C 0.03 -0.0312±0.0048 1.0E-10 442,278 
rs3790085 16 69,887,720 WWP2 intronic A G 0.55 -0.0151±0.0014 3.1E-26 531,503 
rs936994 16 70,442,408 ST3GAL2 intronic T C 0.50 0.0094±0.0014 5.3E-11 507,566 
rs7191938 16 71,407,530 CALB2 intronic A G 0.30 -0.0098±0.0016 5.3E-10 507,143 
rs811054 16 72,251,132 PMFBP1 intergenic T C 0.54 0.0096±0.0014 1.8E-11 529,756 
rs756717 16 72,996,162 ZFHX3 intronic A G 0.40 -0.0096±0.0015 4.6E-11 531,517 
rs4500770 16 74,658,430 RFWD3 intronic A T 0.64 0.0093±0.0015 2.0E-09 442,278 
rs3751859 16 81,735,012 CMIP intronic A G 0.16 -0.0126±0.002 1.8E-10 504,604 
rs7206608 16 82,872,628 CDH13 intronic C G 0.68 -0.0102±0.0015 3.7E-11 508,091 
rs2966859 16 85,324,544 LINC00311 intergenic A G 0.21 0.011±0.0018 1.9E-09 442,278 
rs4843612 16 87,479,339 ZCCHC14 intronic A G 0.14 -0.0117±0.002 1.1E-08 506,494 
rs3743860 16 89,818,491 FANCA intronic T C 0.58 0.0109±0.0015 8.4E-14 494,742 
rs8082551 17 1,310,661 YWHAE intergenic T C 0.12 -0.0144±0.0023 2.6E-10 442,278 
rs546133832 17 1,837,168 RTN4RL1 downstream D I 0.85 0.021±0.0021 5.0E-24 442,278 
17:3986931_
CT_C 
17 3,986,931 ZZEF1 intronic I D 0.36 0.0104±0.0016 3.8E-11 442,278 
rs3026101 17 5,280,440 RABEP1 synonymous T C 0.70 -0.0108±0.0015 2.5E-12 530,658 




intronic T C 0.70 -0.0118±0.0016 7.3E-14 508,030 
rs7213608 17 21,279,289 KCNJ12 upstream T C 0.68 -0.0128±0.0016 1.6E-16 506,308 
rs3115086 17 28,025,949 SSH2 intronic T C 0.50 -0.0104±0.0014 2.3E-13 528,345 
rs3794809 17 28,531,258 SLC6A4 intronic T C 0.44 -0.012±0.0015 1.0E-15 442,278 
17:31471175_
CAAA_C 
17 31,471,175 ASIC2 intronic I D 0.78 0.0116±0.0018 1.7E-10 442,278 
rs12150665 17 34,914,787 GGNBP2 intronic T C 0.59 0.011±0.0014 2.1E-14 531,069 
rs12945575 17 40,713,071 COASY intergenic T C 0.25 0.0103±0.0017 2.2E-09 442,278 
rs8176166 17 41,240,277 BRCA1 intronic T C 0.85 0.0142±0.0021 1.5E-11 442,278 
rs2071167 17 42,287,519 UBTF synonymous T C 0.24 0.0161±0.0017 8.2E-22 531,529 
rs149053776 17 43,130,624 DCAKD intronic D I 0.38 0.0112±0.0015 2.6E-13 442,278 
rs200442988 17 44,566,824 ARL17A intergenic D I 0.31 0.0128±0.0017 1.5E-13 442,278 
rs7221720 17 46,168,892 CBX1 intronic A G 0.89 0.0072±0.0024 2.7E-03 442,278 
rs208015 17 46,252,346 SKAP1 intronic T C 0.07 0.0253±0.0028 5.8E-19 507,186 
rs138774094 17 46,275,597 SKAP1 intronic T C 0.02 0.011±0.0051 3.2E-02 442,278 
rs11079849 17 47,090,785 IGF2BP1 intronic T C 0.33 -0.0146±0.0015 1.8E-21 506,310 
rs4794538 17 52,925,502 TOM1L1 intergenic T C 0.83 -0.012±0.0019 5.2E-10 507,192 




17 63,960,821 CEP112 intronic D I 0.44 0.0089±0.0015 4.0E-09 442,278 
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rs12602912 17 65,870,073 BPTF intronic T C 0.20 0.0201±0.0018 1.5E-29 528,553 
rs142186653 17 73,879,851 TRIM65 intergenic A C 0.77 -0.0125±0.0018 4.4E-12 442,278 
rs11150745 17 78,757,626 RPTOR intronic A G 0.68 0.0126±0.0016 4.0E-15 442,278 
rs9319615 17 79,072,594 BAIAP2 intronic A C 0.45 0.0099±0.0015 3.3E-11 442,278 
rs8086819 18 1,663,417 LINC00470 intergenic A G 0.66 -0.0097±0.0015 1.8E-10 508,096 
rs11664106 18 2,846,812 EMILIN2 upstream A T 0.63 -0.0093±0.0016 4.3E-09 442,278 
rs35939555 18 13,065,174 CEP192 intronic D I 0.67 -0.0103±0.0016 1.1E-10 442,278 
rs891386 18 21,103,971 C18orf8 intronic T G 0.54 0.0171±0.0014 1.5E-32 508,086 
rs16940859 18 22,184,421 LOC729950 intergenic A G 0.81 0.0135±0.0018 2.2E-13 508,054 
rs16975921 18 39,914,870 LINC00907 
ncRNA 
intronic 
A T 0.68 -0.0108±0.0015 2.6E-12 508,029 
rs2052607 18 40,788,387 SYT4 intergenic A G 0.34 -0.0136±0.0015 2.4E-19 507,568 
rs7233512 18 42,595,076 SETBP1 intronic A G 0.30 -0.0107±0.0016 9.1E-12 508,051 
rs7239114 18 45,921,214 CTIF intergenic A G 0.54 0.0088±0.0014 1.0E-09 526,306 
rs3764512 18 52,495,324 RAB27B upstream T G 0.23 0.01±0.0017 4.2E-09 508,101 
rs663129 18 57,838,401 MC4R intergenic A G 0.23 0.0261±0.0017 1.0E-54 530,028 
rs10503034 18 57,977,741 MC4R intergenic T C 0.69 -0.018±0.0015 2.0E-31 527,245 
rs112099489 18 58,417,964 MC4R intergenic T C 0.02 -0.0513±0.0056 5.7E-20 442,278 
rs2012927 18 63,297,672 CDH7 intergenic A G 0.32 0.0108±0.0015 1.5E-12 531,481 
rs8103489 19 3,508,499 FZR1 intronic A G 0.27 0.0103±0.0017 8.3E-10 488,184 
rs188955288 19 4,067,314 ZBTB7A upstream T C 0.19 -0.015±0.0019 5.1E-15 442,278 
rs2620829 19 5,150,934 KDM4B intronic T G 0.74 0.01±0.0017 4.6E-09 442,278 
rs62621197 19 8,670,147 ADAMTS10 missense T C 0.04 -0.0247±0.0041 1.7E-09 442,278 
rs11666430 19 8,673,593 ADAMTS10 intronic T C 0.36 -0.0077±0.0015 5.9E-07 442,278 
rs12979274 19 10,000,925 OLFM2 intronic T C 0.48 0.0093±0.0014 9.9E-11 508,103 
rs4808762 19 18,326,222 PDE4C intronic T C 0.71 -0.0173±0.0016 1.0E-27 505,826 
rs9636202 19 18,449,238 PGPEP1 intergenic A G 0.27 -0.014±0.0016 5.5E-18 526,695 
rs10221489 19 18,826,975 CRTC1 intronic T C 0.34 -0.0138±0.0015 1.5E-19 506,311 
rs3218036 19 30,305,684 CCNE1 intronic A G 0.33 0.0133±0.0015 2.8E-18 519,965 
rs7258937 19 33,938,800 PEPD intronic T C 0.51 0.0154±0.0014 6.5E-27 508,057 
rs11670463 19 34,023,146 PEPD intergenic T C 0.11 -0.0049±0.0024 4.1E-02 442,278 
rs6857 19 45,392,254 PVRL2 UTR3 T C 0.17 -0.0206±0.0019 1.2E-26 500,149 
rs7412 19 45,412,079 APOE missense T C 0.08 0.0201±0.0027 1.0E-13 465,689 
rs1800437 19 46,181,392 GIPR missense C G 0.20 -0.0232±0.0018 1.1E-37 511,388 
rs3810291 19 47,569,003 ZC3H4 UTR3 A G 0.68 0.0119±0.0015 5.9E-15 529,039 
rs16996657 20 15,816,236 MACROD2 intronic T C 0.87 -0.0139±0.0022 1.2E-10 505,104 
rs6083828 20 25,369,918 ABHD12 intronic T C 0.44 0.0119±0.0014 8.4E-17 531,545 
rs2252934 20 25,957,535 
LOC1019269
55 
intergenic C G 0.56 0.0089±0.0015 1.0E-09 500,322 
rs2881138 20 36,834,862 KIAA1755 intergenic A G 0.54 0.0086±0.0014 2.9E-09 507,191 
rs6029180 20 39,178,923 MAFB intergenic A G 0.67 -0.0098±0.0015 2.6E-10 506,305 
rs17265513 20 39,832,628 ZHX3 missense T C 0.80 -0.0123±0.0018 5.7E-12 529,771 
rs6103254 20 41,990,761 SRSF6 intergenic T C 0.87 0.0157±0.0023 3.7E-12 442,278 
rs6031847 20 43,514,203 YWHAB upstream T C 0.27 0.0098±0.0017 4.7E-09 442,278 
rs56218501 20 46,365,636 SULF2 missense T C 0.21 -0.0144±0.0018 2.8E-15 442,278 
rs112852122 20 47,498,117 ARFGEF2 intergenic A G 0.16 -0.0161±0.0021 5.9E-15 442,278 
rs13043475 20 51,209,603 LINC01524 intergenic A G 0.81 0.016±0.0018 3.4E-18 508,105 
rs6023649 20 53,470,583 DOK5 intergenic A G 0.26 0.0108±0.0017 8.8E-11 507,511 
rs62217799 20 62,347,191 ZGPAT intronic T G 0.66 0.0126±0.0016 1.6E-15 442,278 
rs9976423 21 18,093,210 MIR99AHG intergenic A G 0.45 -0.0097±0.0015 1.2E-10 442,278 





T C 0.87 0.0141±0.0022 1.7E-10 442,278 
rs394608 21 46,581,798 ADARB1 intronic T C 0.46 -0.0124±0.0015 1.3E-16 442,278 
rs424708 22 18,214,192 BCL2L13 downstream C G 0.83 -0.0119±0.0019 3.7E-10 507,902 
rs2267373 22 38,600,542 MAFF intronic T C 0.58 -0.0174±0.0015 8.5E-33 506,309 
rs202657 22 41,844,786 TOB2 intergenic T G 0.80 -0.0145±0.0018 5.4E-16 507,603 
rs8137409 22 42,359,793 LINC00634 intergenic A G 0.11 0.0137±0.0023 2.1E-09 505,547 
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rs4253755 22 46,615,376 PPARA intronic A G 0.13 0.0162±0.0022 6.8E-14 506,308 
rs9615905 22 48,875,699 FAM19A5 intergenic T C 0.46 0.0103±0.0014 9.7E-13 506,307 
rs5934505 23 8,913,826 FAM9B intergenic T C 0.73 0.0105±0.0014 4.1E-14 442,278 
rs1379871 23 31,854,782 DMD intronic C G 0.34 0.0133±0.0013 3.5E-24 442,278 
rs201906093 23 53,108,771 GPR173 UTR3 I D 0.15 -0.0114±0.0019 2.2E-09 442,278 
rs78801842 23 53,652,838 HUWE1 intronic A G 0.49 0.0082±0.0013 9.8E-11 442,278 
X:66222744_
CAA_C 
23 66,222,744 EDA2R intergenic I D 0.84 0.0123±0.0017 9.1E-13 442,278 
rs41303733 23 67,652,748 OPHN1 missense T C 0.08 0.0133±0.0022 1.9E-09 442,278 
rs780579062 23 85,580,098 DACH2 intronic D I 0.33 -0.0091±0.0013 3.8E-12 442,278 
rs2248999 23 117,902,604 IL13RA1 intronic C G 0.17 0.0136±0.0017 3.1E-16 442,278 
rs210034 23 129,251,559 ELF4 intergenic A G 0.59 0.0088±0.0013 2.3E-12 442,278 
rs5975828 23 135,986,549 RBMX intergenic T C 0.28 0.0089±0.0014 1.3E-10 442,278 
rs6633949 23 137,059,126 ZIC3 intergenic C G 0.36 0.0078±0.0013 1.1E-09 442,278 
Women 
rs530311131 3 10,096,319 FANCD2 intronic I D 0.06 0.035±0.0058 1.6E-09 240,589 
rs28412751 8 61,639,875 CHD7 intronic T C 0.45 0.016±0.0027 2.4E-09 240,589 
rs1915792 8 64,703,342 LINC01289 intergenic T C 0.48 -0.016±0.0027 2.3E-09 240,589 
rs10823885 10 53,674,590 PRKG1 intronic A T 0.42 0.016±0.0027 4.0E-09 240,589 
rs78378788 11 89,075,754 NOX4 intronic A G 0.93 -0.0312±0.0053 5.3E-09 240,589 
rs11116176 12 84,434,919 SLC6A15 intergenic T G 0.24 -0.0179±0.003 3.0E-09 268,571 
rs12872889 13 28,674,628 FLT3 missens T C 0.77 -0.0202±0.0032 3.2E-10 240,589 
rs1423798 16 65,289,733 LINC00922 intergenic A T 0.64 -0.0155±0.0027 4.9E-09 274,156 





23 72,227,619 PABPC1L2B intergenic I D 0.25 -0.0189±0.0032 3.3E-09 240,589 
Men 
rs6545039 2 48,646,493 PPP1R21 intergenic T C 0.46 -0.0168±0.0027 7.3E-10 231,788 




2 158,119,170 GALNT5 intronic I D 0.89 0.0275±0.0047 4.9E-09 201,689 
rs17058066 5 160,046,184 ATP10B intronic T G 0.93 -0.0316±0.0053 2.8E-09 228,084 
rs71231793 7 76,682,610 PMS2P9 downstream T C 0.84 -0.0287±0.0043 1.6E-11 201,689 
rs2506141 10 33,468,014 NRP1 UTR3 T C 0.54 0.0166±0.0028 2.6E-09 227,007 
rs10766451 11 2,917,510 
SLC22A18A
S 
intronic T C 0.32 0.0183±0.0031 2.8E-09 210,385 
rs10875746 12 48,518,264 PFKM intronic A C 0.76 -0.0187±0.0032 5.3E-09 233,131 
rs770387 13 51,143,755 DLEU1 intergenic T C 0.79 0.0194±0.0033 6.3E-09 232,636 
rs7170961 15 39,493,179 C15orf54 intergenic T C 0.69 -0.0178±0.0029 7.7E-10 246,094 
rs12608143 18 36,492,188 MIR924HG intergenic T C 0.53 -0.0168±0.0028 1.1E-09 232,634 
rs143384 20 34,025,756 GDF5 UTR5 A G 0.59 0.019±0.0027 3.3E-12 245,216 
rs372038686 23 109,852,772 CHRDL1 intergenic T C 0.61 -0.0124±0.0021 6.5E-09 201,689 





Supplementary Table 3.6: Independent variants associated with FFMI at genome-wide 
significance in meta-analyses of GWAS in UK Biobank and exome chip meta-analyses 
 
rsid chr pos Nearest gene Type EA OA EAF Beta±SE p N 
Sex-combined           
rs4648729 1 1,808,769 GNB1 intron T C 0.506 -0.014±0.0014 3.0E-23 442,391 
rs7535528 1 2,444,414 PANK4 missense A G 0.372 -0.0106±0.0014 2.0E-13 442,391 
rs9435184 1 9,343,551 SPSB1 downstream T C 0.134 -0.0159±0.002 7.7E-15 442,391 
rs9442571 1 9,349,611 SPSB1 upstream A T 0.130 -0.0164±0.0021 2.0E-15 442,391 
rs12137140 1 9,454,067 SPSB1 intergenic T G 0.410 -0.0087±0.0014 1.0E-09 442,391 
rs17396340 1 10,286,176 KIF1B intron A G 0.127 -0.0134±0.0021 1.2E-10 442,391 
rs12046278 1 10,799,577 CASZ1 intron T C 0.653 -0.01±0.0014 8.8E-13 535,885 
rs36083532 1 10,839,085 CASZ1 intron T C 0.690 -0.0128±0.0015 2.2E-17 442,391 
1:11254006_AC_A 1 11,254,006 
ANGPTL7, 
MTOR 
intron D I 0.782 -0.0118±0.0017 4.0E-12 442,391 
rs3170740 1 17,312,743 ATP13A2 missense T C 0.529 -0.0142±0.0013 6.8E-26 507,518 
rs12407400 1 19,964,620 MINOS1-NBL1 intron A G 0.238 -0.0114±0.0016 2.5E-12 442,391 
rs945211 1 32,191,798 ADGRB2 downstream C G 0.616 0.0098±0.0014 7.3E-12 442,391 
rs10753280 1 33,774,752 A3GALT2 intron A C 0.317 -0.0109±0.0015 3.2E-13 442,391 
rs61744853 1 35,453,651 ZMYM6 missense A C 0.991 -0.0437±0.007 4.1E-10 535,885 
rs569405229 1 36,581,053 COL8A2 intron T C 0.007 -0.0687±0.0089 1.0E-14 442,391 
1:39738803_AT_A 1 39,738,803 MACF1 intron D I 0.207 0.0143±0.0017 2.3E-16 442,391 
rs151224948 1 39,940,430 MACF1 intron A G 0.031 -0.0335±0.004 4.5E-17 442,391 
1:46154575_AT_A 1 46,154,575 TMEM69 intron D I 0.466 -0.0086±0.0015 3.7E-09 442,391 
rs6669341 1 47,678,458 TAL1 downstream A G 0.418 0.0101±0.0014 5.2E-13 442,391 
rs11205538 1 49,237,594 
AGBL4, 
BEND5 
intron T C 0.714 -0.012±0.0015 5.9E-15 442,391 
rs11205836 1 51,804,731 TTC39A intron T C 0.192 0.0106±0.0017 5.9E-10 514,980 
rs9970807 1 56,965,664 PLPP3 intron T C 0.092 0.0139±0.0023 1.8E-09 514,980 
rs12140153 1 62,579,891 PATJ missense T G 0.095 -0.0213±0.0024 2.6E-19 487,987 
rs61779814 1 65,939,443 LEPR intron C G 0.393 0.0113±0.0014 1.1E-15 442,391 
rs2568958 1 72,765,116 NEGR1 upstream A G 0.603 0.015±0.0014 2.0E-28 535,885 




intron A G 0.426 0.0139±0.0013 4.1E-25 530,616 
rs11162351 1 77,944,732 AK5 intron C G 0.604 -0.0102±0.0014 6.4E-13 442,391 
rs140681455 1 78,444,764 FUBP1 
5' UTR,NMD 
transcript 
I D 0.127 0.0236±0.0021 1.3E-28 442,391 
rs34353539 1 79,331,762 ADGRL4 intergenic D I 0.272 0.0099±0.0016 2.3E-10 442,391 
rs412378 1 82,374,494 ADGRL2 intron A G 0.755 -0.0094±0.0016 6.2E-09 442,391 
rs12089815 1 91,189,933 BARHL2 intergenic A G 0.548 -0.0087±0.0014 5.2E-10 442,391 
rs143792309 1 92,505,309 EPHX4 intron T C 0.064 0.0174±0.0029 1.2E-09 442,391 
rs2391199 1 93,160,902 EVI5 missense T C 0.100 0.0194±0.0022 1.9E-18 535,885 
rs1342396 1 96,281,460 LOC102723661 intergenic T C 0.670 0.0123±0.0015 7.4E-17 442,391 
rs201973270 1 97,074,111 PTBP2 intergenic A G 0.310 0.0144±0.0015 9.7E-22 442,391 
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rs2811218 1 98,027,316 DPYD intron A G 0.186 0.0109±0.0018 9.4E-10 442,391 
rs2622848 1 103,421,003 COL11A1 intron T C 0.729 0.0104±0.0016 1.9E-11 442,391 
rs76210342 1 107,967,807 NTNG1 intron D I 0.616 0.0111±0.0016 9.2E-13 442,391 
rs1933182 1 109,999,838 SYPL2 intergenic A C 0.297 0.0137±0.0015 8.7E-21 512,061 
rs7550711 1 110,082,886 GPR61 
intron NMD 
transcript 
T C 0.027 0.0383±0.0042 3.4E-20 514,980 
rs197402 1 112,302,591 DDX20 intron A G 0.656 -0.0103±0.0015 1.1E-12 442,391 
rs34611728 1 113,255,456 PPM1J missense A C 0.129 0.0121±0.002 9.3E-10 535,885 
rs6674967 1 118,854,698 SPAG17 intergenic A G 0.255 0.012±0.0016 3.9E-14 442,391 
rs984222 1 119,503,843 TBX15 intron C G 0.386 0.0141±0.0014 2.3E-24 508,884 
rs10802069 1 119,517,357 TBX15 intron T C 0.387 0.0143±0.0014 8.3E-24 442,391 
rs11205303 1 149,906,413 MTMR11 missense T C 0.594 0.0199±0.0014 3.8E-49 535,885 
rs2902811 1 151,010,521 BNIPL intron C G 0.768 -0.0126±0.0016 1.4E-14 442,391 
rs1194610 1 154,296,076 AQP10 synonymous T C 0.765 -0.0097±0.0016 2.3E-09 442,391 
rs3753639 1 154,986,091 ZBTB7B intron T C 0.756 -0.0202±0.0016 8.3E-36 442,391 
rs146554560 1 155,661,719 DAP3 intron T C 0.023 0.0508±0.0047 2.7E-27 442,391 
rs2297792 1 156,011,444 UBQLN4 missense T C 0.373 -0.0085±0.0014 6.5E-10 535,885 
rs35208023 1 156,415,673 C1orf61 downstream T C 0.669 0.0115±0.0015 5.9E-15 442,391 
1:170705685_CTA
TATATATA_C 
1 170,705,685 PRRX1 3' UTR I D 0.379 0.0125±0.0014 3.7E-18 442,391 
rs10919515 1 170,869,758 MROH9 intergenic A T 0.095 -0.0197±0.0026 4.1E-14 442,391 
rs4916229 1 171,443,368 PRRC2C intergenic C G 0.904 -0.0185±0.0024 3.8E-15 442,391 
rs139303240 1 173,901,373 RC3H1 3' UTR D I 0.888 -0.0165±0.0022 6.5E-14 442,391 
1:174455489_CT_
C 
1 174,455,489 RABGAP1L intron I D 0.846 -0.0171±0.0021 2.2E-16 442,391 
rs12087196 1 174,962,071 RABGAP1L 3' UTR A G 0.888 -0.0152±0.0022 4.1E-12 442,391 
rs543874 1 177,889,480 SEC16B downstream A G 0.795 -0.0331±0.0016 1.5E-89 532,966 
rs1046934 1 184,023,529 TSEN15 missense A C 0.651 0.0097±0.0014 2.6E-12 535,885 
rs655598 1 190,287,713 BRINP3 intron A G 0.562 -0.012±0.0014 5.9E-18 442,391 
rs778404403 1 191,434,186 RGS18 intergenic D I 0.292 -0.0077±0.0015 6.1E-07 442,391 
rs34781011 1 194,890,316 LINC01724 intergenic I D 0.292 -0.0087±0.0015 1.0E-08 442,391 
1:197133836_AAT
ATATTAT_A 
1 197,133,836 ZBTB41 intron D I 0.280 -0.0101±0.0016 2.3E-10 442,391 
rs3850625 1 201,016,296 CACNA1S missense A G 0.119 -0.0165±0.002 8.4E-16 535,885 
rs2820312 1 201,869,257 LMOD1 missense A G 0.339 0.0163±0.0014 2.4E-31 535,885 
rs4971212 1 203,491,392 ATP2B4 intergenic T G 0.799 -0.0106±0.0017 7.2E-10 442,391 
rs1354853 1 209,557,991 LINC01698 downstream A G 0.867 -0.0126±0.002 6.4E-10 442,391 
rs2605100 1 219,644,224 LOC102723886 intergenic A G 0.315 -0.0086±0.0014 1.8E-09 535,885 
rs10863578 1 221,213,997 HLX intergenic C G 0.670 0.0134±0.0015 9.4E-20 442,391 
rs12079987 1 221,715,102 DUSP10 intergenic A G 0.024 -0.0317±0.0045 2.7E-12 442,391 
rs7518221 1 225,561,346 DNAH14 
intron NMD 
transcript 
T C 0.353 0.0089±0.0014 6.7E-10 442,391 
rs2154367 1 227,153,930 COQ8A intron A G 0.213 0.0136±0.0017 1.2E-15 442,391 
rs12141801 1 227,961,403 SNAP47 intron T C 0.235 0.0113±0.0016 5.5E-12 442,391 
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A G 0.091 -0.0184±0.0024 3.3E-14 442,391 
rs147929768 1 235,473,509 ARID4B intron T G 0.028 0.0251±0.0042 2.6E-09 442,391 
1:243815349_CT_
C 
1 243,815,349 AKT3 intron I D 0.230 0.0113±0.0018 1.7E-10 442,391 
rs300789 2 89,910 FAM110C intergenic A G 0.798 -0.0103±0.0017 3.5E-09 442,391 
rs28715684 2 410,501 LINC01865 intron  T C 0.267 0.0161±0.0017 4.8E-21 442,391 
rs62106258 2 417,167 LINC01874 upstream T C 0.952 0.0678±0.0032 3.0E-98 442,391 
rs546003868 2 558,371 LOC105373352 intron  A C 0.064 -0.0297±0.0031 1.2E-21 442,391 




rs60996394 2 644,512 TMEM18 intergenic A C 0.462 0.0236±0.0018 2.0E-39 442,391 
rs2867115 2 651,382 TMEM18 intergenic T C 0.882 0.0494±0.0024 5.9E-96 442,391 
rs7578605 2 1,643,208 PXDN intron A G 0.937 0.0225±0.0029 3.4E-15 442,391 
rs2609181 2 6,161,899 LOC400940 intergenic C G 0.285 -0.0111±0.0015 6.9E-13 442,391 
rs10203320 2 9,771,620 YWHAQ upstream T C 0.671 -0.0092±0.0015 4.9E-10 442,391 
rs713586 2 25,158,008 DNAJC27 intergenic T C 0.512 -0.0208±0.0013 3.6E-55 535,885 
2:25365642_TAAT
A_T 
2 25,365,642 EFR3B intron D I 0.654 0.0193±0.0015 5.1E-40 442,391 
rs1631026 2 26,953,850 KCNK3 3' UTR T C 0.472 0.0099±0.0014 1.1E-12 442,391 
rs202049562 2 27,779,565 C2orf16 intron A T 0.179 0.0178±0.0019 8.5E-22 442,391 
rs6547820 2 28,281,545 BABAM2 intron A G 0.788 -0.012±0.0017 9.4E-13 442,391 
rs404108 2 33,301,389 LTBP1 intron A G 0.765 -0.0098±0.0016 2.1E-09 442,391 
rs9678810 2 33,398,399 LTBP1 intron A G 0.448 -0.0102±0.0014 1.5E-12 442,391 
rs2305575 2 33,745,336 RASGRP3 intron T C 0.219 -0.0104±0.0017 5.0E-10 442,391 
rs10204994 2 35,443,726 MIR548AD downstream A G 0.229 -0.011±0.0016 2.2E-11 442,391 
rs62132389 2 36,478,876 LOC100288911 intergenic C G 0.074 0.0156±0.0027 4.7E-09 442,391 
rs7589518 2 37,995,422 LINC00211 regulatory A T 0.486 0.0124±0.0015 2.4E-17 442,391 
rs6713781 2 40,291,940 SLC8A1-AS1 intron  C G 0.400 -0.0097±0.0014 1.1E-11 442,391 
rs6742827 2 40,640,326 SLC8A1 intron T C 0.169 0.0117±0.0018 2.4E-10 442,391 
rs11690012 2 43,542,480 THADA intron C G 0.230 -0.0096±0.0016 5.9E-09 442,391 
rs35809007 2 47,019,521 LINC01118 intergenic A G 0.363 -0.0111±0.0014 1.5E-14 442,391 
rs72618637 2 48,953,979 
LHCGR,STON
1-GTF2A1L 
intron A T 0.189 -0.0137±0.0018 2.7E-14 442,391 
rs9636391 2 50,201,110 NRXN1 missense A G 0.163 0.0151±0.0019 8.4E-16 442,391 
rs6724631 2 50,713,331 NRXN1 intron  C G 0.536 -0.0103±0.0014 9.9E-14 442,391 
rs6760379 2 55,279,536 RTN4 intron T C 0.693 0.0098±0.0015 8.3E-11 442,391 
rs3791679 2 56,096,892 EFEMP1 intron A G 0.773 -0.016±0.0016 3.8E-24 535,885 
rs11688767 2 57,988,194 VRK2 intron  A T 0.514 0.0096±0.0014 3.5E-12 442,391 
rs2708149 2 58,951,187 LINC01122 intron  A G 0.431 -0.0155±0.0014 2.6E-28 442,391 
rs7424120 2 59,313,974 LINC01122 intergenic T C 0.601 -0.0107±0.0014 5.1E-14 442,391 
rs12476772 2 60,203,917 MIR4432HG intron  A C 0.331 0.0099±0.0015 1.9E-11 442,391 
rs76511385 2 61,734,552 XPO1 intron T C 0.987 -0.0377±0.0062 9.2E-10 442,391 
rs10192894 2 62,838,936 EHBP1 intron  A G 0.560 -0.0087±0.0014 4.5E-10 442,391 
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rs2861691 2 67,838,694 LINC01812 intron  C G 0.389 -0.0104±0.0014 2.4E-13 442,391 
rs34355307 2 86,800,506 
RNF103-
CHMP3 
intron  A G 0.610 -0.0111±0.0014 8.5E-15 442,391 
rs11692215 2 100,746,573 AFF3 intron T C 0.242 -0.0119±0.0016 1.6E-13 442,391 
rs10489971 2 102,527,827 MAP4K4 intergenic T C 0.307 -0.009±0.0015 2.1E-09 442,391 
2:104130139_AT_
A 
2 104,130,139 LINC01935 intergenic D I 0.497 0.0093±0.0014 3.4E-11 442,391 
rs6739701 2 105,132,332 LINC01102 intron  A G 0.568 0.0102±0.0014 3.4E-13 442,391 
rs10197031 2 105,454,590 LINC01158 intron  T C 0.714 -0.0132±0.0015 5.7E-18 442,391 
2:144001846_GA_
G 
2 144,001,846 ARHGAP15 intron D I 0.140 0.0127±0.002 3.4E-10 442,391 
rs497418 2 147,842,671 PABPC1P2 intergenic A C 0.385 0.0113±0.0014 2.5E-15 442,391 
2:157597637_GA_
G 
2 157,597,637 GPD2 intergenic D I 0.398 0.0086±0.0014 2.1E-09 442,391 
rs13023477 2 161,111,887 LINC02478 intron  T C 0.186 0.0127±0.0018 9.7E-13 442,391 
rs767585131 2 164,541,449 FIGN intron D I 0.147 0.0133±0.002 3.3E-11 442,391 
rs765335847 2 172,425,405 CYBRD1 intergenic D I 0.250 -0.0142±0.0016 8.5E-19 442,391 
rs34234296 2 175,166,636 LINC01305 upstream A G 0.393 -0.0086±0.0014 1.9E-09 442,391 
rs72923454 2 176,984,544 HOXD10 3' UTR T C 0.025 0.0305±0.0044 5.2E-12 442,391 
rs9630985 2 181,607,676 SCHLAP1 regulatory A C 0.334 -0.0097±0.0015 3.3E-11 442,391 
rs7422875 2 190,163,961 COL5A2 intergenic T C 0.956 -0.02±0.0034 2.7E-09 442,391 
rs61327788 2 198,338,222 COQ10B intron A G 0.499 -0.015±0.0014 6.2E-27 442,391 
rs1064213 2 198,950,240 PLCL1 missense A G 0.478 0.0172±0.0013 2.2E-38 532,966 
rs10497820 2 199,612,796 SATB2 intron  A C 0.341 0.0107±0.0015 4.0E-13 442,391 
rs6705250 2 200,307,014 SATB2 intron A G 0.862 -0.0132±0.002 6.1E-11 442,391 
rs4673627 2 200,848,896 MAIP1 intron A G 0.560 0.0081±0.0014 5.9E-09 442,391 
rs4482463 2 205,375,909 PARD3B downstream A C 0.924 -0.0208±0.0026 1.7E-15 442,391 
rs13000757 2 207,145,906 ZDBF2 intron T G 0.507 0.01±0.0014 6.0E-13 442,391 
rs1263615 2 207,959,238 KLF7 intron T C 0.758 -0.0107±0.0016 3.3E-11 442,391 
rs1047891 2 211,540,507 CPS1 missense A C 0.316 0.0158±0.0015 2.4E-26 442,391 
rs6435622 2 212,296,094 ERBB4 intron C G 0.311 0.0089±0.0015 2.5E-09 442,391 
rs13427822 2 213,414,265 ERBB4 intergenic A G 0.728 0.0131±0.0016 7.7E-17 442,391 
rs2712184 2 217,682,779 TNP1 intron  A C 0.574 0.0119±0.0014 2.7E-18 508,913 
rs2230115 2 219,509,618 ZNF142 missense A C 0.571 -0.0127±0.0013 4.2E-21 535,885 
rs11683846 2 220,205,929 RESP18 intergenic A C 0.151 -0.0158±0.0019 3.9E-16 442,391 
rs55760516 2 220,354,108 SPEG missense A G 0.676 0.0114±0.0014 7.3E-16 535,885 
rs2197780 2 223,960,207 KCNE4 intron  T C 0.280 -0.0093±0.0015 1.4E-09 442,391 
rs1515098 2 227,073,854 LOC646736 intergenic T C 0.681 0.0101±0.0015 1.1E-11 442,391 
rs10195674 2 229,016,094 SPHKAP intron A G 0.339 0.009±0.0015 7.8E-10 442,391 
rs111828944 2 230,250,876 DNER intron A G 0.092 0.014±0.0024 4.7E-09 442,391 
2:230754796_CT_
C 
2 230,754,796 TRIP12 intron I D 0.248 -0.011±0.0016 2.3E-11 442,391 
rs2101435 2 233,115,158 DIS3L2 intron C G 0.722 -0.0103±0.0015 2.8E-11 442,391 
rs7568228 2 236,848,488 AGAP1 intron C G 0.526 -0.0089±0.0014 1.2E-10 442,391 
rs7340253 2 239,374,836 ASB1 intergenic A G 0.560 -0.0086±0.0014 6.6E-10 442,391 
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rs7559460 2 241,341,322 GPC1 intergenic T C 0.613 0.0088±0.0014 8.2E-10 442,391 
rs2108485 2 242,021,742 SNED1 missense T G 0.155 -0.0144±0.0018 3.3E-15 535,885 
rs4428159 3 11,196,516 HRH1 intron C G 0.095 0.0158±0.0025 1.1E-10 442,391 
rs17776482 3 11,633,951 VGLL4 intron A G 0.140 0.0157±0.002 7.1E-15 442,391 
rs3732671 3 13,407,556 NUP210 missense T C 0.433 0.0085±0.0013 2.2E-10 535,885 
rs2167196 3 13,593,475 FBLN2 intron T G 0.813 0.0135±0.0018 3.4E-14 442,391 
rs2607744 3 14,235,285 LSM3 intron C G 0.510 -0.0084±0.0014 1.4E-09 442,391 
rs2470537 3 15,716,898 ANKRD28 intron T C 0.598 -0.0085±0.0014 1.5E-09 442,391 
rs34373881 3 20,432,033 LOC101927829 
non-coding 
exon  
A G 0.277 -0.0109±0.0016 2.2E-12 442,391 
rs7619139 3 25,110,415 RARB intron  A T 0.589 0.0099±0.0014 3.0E-12 442,391 
rs11921432 3 35,117,776 LOC101928135 intergenic T C 0.886 -0.0129±0.0022 5.0E-09 442,391 
rs6599205 3 38,529,440 ACVR2B 3' UTR C G 0.386 -0.0146±0.0014 9.1E-25 442,391 
rs111768603 3 42,329,113 CCK intergenic T G 0.110 -0.0148±0.0022 2.2E-11 442,391 
rs123509 3 42,733,468 KLHL40 missense T C 0.248 0.0117±0.0015 4.4E-14 531,394 
rs11711770 3 43,066,768 FAM198A 
intron NMD 
transcript 
A G 0.829 -0.0108±0.0018 5.0E-09 442,391 
rs9852062 3 45,373,442 LARS2 intergenic A T 0.556 -0.0095±0.0014 1.4E-11 442,391 
rs62246403 3 47,095,177 SETD2 
intron NMD 
transcript 
T C 0.036 0.0237±0.0037 2.3E-10 442,391 
rs72906474 3 47,817,007 SMARCC1 intron T G 0.584 -0.0124±0.0014 2.9E-18 442,391 
rs55786114 3 48,982,335 ARIH2 intron T C 0.074 0.0211±0.0027 1.7E-15 442,391 
rs55754265 3 49,687,486 BSN intron T C 0.139 0.0212±0.002 4.0E-26 442,391 
rs2526389 3 50,192,826 SEMA3F-AS1 5' UTR T C 0.426 0.0209±0.0014 7.7E-50 442,391 
3:50785304_AG_A 3 50,785,304 DOCK3 intron D I 0.864 0.0208±0.002 1.8E-24 442,391 
rs10433609 3 51,311,574 DOCK3 intron A T 0.821 0.0199±0.0018 5.7E-28 442,391 
rs141434554 3 52,208,046 POC1A intergenic D I 0.780 -0.0128±0.0017 1.5E-13 442,391 
rs772585020 3 52,725,718 GNL3 intron D I 0.490 0.0177±0.0014 7.3E-37 442,391 
rs150638279 3 53,426,450 DCP1A upstream D I 0.931 0.0192±0.0027 2.7E-12 442,391 
rs1564907 3 56,193,500 ERC2 intron T C 0.107 0.014±0.0022 4.5E-10 442,391 
rs6445198 3 61,219,865 FHIT intron T G 0.416 -0.0112±0.0014 1.6E-15 442,391 
rs56358876 3 61,544,965 PTPRG upstream T G 0.888 -0.0145±0.0022 4.2E-11 442,391 
rs925018 3 62,713,143 CADPS intron C G 0.685 -0.0108±0.0015 4.1E-13 442,391 
rs4142723 3 66,683,941 LOC105377143 upstream A T 0.236 -0.0101±0.0016 7.6E-10 442,391 
rs17732997 3 70,470,834 SAMMSON intergenic C G 0.569 -0.0097±0.0014 4.9E-12 442,391 
rs68093214 3 70,657,785 FOXP1 intergenic T C 0.751 0.0111±0.0016 5.2E-12 442,391 
rs9809116 3 72,397,279 RYBP regulatory A G 0.593 -0.0098±0.0014 5.5E-12 442,391 
rs6805432 3 78,870,517 ROBO1 intron T C 0.703 0.0108±0.0015 1.1E-12 442,391 
rs116631513 3 84,603,308 LINC00971 intergenic A T 0.946 0.0246±0.0031 1.2E-15 442,391 
3:85660399_GT_
G 
3 85,660,399 CADM2 intron D I 0.640 -0.0161±0.0015 3.9E-28 442,391 
rs9851777 3 88,267,467 C3orf38 intergenic T C 0.116 -0.0144±0.0022 2.6E-11 442,391 
rs1454687 3 94,038,085 NSUN3 intergenic C G 0.484 0.0146±0.0014 6.5E-26 442,391 
3:104629856_CT_
C 
3 104,629,856 ALCAM intergenic I D 0.236 -0.0112±0.0017 1.7E-11 442,391 
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rs2399213 3 107,395,302 BBX intron T C 0.819 -0.014±0.0018 1.2E-14 442,391 
rs1471093 3 108,031,094 HHLA2 intron A G 0.617 0.0089±0.0014 6.0E-10 442,391 
rs17619973 3 114,417,675 ZBTB20 intron A G 0.925 0.0158±0.0026 2.2E-09 442,391 
rs9881641 3 117,602,500 LINC02024 intron  T C 0.687 -0.009±0.0015 1.9E-09 442,391 
rs1870931 3 119,757,013 GSK3B intron C G 0.828 0.0105±0.0018 1.2E-08 442,391 
rs17282078 3 124,481,760 ITGB5 3' UTR A T 0.131 -0.0146±0.0021 1.5E-12 442,391 
rs76594121 3 128,189,391 DNAJB8-AS1 intron  T G 0.953 0.0239±0.0034 1.1E-12 442,391 
rs1225004 3 131,626,991 CPNE4 intron T C 0.722 -0.016±0.0015 5.7E-25 442,391 
rs138628404 3 131,771,462 CPNE4 intron T C 0.833 -0.0164±0.0019 3.5E-17 442,391 
rs9827728 3 133,971,558 RYK upstream A T 0.880 -0.0149±0.0021 3.1E-12 442,391 
rs9844666 3 135,974,216 PCCB 5' UTR A G 0.240 0.017±0.0016 1.1E-27 532,966 
rs13080786 3 136,543,708 SLC35G2 intron A G 0.762 -0.0163±0.0016 1.3E-23 442,391 
rs59714050 3 141,267,294 RASA2 intron A T 0.066 0.0213±0.0028 2.9E-14 442,391 
rs9438 3 154,018,887 DHX36 missense C G 0.394 0.0112±0.0014 2.7E-16 529,789 




A G 0.663 -0.0113±0.0015 1.1E-14 442,391 
rs62644679 3 157,946,897 RSRC1 intron A G 0.323 -0.0105±0.0016 9.8E-11 442,391 
rs67481408 3 170,734,443 SLC2A2 intron D I 0.726 -0.0126±0.0016 9.0E-16 442,391 
rs13085472 3 171,129,859 TNIK intron T C 0.332 0.0091±0.0015 8.7E-10 442,391 
rs556464 3 173,113,680 NLGN1 upstream C G 0.472 -0.0104±0.0014 1.0E-13 442,391 
rs9841616 3 181,167,585 SOX2-OT intron  A T 0.170 0.0116±0.0019 3.7E-10 442,391 
rs11546878 3 183,976,103 ECE2 missense T C 0.176 -0.0162±0.0018 2.9E-20 535,885 
rs1001817 3 183,995,341 ECE2 intron T C 0.493 -0.012±0.0013 1.7E-19 535,885 
rs9816226 3 185,834,499 ETV5 intron  A T 0.185 -0.0256±0.0017 1.2E-48 498,816 
rs74935402 3 195,747,247 TFRC intergenic T C 0.970 0.0246±0.0042 4.3E-09 442,391 
rs2051559 4 3,298,800 RGS12 intron  T C 0.867 -0.0146±0.0021 1.1E-12 442,391 
rs11377284 4 4,800,758 LOC101928279 intergenic D I 0.306 -0.0093±0.0015 1.2E-09 442,391 
rs11722554 4 5,016,883 CYTL1 missense A G 0.038 0.0259±0.0035 1.4E-13 522,343 
rs11721374 4 8,599,520 CPZ intron A G 0.435 0.0093±0.0014 3.4E-11 442,391 
rs6833878 4 10,005,555 SLC2A9 intron A T 0.732 -0.0095±0.0016 1.3E-09 442,391 
rs5856175 4 12,918,813 RAB28 intergenic I D 0.858 0.0125±0.002 3.8E-10 442,391 
rs6449393 4 18,507,692 LCORL intergenic A C 0.667 -0.009±0.0015 1.0E-09 442,391 
rs544200874 4 20,124,826 SLIT2 intergenic T C 0.082 0.0193±0.0027 2.0E-12 442,391 
rs34811474 4 25,408,838 ANAPC4 missense A G 0.231 -0.023±0.0016 5.6E-48 535,885 
rs73245728 4 26,206,514 RBPJ intron A C 0.936 0.0206±0.0029 5.1E-13 442,391 
rs9999056 4 26,880,639 STIM2 intron T C 0.774 -0.0103±0.0017 5.2E-10 442,391 
4:28526950_AAA
AC_A 
4 28,526,950 MIR4275 intron  D I 0.166 -0.0127±0.0019 1.2E-11 442,391 
rs7434610 4 30,839,793 PCDH7 intron A G 0.460 -0.0126±0.0014 1.3E-19 442,391 
rs139430988 4 31,031,755 PCDH7 intron  D I 0.645 -0.0125±0.0015 6.0E-16 442,391 
rs3209570 4 38,699,657 KLF3 3' UTR A G 0.399 -0.0095±0.0014 2.8E-11 442,391 
rs10938397 4 45,182,527 GNPDA2 intergenic A G 0.565 -0.018±0.0014 4.2E-40 515,854 
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4:53738084_AT_A 4 53,738,084 SCFD2 downstream D I 0.356 0.0103±0.0016 3.3E-10 442,391 
rs147565558 4 54,330,689 LNX1 intron D I 0.848 0.0125±0.0019 1.3E-10 442,391 
rs34772064 4 55,495,948 LINC02260 intergenic T G 0.443 0.0106±0.0014 4.5E-14 442,391 
rs781659 4 57,779,851 REST intron A G 0.573 -0.0092±0.0014 6.4E-11 442,391 
rs78862524 4 73,171,190 ADAMTS3 intron A C 0.055 0.0135±0.0031 1.6E-05 442,391 
rs141374503 4 73,179,445 ADAMTS3 missense T C 0.004 0.0747±0.0107 2.6E-12 535,885 
rs10518106 4 73,519,842 ADAMTS3 intergenic T C 0.064 -0.0389±0.0028 1.1E-42 442,391 
rs56091759 4 73,678,173 COX18 downstream T C 0.611 -0.0051±0.0014 3.6E-04 442,391 
rs139457833 4 77,126,502 SCARB2 intron D I 0.849 -0.0111±0.0019 1.1E-08 442,391 
rs994014 4 82,165,790 PRKG2 intergenic T C 0.694 0.0106±0.0015 2.4E-12 442,391 
rs1054627 4 88,732,692 IBSP missense A G 0.313 0.0098±0.0014 1.0E-11 532,966 
rs2199936 4 89,045,331 ABCG2 intron A G 0.114 -0.0148±0.0022 1.2E-11 442,391 
rs9993839 4 95,307,863 HPGDS intergenic T C 0.804 0.0115±0.0017 5.9E-11 442,391 
rs17620626 4 101,086,037 DDIT4L intron  A G 0.056 0.0174±0.003 9.3E-09 442,391 
rs201081507 4 102,681,041 BANK1 intron A G 0.943 -0.022±0.0033 1.4E-11 442,391 
rs13107325 4 103,188,709 SLC39A8 missense T C 0.074 0.0289±0.0026 1.4E-29 535,885 
4:103981698_GT_
G 
4 103,981,698 SLC9B2 intron D I 0.404 -0.0103±0.0014 4.7E-13 442,391 
rs75544266 4 104,584,997 TACR3 intron T C 0.056 -0.0215±0.003 1.5E-12 442,391 
rs77096252 4 105,537,183 CXXC4-AS1 intron  A G 0.956 0.0201±0.0034 4.2E-09 442,391 
rs17509519 4 109,192,790 LEF1-AS1 intergenic T C 0.423 -0.0091±0.0014 9.2E-11 442,391 
rs2595105 4 111,552,761 PITX2 intron T C 0.302 0.0102±0.0015 1.8E-11 442,391 
rs9991259 4 112,686,354 C4orf32 intergenic A G 0.633 0.0086±0.0014 2.4E-09 442,391 
rs57590313 4 113,323,430 ALPK1 intron A C 0.193 0.0128±0.0018 1.5E-12 442,391 
rs28454448 4 115,125,392 ARSJ intergenic A G 0.280 0.0098±0.0015 2.8E-10 442,391 
rs7671759 4 120,248,094 FABP2 upstream A C 0.661 -0.0142±0.0015 4.0E-22 442,391 
rs7688177 4 120,760,872 LINC01365 intergenic T C 0.770 -0.0112±0.0017 1.5E-11 442,391 
rs2952862 4 130,758,713 LINC02466 intron  T C 0.344 0.0094±0.0015 1.6E-10 442,391 
rs1283032 4 137,098,470 LINC00613 intron  T C 0.412 0.0119±0.0014 6.9E-17 442,391 
rs35107973 4 143,125,948 INPP4B intron T C 0.119 0.0126±0.0021 4.0E-09 442,391 
rs7666785 4 144,060,464 LOC105377623 intron  A G 0.400 0.0094±0.0014 9.6E-12 514,980 
rs11933087 4 145,722,862 HHIP intergenic A T 0.629 0.012±0.0014 1.1E-16 442,391 
rs28605564 4 147,388,846 SLC10A7 intron C G 0.752 0.0095±0.0016 3.2E-09 442,391 
rs35016840 4 151,239,774 LRBA intron T C 0.641 -0.0096±0.0014 3.0E-11 442,391 
rs6843852 4 162,132,758 FSTL5 intergenic T C 0.508 0.0104±0.0014 6.7E-14 442,391 
rs148636479 4 164,359,678 KTL2 intergenic A T 0.971 0.0266±0.0044 1.9E-09 442,391 
rs111598585 4 171,635,471 LINC02382 intergenic T C 0.208 -0.0122±0.0017 1.1E-12 442,391 
rs7683836 4 180,167,906 LINC01098 intergenic A G 0.558 -0.0088±0.0014 3.0E-10 442,391 
rs10866554 5 3,489,595 LINC01019 intron  T C 0.481 0.0082±0.0014 3.4E-09 442,391 
rs3792752 5 32,768,634 NPR3 intron A G 0.742 0.0141±0.0016 6.9E-19 442,391 
rs11952835 5 42,331,880 GHR intergenic T G 0.101 0.0126±0.0023 7.3E-08 442,391 
rs13176429 5 43,152,216 ZNF131 intron T C 0.313 -0.0115±0.0015 1.2E-14 442,391 
rs114263339 5 50,932,343 ISL1 intergenic T C 0.026 0.0242±0.0044 3.0E-08 442,391 
Supplementary materials 
 289 
rsid chr pos Nearest gene Type EA OA EAF Beta±SE p N 
rs6871876 5 53,120,750 LINC02105 intergenic A G 0.463 0.0114±0.0014 3.6E-16 442,391 
rs4865796 5 53,272,664 ARL15 intron A G 0.692 -0.0101±0.0015 2.2E-11 442,391 
rs700910 5 53,439,777 ARL15 intron T C 0.838 -0.0105±0.0019 2.9E-08 442,391 
rs459193 5 55,806,751 C5orf67 downstream A G 0.254 -0.0132±0.0015 7.3E-18 532,966 
rs13179413 5 55,868,097 C5orf67 intron T C 0.285 0.0104±0.0016 2.5E-11 442,391 
rs60593437 5 56,253,216 MIER3 intron I D 0.355 0.0132±0.0015 1.2E-19 442,391 
5:60708793_AT_A 5 60,708,793 ZSWIM6 intron D I 0.362 -0.0115±0.0014 2.8E-15 442,391 
rs12523594 5 63,967,230 FAM159B upstream A G 0.389 0.0106±0.0014 1.9E-13 442,391 
rs764487108 5 64,488,059 ADAMTS6 intron  D I 0.402 0.0097±0.0014 1.1E-11 442,391 
rs55963623 5 64,555,615 ADAMTS6 
intron NMD 
transcript 
T C 0.456 0.013±0.0014 1.3E-20 442,391 
rs62360508 5 65,177,737 ERBIN intergenic T C 0.913 0.0154±0.0025 4.9E-10 442,391 
rs4703855 5 71,693,899 PTCD2 intergenic T C 0.295 0.0108±0.0015 1.9E-12 442,391 
rs4704187 5 74,480,288 ANKRD31 intron T C 0.530 0.0137±0.0014 9.4E-23 442,391 
rs2307111 5 75,003,678 POC5 missense T C 0.607 0.0174±0.0014 3.2E-36 516,336 
rs59893724 5 80,830,788 SSBP2 intron A G 0.756 0.0111±0.0016 7.3E-12 442,391 
rs61749613 5 82,815,170 VCAN 
missense 
splice region 
A G 0.959 -0.0379±0.0033 8.4E-30 535,885 
rs10942491 5 86,382,726 MIR4280 intron  C G 0.553 -0.0095±0.0014 1.3E-11 442,391 
rs7442885 5 87,682,877 
TMEM161B-
AS1 
intron  C G 0.789 0.0168±0.0017 7.7E-23 442,391 
rs17561711 5 88,248,730 MEF2C-AS1 intron  A C 0.917 0.0162±0.0025 1.3E-10 442,391 
rs35843836 5 88,798,726 MEF2C-AS1 intergenic A T 0.633 -0.0145±0.0014 8.2E-24 442,391 
rs6235 5 95,728,898 PCSK1 missense C G 0.732 -0.0113±0.0015 7.6E-14 522,505 
rs2611742 5 95,856,501 LOC101929710 intron  T C 0.607 -0.0132±0.0014 1.9E-20 442,391 
rs200755293 5 102,072,999 PAM intergenic D I 0.425 0.0108±0.0014 1.8E-14 442,391 
rs252818 5 106,725,691 EFNA5 intron T C 0.816 0.0117±0.0018 1.1E-10 442,391 
rs149457 5 107,438,057 FBXL17 intron T C 0.170 -0.0189±0.0019 2.3E-24 442,391 
rs5019041 5 108,179,863 FER intron A G 0.762 0.015±0.0016 9.5E-20 442,391 
rs1402025 5 113,987,898 LOC101927078 intron  T C 0.774 -0.0108±0.0017 6.5E-11 442,391 
rs72800433 5 115,033,709 LOC102467217 intergenic T C 0.722 0.0091±0.0015 4.7E-09 442,391 
rs11438541 5 122,080,320 LINC02201 intergenic I D 0.420 0.0077±0.0014 5.4E-08 442,391 
rs34984032 5 122,692,653 CEP120 intron D I 0.536 0.0129±0.0014 2.2E-20 442,391 
rs152120 5 126,656,500 MEGF10 intron T C 0.570 -0.008±0.0014 1.4E-08 442,391 
rs2250127 5 127,388,844 LINC01184 intron  A G 0.247 0.0184±0.0016 4.4E-30 442,391 
rs78727187 5 127,668,685 FBN2 missense T G 0.006 -0.0569±0.0087 5.8E-11 535,885 
rs329120 5 133,861,756 JADE2 intron T C 0.419 -0.0116±0.0014 1.6E-16 442,391 
rs757647 5 137,707,315 KDM3B intron A G 0.204 0.0109±0.0017 4.1E-11 535,885 
rs13174863 5 139,080,745 CXXC5 intron  A G 0.852 -0.0147±0.002 8.3E-14 442,391 
rs7268 5 139,712,550 HBEGF 3' UTR A C 0.439 -0.0108±0.0014 1.1E-14 442,391 
rs1479585 5 140,976,528 DIAPH1 intron C G 0.607 0.0111±0.0014 6.7E-15 442,391 
rs72801007 5 152,196,711 LINC01470 intron  C G 0.715 0.0077±0.0015 6.3E-07 442,391 
rs1438945 5 152,510,937 LINC01470 intron  A T 0.714 -0.0098±0.0015 2.2E-10 442,391 
rs4958702 5 153,544,512 GALNT10 intron  T C 0.427 0.01±0.0014 8.8E-13 442,391 
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rs62385430 5 158,465,102 EBF1 intron C G 0.573 0.0105±0.0014 9.7E-14 442,391 
rs6868089 5 159,241,494 LINC01847 intron  A G 0.951 0.0194±0.0032 1.7E-09 442,391 
rs34259768 5 166,179,473 
LINC01947(dist
=152753) 
intergenic D I 0.589 -0.0086±0.0014 1.3E-09 442,391 
rs1014194 5 168,192,944 SLIT3 intron A C 0.641 0.0094±0.0015 9.6E-11 442,391 
rs35239894 5 168,312,829 SLIT3 intron A T 0.456 0.0091±0.0014 1.0E-10 442,391 
rs245769 5 170,529,335 RANBP17 
intron NMD 
transcript 
T C 0.729 0.0111±0.0016 1.2E-12 442,391 
rs351855 5 176,520,243 FGFR4 missense A G 0.297 0.0163±0.0015 4.1E-28 504,952 
rs3822593 5 178,551,299 ADAMTS2 intron T G 0.417 -0.0108±0.0014 2.4E-14 442,391 
rs11382360 6 2,094,804 GMDS intron D I 0.456 -0.0094±0.0014 2.2E-11 442,391 
rs220025 6 12,154,333 HIVEP1 intron A G 0.707 -0.0091±0.0015 3.0E-09 442,391 
rs6916983 6 18,575,300 MIR548A1 downstream T C 0.719 -0.0112±0.0015 5.0E-13 442,391 
rs9350100 6 19,076,417 LOC101928519 intergenic T C 0.801 -0.0137±0.0017 3.7E-15 442,391 
rs9466957 6 23,874,157 NRSN1 intergenic T G 0.348 0.0104±0.0015 6.5E-12 442,391 
6:26316118_TTTT
CTTTC_T 
6 26,316,118 BTN3A2 intergenic D I 0.609 0.0098±0.0014 6.4E-12 442,391 
rs210140 6 33,544,293 BAK1 intron T C 0.365 -0.0082±0.0014 1.3E-08 442,391 
rs79984746 6 34,201,127 HMGA1 upstream A C 0.047 -0.0262±0.0033 9.4E-16 442,391 
rs206936 6 34,302,869 
NUDT3,RPS10-
NUDT3 
intron A G 0.813 -0.0193±0.0017 1.8E-29 535,885 
rs113344808 6 34,701,981 SNRPC intergenic I D 0.314 0.0186±0.0015 1.9E-34 442,391 
rs35104496 6 39,273,821 KCNK17 intron I D 0.176 0.0114±0.0019 3.4E-09 442,391 
rs34045288 6 40,369,081 LRFN2 intron T C 0.336 0.0146±0.0015 3.4E-23 442,391 
rs776152132 6 41,902,508 CCND3 downstream I D 0.749 0.011±0.0016 7.0E-12 442,391 
rs9394951 6 43,350,753 ZNF318 intergenic T C 0.567 -0.0093±0.0014 3.7E-11 442,391 





6 44,961,164 SUPT3H intron D I 0.289 -0.012±0.0016 1.2E-14 442,391 
rs71568416 6 47,474,426 CD2AP intron C G 0.690 -0.0112±0.0015 1.1E-13 442,391 
rs2206277 6 50,798,526 TFAP2B intron T C 0.180 0.0285±0.0017 3.4E-60 534,021 
rs2635727 6 50,820,940 TFAP2B downstream T C 0.245 -0.0187±0.0016 7.5E-31 442,391 
rs7771607 6 51,803,390 PKHD1 intron T C 0.301 0.0098±0.0015 1.6E-10 442,391 
rs9475170 6 55,011,619 HCRTR2 intergenic A T 0.658 0.0106±0.0015 6.1E-13 442,391 
rs78856780 6 56,939,238 ZNF451 intergenic A G 0.856 -0.0121±0.002 1.2E-09 442,391 
rs147380831 6 81,150,794 BCKDHB upstream D I 0.900 0.0142±0.0024 1.4E-09 442,391 
rs2917460 6 83,343,317 UBE3D intergenic A C 0.523 -0.01±0.0014 1.0E-12 442,391 






intergenic D I 0.347 -0.0097±0.0015 4.9E-11 442,391 
rs11961595 6 100,052,886 PRDM13 upstream A T 0.268 0.0092±0.0016 6.3E-09 442,391 
rs240164 6 101,044,487 ASCC3 intron A T 0.529 -0.0119±0.0014 1.6E-17 442,391 
rs270689 6 104,790,532 HACE1 intergenic A T 0.198 -0.0126±0.0017 3.9E-13 442,391 
rs314274 6 105,412,932 LIN28B intron A C 0.336 -0.0145±0.0014 3.0E-24 514,980 
Supplementary materials 
 291 
rsid chr pos Nearest gene Type EA OA EAF Beta±SE p N 
rs2153960 6 108,988,184 FOXO3 intron A G 0.711 0.0143±0.0015 2.9E-22 532,966 
rs1064583 6 116,446,576 COL10A1 missense A G 0.604 0.0086±0.0014 2.5E-10 534,313 
6:120064242_TA_
T 
6 120,064,242 LOC105377975 intergenic D I 0.137 0.0154±0.0023 7.3E-12 442,391 
rs12332861 6 123,795,554 TRDN intron T C 0.826 0.0122±0.0018 3.2E-11 442,391 
rs13209968 6 126,089,285 HEY2 intergenic C G 0.526 0.0089±0.0014 1.3E-10 442,391 
rs6899976 6 130,358,428 L3MBTL3 intron A G 0.698 -0.0106±0.0015 4.1E-13 514,980 
rs4896582 6 142,703,877 ADGRG6 intron A G 0.301 0.0146±0.0015 2.0E-23 514,980 
rs11380190 6 147,357,397 STXBP5-AS1 intron  I D 0.367 0.009±0.0014 5.6E-10 442,391 
rs9371672 6 153,422,140 RGS17 intron C G 0.711 -0.0098±0.0015 1.9E-10 442,391 
rs369809361 6 154,335,717 OPRM1 intron D I 0.180 0.0114±0.0018 3.1E-10 442,391 
rs13191362 6 163,033,350 PRKN intron A G 0.875 0.016±0.0021 3.8E-14 442,391 
rs4719730 7 929,123 GET4 intron T C 0.175 -0.011±0.0018 1.9E-09 442,391 
rs756700851 7 1,271,233 UNCX upstream I D 0.203 -0.0129±0.0017 8.1E-14 442,391 
rs4721089 7 1,872,921 MAD1L1 intron T C 0.784 0.0107±0.0017 2.3E-10 442,391 
rs62441156 7 5,347,446 TNRC18 3' UTR A G 0.773 -0.0102±0.0017 3.0E-09 442,391 
7:6411992_CA_C 7 6,411,992 RAC1 upstream I D 0.528 -0.0085±0.0014 3.0E-09 442,391 
rs12669977 7 13,132,400 ARL4A intergenic T G 0.502 0.0082±0.0014 3.1E-09 442,391 
rs9638713 7 14,645,949 DGKB intron A G 0.025 0.0317±0.0045 1.6E-12 442,391 
rs17141862 7 19,770,756 TMEM196 intron T C 0.137 -0.0139±0.002 6.4E-12 442,391 
rs73086541 7 20,376,103 ITGB8 intron A C 0.395 0.0104±0.0014 2.8E-13 442,391 
rs28423374 7 20,579,647 ABCB5 intergenic T C 0.736 -0.0114±0.0016 6.8E-13 442,391 
rs2711111 7 24,529,055 MPP6 intergenic A G 0.434 0.0082±0.0014 1.0E-08 442,391 




C G 0.715 0.0111±0.0016 1.2E-12 442,391 
rs7384844 7 28,025,308 JAZF1 intron A T 0.556 0.0086±0.0014 8.1E-10 442,391 
rs864745 7 28,180,556 JAZF1 intron T C 0.495 -0.0155±0.0013 4.9E-31 535,885 
rs554794335 7 32,931,486 KBTBD2 5' UTR D I 0.689 0.0095±0.0015 4.0E-10 442,391 
rs329270 7 35,075,619 DPY19L1 intron A G 0.515 0.0101±0.0014 5.0E-13 442,391 
rs3778934 7 39,445,385 POU6F2-AS1 intron A C 0.659 0.0095±0.0015 9.0E-11 442,391 
rs799449 7 44,784,697 ZMIZ2 upstream T C 0.558 0.0108±0.0014 1.9E-14 442,391 
rs80077929 7 46,094,089 IGFBP3 intergenic T C 0.119 0.0218±0.0022 1.3E-23 442,391 
rs2881198 7 46,634,506 LOC730338 intergenic C G 0.533 -0.0126±0.0014 2.3E-19 442,391 
rs12718611 7 50,593,906 DDC intron A G 0.860 -0.0137±0.002 8.5E-12 442,391 
rs2866719 7 70,106,061 AUTS2 intron T C 0.369 0.0088±0.0014 1.2E-09 442,391 
rs861491 7 71,586,049 CALN1 intron T C 0.660 0.0091±0.0015 6.2E-10 442,391 
rs139709472 7 72,140,581 TYW1B intron T C 0.963 -0.027±0.0042 1.9E-10 442,391 
rs3812316 7 73,020,337 MLXIPL missense C G 0.872 -0.018±0.002 2.9E-19 523,409 
rs6955671 7 74,489,486 RCC1L missense T C 0.540 -0.0134±0.0014 8.9E-22 442,391 




T C 0.429 -0.016±0.0015 5.0E-28 442,391 
rs1167800 7 75,176,196 HIP1 intron A G 0.560 0.0147±0.0013 6.5E-28 535,885 
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rs200778979 7 76,686,511 SPDYE18 intron  A G 0.129 0.0242±0.0022 1.7E-27 442,391 
rs740158 7 77,055,836 LOC101927243 upstream T C 0.512 0.0089±0.0014 3.6E-11 514,980 
rs1852006 7 77,829,768 MAGI2 intron A G 0.357 -0.0088±0.0015 1.2E-09 442,391 
7:78141093_TA_T 7 78,141,093 MAGI2 intron D I 0.263 0.0096±0.0016 1.4E-09 442,391 
7:93148206_TA_T 7 93,148,206 CALCR intron D I 0.477 0.0109±0.0014 8.8E-15 442,391 
rs3763469 7 94,021,475 COL1A2-AS1 upstream T C 0.778 -0.0123±0.0017 5.3E-13 442,391 
rs1207728 7 96,638,021 DLX6-AS1 intron C G 0.225 0.01±0.0017 2.1E-09 442,391 
rs28566086 7 99,025,490 
ATP5J2-
PTCD1,PTCD1 
intron C G 0.114 -0.0176±0.0022 1.1E-15 442,391 
rs1133790 7 99,632,982 ZKSCAN1 3' UTR T C 0.676 -0.0096±0.0015 1.7E-10 442,391 
rs12669944 7 100,446,365 SLC12A9-AS1 intron  A G 0.350 -0.0076±0.0015 2.9E-07 442,391 
rs2239538 7 100,798,728 AP1S1 intron A G 0.147 0.0127±0.002 1.1E-10 442,391 
rs39328 7 103,444,978 RELN intron T C 0.424 0.0138±0.0014 1.1E-22 442,391 
rs4730494 7 111,340,760 DOCK4 intergenic T C 0.216 0.0104±0.0017 1.0E-09 442,391 
7:112946725_CTG
TT_C 
7 112,946,725 LINC00998 intergenic I D 0.637 0.0094±0.0014 1.1E-10 442,391 
rs6962980 7 113,452,183 PPP1R3A intergenic A C 0.442 0.0122±0.0014 3.3E-18 442,391 
rs10500039 7 114,351,267 FOXP2 intergenic T C 0.578 -0.0109±0.0014 1.1E-14 442,391 
rs62621812 7 127,015,083 ZNF800 missense A G 0.022 0.0457±0.0047 5.5E-22 535,885 
rs112320081 7 127,519,243 SND1 intron T C 0.988 -0.0402±0.0065 5.5E-10 442,391 
7:129965811_CAT
_C 
7 129,965,811 CPA4 downstream I D 0.768 -0.0117±0.0017 4.2E-12 442,391 
rs273957 7 137,600,690 CREB3L2 missense T C 0.614 -0.0103±0.0014 4.8E-14 535,885 
rs11525873 7 138,817,193 TTC26 upstream T C 0.902 0.0202±0.0023 5.6E-18 442,391 
rs822531 7 148,629,759 EZH2 intergenic T C 0.795 -0.0123±0.0017 1.2E-12 442,391 
rs10236214 7 150,668,070 KCNH2 intron T C 0.642 0.0144±0.0015 4.2E-23 442,391 
rs759544745 7 150,759,219 SLC4A2 intron I D 0.423 0.0085±0.0014 1.9E-09 442,391 
rs2407940 8 4,134,874 CSMD1 intron T C 0.503 -0.0083±0.0014 3.7E-09 442,391 
rs1658820 8 4,288,577 CSMD1 intron T G 0.245 0.0097±0.0016 3.2E-09 442,391 
rs6985109 8 10,761,585 XKR6 intron A G 0.542 -0.0185±0.0014 7.2E-40 442,391 
8:12184258_A_G 8 12,184,258 DEFB130B intergenic A G 0.699 0.0191±0.0023 7.7E-17 442,391 
rs7010322 8 13,196,821 DLC1 intron T C 0.360 -0.009±0.0015 7.4E-10 442,391 
rs13263601 8 14,095,900 SGCZ intron A C 0.652 -0.011±0.0015 4.8E-14 442,391 
rs146032132 8 15,136,469 SGCZ intergenic I D 0.113 0.0127±0.0022 9.5E-09 442,391 
rs71211068 8 15,538,727 TUSC3 intron I D 0.777 0.0118±0.0018 4.8E-11 442,391 
rs2616143 8 20,632,022 SNORD3F intergenic A G 0.321 -0.0098±0.0015 4.9E-11 442,391 
rs3174040 8 23,431,407 SLC25A37 missense A G 0.795 0.0103±0.0017 2.4E-09 442,391 
rs7823498 8 32,403,573 NRG1 intron T C 0.780 0.0112±0.0017 2.9E-11 442,391 
rs6996013 8 33,276,170 FUT10 intron A G 0.765 0.0106±0.0017 2.1E-10 442,391 
rs10091344 8 34,132,075 LINC01288 intron  A G 0.328 -0.0101±0.0015 1.1E-11 442,391 
rs4082204 8 38,328,902 FGFR1 upstream A G 0.402 0.0097±0.0014 1.0E-11 442,391 
rs35392772 8 57,026,229 MOS missense A C 0.157 -0.0107±0.0018 6.2E-09 534,021 
rs13264909 8 64,702,385 LINC01289 intron  A T 0.571 0.0099±0.0014 2.1E-12 442,391 
rs7006364 8 67,199,420 LINC00967 intergenic A G 0.273 -0.011±0.0015 4.1E-13 514,980 
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rs35957544 8 73,440,371 KCNB2 intergenic T G 0.575 -0.0102±0.0014 4.1E-13 442,391 
rs28611482 8 74,490,314 STAU2 intron A C 0.798 -0.0125±0.0017 7.0E-13 442,391 
rs2977324 8 76,716,737 HNF4G intergenic T G 0.300 -0.0125±0.0015 3.3E-16 442,391 
rs960923 8 77,228,925 LINC01111 intergenic A G 0.433 -0.0125±0.0014 7.9E-19 442,391 
rs406629 8 81,458,387 ZBTB10 downstream T G 0.310 -0.0099±0.0015 4.6E-11 442,391 
rs7821259 8 85,081,619 RALYL upstream T G 0.265 -0.0115±0.0016 3.6E-13 442,391 
rs28676726 8 85,619,884 RALYL intron T G 0.228 -0.0117±0.0017 1.9E-12 442,391 
rs2664371 8 89,056,962 MMP16 intron A T 0.690 0.0085±0.0015 2.0E-08 442,391 
rs2134963 8 89,407,821 MMP16 intron  A C 0.306 -0.0163±0.0015 3.9E-27 442,391 
rs2114210 8 95,595,162 VIRMA intergenic A G 0.335 0.0114±0.0015 1.1E-14 442,391 
rs71506350 8 101,962,901 YWHAZ intron A G 0.387 -0.0088±0.0014 8.7E-10 442,391 
rs3808424 8 116,518,399 TRPS1 intron T C 0.781 0.0119±0.0017 2.0E-12 442,391 
rs147009081 8 118,882,739 EXT1 intron I D 0.106 0.0157±0.0023 5.4E-12 442,391 
rs4144738 8 130,760,850 GSDMC missense A G 0.539 -0.0107±0.0013 1.4E-15 535,885 
rs4507813 8 141,796,344 PTK2 intron T C 0.422 0.0082±0.0014 7.0E-09 442,391 
rs7838717 8 145,504,343 BOP1 intron T C 0.365 -0.0097±0.0015 3.6E-11 442,391 
rs10815306 9 5,914,727 KIAA2026 
intron NMD 
transcript 
A C 0.200 0.0104±0.0017 2.5E-09 442,391 
rs13292799 9 6,448,764 UHRF2 intron A G 0.807 -0.0107±0.0018 1.1E-09 442,391 
rs10960276 9 11,819,686 TYRP1 intergenic A C 0.356 -0.0093±0.0015 1.8E-10 442,391 
rs12335987 9 13,235,045 MPDZ intron A C 0.870 0.0129±0.0021 5.8E-10 442,391 
rs35249758 9 13,933,542 LINC00583 intron  T C 0.184 -0.0116±0.0018 1.2E-10 442,391 
rs927520 9 14,347,235 NFIB intron T G 0.336 0.0092±0.0015 5.9E-10 442,391 
rs4741546 9 15,846,112 CCDC171 intron T C 0.396 -0.0082±0.0014 1.0E-08 442,391 
rs10962552 9 16,723,742 BNC2 intron T C 0.166 0.0163±0.0019 3.4E-18 442,391 
rs539864802 9 17,023,805 CNTLN intergenic D I 0.847 -0.0124±0.002 3.6E-10 442,391 
rs66801939 9 19,024,042 SAXO1 intron T C 0.618 0.0098±0.0014 1.1E-11 442,391 
rs1541104 9 23,348,762 LOC101929563 intergenic A G 0.414 -0.0087±0.0014 8.4E-10 442,391 
9:27621063_AC_A 9 27,621,063 C9orf72 intergenic D I 0.251 -0.009±0.0016 2.7E-08 442,391 
rs3922980 9 27,803,737 LINGO2 intergenic T G 0.502 -0.0098±0.0014 2.6E-12 442,391 
rs10968576 9 28,414,339 LINGO2 intron A G 0.677 -0.0168±0.0014 4.2E-32 535,885 
rs10969334 9 29,717,279 LINGO2 intergenic A C 0.394 -0.0083±0.0014 4.9E-09 442,391 
rs544957562 9 33,978,015 UBAP2 intron A T 0.845 0.0164±0.002 1.1E-15 442,391 
rs13290451 9 34,581,819 CNTFR-AS1 intron A T 0.524 -0.0089±0.0014 1.6E-10 442,391 
rs10687055 9 37,083,295 EBLN3P intron  D I 0.464 0.0101±0.0014 5.6E-13 442,391 
rs148434637 9 73,811,782 TRPM3 intron  D I 0.557 -0.0119±0.0014 1.3E-16 442,391 
rs35307904 9 78,511,889 PCSK5 intron A G 0.122 0.0211±0.0021 6.1E-23 442,391 
rs958225 9 78,759,705 PCSK5 intron A T 0.057 -0.0167±0.003 3.3E-08 442,391 
rs10870005 9 80,626,343 GNAQ intron T C 0.532 -0.0093±0.0014 2.9E-11 442,391 
rs9314675 9 81,371,636 LOC101927450 intergenic T G 0.447 -0.0085±0.0014 1.5E-09 442,391 
rs7874181 9 85,858,511 FRMD3 intron T G 0.847 -0.012±0.0019 6.4E-10 442,391 
rs1982151 9 86,617,265 RMI1 missense A G 0.257 -0.0114±0.0015 8.5E-14 532,966 
rs353834 9 89,073,689 ZCCHC6 intergenic A G 0.507 0.0083±0.0014 4.0E-09 442,391 
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rs35870355 9 92,039,730 SEMA4D intron A T 0.235 0.0101±0.0016 7.3E-10 442,391 
rs10820852 9 94,186,973 NFIL3 upstream A C 0.275 -0.0122±0.0016 5.5E-15 442,391 
rs10761129 9 94,486,321 ROR2 missense T C 0.671 0.0138±0.0014 4.5E-22 524,369 
rs10761155 9 95,153,729 CENPP,OGN intron C G 0.731 -0.0146±0.0016 2.1E-20 442,391 
rs9650755 9 96,484,342 PHF2 intergenic A G 0.737 -0.0138±0.0016 3.2E-18 442,391 
rs72753485 9 96,673,230 BARX1 regulatory C G 0.097 0.019±0.0025 7.1E-14 442,391 
rs370727606 9 98,268,396 PTCH1 intron A G 0.011 -0.0412±0.0068 1.5E-09 442,391 
rs2672813 9 98,781,179 
ERCC6L2,LIN
C00092 
downstream A G 0.440 -0.0101±0.0014 4.8E-13 442,391 
rs62565259 9 102,162,570 NAMA regulatory T C 0.173 -0.011±0.0019 3.1E-09 442,391 
9:103113656_AC_
A 
9 103,113,656 TEX10 intron D I 0.379 0.0105±0.0015 7.2E-13 442,391 
rs13294145 9 109,138,289 MIR8081 intron  T C 0.172 0.013±0.0018 2.0E-12 442,391 
rs2417998 9 111,958,746 EPB41L4B intron C G 0.293 0.0093±0.0015 1.2E-09 442,391 
rs10441737 9 114,301,585 ZNF483 intron T C 0.652 0.0098±0.0015 2.3E-11 442,391 
rs2274159 9 117,166,246 WHRN missense A G 0.506 0.0079±0.0013 3.2E-09 535,885 
rs3838333 9 117,787,666 TNC intron I D 0.429 0.0089±0.0014 2.7E-10 442,391 
rs80031633 9 120,687,550 TLR4 intergenic A T 0.457 -0.009±0.0014 2.8E-10 442,391 
rs10760277 9 126,093,999 CRB2 intergenic T C 0.386 0.0094±0.0014 5.6E-11 442,391 
rs7024161 9 127,011,695 NEK6 intergenic T C 0.385 -0.0131±0.0014 6.0E-20 442,391 
rs77752857 9 127,085,612 NEK6 intron T G 0.099 0.0184±0.0023 2.7E-15 442,391 
rs396015 9 128,028,603 GAPVD1 intron A T 0.466 -0.0088±0.0014 4.6E-10 442,391 
rs7030609 9 129,415,775 LMX1B intron A G 0.910 -0.0191±0.0024 5.2E-15 442,391 
rs10987417 9 129,462,501 LMX1B 3' UTR T G 0.385 0.0094±0.0014 8.5E-11 442,391 
rs2267958 9 131,015,279 DNM1 intron A G 0.512 -0.0088±0.0014 7.2E-10 442,391 




T G 0.064 -0.0188±0.0027 6.4E-12 535,885 
rs10858334 9 137,989,785 OLFM1 3' UTR C G 0.856 -0.012±0.002 2.1E-09 442,391 
rs36094334 9 139,140,538 QSOX2 upstream C G 0.661 0.011±0.0015 1.7E-13 442,391 
9:140265782_C_T 9 140,265,782 EXD3 intron T C 0.124 -0.015±0.0021 1.3E-12 442,391 
rs35741360 10 12,945,180 CCDC3 intron A G 0.283 0.0105±0.0015 1.1E-11 442,391 
rs202121703 10 16,753,335 RSU1 intron I D 0.371 -0.0082±0.0014 1.5E-08 442,391 
rs73601548 10 18,549,889 CACNB2 5' UTR T C 0.115 0.015±0.0022 8.0E-12 442,391 
rs35043348 10 21,993,540 MLLT10 intron I D 0.581 -0.0111±0.0015 8.3E-14 442,391 
rs112276510 10 25,056,538 ARHGAP21 intergenic D I 0.269 0.0108±0.0016 8.6E-12 442,391 
rs117799729 10 27,434,230 YME1L1 intron A C 0.071 0.0188±0.0028 1.5E-11 442,391 
rs112157102 10 29,083,096 
LINC00837,LI
NC01517 
intron  A T 0.579 0.0091±0.0014 1.6E-10 442,391 
rs2247538 10 34,444,740 PARD3 intron T C 0.316 -0.011±0.0015 2.3E-13 442,391 
rs796709989 10 35,051,218 PARD3 intron I D 0.709 0.0092±0.0016 4.9E-09 442,391 
rs2435381 10 43,678,796 CSGALNACT2 missense T C 0.277 -0.0098±0.0016 3.5E-10 442,391 
rs11006229 10 52,350,006 SGMS1 
splice 
region,5' UTR 
T C 0.200 0.01±0.0017 2.3E-09 535,885 
rs4595495 10 53,673,286 PRKG1 intron A G 0.579 -0.0085±0.0014 1.8E-09 442,391 
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rs181130148 10 63,204,424 TMEM26 intron A G 0.966 0.0235±0.0039 2.3E-09 442,391 
rs12761779 10 63,782,043 ARID5B intron C G 0.652 0.0104±0.0015 2.4E-12 442,391 
rs7924036 10 65,191,645 JMJD1C intron T G 0.503 -0.0122±0.0014 1.9E-18 442,391 
rs68049170 10 72,432,047 ADAMTS14 upstream A G 0.277 -0.014±0.0016 2.9E-19 442,391 
10:76097518_AT_
A 
10 76,097,518 ADK intron D I 0.388 0.0102±0.0015 8.9E-12 442,391 
rs4255484 10 77,215,583 LRMDA intergenic C G 0.441 0.0111±0.0014 2.3E-15 442,391 
10:87354315_AGC
T_A 
10 87,354,315 GRID1-AS1 downstream D I 0.050 0.0247±0.0032 1.2E-14 442,391 
rs2631681 10 93,032,943 PCGF5 intron T C 0.323 -0.0114±0.0014 2.9E-15 514,980 
rs7916961 10 94,997,875 MYOF intergenic T C 0.859 0.0117±0.002 5.0E-09 442,391 
rs2274224 10 96,039,597 PLCE1 missense C G 0.432 0.0194±0.0014 9.7E-46 511,156 
rs35808802 10 97,143,826 SORBS1 missense T C 0.939 0.0185±0.0028 3.1E-11 535,885 
rs150407151 10 97,784,002 ENTPD1-AS1 intron D I 0.649 -0.0092±0.0015 6.4E-10 442,391 
rs11595634 10 99,001,779 
ARHGAP19-
SLIT1 
intron A T 0.586 -0.0088±0.0015 2.2E-09 442,391 
rs1983864 10 100,017,453 LOXL4 missense T G 0.661 0.0153±0.0014 1.5E-27 535,885 
rs603424 10 102,075,479 PKD2L1 intron A G 0.170 0.0098±0.0019 1.2E-07 442,391 
rs41310284 10 102,447,647 PAX2 intergenic A C 0.102 -0.0154±0.0023 2.8E-11 442,391 
rs10883560 10 102,673,707 SLF2 intron C G 0.571 -0.0106±0.0014 5.9E-14 442,391 
rs3915773 10 103,366,837 DPCD intron A C 0.713 -0.0092±0.0016 3.2E-09 442,391 
rs372582961 10 103,958,317 ELOVL3 intergenic D I 0.847 0.0146±0.0019 5.8E-14 442,391 
rs12413409 10 104,719,096 CNNM2 intron A G 0.078 0.0232±0.0025 1.4E-20 535,885 
rs3824780 10 105,384,826 SH3PXD2A intron  T C 0.356 0.0094±0.0015 1.2E-10 442,391 
rs6585201 10 114,768,783 TCF7L2 intron A G 0.454 -0.0101±0.0014 5.9E-13 442,391 
rs11197866 10 118,777,633 SHTN1 intron T C 0.747 -0.0101±0.0016 6.1E-10 442,391 
rs4336954 10 120,976,553 GRK5 intron T C 0.386 0.0085±0.0014 3.6E-09 442,391 
rs845085 10 125,217,896 GPR26 intron  A G 0.472 -0.0109±0.0014 7.0E-16 514,980 
rs72828952 10 126,629,608 ZRANB1 intron  A G 0.576 0.0114±0.0014 2.0E-15 442,391 
rs11245187 10 128,538,476 DOCK1 intergenic T C 0.796 0.0101±0.0017 4.7E-09 442,391 
rs117118217 10 131,783,328 EBF3 intergenic C G 0.018 0.0327±0.0055 2.9E-09 442,391 
rs11146237 10 134,004,746 DPYSL4 intron A G 0.507 0.009±0.0014 6.0E-10 442,391 
rs76560824 11 370,252 B4GALNT4 intron T C 0.898 0.0144±0.0023 5.0E-10 442,391 
rs7103389 11 881,639 CHID1 intron T C 0.381 -0.0122±0.0014 2.6E-17 442,391 
rs10840606 11 2,234,690 MIR4686 regulatory A G 0.822 -0.013±0.0018 1.8E-12 442,391 




A G 0.880 0.0158±0.0022 3.1E-13 442,391 
rs4929923 11 8,639,200 TRIM66 3' UTR T C 0.354 -0.011±0.0014 4.2E-15 535,885 
rs2957694 11 10,369,014 CAND1.11 intron  A G 0.416 -0.0103±0.0014 4.2E-13 442,391 
rs11824377 11 11,787,253 MIR8070 intergenic A G 0.441 0.0087±0.0014 4.8E-10 442,391 
rs900144 11 13,294,268 ARNTL upstream T C 0.568 0.0098±0.0014 2.3E-12 442,391 
rs72632979 11 16,615,883 SOX6 intron  A G 0.829 -0.0125±0.0019 1.3E-11 442,391 
rs5215 11 17,408,630 KCNJ11 missense T C 0.640 0.0118±0.0014 2.3E-17 535,885 
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rs6265 11 27,679,916 BDNF missense T C 0.189 -0.0299±0.0017 1.6E-68 531,102 
rs10835367 11 28,642,593 MIR8068 intergenic A C 0.386 -0.0094±0.0014 8.0E-11 442,391 
rs1607227 11 28,808,617 MIR8068 intron  T G 0.295 -0.0125±0.0015 3.5E-16 442,391 
rs35381476 11 29,309,284 LINC01616 intergenic I D 0.261 -0.0102±0.0016 2.2E-10 442,391 
rs7941828 11 30,430,331 MPPED2 intron T C 0.361 -0.0124±0.0014 1.3E-17 442,391 
rs1806153 11 31,850,105 PAUPAR intron  T G 0.231 -0.0103±0.0017 5.1E-10 442,391 
rs9651614 11 43,849,913 HSD17B12 intron T C 0.646 -0.0136±0.0015 8.1E-20 442,391 
rs7115013 11 43,934,592 ALKBH3-AS1 intron T C 0.443 -0.0091±0.0014 1.2E-10 442,391 
rs34042421 11 45,420,233 LOC399886 intron  A G 0.695 0.0111±0.0015 2.1E-13 442,391 
rs3817334 11 47,650,993 MTCH2 intron T C 0.408 0.0103±0.0014 4.9E-14 535,885 
rs78287937 11 64,773,101 ARL2-SNX15 intergenic T G 0.909 -0.0159±0.0024 5.1E-11 442,391 




T C 0.639 -0.0165±0.0014 4.0E-30 442,391 
rs4930394 11 66,680,543 PC intron T C 0.450 0.0109±0.0014 7.6E-15 442,391 




A G 0.084 0.0167±0.0025 2.8E-11 442,391 
11:68271686_GT_
G 
11 68,271,686 PPP6R3 intron D I 0.276 -0.0138±0.0016 1.0E-18 442,391 
rs597539 11 68,601,974 CPT1A intron C G 0.686 -0.0109±0.0015 3.8E-13 442,391 
rs4980661 11 69,306,579 LINC01488 intergenic A G 0.528 -0.0145±0.0014 2.4E-25 442,391 
rs1192925 11 69,476,279 ORAOV1 intron T C 0.631 0.0132±0.0014 7.9E-20 442,391 
rs584961 11 75,277,628 SERPINH1 synonymous A G 0.114 -0.0139±0.0022 2.8E-10 442,391 
11:77923601_CCT
AT_C 
11 77,923,601 USP35 intron I D 0.836 0.0136±0.0019 4.0E-13 442,391 
11:84790528_ATT
_A 
11 84,790,528 DLG2 intron D I 0.526 -0.011±0.0014 1.4E-14 442,391 
rs610476 11 86,184,102 ME3 intron A G 0.410 -0.0085±0.0014 1.9E-09 442,391 
rs61903695 11 89,922,417 NAALAD2 intron A G 0.744 -0.0099±0.0016 4.9E-10 442,391 
rs680071 11 103,088,414 DYNC2H1 intron T C 0.119 -0.0134±0.0022 4.1E-10 442,391 
rs1801516 11 108,175,462 ATM missense A G 0.146 -0.0115±0.0019 9.7E-10 535,885 
rs1048932 11 115,044,850 CADM1 3' UTR A C 0.413 -0.0134±0.0014 2.7E-21 442,391 
rs1064939 11 118,396,331 LOC101929089 3' UTR A T 0.977 0.0335±0.0047 1.6E-12 442,391 
rs1784302 11 118,940,957 VPS11 synonymous C G 0.597 -0.0081±0.0014 3.4E-09 529,789 
rs12574203 11 119,901,007 TRIM29 intergenic A G 0.837 0.0122±0.0019 9.9E-11 442,391 
rs11218510 11 121,922,587 MIR100HG intron  A G 0.401 -0.009±0.0014 2.3E-10 442,391 
rs10893502 11 126,254,018 ST3GAL4 intron T C 0.408 0.0082±0.0014 1.0E-08 442,391 
rs7936928 11 130,279,168 ADAMTS8 intron T C 0.397 0.0087±0.0014 1.1E-09 442,391 
rs7933085 11 130,796,248 SNX19 intergenic A G 0.492 -0.0088±0.0014 3.6E-10 442,391 
rs12788343 11 131,452,912 NTM intron T C 0.589 -0.0086±0.0014 1.0E-09 442,391 
rs7480395 11 133,667,674 LOC646522 intron  A G 0.523 -0.0091±0.0014 8.6E-11 442,391 
rs12364470 11 134,601,012 LOC283177 upstream T G 0.835 -0.0124±0.0019 4.0E-11 442,391 
rs55726687 12 991,306 WNK1 intron A G 0.211 0.0181±0.0017 2.8E-26 442,391 
rs10774018 12 2,157,925 CACNA1C-IT2 intron  C G 0.219 0.0103±0.0017 1.3E-09 442,391 
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12 3,338,920 TSPAN9 intron D I 0.214 0.012±0.0017 3.3E-12 442,391 
rs76895963 12 4,384,844 CCND2-AS1 intron T G 0.979 -0.0316±0.0054 4.1E-09 442,391 
rs778329432 12 9,100,432 M6PR intron D I 0.647 0.0091±0.0015 3.4E-09 442,391 
rs10744137 12 16,993,026 SKP1P2 intergenic T C 0.231 0.0103±0.0017 4.9E-10 442,391 
rs10846458 12 17,169,641 SKP1P2 intergenic A T 0.302 -0.0072±0.0015 2.1E-06 442,391 
rs10771041 12 24,058,135 SOX5 intron T C 0.114 0.0147±0.0022 1.9E-11 442,391 
rs74567249 12 28,453,440 CCDC91 intron D I 0.694 -0.0113±0.0015 9.7E-14 442,391 
rs2730829 12 41,831,174 PDZRN4 intron T C 0.477 0.0099±0.0014 2.4E-13 514,980 
rs7134130 12 42,861,370 PRICKLE1 intron T C 0.440 0.0095±0.0014 1.3E-11 442,391 
12:46752872_CA_
C 
12 46,752,872 SLC38A2 3' UTR I D 0.421 -0.0118±0.0014 2.1E-16 442,391 
rs145878042 12 48,143,315 RAPGEF3 missense A G 0.989 -0.0548±0.0064 9.8E-18 534,021 
rs12228854 12 48,396,920 COL2A1 intron T G 0.223 -0.015±0.0017 3.0E-19 442,391 
rs1126930 12 49,399,132 PRKAG1 missense C G 0.036 0.0313±0.0036 4.7E-18 529,789 
rs7132908 12 50,263,148 FAIM2 3' UTR A G 0.383 0.0174±0.0014 3.2E-35 489,220 
rs10783377 12 50,983,046 DIP2B intron A C 0.346 -0.0121±0.0015 1.3E-16 442,391 
12:51589293_TA_
T 
12 51,589,293 POU6F1 intron D I 0.784 -0.0081±0.0017 3.2E-06 442,391 
rs36120387 12 53,831,064 PRR13 upstream T C 0.110 -0.0123±0.0022 4.5E-08 442,391 
rs17110109 12 54,668,908 CBX5 intron T C 0.610 0.0114±0.0014 1.6E-15 442,391 
rs4759228 12 56,508,409 PA2G4 upstream C G 0.296 -0.0144±0.0015 3.6E-21 442,391 
rs730560 12 57,938,565 DCTN2 intron A G 0.582 0.01±0.0014 1.9E-12 442,391 
rs113221802 12 58,624,856 LINC02403 intergenic A G 0.126 0.0131±0.0021 4.8E-10 442,391 
rs1154752 12 68,089,328 LINC02421 intergenic T C 0.606 -0.0085±0.0014 2.2E-09 442,391 




A G 0.274 0.0109±0.0016 2.5E-12 442,391 
12:90599240_TA_
T 
12 90,599,240 LINC02392 intergenic D I 0.735 -0.0104±0.0016 7.2E-11 442,391 
rs10860392 12 99,498,187 LOC101928937 intron T C 0.633 -0.0104±0.0014 1.2E-13 514,980 
rs35159593 12 103,651,399 C12orf42 
intron NMD 
transcript 
D I 0.676 0.0145±0.0015 2.8E-22 442,391 
12:110289655_CT
_C 
12 110,289,655 GLTP 3' UTR I D 0.416 -0.0085±0.0014 3.6E-09 442,391 
rs4766500 12 110,993,791 PPTC7 intron A G 0.634 -0.0087±0.0014 2.1E-09 442,391 
rs653178 12 112,007,756 ATXN2 intron T C 0.518 0.0101±0.0013 3.8E-14 535,885 
rs3825200 12 113,503,897 DTX1 intron T C 0.293 -0.0091±0.0015 4.0E-09 442,391 
rs60804348 12 114,419,506 RBM19 intergenic A G 0.068 -0.0189±0.0028 9.2E-12 442,391 
12:117595440_CA
CT_C 
12 117,595,440 FBXO21 intron I D 0.778 -0.0128±0.0017 2.3E-14 442,391 
rs117923369 12 120,840,074 MSI1 regulatory T C 0.051 -0.0245±0.0032 2.0E-14 442,391 
rs10846920 12 122,943,231 ZCCHC8 intergenic T C 0.740 0.0107±0.0016 1.4E-11 442,391 
rs2229840 12 124,826,462 NCOR2 missense T C 0.160 0.0122±0.0018 2.5E-11 535,885 
rs35221880 12 133,301,500 ANKLE2 upstream T C 0.269 0.0095±0.0016 1.7E-09 442,391 
rs9579775 13 20,616,557 ZMYM2 intron A C 0.864 -0.0125±0.0021 4.1E-09 442,391 
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rs61944841 13 27,049,616 CDK8 intergenic A G 0.415 0.0118±0.0015 7.9E-16 442,391 
rs9512696 13 28,012,527 MTIF3 intron A G 0.338 -0.0107±0.0015 3.5E-13 442,391 
rs1933437 13 28,624,294 FLT3 missense A G 0.625 -0.0115±0.0014 9.1E-17 532,966 
13:31010888_CAA
_C 
13 31,010,888 LINC01058 intergenic I D 0.356 -0.0112±0.0015 1.2E-13 442,391 
rs7332115 13 33,147,548 PDS5B intergenic T G 0.628 0.0117±0.0014 5.6E-17 530,616 
rs75983170 13 40,788,838 LINC00548 intergenic T G 0.665 -0.0091±0.0015 1.8E-09 442,391 
13:50426772_TTT
TA_T 
13 50,426,772 CTAGE10P intergenic D I 0.307 0.0101±0.0015 3.5E-11 442,391 
rs4942930 13 51,173,280 DLEU1 intron  T C 0.539 0.009±0.0014 1.4E-10 442,391 
rs12429545 13 54,102,206 LINC00558 intergenic A G 0.129 0.0178±0.002 2.2E-18 512,061 
rs2121058 13 58,627,256 LINC02338 intergenic T C 0.772 0.0174±0.0017 1.7E-25 442,391 
rs34500367 13 58,686,522 LINC02338 intergenic A T 0.967 0.0423±0.0062 8.6E-12 442,391 
rs4055791 13 59,266,053 LINC00374 intergenic T C 0.418 -0.014±0.0014 3.8E-23 442,391 
rs1949204 13 65,475,834 LINC01052 intergenic T G 0.239 -0.0102±0.0016 4.2E-10 442,391 
rs59041875 13 66,203,733 LINC01052 intergenic D I 0.563 -0.0101±0.0015 5.9E-12 442,391 
rs2010695 13 67,424,416 PCDH9-AS2 intron T C 0.347 -0.0088±0.0015 2.1E-09 442,391 
rs1360371 13 78,455,230 EDNRB-AS1 intergenic T C 0.225 -0.0129±0.0017 1.3E-14 442,391 
rs1441264 13 79,580,919 LINC00331 intergenic A G 0.592 0.0117±0.0015 7.9E-16 442,391 
rs61975177 13 96,309,730 DZIP1 intron  A C 0.278 0.0092±0.0016 3.4E-09 442,391 
rs55911231 13 96,983,940 HS6ST3 intron T C 0.411 0.0113±0.0014 1.9E-15 442,391 
rs7333559 13 100,546,450 LOC101927437 3' UTR A G 0.790 -0.0114±0.0017 3.2E-11 442,391 
rs9559013 13 108,000,884 FAM155A intron A G 0.138 0.0125±0.002 6.6E-10 442,391 
rs750598 13 111,028,978 COL4A2 intron A G 0.338 0.0087±0.0015 4.0E-09 442,391 
rs9560114 13 112,187,882 LINC02337 intergenic A T 0.735 0.0117±0.0016 2.3E-13 442,391 
14:25931404_GTC
_G 
14 25,931,404 STXBP6 intergenic D I 0.679 0.0159±0.0015 1.9E-26 442,391 
rs11624548 14 29,737,466 PRKD1 intron  T G 0.643 0.012±0.0015 2.1E-16 442,391 
rs61980001 14 30,430,683 PRKD1 intron  T C 0.038 0.0235±0.0037 3.0E-10 442,391 
14:33298731_CA_
C 
14 33,298,731 AKAP6 intron I D 0.546 -0.0113±0.0014 1.1E-15 442,391 




I D 0.177 -0.0127±0.0018 5.8E-12 442,391 
rs872281 14 40,834,177 LINC02315 intergenic T C 0.177 -0.011±0.0018 2.4E-09 442,391 
rs12889085 14 42,885,336 LRFN5 intron  A G 0.575 -0.0085±0.0014 2.2E-09 442,391 
rs5808362 14 47,321,109 MDGA2 intron D I 0.557 -0.0126±0.0014 1.3E-18 442,391 
rs2065999 14 54,656,551 CDKN3 regulatory T C 0.618 0.0091±0.0014 2.3E-10 442,391 
14:56116712_TA_
T 
14 56,116,712 KTN1 intron D I 0.371 -0.0103±0.0015 2.6E-12 442,391 
rs148410947 14 66,498,900 FUT8 intergenic T C 0.222 0.0118±0.0017 2.5E-12 442,391 
rs35230100 14 70,348,141 SMOC1 intron I D 0.433 -0.0098±0.0015 1.7E-11 442,391 
rs763388 14 73,322,566 DPF3 
intron NMD 
transcript 
T C 0.615 0.0111±0.0014 1.1E-14 442,391 
rs10142359 14 73,884,540 NUMB intron A G 0.520 -0.0089±0.0014 1.5E-10 442,391 
rs7141420 14 79,899,454 NRXN3 intron T C 0.516 0.0128±0.0014 1.1E-19 442,391 
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rs57984207 14 80,641,446 DIO2 intergenic C G 0.896 -0.0141±0.0023 7.7E-10 442,391 
14:91499131_GA_
G 
14 91,499,131 RPS6KA5 intron D I 0.603 0.0146±0.0015 9.4E-24 442,391 
rs7153027 14 92,427,222 TRIP11 intergenic A C 0.576 -0.0109±0.0014 1.2E-15 526,523 
rs10498635 14 93,103,309 RIN3 intron T C 0.183 0.0133±0.0017 1.4E-14 534,021 
rs1015032 14 93,903,994 UNC79 intron A G 0.562 0.0139±0.0014 4.9E-23 442,391 
rs28929474 14 94,844,947 SERPINA1 missense T C 0.020 -0.0415±0.0048 3.9E-18 535,885 
rs4082793 14 99,700,080 BCL11B intron T C 0.427 -0.0091±0.0014 1.4E-10 442,391 
rs7161194 14 101,529,005 MIR377 upstream A G 0.336 0.0146±0.0015 3.9E-21 442,391 
rs8022504 14 102,740,275 MOK intron A C 0.915 -0.0192±0.0025 1.9E-14 442,391 
rs3803286 14 103,246,470 TRAF3 intron A G 0.333 0.0122±0.0015 1.9E-16 442,391 
rs1136165 14 103,988,180 CKB synonymous T G 0.628 0.0141±0.0015 1.8E-22 442,391 
rs1818917 15 23,941,678 NDN intergenic T C 0.512 -0.0084±0.0014 2.3E-09 442,391 
rs4779541 15 31,851,884 OTUD7A intron T C 0.534 -0.0083±0.0014 3.1E-09 442,391 
rs2178004 15 41,991,315 MGA missense A T 0.184 0.0122±0.0017 1.9E-12 524,520 
rs2453533 15 45,641,225 GATM intergenic A C 0.371 0.0082±0.0014 4.0E-09 535,885 
rs12439798 15 46,584,787 LOC105370802 intergenic T G 0.433 0.0111±0.0014 3.0E-15 442,391 
rs113875061 15 48,930,234 FBN1 intron I D 0.125 0.0132±0.0022 4.7E-09 442,391 
rs6493534 15 52,379,736 MAPK6 intron  T C 0.421 -0.0091±0.0014 1.8E-10 442,391 
15:53492263_AT_
A 
15 53,492,263 LINC02490 intergenic D I 0.059 -0.0221±0.003 1.5E-13 442,391 
rs147384209 15 55,454,511 LOC105370829 intergenic T C 0.024 -0.0277±0.0046 2.0E-09 442,391 




T C 0.615 -0.0088±0.0014 8.0E-10 442,391 
rs890156 15 60,913,340 RORA-AS1 intron A T 0.448 0.0083±0.0014 3.8E-09 442,391 
rs72749772 15 62,367,013 C2CD4A downstream T C 0.981 0.032±0.0052 6.8E-10 442,391 
rs56187480 15 63,789,479 USP3 intergenic A G 0.345 -0.0095±0.0015 8.9E-11 442,391 
15:64898757_CA_
C 
15 64,898,757 ZNF609 intron I D 0.084 0.0188±0.0031 1.2E-09 442,391 
rs144910307 15 66,506,435 MEGF11 intron A G 0.733 0.0099±0.0016 4.8E-10 442,391 
rs11631381 15 67,339,185 LOC102723493 intron  A G 0.488 -0.0117±0.0014 7.0E-17 442,391 
rs35874463 15 67,457,698 SMAD3 missense A G 0.942 0.0216±0.003 4.2E-13 442,391 
rs4776970 15 68,080,886 MAP2K5 intron A T 0.644 0.0164±0.0015 2.4E-29 442,391 
rs2241423 15 68,086,838 MAP2K5 intron A G 0.223 -0.0172±0.0016 7.0E-27 532,966 
15:73049542_CT_
C 




I D 0.345 -0.0097±0.0016 7.3E-10 442,391 
rs74022954 15 73,657,063 HCN4 intron T C 0.073 -0.0169±0.0027 3.2E-10 442,391 
rs28588430 15 74,223,430 LOXL1 intron C G 0.492 0.0159±0.0014 4.9E-30 442,391 
rs572865226 15 74,380,752 GOLGA6A intergenic T G 0.925 -0.0252±0.0031 6.3E-16 442,391 
rs35032603 15 74,753,425 UBL7 5' UTR T C 0.963 -0.0224±0.0037 1.2E-09 442,391 
rs11636613 15 77,335,902 TSPAN3 upstream A G 0.321 -0.0135±0.0015 1.4E-20 522,343 
rs11854808 15 78,011,104 LINGO1 intron A G 0.283 -0.0098±0.0016 5.3E-10 442,391 
rs1443658 15 79,386,366 RASGRF1 upstream A G 0.580 0.0118±0.0014 1.0E-16 442,391 
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rs2759301 15 80,994,288 ABHD17C intron A G 0.449 0.0106±0.0014 4.6E-14 442,391 
rs301853 15 84,078,467 SH3GL3 intron  A T 0.834 -0.0111±0.0019 4.8E-09 442,391 
rs11259936 15 84,580,582 ADAMTSL3 intron A C 0.479 0.0274±0.0013 1.1E-92 535,885 
rs150961 15 85,086,552 UBE2Q2P1 intron  A G 0.710 0.0135±0.0016 3.4E-18 442,391 
rs11633157 15 89,398,939 ACAN synonymous T C 0.019 0.0438±0.0054 6.8E-16 442,391 
rs3817428 15 89,415,247 ACAN missense C G 0.733 -0.0233±0.0015 3.5E-53 529,789 
rs62020775 15 89,960,286 MIR9-3HG regulatory A T 0.142 -0.0135±0.002 2.1E-11 442,391 
rs7173947 15 95,270,467 LOC440311 intergenic T C 0.643 -0.013±0.0014 3.1E-20 514,980 
rs289482 15 98,232,714 LINC00923 intergenic T C 0.435 -0.0087±0.0014 8.0E-10 442,391 
rs2715423 15 99,511,873 PGPEP1L missense A G 0.285 -0.0115±0.0015 6.5E-15 534,313 
rs2581348 15 100,514,063 ADAMTS17 3' UTR T C 0.648 -0.0098±0.0015 1.9E-11 442,391 
rs72755233 15 100,692,953 ADAMTS17 missense A G 0.113 0.0338±0.0021 1.1E-57 535,885 
rs28583508 15 100,800,049 ADAMTS17 intron T G 0.661 0.012±0.0015 7.5E-16 442,391 
rs7201895 16 407,723 AXIN1 intergenic A G 0.355 -0.0093±0.0015 2.5E-10 442,391 
rs34762152 16 1,634,385 IFT140 
missense,NM
D transcript 
T C 0.064 0.0164±0.0027 1.7E-09 535,885 
rs75510884 16 2,161,796 PKD1 synonymous A G 0.098 -0.0144±0.0024 9.2E-10 442,391 
rs3794701 16 3,730,578 TRAP1 intron A G 0.480 -0.0102±0.0014 3.3E-13 442,391 
rs879620 16 4,015,729 ADCY9 3' UTR T C 0.615 0.0151±0.0014 7.5E-26 442,391 
rs4786924 16 6,772,948 RBFOX1 intron A C 0.206 -0.0102±0.0017 3.9E-09 442,391 
rs8062638 16 9,720,130 GRIN2A intergenic A C 0.306 -0.0094±0.0015 5.0E-10 442,391 
rs6497676 16 10,180,223 GRIN2A intron A G 0.629 -0.0097±0.0014 2.0E-11 442,391 
rs12444979 16 19,933,600 GPRC5B intergenic T C 0.142 -0.0301±0.0019 6.4E-56 535,885 
rs868554 16 20,050,466 GPR139 
intron NMD 
transcript 
C G 0.760 -0.0143±0.0016 3.6E-18 442,391 
16:20259934_AT_
A 
16 20,259,934 GP2 intergenic D I 0.130 -0.0123±0.0021 8.8E-09 442,391 
rs9652589 16 20,370,816 PDILT missense T C 0.514 -0.0105±0.0013 5.0E-15 532,966 
rs9922288 16 24,550,930 RBBP6 5' UTR A G 0.236 0.0169±0.0017 3.1E-24 442,391 
rs78457529 16 24,950,880 ARHGAP17 missense T C 0.012 -0.0464±0.0061 3.3E-14 535,885 
16:28556564_CT_
C 
16 28,556,564 NUPR1 downstream I D 0.630 -0.0122±0.0014 2.9E-17 442,391 
rs3814883 16 29,994,922 TAOK2 synonymous T C 0.483 0.0175±0.0014 4.4E-36 442,391 
rs111739641 16 30,510,984 ITGAL intron D I 0.498 0.0116±0.0014 1.4E-16 442,391 
rs12716979 16 31,011,821 STX1B intron T G 0.625 0.0144±0.0014 3.1E-23 442,391 
rs8050390 16 31,539,386 AHSP intron A G 0.360 0.0104±0.0015 6.0E-13 442,391 
rs6500208 16 49,011,249 CBLN1 intergenic A G 0.207 0.0103±0.0017 2.6E-09 442,391 
rs4533281 16 49,725,798 ZNF423 intron A G 0.755 0.0106±0.0016 7.3E-11 442,391 
rs12927850 16 50,044,403 CNEP1R1 intergenic A G 0.373 0.0095±0.0015 1.3E-10 442,391 
rs76488452 16 53,756,885 FTO intron A G 0.948 -0.0118±0.0031 1.7E-04 442,391 








rs11373 16 56,545,175 BBS2 missense T C 0.827 -0.011±0.0018 4.2E-10 535,885 
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rs73586863 16 67,011,228 CES3 downstream A G 0.960 -0.0226±0.0036 2.4E-10 442,391 
16:67554712_GA_
G 
16 67,554,712 LOC100505942 intron D I 0.078 0.0185±0.0026 2.8E-12 442,391 
rs2307022 16 68,381,978 PRMT7 intron A G 0.331 0.0133±0.0015 3.1E-19 442,391 
rs5011579 16 69,187,318 UTP4 intron C G 0.285 -0.0111±0.0015 7.7E-13 442,391 
rs1364063 16 69,588,572 MIR1538 
TF binding 
site 
T C 0.589 0.0128±0.0014 5.8E-21 535,885 
16:70252464_CA_
C 
16 70,252,464 SMG1P7 downstream I D 0.494 -0.0123±0.0014 3.3E-18 442,391 
rs117512594 16 71,685,344 PHLPP2 intron A G 0.915 -0.0156±0.0025 8.2E-10 442,391 
rs811054 16 72,251,132 PMFBP1 intergenic T C 0.537 0.0094±0.0014 2.0E-11 442,391 
rs62053191 16 72,993,706 ZFHX3 synonymous A G 0.084 -0.0148±0.0025 4.0E-09 442,391 
rs4493083 16 75,294,589 BCAR1 intron T C 0.507 -0.0109±0.0014 9.1E-15 442,391 
rs4074541 16 78,345,435 WWOX intron A C 0.659 -0.009±0.0015 8.2E-10 442,391 
rs12599980 16 81,587,084 CMIP intron T C 0.408 -0.01±0.0014 1.8E-12 442,391 




T C 0.530 0.0065±0.0014 2.9E-06 442,391 
rs2303232 16 84,808,969 USP10 intron C G 0.488 0.0096±0.0014 3.0E-11 442,391 
rs1552657 16 86,424,697 LINC00917 intergenic A G 0.444 -0.0087±0.0014 6.4E-10 442,391 
rs76520574 16 88,321,027 LINC02182 intron  T C 0.041 -0.0239±0.0036 2.5E-11 442,391 
rs62068640 16 89,496,727 ANKRD11 intron T C 0.442 -0.0086±0.0014 2.5E-09 442,391 
rs57207396 17 1,630,208 WDR81 missense T C 0.261 0.0093±0.0015 9.8E-10 531,750 
rs758959824 17 1,823,490 RTN4RL1 intergenic D I 0.156 -0.0147±0.0019 3.7E-14 442,391 
rs10852932 17 2,143,460 SMG6 5' UTR T G 0.351 0.0148±0.0014 6.9E-26 534,313 
17:4175556_GTA
TA_G 
17 4,175,556 UBE2G1 3' UTR D I 0.021 -0.0302±0.0049 9.6E-10 442,391 
rs78378222 17 7,571,752 TP53 3' UTR T G 0.988 -0.0606±0.0064 3.9E-21 442,391 
rs57828851 17 7,732,351 DNAH2 intron A T 0.581 -0.0094±0.0014 3.6E-11 442,391 
rs10684399 17 15,945,474 NCOR1 intron I D 0.558 0.0087±0.0014 6.3E-10 442,391 
rs2605136 17 18,136,750 LLGL1 intron T C 0.355 0.009±0.0015 7.1E-10 442,391 
rs1320251 17 21,264,396 KCNJ12 regulatory T C 0.454 -0.0123±0.0014 1.6E-18 442,391 




T C 0.049 -0.0199±0.0033 1.1E-09 442,391 
rs536851066 17 30,251,481 SUZ12 intergenic I D 0.089 -0.016±0.0027 2.2E-09 442,391 
rs11868042 17 32,250,375 ASIC2 intron A T 0.183 0.0116±0.0018 2.7E-10 442,391 
rs2306593 17 34,866,546 MYO19 intron T C 0.488 -0.0107±0.0014 1.6E-14 442,391 
rs12450937 17 35,494,511 ACACA intron T C 0.357 0.0089±0.0015 9.7E-10 442,391 





17 42,325,043 SLC4A1 downstream I D 0.975 -0.0315±0.0046 6.2E-12 442,391 
rs188710438 17 43,573,649 PLEKHM1 intergenic T C 0.226 0.014±0.0017 3.5E-17 442,391 
rs138464472 17 44,130,160 KANSL1 intron D I 0.286 0.0145±0.0016 2.5E-20 442,391 
rs56755526 17 44,793,627 NSF intron I D 0.743 -0.0127±0.0016 1.2E-14 442,391 
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17:45481842_TAA
_T 
17 45,481,842 EFCAB13 intron D I 0.080 -0.0205±0.0026 5.7E-15 442,391 
rs376610477 17 46,292,292 SKAP1 intron D I 0.649 0.0146±0.0016 2.1E-19 442,391 
rs12603429 17 46,836,576 TTLL6 downstream C G 0.456 0.0111±0.0014 2.2E-15 442,391 
rs11079849 17 47,090,785 IGF2BP1 intron T C 0.328 -0.0129±0.0015 5.3E-18 442,391 
17:47382240_GTA
_G 
17 47,382,240 ZNF652 intron D I 0.394 -0.017±0.0015 2.6E-30 442,391 
rs28412876 17 47,454,515 LOC102724596 intron  T G 0.376 0.0156±0.0014 6.1E-27 442,391 
rs74929176 17 54,905,494 C17orf67 intron T C 0.227 -0.0111±0.0017 3.4E-11 442,391 
rs72845886 17 61,666,687 DCAF7 3' UTR T C 0.058 -0.0173±0.0029 1.3E-09 535,885 
rs236531 17 68,217,860 KCNJ2 intergenic T C 0.416 0.0089±0.0014 2.5E-10 481,528 
rs2019877 17 71,759,960 LINC00469 intron  T C 0.436 -0.0083±0.0014 6.3E-09 442,391 
rs7218677 17 76,146,520 C17orf99 intron A T 0.688 0.0092±0.0015 2.7E-09 442,391 
rs12941365 17 76,897,733 
CEP295NL,TI
MP2 
intron T G 0.412 0.0096±0.0014 1.2E-11 442,391 
rs2587507 17 77,790,135 LINC01977 intergenic T C 0.494 0.0093±0.0013 3.8E-12 528,831 
rs11150745 17 78,757,626 RPTOR intron A G 0.681 0.0138±0.0015 4.4E-20 442,391 
rs3935190 17 79,084,367 BAIAP2 intron A G 0.536 -0.0114±0.0014 5.1E-16 442,391 




D I 0.344 0.0095±0.0015 1.5E-10 442,391 
rs4625783 17 80,086,395 CCDC57 missense T C 0.407 0.01±0.0014 4.9E-13 512,821 
rs6506537 18 794,273 YES1 intron T C 0.754 -0.01±0.0016 8.7E-10 442,391 
rs60764613 18 1,839,911 LINC00470 intergenic T G 0.145 0.0121±0.002 1.2E-09 442,391 
rs5822974 18 7,548,483 PTPRM intergenic D I 0.812 0.0111±0.0018 7.3E-10 442,391 
rs17498752 18 9,254,785 ANKRD12 missense T C 0.087 -0.0153±0.0024 1.4E-10 535,885 
rs1788808 18 21,090,023 C18orf8 intron A G 0.504 0.0101±0.0014 4.8E-13 442,391 
rs34866209 18 30,458,628 CCDC178 intron  D I 0.222 0.01±0.0017 2.4E-09 442,391 
rs1941706 18 31,223,776 ASXL3 intron A G 0.537 -0.0105±0.0014 8.1E-14 442,391 
rs1443641 18 32,690,756 MAPRE2 intron A T 0.542 -0.008±0.0014 1.5E-08 442,391 
rs559231 18 39,644,247 PIK3C3 intron T G 0.393 0.0086±0.0014 1.9E-09 442,391 
rs9956387 18 44,773,382 SKOR2 missense A T 0.497 0.0083±0.0014 3.0E-09 442,391 
rs7239114 18 45,921,214 ZBTB7C intron A G 0.542 0.0082±0.0014 6.0E-09 442,391 
rs7243172 18 52,472,235 RAB27B intron T G 0.542 -0.009±0.0014 1.5E-10 442,391 
rs11659764 18 53,335,512 LINC01415 upstream A T 0.053 -0.0255±0.0031 4.5E-16 442,391 
rs200519957 18 56,878,075 GRP intergenic D I 0.835 0.0132±0.0019 2.7E-12 442,391 
rs8086105 18 57,685,001 PMAIP1 upstream T C 0.745 0.0145±0.0016 4.1E-19 442,391 




rs201873971 18 57,863,192 MC4R upstream T C 0.879 -0.0426±0.0026 1.8E-62 442,391 
rs12457883 18 57,870,593 MC4R intergenic A T 0.930 0.0268±0.0027 1.6E-22 442,391 
rs2331933 18 57,955,945 MC4R intergenic T G 0.650 -0.0204±0.0015 1.9E-43 442,391 
rs111389401 18 58,420,595 MC4R intron  T C 0.019 -0.0475±0.0053 1.6E-19 442,391 
rs12454712 18 60,845,884 BCL2 intron T C 0.624 -0.0106±0.0014 1.9E-13 442,391 
rs8089514 18 69,224,478 LINC01541 intron  A T 0.368 0.0087±0.0015 2.9E-09 442,391 
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rs11150911 18 73,498,528 LINC01898 intergenic A C 0.276 0.0097±0.0016 6.8E-10 442,391 
rs3957285 19 1,891,992 ABHD17A intergenic A G 0.544 0.0107±0.0014 3.3E-14 442,391 
19:2230029_CTT_
C 
19 2,230,029 DOT1L 3' UTR I D 0.942 -0.0215±0.003 9.7E-13 442,391 
rs7351050 19 4,044,579 ZBTB7A 3' UTR A G 0.162 -0.0129±0.0019 1.6E-11 442,391 
rs243342 19 4,406,160 CHAF1A intron A G 0.545 0.0105±0.0014 5.6E-14 442,391 
rs11878235 19 7,976,698 MAP2K7 intron A G 0.595 -0.0099±0.0014 4.6E-12 442,391 
rs62621197 19 8,670,147 ADAMTS10 missense T C 0.037 0.0414±0.0038 5.7E-27 442,391 
19:8675220_AAC
AC_A 
19 8,675,220 ADAMTS10 intron  D I 0.628 -0.0079±0.0015 7.2E-08 442,391 
rs35915221 19 9,498,618 
ZNF559-
ZNF177 
intergenic I D 0.586 0.0115±0.0014 6.7E-16 442,391 
rs2878723 19 10,011,375 OLFM2 intron T C 0.689 -0.0097±0.0015 2.2E-10 442,391 




T C 0.732 -0.0109±0.0015 5.6E-13 532,966 




I D 0.334 0.0101±0.0015 1.6E-11 442,391 
rs7246865 19 17,219,105 MYO9B intron A G 0.259 -0.0117±0.0016 3.1E-13 442,391 
rs199590561 19 18,381,169 KIAA1683 intron I D 0.269 0.0107±0.0016 4.1E-11 442,391 
rs113230003 19 18,460,956 PGPEP1 intron A G 0.260 -0.012±0.0016 6.6E-14 442,391 
rs2051815 19 18,835,115 CRTC1 intron A G 0.324 -0.0123±0.0015 2.3E-16 442,391 
rs1064395 19 19,361,735 NCAN 3' UTR A G 0.160 -0.0207±0.0018 1.5E-29 530,616 
rs75270598 19 19,864,849 LINC00663 downstream T C 0.154 -0.0133±0.0019 7.6E-12 442,391 
rs8102137 19 30,296,853 CCNE1 regulatory T C 0.670 -0.0135±0.0014 4.6E-21 530,616 
rs73019624 19 30,709,251 ZNF536 downstream A G 0.207 -0.0115±0.0017 3.3E-11 442,391 
rs73026723 19 31,017,177 ZNF536 intron T C 0.155 -0.0173±0.0019 2.6E-19 442,391 
rs29941 19 34,309,532 KCTD15 downstream A G 0.327 -0.0135±0.0014 7.4E-21 512,061 
rs2075650 19 45,395,619 TOMM40 intron A G 0.854 0.0127±0.0019 2.5E-11 535,885 
rs1800437 19 46,181,392 GIPR missense C G 0.195 -0.0202±0.0017 1.0E-32 528,184 
rs3810291 19 47,569,003 ZC3H4 3' UTR A G 0.676 0.0231±0.0014 3.6E-58 531,792 
rs200876443 19 50,363,585 PTOV1 3' UTR I D 0.964 -0.0377±0.0038 1.3E-23 442,391 
rs760129606 19 51,812,546 IGLON5 upstream D I 0.462 0.0105±0.0014 1.6E-13 442,391 
rs6132308 20 2,102,598 STK35 intron T C 0.578 0.0083±0.0014 5.2E-09 442,391 
rs633284 20 2,904,143 PTPRA intron A T 0.484 0.0094±0.0014 3.3E-11 442,391 
rs2145270 20 6,621,685 LINC01713 intergenic T C 0.621 0.0179±0.0014 2.0E-38 535,885 
rs1578407 20 17,196,608 PCSK2 intergenic T C 0.728 0.01±0.0016 1.9E-10 442,391 
rs742698 20 20,083,949 CFAP61 intron T C 0.301 0.0096±0.0015 3.2E-10 442,391 




C G 0.331 0.0094±0.0014 6.4E-11 526,353 
rs116948922 20 25,534,854 NINL intron T C 0.033 -0.0235±0.004 3.0E-09 442,391 
rs375341392 20 30,986,406 ASXL1 intron D I 0.182 0.011±0.0018 2.2E-09 442,391 
20:32563820_GTA
TATA_G 
20 32,563,820 RALY-AS1 intergenic D I 0.601 0.01±0.0014 2.3E-12 442,391 
rs7268343 20 42,754,240 JPH2 intron A G 0.122 0.0141±0.0021 4.7E-11 442,391 
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rs2425847 20 44,907,927 CDH22 intron A G 0.591 -0.009±0.0014 2.5E-10 442,391 
rs112852122 20 47,498,117 ARFGEF2 intergenic A G 0.159 -0.0112±0.0019 8.0E-09 442,391 
rs5014389 20 48,597,280 SNAI1 upstream A T 0.104 0.0148±0.0023 1.0E-10 442,391 
rs6096548 20 50,347,558 ATP9A intron A T 0.257 0.0094±0.0016 4.1E-09 442,391 
rs6096886 20 50,951,298 ZFP64 intron  A G 0.810 0.0183±0.0018 8.8E-25 442,391 
rs2207895 20 54,387,375 CBLN4 intergenic A G 0.190 -0.0113±0.0018 2.6E-10 442,391 
rs61734651 20 61,451,332 COL9A3 
missense,splic
e region 
T C 0.071 -0.0246±0.0028 4.0E-18 442,391 
rs150998792 20 62,130,403 EEF1A2 
splice 
region,intron 
T G 0.050 -0.0203±0.0033 9.8E-10 442,391 
rs7264802 20 62,692,440 TCEA2 intron A G 0.252 -0.0119±0.0016 2.3E-13 442,391 
rs2823991 21 18,082,592 MIR99AHG regulatory T G 0.740 -0.0107±0.0016 3.0E-11 442,391 
rs2830585 21 28,305,212 ADAMTS5 missense T C 0.160 0.0124±0.0018 1.4E-11 532,966 
rs13047416 21 40,309,436 LOC400867 intron  C G 0.623 0.0102±0.0014 2.0E-12 442,391 
rs394608 21 46,581,798 ADARB1 intron T C 0.462 -0.01±0.0014 1.6E-12 442,391 
rs4680 22 19,951,271 COMT 
missense,NM
D transcript 
A G 0.517 0.01±0.0013 1.3E-13 531,750 
rs35359276 22 20,769,186 ZNF74 downstream I D 0.293 0.0093±0.0016 3.7E-09 442,391 
rs878718 22 31,552,702 MIR3928 upstream A G 0.436 0.0102±0.0014 5.9E-13 442,391 
rs470072 22 32,263,131 DEPDC5 intron T C 0.459 -0.0103±0.0014 7.1E-14 510,887 
rs75425504 22 40,684,279 TNRC6B intron D I 0.650 0.0176±0.0015 6.2E-33 442,391 
rs139497 22 41,640,098 RANGAP1 upstream T C 0.688 -0.0128±0.0015 4.5E-17 442,391 
rs5751239 22 42,592,239 TCF20 intron T C 0.522 0.0085±0.0014 1.6E-09 442,391 
rs9614666 22 45,829,560 RIBC2 downstream A G 0.837 0.0144±0.0019 3.3E-14 442,391 
rs9617050 22 50,708,731 MAPK11 5' UTR A G 0.519 -0.0083±0.0014 7.8E-09 442,391 
rs1379871 23 31,854,782 DMD intron C G 0.343 0.0097±0.0012 3.0E-15 442,391 
rs35473057 23 53,601,990 HUWE1 intron A C 0.466 -0.0137±0.0012 7.9E-32 442,391 
rs41303733 23 67,652,748 OPHN1 missense T C 0.085 -0.0128±0.0021 7.1E-10 442,391 
rs11539157 23 68,381,264 PJA1 missense A C 0.238 -0.0181±0.0014 3.0E-40 442,391 
rs5922922 23 83,467,844 JDP2 intergenic A G 0.147 0.0096±0.0016 4.7E-09 442,391 
rs6524628 23 85,558,345 DACH2 intron A G 0.414 -0.0081±0.0012 5.5E-12 442,391 
rs5920845 23 99,966,059 SYTL4 intron T C 0.332 0.0085±0.0012 6.6E-12 442,391 
rs12833777 23 100,785,073 ARMCX4 
intron NMD 
transcript 
A T 0.555 -0.0069±0.0012 2.9E-09 442,391 
rs12560103 23 101,383,199 TCEAL2 downstream T C 0.641 0.0094±0.0012 9.9E-15 442,391 
rs6567865 23 109,701,864 RGAG1 downstream A C 0.399 0.0088±0.0012 8.6E-14 442,391 
rs138073470 23 117,843,442 IL13RA1 intergenic A G 0.831 -0.0157±0.0016 1.0E-23 442,391 
rs747153900 23 131,290,808 FRMD7 intergenic A G 0.228 -0.012±0.0014 1.5E-17 442,391 




C G 0.502 -0.0077±0.0012 3.4E-11 442,391 
rs750212356 23 137,050,402 ZIC3 intergenic I D 0.154 -0.0149±0.0017 3.7E-18 442,391 
Women-only           
rs55656112 1 172,189,764 DNM3 intron A C 0.788 0.0209±0.0033 1.2E-10 240,552 
rs925422 4 60,254,101 LINC02429 intergenic T G 0.259 0.019±0.0031 6.0E-10 240,552 
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rs2667360 4 140,793,531 MAML3 intron A T 0.694 0.0175±0.0029 2.0E-09 240,552 
rs11424823 5 171,284,642 FBXW11 downstream D I 0.380 0.0169±0.0029 3.6E-09 240,552 
rs41271299 6 19,839,415 ID4 intron T C 0.052 -0.0378±0.006 4.1E-10 240,552 
15:59278382_TTG
_T 
15 59,278,382 RNF111 intron D I 0.751 0.0202±0.0032 4.8E-10 240,552 
rs727702 15 70,006,236 PCAT29 intergenic A G 0.117 0.0244±0.0042 4.9E-09 240,552 
17:56542985_CA_
C 
17 56,542,985 HSF5 intron I D 0.273 0.0189±0.0032 3.3E-09 240,552 
Men-only           
rs60745892 1 66393106 PDE4B intron D I 0.658 0.0192±0.0031 4.0E-10 201,839 
rs823094 1 205689807 NUCKS1 intron T G 0.574 0.0192±0.0029 6.2E-11 201,839 




T C 0.839 -0.0246±0.004 8.6E-10 201,839 
rs77169818 18 74980601 GALR1 missense A T 0.957 0.0422±0.0066 1.7E-10 235,388 
rs4804524 19 10867448 DNM2 intron A G 0.612 -0.0179±0.003 2.4E-09 201,839 





Supplementary Table 3.7: 119 variants for FFMI which are solely driven by the association 
with height 
 
rsid chr Position 
Nearest 
gene 







p diff p FFMI p FFM p hght 
rs9970807 1 56965664 PLPP3 T C 0.092 0.014 0.026 4.9E-02 1.8E-09 7.6E-02 2.2E-06 
rs12089815 1 91189933 
BARHL
2 
A G 0.548 -0.009 -0.016 5.2E-02 5.2E-10 2.0E-02 1.7E-07 
rs143792309 1 92505309 EPHX4 T C 0.064 0.017 0.040 2.1E-03 1.2E-09 2.2E-01 5.6E-11 
rs984222 1 119503843 TBX15 C G 0.386 0.014 0.027 4.2E-04 2.3E-24 8.8E-05 1.7E-16 
rs10802069 1 119517357 TBX15 T C 0.387 0.014 0.027 2.7E-04 8.3E-24 7.6E-05 2.1E-16 
rs1194610 1 154296076 AQP10 T C 0.765 -0.010 -0.014 2.6E-01 2.3E-09 1.1E-02 3.2E-05 
rs35208023 1 156415673 C1orf61 T C 0.669 0.012 0.018 9.5E-02 5.9E-15 4.0E-03 2.3E-08 
rs10919515 1 170869758 MROH9 A T 0.095 -0.020 -0.037 1.1E-02 4.1E-14 1.7E-02 1.1E-10 
rs4916229 1 171443368 PRRC2C C G 0.904 -0.019 -0.028 1.1E-01 3.8E-15 1.2E-03 3.9E-07 
rs12079987 1 221715102 DUSP10 A G 0.024 -0.032 -0.057 2.5E-02 2.7E-12 1.2E-02 1.9E-08 
rs300789 2 89910 
FAM11
0C 
A G 0.798 -0.010 -0.027 1.3E-04 3.5E-09 4.4E-01 8.3E-13 
rs404108 2 33301389 LTBP1 A G 0.765 -0.010 -0.025 1.8E-04 2.1E-09 3.4E-01 1.8E-11 
rs11690012 2 43542480 
THAD
A 
C G 0.23 -0.010 -0.017 6.9E-02 5.9E-09 5.7E-03 2.4E-06 
rs6760379 2 55279536 RTN4 T C 0.693 0.010 0.018 3.3E-02 8.3E-11 8.4E-03 2.5E-07 
rs12476772 2 60203917 
MIR443
2HG 
A C 0.331 0.010 0.019 1.0E-02 1.9E-11 1.1E-02 2.5E-08 
rs34355307 2 86800506 
RNF103
-CHMP3 
A G 0.61 -0.011 -0.019 2.6E-02 8.5E-15 2.3E-04 5.6E-09 
rs10489971 2 102527827 
MAP4K
4 
T C 0.307 -0.009 -0.014 2.1E-01 2.1E-09 2.2E-03 4.4E-05 
rs10497820 2 199612796 SATB2 A C 0.341 0.011 0.017 1.0E-01 4.0E-13 1.5E-04 1.8E-06 
rs2108485 2 242021742 SNED1 T G 0.155 -0.014 -0.028 3.9E-03 3.3E-15 1.1E-02 1.3E-11 
rs9852062 3 45373442 LARS2 A T 0.556 -0.010 -0.016 6.6E-02 1.4E-11 3.2E-03 3.1E-06 
rs72906474 3 47817007 
SMARC
C1 
T G 0.584 -0.012 -0.025 8.5E-04 2.9E-18 8.8E-04 7.1E-14 
rs141434554 3 52208046 POC1A D I 0.78 -0.013 -0.030 8.8E-05 1.5E-13 8.6E-02 3.8E-14 
rs68093214 3 70657785 FOXP1 T C 0.751 0.011 0.016 2.3E-01 5.2E-12 1.2E-03 2.2E-05 
rs2399213 3 107395302 BBX T C 0.819 -0.014 -0.021 1.2E-01 1.2E-14 1.9E-04 1.5E-07 
rs17619973 3 114417675 ZBTB20 A G 0.925 0.016 0.041 2.0E-04 2.2E-09 2.0E-01 2.8E-11 
rs9881641 3 117602500 
LINC02
024 
T C 0.687 -0.009 -0.018 1.4E-02 1.9E-09 7.3E-02 2.2E-07 
rs17282078 3 124481760 ITGB5 A T 0.131 -0.015 -0.025 4.0E-02 1.5E-12 7.7E-03 1.1E-07 
rs76594121 3 128189391 
DNAJB
8-AS1 
T G 0.953 0.024 0.043 2.4E-02 1.1E-12 1.8E-02 9.3E-09 
rs9827728 3 133971558 RYK A T 0.88 -0.015 -0.034 5.8E-04 3.1E-12 1.1E-01 2.7E-12 
rs2051559 4 3298800 RGS12 T C 0.867 -0.015 -0.029 5.2E-03 1.1E-12 5.8E-02 9.7E-10 
rs6833878 4 10005555 SLC2A9 A T 0.732 -0.010 -0.021 3.7E-03 1.3E-09 1.4E-01 3.6E-09 
rs3209570 4 38699657 KLF3 A G 0.399 -0.010 -0.014 1.8E-01 2.8E-11 1.2E-03 5.6E-06 
rs781659 4 57779851 REST A G 0.573 -0.009 -0.021 8.6E-04 6.4E-11 3.6E-02 1.4E-10 
rs141374503 4 73179445 
ADAM
TS3 
T C 0.004 0.075 0.158 2.6E-03 2.6E-12 2.4E-02 2.9E-09 
rs1054627 4 88732692 IBSP A G 0.313 0.010 0.015 1.9E-01 1.0E-11 4.8E-03 2.5E-05 
rs201081507 4 102681041 BANK1 A G 0.943 -0.022 -0.050 6.7E-04 1.4E-11 2.3E-02 4.2E-11 
4:103981698_
GT_G 
4 103981698 SLC9B2 D I 0.404 -0.010 -0.019 2.1E-02 4.7E-13 1.0E-03 4.0E-08 
rs75544266 4 104584997 TACR3 T C 0.056 -0.022 -0.037 4.1E-02 1.5E-12 3.8E-03 3.2E-08 
Supplementary materials 
 307 
rsid chr Position 
Nearest 
gene 







p diff p FFMI p FFM p hght 
rs7688177 4 120760872 
LINC01
365 
T C 0.77 -0.011 -0.023 7.6E-03 1.5E-11 1.4E-02 6.9E-09 
rs7666785 4 144060464 
LOC105
377623 
A G 0.4 0.009 0.015 1.2E-01 9.6E-12 1.1E-02 1.2E-06 
rs11933087 4 145722862 HHIP A T 0.629 0.012 0.014 5.7E-01 1.1E-16 8.1E-05 3.5E-06 
rs35016840 4 151239774 LRBA T C 0.641 -0.010 -0.016 9.0E-02 3.0E-11 7.1E-03 2.1E-06 
rs459193 5 55806751 C5orf67 A G 0.254 -0.013 -0.024 1.1E-02 7.3E-18 1.7E-03 1.5E-11 
rs55963623 5 64555615 
ADAM
TS6 
T C 0.456 0.013 0.020 4.9E-02 1.3E-20 8.7E-05 1.5E-11 
rs62360508 5 65177737 ERBIN T C 0.913 0.015 0.035 2.3E-03 4.9E-10 2.2E-02 3.5E-10 
rs10942491 5 86382726 
MIR428
0 
C G 0.553 -0.010 -0.014 1.9E-01 1.3E-11 5.1E-04 1.5E-05 
rs35843836 5 88798726 
MEF2C-
AS1 
A T 0.633 -0.015 -0.029 7.1E-05 8.2E-24 1.5E-04 8.5E-20 
rs149457 5 107438057 FBXL17 T C 0.17 -0.019 -0.031 1.0E-02 2.3E-24 8.1E-05 8.9E-13 
rs1479585 5 140976528 
DIAPH
1 
C G 0.607 0.011 0.019 1.9E-02 6.7E-15 4.5E-04 4.7E-08 
rs9394951 6 43350753 ZNF318 T C 0.567 -0.009 -0.023 9.8E-05 3.7E-11 1.7E-01 3.1E-12 
rs78856780 6 56939238 ZNF451 A G 0.856 -0.012 -0.028 1.2E-03 1.2E-09 6.6E-02 7.0E-09 
rs4719730 7 929123 GET4 T C 0.175 -0.011 -0.017 2.1E-01 1.9E-09 1.6E-03 1.4E-05 
rs4721089 7 1872921 
MAD1L
1 
T C 0.784 0.011 0.017 1.3E-01 2.3E-10 3.0E-04 1.6E-05 
rs62441156 7 5347446 
TNRC1
8 
A G 0.773 -0.010 -0.025 4.0E-04 3.0E-09 8.6E-02 1.3E-10 
rs12669977 7 13132400 ARL4A T G 0.502 0.008 0.015 4.0E-02 3.1E-09 2.8E-01 1.3E-06 
rs17141862 7 19770756 
TMEM1
96 
T C 0.137 -0.014 -0.031 9.1E-04 6.4E-12 4.0E-02 1.9E-12 
rs28423374 7 20579647 ABCB5 T C 0.736 -0.011 -0.017 1.7E-01 6.8E-13 1.0E-03 7.8E-06 
rs2067087 7 27241660 HOTTIP C G 0.715 0.011 0.022 4.9E-03 1.2E-12 1.3E-02 4.4E-10 
rs7384844 7 28025308 JAZF1 A T 0.556 0.009 0.016 3.5E-02 8.1E-10 9.0E-03 2.2E-05 
rs554794335 7 32931486 KBTBD2 D I 0.689 0.010 0.020 6.9E-03 4.0E-10 7.1E-02 6.4E-08 
rs329270 7 35075619 
DPY19L
1 
A G 0.515 0.010 0.022 6.9E-04 5.0E-13 2.6E-02 2.2E-12 
rs1207728 7 96638021 
DLX6-
AS1 
C G 0.225 0.010 0.020 2.1E-02 2.1E-09 6.8E-02 1.3E-07 




C G 0.114 -0.018 -0.036 1.1E-03 1.1E-15 4.4E-03 3.6E-14 
rs12669944 7 100446365 
SLC12A
9-AS1 
A G 0.35 -0.008 -0.016 2.3E-02 2.9E-07 1.3E-01 1.8E-07 
rs10500039 7 114351267 FOXP2 T C 0.578 -0.011 -0.012 7.9E-01 1.1E-14 8.0E-05 4.6E-05 
rs7010322 8 13196821 DLC1 T C 0.36 -0.009 -0.017 2.4E-02 7.4E-10 2.7E-02 1.0E-06 
rs4082204 8 38328902 FGFR1 A G 0.402 0.010 0.014 2.1E-01 1.0E-11 4.3E-03 5.9E-06 
rs7838717 8 145504343 BOP1 T C 0.365 -0.010 -0.017 6.7E-02 3.6E-11 2.0E-02 1.5E-07 
rs10960276 9 11819686 TYRP1 A C 0.356 -0.009 -0.016 1.0E-01 1.8E-10 1.2E-02 1.9E-06 
rs4741546 9 15846112 
CCDC1
71 
T C 0.396 -0.008 -0.013 1.7E-01 1.0E-08 1.4E-02 3.1E-05 
rs544957562 9 33978015 UBAP2 A T 0.845 0.016 0.022 2.5E-01 1.1E-15 3.5E-04 2.7E-06 
rs7874181 9 85858511 FRMD3 T G 0.847 -0.012 -0.018 2.5E-01 6.4E-10 2.0E-03 7.3E-06 
rs35870355 9 92039730 
SEMA4
D 
A T 0.235 0.010 0.019 3.5E-02 7.3E-10 2.8E-02 1.2E-05 




A G 0.44 -0.010 -0.024 1.2E-04 4.8E-13 2.0E-01 8.4E-13 
rs3838333 9 117787666 TNC I D 0.429 0.009 0.017 1.7E-02 2.7E-10 5.6E-02 3.2E-08 
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rsid chr Position 
Nearest 
gene 







p diff p FFMI p FFM p hght 
rs80031633 9 120687550 TLR4 A T 0.457 -0.009 -0.014 1.5E-01 2.8E-10 3.2E-03 4.9E-05 
rs2267958 9 131015279 DNM1 A G 0.512 -0.009 -0.020 1.6E-03 7.2E-10 4.1E-02 7.3E-10 
rs2435381 10 43678796 
CSGAL
NACT2 
T C 0.277 -0.010 -0.020 1.3E-02 3.5E-10 3.7E-02 4.2E-09 
rs3824780 10 105384826 
SH3PX
D2A 
T C 0.356 0.009 0.023 2.6E-04 1.2E-10 8.0E-02 7.3E-12 
rs117118217 10 131783328 EBF3 C G 0.018 0.033 0.057 8.6E-02 2.9E-09 8.6E-03 4.3E-05 
rs11824377 11 11787253 
MIR807
0 
A G 0.441 0.009 0.013 2.0E-01 4.8E-10 2.8E-04 2.3E-05 
rs900144 11 13294268 ARNTL T C 0.568 0.010 0.014 2.7E-01 2.3E-12 1.0E-04 6.8E-06 
rs72632979 11 16615883 SOX6 A G 0.829 -0.013 -0.021 8.2E-02 1.3E-11 3.1E-02 1.3E-06 
rs610476 11 86184102 ME3 A G 0.41 -0.009 -0.014 1.6E-01 1.9E-09 2.1E-03 2.0E-05 
rs1064939 11 118396331 
LOC101
929089 
A T 0.977 0.034 0.072 2.0E-03 1.6E-12 3.3E-02 2.7E-10 
rs11218510 11 121922587 
MIR100
HG 
A G 0.401 -0.009 -0.016 7.5E-02 2.3E-10 9.4E-03 4.0E-06 
rs10893502 11 126254018 
ST3GA
L4 
T C 0.408 0.008 0.021 4.2E-04 1.0E-08 3.0E-01 3.4E-10 
rs7936928 11 130279168 
ADAM
TS8 
T C 0.397 0.009 0.018 1.1E-02 1.1E-09 4.4E-02 8.7E-09 
rs145878042 12 48143315 
RAPGE
F3 
A G 0.989 -0.055 -0.121 6.3E-05 9.8E-18 1.1E-02 3.0E-16 
12:51589293_
TA_T 
12 51589293 POU6F1 D I 0.784 -0.008 -0.019 1.1E-02 3.2E-06 2.5E-01 2.9E-06 
rs730560 12 57938565 DCTN2 A G 0.582 0.010 0.015 2.4E-01 1.9E-12 3.8E-04 1.5E-05 
rs1154752 12 68089328 
LINC02
421 
T C 0.606 -0.009 -0.015 8.2E-02 2.2E-09 3.7E-02 2.8E-06 






I D 0.356 -0.011 -0.015 3.9E-01 1.2E-13 4.9E-04 3.9E-05 
rs9560114 13 112187882 
LINC02
337 
A T 0.735 0.012 0.021 2.4E-02 2.3E-13 2.8E-04 1.1E-08 
rs10142359 14 73884540 NUMB A G 0.52 -0.009 -0.022 1.3E-04 1.5E-10 2.2E-01 1.7E-12 
15:73049542_
CT_C 
15 73049542 ADPGK I D 0.345 -0.010 -0.015 2.2E-01 7.3E-10 2.5E-03 2.8E-05 
rs35032603 15 74753425 UBL7 T C 0.963 -0.022 -0.053 1.5E-03 1.2E-09 1.6E-01 1.0E-09 
rs2715423 15 99511873 
PGPEP1
L 
A G 0.285 -0.012 -0.021 1.1E-02 6.5E-15 3.4E-02 7.5E-10 
rs3794701 16 3730578 TRAP1 A G 0.48 -0.010 -0.019 1.4E-02 3.3E-13 1.1E-03 1.1E-08 






D I 0.078 0.019 0.036 7.0E-03 2.8E-12 2.1E-02 4.1E-09 
rs5011579 16 69187318 UTP4 C G 0.285 -0.011 -0.022 4.9E-03 7.7E-13 3.6E-02 2.9E-11 
rs2303232 16 84808969 USP10 C G 0.488 0.010 0.020 7.4E-03 3.0E-11 8.0E-03 3.9E-10 
rs57828851 17 7732351 DNAH2 A T 0.581 -0.009 -0.022 5.4E-04 3.6E-11 2.8E-02 1.1E-11 
rs2605136 17 18136750 LLGL1 T C 0.355 0.009 0.020 2.7E-03 7.1E-10 6.8E-02 3.5E-09 
rs113000401 17 27530458 
MYO18
A 
T C 0.049 -0.020 -0.043 5.3E-03 1.1E-09 7.8E-02 1.0E-08 
rs138464472 17 44130160 
KANSL
1 
D I 0.286 0.015 0.030 1.5E-04 2.5E-20 5.4E-04 4.6E-15 
rs376610477 17 46292292 SKAP1 D I 0.649 0.015 0.022 7.1E-02 2.1E-19 2.0E-04 1.0E-08 
rs7218677 17 76146520 C17orf99 A T 0.688 0.009 0.014 2.5E-01 2.7E-09 2.1E-02 3.6E-05 




T G 0.412 0.010 0.017 3.5E-02 1.2E-11 5.9E-03 1.3E-07 
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p diff p FFMI p FFM p hght 
rs4625783 17 80086395 
CCDC5
7 
T C 0.407 0.010 0.024 1.3E-04 4.9E-13 3.0E-01 7.4E-12 
rs5822974 18 7548483 PTPRM D I 0.812 0.011 0.026 1.6E-03 7.3E-10 5.8E-02 1.7E-09 
19:2230029_
CTT_C 
19 2230029 DOT1L I D 0.942 -0.022 -0.032 1.7E-01 9.7E-13 9.1E-04 4.7E-07 
rs75270598 19 19864849 
LINC00
663 
T C 0.154 -0.013 -0.021 1.0E-01 7.6E-12 4.3E-03 1.1E-05 
rs2425847 20 44907927 CDH22 A G 0.591 -0.009 -0.020 1.5E-03 2.5E-10 4.7E-02 8.1E-09 
rs6096548 20 50347558 ATP9A A T 0.257 0.009 0.020 6.8E-03 4.1E-09 2.9E-02 6.1E-07 
rs150998792 20 62130403 
EEF1A
2 
T G 0.05 -0.020 -0.041 1.5E-02 9.8E-10 2.7E-02 2.5E-06 
rs7264802 20 62692440 TCEA2 A G 0.252 -0.012 -0.019 9.6E-02 2.3E-13 3.9E-03 4.3E-07 




Supplementary Table 3.8: Low-frequency and rare coding variants reaching genome-wide significance for BF% 
 
MarkerName Chr Pos EA OA Annotation Gene EAF MAF Beta SE P value N Analysis 
Sex-combined analysis             
rs9429157 1 45,808,863 A G nonsynonymous TOE1 0.041 0.041 -0.02 0.004 4.08E-10 550,180 Exome-Sex-combined 
rs148330006 1 86,048,526 C G nonsynonymous CYR61 0.992 0.008 -0.05 0.008 4.06E-12 511,386 Exome-Sex-combined 
rs56228576 1 150,530,548 C G missense_variant ADAMTSL4 0.969 0.031 0.03 0.004 1.06E-14 442,278 GWAS-Sex-combined 
rs72704117 1 155,175,089 T C nonsynonymous THBS3 0.023 0.023 -0.03 0.005 1.82E-12 550,180 Exome-Sex-combined 
rs41314549 1 155,290,231 T C nonsynonymous FDPS 0.972 0.028 0.03 0.004 5.23E-10 550,180 Exome-Sex-combined 
rs61741479 1 173,915,909 C G nonsynonymous RC3H1 0.031 0.031 -0.03 0.004 9.21E-11 528,666 Exome-Sex-combined 
rs34246968 1 177,929,501 C G missense_variant SEC16B 0.969 0.031 -0.03 0.004 2.02E-09 442,278 GWAS-Sex-combined 
rs1229984 4 100,239,319 T C nonsynonymous ADH1B 0.025 0.025 -0.03 0.005 4.59E-11 472,606 Exome-Sex-combined 
rs61749613 5 82,815,170 A G nonsynonymous VCAN 0.959 0.041 0.03 0.004 5.45E-17 550,180 Exome-Sex-combined 
rs114285050 5 145,895,394 A G stopgain GPR151 0.008 0.008 -0.05 0.008 5.52E-10 550,180 Exome-Sex-combined 
rs11538263 6 31,601,735 A G nonsynonymous PRRC2A 0.044 0.044 -0.02 0.004 1.04E-11 529,263 Exome-Sex-combined 
rs2228265 6 35,253,974 T C nonsynonymous ZNF76 0.021 0.021 0.03 0.005 2.62E-09 544,113 Exome-Sex-combined 
rs33959228 6 35,259,397 T C nonsynonymous ZNF76 0.022 0.022 0.04 0.005 4.52E-14 550,180 Exome-Sex-combined 
rs3087653 9 15,459,821 A C nonsynonymous SNAPC3 0.952 0.048 0.02 0.003 8.00E-14 518,951 Exome-Sex-combined 
rs150090666 11 14,865,399 T C stop_gained PDE3B 0.001 0.001 0.15 0.025 2.56E-09 442,278 GWAS-Sex-combined 
rs3730071 12 49,168,798 A C nonsynonymous ADCY6 0.030 0.030 -0.02 0.004 2.99E-09 548,316 Exome-Sex-combined 
rs11551274 12 49,224,108 C G missense_variant DDX23 0.031 0.031 -0.03 0.004 3.44E-09 442,278 GWAS-Sex-combined 
rs61754230 12 72,179,446 T C nonsynonymous RAB21 0.020 0.020 0.03 0.005 1.93E-10 550,180 Exome-Sex-combined 
rs145350287 12 120,907,309 A T nonsynonymous SRSF9 0.040 0.040 -0.03 0.004 2.16E-17 513,150 Exome-Sex-combined 
rs527456159 12 122,685,176 A G missense_variant LRRC43 0.044 0.044 -0.02 0.004 1.82E-10 442,278 GWAS-Sex-combined 
rs72681869 14 50,655,357 C G nonsynonymous SOS2 0.011 0.011 -0.06 0.007 1.29E-15 523,167 Exome-Sex-combined 
rs72683923 14 50,735,947 T C synonymous_variant L2HGDH 0.980 0.020 0.04 0.005 5.10E-11 442,278 GWAS-Sex-combined 
rs12595158 15 62,316,035 T C missense_variant VPS13C 0.025 0.025 -0.03 0.005 3.81E-09 525,103 GWAS-Sex-combined 
rs117133016 16 2,816,627 C G missense_variant SRRM2 0.010 0.010 0.05 0.007 1.38E-11 442,278 GWAS-Sex-combined 
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rs78457529 16 24,950,880 T C nonsynonymous ARHGAP17 0.012 0.012 0.04 0.006 1.49E-09 550,180 Exome-Sex-combined 
rs2229616 18 58,039,276 T C missense_variant MC4R 0.020 0.020 -0.07 0.005 1.02E-40 522,124 GWAS-Sex-combined 
rs62621197 19 8,670,147 T C missense_variant ADAMTS10 0.037 0.037 -0.02 0.004 1.67E-09 442,278 GWAS-Sex-combined 
rs112693590 19 46,274,553 A G missense_variant DMPK 0.049 0.049 -0.02 0.004 9.23E-13 463,359 GWAS-Sex-combined 
rs6050446 20 25,195,509 A G nonsynonymous ENTPD6 0.033 0.033 -0.03 0.004 3.60E-13 547,742 Exome-Sex-combined 
rs41278126 20 40,079,655 C G nonsynonymous CHD6 0.044 0.044 0.02 0.004 3.64E-09 544,084 Exome-Sex-combined 
Women analysis              
rs74580294 12 122,622,795 A G nonsynonymous MLXIP 0.950 0.050 0.04 0.006 5.42E-11 266,853 Exome-Women 
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Supplementary Table 3.9: Low-frequency and rare coding variants reaching genome-wide 
significance for FFMI 
 
rsid MarkerName EA OA EAF Gene Type Beta SE p-value N 
Sex-combined           
rs61744853 chr1:35453651 a c 0.991 ZMYM6 missense -0.044 0.007 4.1E-10 535,885 
rs75770915 chr1:39799912 t c 0.046 MACF1 missense -0.025 0.003 2.2E-15 535,885 
rs1746842 chr1:39878815 a g 0.955 KIAA0754 missense 0.026 0.003 1.1E-15 514,980 
rs141845046 chr1:154987704 t c 0.023 ZBTB7B missense 0.034 0.005 8.8E-14 535,885 
rs11465205 chr1:155160941 t c 0.031 MUC1 missense 0.026 0.004 4.0E-11 517,010 
rs72704117 chr1:155175089 t c 0.023 THBS3 missense 0.050 0.005 8.9E-29 535,885 
rs41314549 chr1:155290231 t c 0.972 FDPS missense -0.040 0.004 3.8E-23 535,885 
rs76381440 chr1:156146546 t c 0.021 SEMA4A missense 0.040 0.005 1.0E-17 535,885 
rs34246968 chr1:177929501 c g 0.969 SEC16B missense -0.031 0.004 1.4E-14 442,391 
rs2293072 chr2:220045454 a g 0.039 FAM134A missense -0.025 0.004 4.9E-12 442,391 
rs41291734 chr3:50513613 t c 0.035 CACNA2D2 missense 0.024 0.004 2.5E-11 535,885 
rs11722554 chr4:5016883 a g 0.038 CYTL1 missense 0.026 0.004 1.4E-13 522,343 
rs141374503 chr4:73179445 t c 0.004 ADAMTS3 missense 0.075 0.011 2.6E-12 535,885 
rs61749613 chr5:82815170 a g 0.959 VCAN missense -0.038 0.003 8.4E-30 535,885 
rs78727187 chr5:127668685 t g 0.006 FBN2 missense -0.057 0.009 5.8E-11 535,885 
rs41290587 chr5:151045923 t c 0.007 SPARC missense 0.051 0.008 3.0E-10 535,885 
rs78247455 chr5:176722005 a g 0.026 NSD1 missense 0.033 0.004 7.7E-15 535,885 
rs34672415 chr6:34839644 a g 0.016 UHRF1BP1 missense 0.047 0.005 2.4E-18 535,885 
rs7761870 chr6:35423886 t c 0.016 FANCE missense 0.045 0.005 2.8E-17 535,885 
rs2766597 chr6:35765043 a g 0.986 CLPS missense -0.036 0.006 1.6E-09 531,750 
rs41271629 chr6:86257229 t g 0.971 SNX14 missense 0.025 0.004 3.0E-10 512,183 
rs62621812 chr7:127015083 a g 0.022 ZNF800 missense 0.046 0.005 5.5E-22 535,885 
rs34804482 chr11:27389739 t c 0.974 LGR4 missense 0.035 0.004 1.7E-16 535,885 
rs145878042 chr12:48143315 a g 0.989 RAPGEF3 missense -0.055 0.006 9.8E-18 534,021 
rs1126930 chr12:49399132 c g 0.036 PRKAG1 missense 0.031 0.004 4.7E-18 529,789 
rs78607331 chr12:57648644 t c 0.045 R3HDM2 missense 0.020 0.003 7.5E-10 495,549 
rs28929474 chr14:94844947 t c 0.020 SERPINA1 missense -0.042 0.005 3.9E-18 535,885 
rs3784635 chr15:62254989 t c 0.976 VPS13C missense 0.027 0.004 9.0E-10 532,966 
rs12595158 chr15:62316035 t c 0.021 VPS13C missense -0.029 0.005 7.5E-10 535,885 
rs28559926 chr15:89400043 c g 0.039 ACAN missense 0.031 0.004 9.8E-17 442,391 
rs28407189 chr15:89400680 a g 0.971 ACAN missense -0.034 0.004 7.4E-18 535,885 
rs78457529 chr16:24950880 t c 0.012 ARHGAP17 missense -0.046 0.006 3.3E-14 535,885 
rs16957289 chr16:67325711 t c 0.043 KCTD19 missense 0.021 0.003 5.8E-10 514,980 
rs9922085 chr16:67397580 c g 0.044 LRRC36 missense 0.020 0.003 1.1E-09 529,789 
rs8052655 chr16:67409180 a g 0.044 LRRC36 missense 0.020 0.003 1.4E-09 530,616 
rs16957415 chr16:67418957 a g 0.958 LRRC36 missense -0.020 0.003 1.3E-09 535,885 
rs5030980 chr16:67516945 t c 0.042 AGRP missense 0.021 0.003 4.3E-10 535,885 
rs79051270 chr16:69153251 t g 0.040 CHTF8 missense -0.021 0.004 1.7E-09 442,391 
rs149615348 chr16:84900645 a g 0.007 CRISPLD2 missense 0.049 0.008 5.6E-10 535,885 
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rs5036 chr17:42338945 t c 0.978 SLC4A1 missense -0.030 0.005 1.0E-10 522,343 
rs2229616 chr18:58039276 t c 0.020 MC4R missense -0.065 0.005 3.1E-39 442,391 
rs62621197 chr19:8670147 t c 0.037 ADAMTS10 missense 0.041 0.004 5.7E-27 442,391 
rs35384424 chr19:46145661 t c 0.044 C19orf83 missense -0.021 0.004 4.3E-09 442,391 
Men-only           





Supplementary Table 4.1: Loci reaching genome-wide significance in meta-GWAS for unadjusted fat and lean mass compartments 
Locus Chr:pos Sentinel variant EA OA EAF Nearest gene Phenotype Beta±SE p-value hetpval N 
Lead variant for trait (if other than sentinel 
variant) 
1 1:11125729 rs2039841 t c 0.30 EXOSC10 Leg fat 0.0742±0.0131 1.5E-08 5.7E-01 14,736   
2 1:41544279 rs2885697 g t 0.33 SCMH1 Lean arm 0.0534±0.0094 1.3E-08 2.1E-01 25,429   
3 1:103549862 rs4391683 a g 0.59 COL11A1 
Android lean -0.0506±0.0091 2.2E-08 5.6E-01 25,419  
Trunk lean -0.0509±0.009 1.8E-08 9.5E-01 25,425   
4 2:610603 rs2867131 t c 0.17 TMEM18 
Android lean -0.0675±0.0118 1.2E-08 2.1E-03 25,419 rs2683992 
Trunk lean -0.0676±0.0118 1.1E-08 2.0E-03 25,425 rs2683992 
Appendicular lean -0.0746±0.0118 2.7E-10 3.3E-05 25,428  
Leg lean -0.0781±0.0118 3.8E-11 1.0E-05 25,426  
Total lean -0.0745±0.0118 3.0E-10 1.5E-04 25,427  
Gynoid lean -0.0725±0.0127 1.2E-08 5.5E-05 25,418 rs7563362 
5 2:165543199 rs3769869 g a 0.20 COBLL1 Leg fat 0.0606±0.0111 4.8E-08 4.7E-02 25,426   
6 2:227637763 rs4675093 a t 0.93 IRS1 
Android lean 0.0958±0.0175 4.3E-08 4.6E-01 25,419 rs13401886 
Total lean 0.0955±0.0175 4.5E-08 4.2E-01 25,427 rs13401886 
Trunk lean 0.1002±0.0175 9.6E-09 8.8E-01 14,736 rs13401886 
Gynoid lean 0.0961±0.0175 3.9E-08 5.3E-01 25,418   
7 3:12365308 rs13083375 t g 0.12 PPARG Arm fat 0.0864±0.0138 3.6E-10 1.5E-01 25,424   
8 3:65024223 rs371476659 c g 0.98 ADAMTS9-AS2 Visceral fat -0.2729±0.0496 3.8E-08 2.5E-01 14,736   
9 3:129131263 rs4688812 a g 0.99 EFCAB12 Trunk lean 0.355±0.0639 2.8E-08 6.3E-03 14,736   
10 3:172168507 rs519384 t a 0.71 GHSR 
Appendicular lean -0.06±0.0098 9.6E-10 6.0E-01 25,428  
Leg lean -0.0616±0.0098 3.6E-10 6.3E-01 25,426  
Total lean -0.0658±0.0098 2.1E-11 4.5E-01 25,427  
Trunk lean -0.0645±0.0098 5.2E-11 2.6E-01 25,425  
Gynoid lean -0.0592±0.0098 1.8E-09 6.2E-01 25,418 rs12638147 
Android lean -0.0631±0.0098 1.4E-10 2.6E-01 25,419 rs6765792 
11 4:17998426 rs2061456 c a 0.74 LCORL 
Android lean -0.0657±0.0101 8.8E-11 8.2E-01 25,419  
Appendicular lean -0.0583±0.0101 8.1E-09 1.9E-01 25,428  
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Locus Chr:pos Sentinel variant EA OA EAF Nearest gene Phenotype Beta±SE p-value hetpval N 
Lead variant for trait (if other than sentinel 
variant) 
Gynoid lean -0.0625±0.0101 6.8E-10 5.7E-01 25,418  
Leg lean -0.0593±0.0101 4.5E-09 2.7E-01 25,426  
Total lean -0.0702±0.0101 3.9E-12 3.6E-01 25,427  
Trunk lean -0.0762±0.0101 4.8E-14 7.1E-01 25,425   
12 4:56683846 rs7679852 t c 0.66 LOC644145 
Appendicular lean 0.0514±0.0093 3.6E-08 2.1E-02 25,428  
Lean arm 0.048±0.0093 2.8E-07 8.0E-03 25,429 rs11722734 
13 4:89737457 rs7694958 t c 0.47 FAM13A Leg fat -0.0499±0.0089 2.0E-08 5.1E-01 25,426   
14 4:146164089 rs12504656 t g 0.33 OTUD4 Gynoid lean 0.0542±0.0096 1.5E-08 7.6E-01 25,418   
15 6:26233387 rs10946808 a g 0.72 HIST1H1D 
Total lean 0.0561±0.0098 1.1E-08 8.9E-01 25,427  
Trunk lean 0.0563±0.0098 9.5E-09 6.9E-01 25,425   
16 6:27884127 rs148298110 a t 0.93 OR2B2 
Leg fat 0.1029±0.0175 4.3E-09 9.2E-01 25,426  
Peripheral fat 0.1001±0.0175 1.1E-08 9.2E-01 25,424   
17 6:31270735 rs6908171 c a 0.41 HLA-C 
Gynoid lean 0.0716±0.0119 1.7E-09 6.2E-01 14,736  
Leg lean 0.0656±0.0119 3.1E-08 6.4E-01 14,736   
18 6:34161299 rs56348792 t c 0.13 GRM4 
Android lean 0.0763±0.0132 7.5E-09 4.2E-01 25,419  
Appendicular lean 0.0774±0.0132 4.4E-09 8.2E-01 25,428  
Leg lean 0.0762±0.0132 7.5E-09 7.1E-01 25,426  
Total lean 0.0829±0.0132 3.2E-10 8.3E-01 25,427  
Trunk lean 0.0787±0.0132 2.5E-09 6.9E-01 25,425 rs10807137 
19 6:43757896 rs998584 c a 0.52 VEGFA Leg fat 0.0494±0.009 3.4E-08 4.1E-02 25,426   
20 6:108945370 rs2022464 c a 0.71 FOXO3 
Gynoid lean 0.0537±0.0097 3.6E-08 7.8E-01 25,418 rs2764264 
Android lean 0.0608±0.0097 4.4E-10 1.3E-01 25,419  
Leg lean 0.0537±0.0097 3.3E-08 6.6E-01 25,426  
Total lean 0.0577±0.0097 3.0E-09 4.6E-01 25,427  
Trunk lean 0.0547±0.0097 2.0E-08 2.1E-01 25,425   
21 6:127036174 rs853965 t c 0.50 MIR588 
Appendicular lean -0.0511±0.0089 8.1E-09 2.1E-01 25,428 rs6569469 
Gynoid lean -0.0554±0.0089 4.4E-10 2.7E-01 25,418  
Leg lean -0.0514±0.0089 6.8E-09 2.1E-01 25,426  
Total lean -0.0593±0.0089 2.1E-11 1.0E-01 25,427  
Trunk lean -0.0619±0.0089 2.9E-12 8.4E-02 25,425  
Android lean 0.0603±0.0089 1.1E-11 2.8E-01 25,419 rs853971 
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Locus Chr:pos Sentinel variant EA OA EAF Nearest gene Phenotype Beta±SE p-value hetpval N 
Lead variant for trait (if other than sentinel 
variant) 
6:127454893 rs72959041 g a 0.95 RSPO3 
Gynoid fat 0.1191±0.0205 6.6E-09 9.1E-02 25,417 rs577721086 
Leg fat 0.139±0.0205 1.2E-11 2.3E-01 25,426  
Peripheral fat 0.1242±0.0205 1.4E-09 1.5E-01 25,424   
22 6:130374461 rs7740107 t a 0.26 L3MBTL3 
Gynoid lean 0.0582±0.0101 7.4E-09 4.4E-01 25,418 rs6926186 
Total lean 0.0687±0.0101 8.4E-12 4.8E-01 25,427 rs6926186 
Lean arm 0.0722±0.0101 7.2E-13 5.1E-01 25,429 rs7744830 
Android lean 0.0601±0.0101 2.4E-09 6.4E-01 25,419  
Trunk lean 0.0611±0.0101 1.3E-09 6.9E-01 25,425  
Appendicular lean 0.0675±0.0101 1.8E-11 3.8E-01 25,428 rs12661188 
Leg lean 0.0624±0.0101 5.4E-10 3.6E-01 25,426 rs9402214 
23 7:92236829 rs4272 g a 0.21 CDK6 
Leg lean 0.0626±0.0109 1.0E-08 6.3E-01 25,426 rs2190507 
Android lean 0.0695±0.011 2.2E-10 4.7E-02 25,419  
Total lean 0.0652±0.0109 2.5E-09 4.0E-01 25,427  
Trunk lean 0.0696±0.0109 2.0E-10 1.3E-01 25,425  
Appendicular lean 0.0613±0.0109 2.0E-08 6.4E-01 25,428 rs42038 
Gynoid lean 0.071±0.011 9.2E-11 6.0E-01 25,418 rs42038 
24 7:150681914 rs6951150 c t 0.63 NOS3 
Total lean 0.0544±0.0091 2.7E-09 3.1E-01 25,427 rs6951150 
Appendicular lean 0.0583±0.0091 1.7E-10 4.8E-01 25,428  
Leg lean 0.0606±0.0091 3.4E-11 4.7E-01 25,426   
25 8:57259146 rs78329725 a g 0.74 SDR16C5 Trunk lean -0.058±0.0102 1.1E-08 3.3E-01 25,425   
26 8:78086732 rs1377246 g c 0.62 PEX2 
Appendicular lean 0.0543±0.0091 2.9E-09 3.1E-01 25,428 rs1466190 
Leg lean 0.0549±0.0091 1.8E-09 3.0E-01 25,426  
Total lean 0.0544±0.0091 2.6E-09 3.8E-01 25,427   
27 9:103385293 rs200914342 a g 0.18 CAVIN4 Trunk lean -0.1062±0.0188 1.7E-08 1.9E-01 14,736   
28 10:118613931 rs9421247 t c 0.26 ENO4 
Gynoid fat 0.0555±0.0101 4.5E-08 2.9E-01 25,417  
Leg fat 0.0581±0.0101 9.7E-09 1.3E-01 25,426  
Peripheral fat 0.0582±0.0101 9.3E-09 2.2E-01 25,424   
29 11:27703188 rs6484320 a t 0.79 BDNF-AS 
Appendicular lean 0.0608±0.0108 2.0E-08 7.9E-01 25,428  
Leg lean 0.0608±0.0108 2.1E-08 6.7E-01 25,426  
Total lean 0.0624±0.0108 8.5E-09 6.6E-01 25,427  
Gynoid lean 0.0565±0.0109 1.9E-07 3.4E-01 25,418 rs12273363 
30 12:4384844 rs76895963 g t 0.02 CCND2-AS1 Android lean 0.2324±0.0348 2.3E-11 5.1E-01 25,419  
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Locus Chr:pos Sentinel variant EA OA EAF Nearest gene Phenotype Beta±SE p-value hetpval N 
Lead variant for trait (if other than sentinel 
variant) 
Appendicular lean 0.2396±0.0347 5.1E-12 1.6E-01 25,428  
Lean arm 0.199±0.0347 1.0E-08 2.2E-01 25,429  
Gynoid lean 0.2607±0.0348 6.3E-14 2.2E-01 25,418  
Leg lean 0.2412±0.0347 3.7E-12 1.9E-01 25,426  
Total lean 0.2521±0.0347 3.6E-13 1.4E-01 25,427  
Trunk lean 0.2347±0.0347 1.4E-11 1.6E-01 25,425   
31 12:46707618 rs1586905 a t 0.61 SLC38A2 
Trunk lean 0.0665±0.012 3.3E-08 1.5E-01 14,736  
Gynoid lean 0.0677±0.0121 2.3E-08 5.9E-01 14,736   
32 12:50261809 rs3205718 t c 0.38 FAIM2 Leg lean 0.0553±0.0093 2.3E-09 1.4E-01 25,426   
33 12:104001177 rs11111676 a t 0.86 STAB2 
Lean arm 0.1177±0.0214 3.7E-08 1.1E-01 14,736  
Total lean 0.1192±0.0214 2.4E-08 2.3E-02 14,736   
34 12:124409502 rs7133378 a g 0.33 DNAH10 Leg fat 0.0607±0.0095 1.4E-10 6.3E-02 25,426   
35 13:51088356 rs1638703 g c 0.74 DLEU1 
Appendicular lean 0.0674±0.0102 3.4E-11 8.5E-01 25,428  
Leg lean 0.07±0.0102 5.5E-12 8.3E-01 25,426  
Total lean 0.0597±0.0102 4.2E-09 8.9E-01 25,427   
36 16:29923510 rs4548895 a g 0.61 KCTD13 
Appendicular lean 0.0531±0.0092 8.1E-09 6.9E-01 25,428  
Lean arm 0.051±0.0092 3.1E-08 2.0E-01 25,429  
Leg lean 0.0513±0.0092 2.5E-08 8.0E-01 25,426 rs9921544 
37 16:53845487 rs11642841 a c 0.40 FTO 
Subcutaneous android fat 0.0619±0.009 7.1E-12 2.5E-01 25,351 rs56094641 
Visceral fat 0.0599±0.009 3.4E-11 6.5E-02 25,347 rs56094641 
Arm fat 0.0676±0.009 6.1E-14 5.8E-01 25,424 rs55872725 
Total fat 0.0681±0.009 4.1E-14 4.8E-01 25,429 rs55872725 
Leg lean 0.0582±0.009 1.0E-10 4.6E-01 25,426 rs55872725 
Fat and 0.0669±0.009 1.2E-13 2.0E-01 25,423 rs62033400 
Peripheral fat 0.0586±0.009 8.1E-11 7.1E-01 25,424 rs62033400 
Trunk fat 0.069±0.009 1.9E-14 2.4E-01 25,430 rs62033400 
Gynoid fat 0.0615±0.009 9.8E-12 6.3E-01 25,417  
Leg fat 0.0535±0.009 3.0E-09 6.6E-01 25,426  
Appendicular lean 0.0573±0.009 1.9E-10 4.0E-01 25,428  
Total lean 0.0541±0.009 1.8E-09 2.9E-01 25,427   
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Locus Chr:pos Sentinel variant EA OA EAF Nearest gene Phenotype Beta±SE p-value hetpval N 
Lead variant for trait (if other than sentinel 
variant) 
38 17:29211667 rs7223535 g a 0.73 ATAD5 
Appendicular lean 0.081±0.0099 3.6E-16 1.8E-01 25,428  
Lean arm 0.0674±0.0099 1.2E-11 1.2E-01 25,429  
Gynoid lean 0.0612±0.01 7.9E-10 1.7E-01 25,418  
Leg lean 0.0814±0.0099 2.5E-16 1.7E-01 25,426  
Total lean 0.076±0.0099 2.0E-14 2.1E-01 25,427  
Android lean 0.0585±0.01 5.0E-09 7.7E-01 25,419 rs113934718 
Trunk lean 0.0636±0.01 2.0E-10 4.8E-01 25,425 rs113934718 
39 17:48628160 rs62621401 a g 0.98 SPATA20 Arm fat 0.2224±0.0364 1.0E-09 5.4E-01 25,424   
40 17:61998879 rs2040347 a g 0.33 GH1 
Appendicular lean -0.0522±0.0094 2.9E-08 4.3E-01 25,428 rs2854152 
Leg lean -0.0528±0.0094 2.0E-08 4.7E-01 25,426 rs2854152 
Android lean -0.0538±0.0094 1.2E-08 5.5E-01 25,419  
Total lean -0.0597±0.0094 2.2E-10 5.6E-01 25,427  
Trunk lean -0.0615±0.0094 6.4E-11 6.9E-01 25,425  
Gynoid lean -0.0599±0.0094 2.1E-10 6.7E-01 25,418 rs1051684 
41 18:57913965 rs35693910 a g 0.27 MC4R 
Leg lean 0.072±0.0101 1.1E-12 5.4E-01 25,426 rs538656 
Android lean 0.0648±0.0101 1.6E-10 5.2E-01 25,419  
Appendicular lean 0.0747±0.0101 1.5E-13 4.9E-01 25,428  
Lean arm 0.0694±0.0101 7.2E-12 5.6E-01 25,429  
Gynoid lean 0.0678±0.0101 2.1E-11 4.4E-01 25,418  
Total lean 0.0763±0.0101 4.4E-14 4.3E-01 25,427  
Trunk lean 0.0729±0.0101 5.7E-13 2.7E-01 25,425   
42 19:437256 rs4605291 t c 0.99 SHC2 Trunk lean 0.2309±0.0406 1.3E-08 3.7E-07 25,425   
43 19:49650319 rs6509418 g a 0.60 PPFIA3 
Lean arm 0.0512±0.0091 2.1E-08 4.8E-01 25,429  
Total lean 0.0498±0.0091 4.8E-08 4.3E-01 25,427   
44 20:32263624 rs3213180 g c 0.90 E2F1 Trunk lean 0.0873±0.0149 5.0E-09 5.6E-01 25,425   
45 20:34025756 rs143384 a g 0.59 GDF5 
Android lean -0.0531±0.009 4.2E-09 6.1E-01 25,419  
Appendicular lean -0.0664±0.009 1.7E-13 4.6E-01 25,428  
Gynoid lean -0.0738±0.009 2.8E-16 3.6E-01 25,418  
Leg lean -0.0704±0.009 5.5E-15 3.3E-01 25,426  
Total lean -0.0607±0.009 1.7E-11 5.8E-01 25,427  






Analysis plan 1: Exome chip analyses for BF% and FFMI 
 
This protocol was modified from the GIANTexome Analysis Plan – 22/April/2014 – prepared 
by Ruth Loos and her colleagues for the GIANT Consortium ExomeChip effort. 
 
1. Introduction 
AIM: This analysis plan aims to coordinate collection of summary statistics data of ExomeChip 
analyses for body fat percentage and related traits: 
• Fat percentage (FatPCT) in % 
• Fat free mass-index (FFMi) in kg per m2 
• Circulating leptin levels in ng/ml 
• Plasma adiponectin levels in µg/ml 
Note: Fat percentage can be measured via dual-energy x-ray absorptiometry (DEXA) and with a 
portable bioimpedance monitor only. If you are using DEXA, we would like you to use the “Lean 
mass” variable (rather than the “fat free mass” variable, as this includes bone mineral content). 
Many of you have run single variant analyses before. For this effort, we will use either 
RAREMETALWORKER or RvTests because: 
1. We can perform multi-variant tests such as gene burden tests centrally using summary stats 
you will generate in your individual studies. 
2. We can perform conditional analyses centrally because the software generates LD matrices 
for all variants within 1Mb windows. 
3. We can correct for population stratification and cryptic relatedness in the best possible 
way. 
All of this can be done with just a few commands in RAREMETALWORKER or RvTests and 
this analysis plan describes how to do it. The only part that requires special attention is the 
generation of a *.vcf file containing your genotypes and the steps required to ensure all alleles are 
on the correct strand AND that you have labelled the correct alleles as reference and non-
reference. These steps are described below. 
 
 
Please contact us if you have any question: 
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Ruth Loos (ruth.loos@mssm.edu), Claudia Schurmann (claudia.schurmann@mssm.edu) 
 
2. General methodology 
Each individual study will perform data quality control (QC) and analysis and provide summary 
results for meta-analysis. Results files will be deposited to a central repository, where QC/data 
cleaning and meta-analysis will be performed within each trait working group. 
OUTCOMES 
- Fat percentage (FatPCT) in % 
- Fat free mass-index (FFMi) in kg per m2 
- Circulating leptin levels in ng/ml 
- Circulating leptin levels in ng/ml adjusted for body mass index (BMI) 
- Circulating leptin levels in ng/ml adjusted for FatPCT 
- Plasma adiponectin levels in µg/ml 
- Plasma adiponectin levels in µg/ml adjusted for body mass index (BMI) 
- Plasma adiponectin levels in µg/ml adjusted for FatPCT 
EXCLUSIONS 
- Individuals < 18 years 
- Pregnant women 
STRATIFYING ANALYSES BY 
- Race/ethnicity 
- Disease status; i.e. analyze cases and controls separately, if the disease status influences the 
outcome. 
ANALYSES TO PERFORM 
- ALL individuals 
- MEN only 
- WOMEN only 
NOTES 
- With longitudinal data, please use an examination that maximizes sample size, restricting 
to adult subjects (≥ 18 years of age). All subjects included in analysis should utilize data 
obtained from the same examination. 
- For studies with “unrelated” individuals (i.e. not family-based), we are specifically asking 
you to NOT exclude people who you find might be closely/cryptically related. Instead 
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family/cryptic relatedness will be handled by the genomic relationship matrix created and 
used in the RAREMETALWORKER and RvTests part of the protocol (described below). 
IMPORTANT: 
Throughout the text we refer to principal components (PCs), which are used to control for 
population stratification and other confounders. Here, we don’t distinguish between PCs 
generated using software like smartPCA/EIGENSOFT or components calculated using 
multidimensional scaling (MDS) as implemented in PLINK. For your analyses, you should include 
either PCs or MDS components as covariates in the models. Principal components in studies with 
related individuals to be calculated in founders. 
 
3. Preparing data for analysis – Files and software to download 
A. FILES TO DOWNLOAD 





For studies from the CHARGE Consortium only (and only if variants have not yet been 
flipped to the “+” strand): 
/data/RELEVANT_FILES/FORWARD_TO_POSTIVE_FLIPPING_LIST_CHARGE/SNP_list_to_be_flipped_KL_TW.txt 
 





B. SOFTWARE TO BE DOWNLOADED 
B.1. SOFTWARE TO PREPARE GENOTYPE FILES 
B.1.1. Download PLINK 
Download PLINK from 
http://pngu.mgh.harvard.edu/~purcell/plink/download.shtml#download 
 
B.1.2. Download PLINK/SEQ 
Download PLINK/SEQ from https://atgu.mgh.harvard.edu/plinkseq/download.shtml 
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Download the LOCDB, REFDB and SEQDB files for the hg19 reference genome 
(http://atgu.mgh.harvard.edu/plinkseq/resources.shtml) and save them in a resources directory: 
/path/to/hg19. 
The guidelines about how to use PLINK/SEQ can be found at 
https://atgu.mgh.harvard.edu/plinkseq/. 
B.1.3. Download tabix 
You can download tabix at http://sourceforge.net/projects/samtools/files/. 
 
B.1.4. Download checkVCF 
Download the necessary resource files (checkVCF-20140116.tar.gz) and scripts at 
https://github.com/zhanxw/checkVCF. 
 
B.1.5. Download Python 
Download Python from https://www.python.org/downloads/ 
 
B.2. ANALYSIS SOFTWARE 
Analysts are free to choose which software (RvTests or RAREMETALWORKER) they use. The 
most notable differences to users are the interface, in particular the way covariates are organized. 
RvTests organizes covariates in a similar way to PLINK, where covariates are provided in a 
separate file. RAREMETALWORKER was derived from Merlin, so it supports inputs more 
similar to Merlin, in that covariates are stored in PED file, and you also need a DAT file to describe 
the covariates. Both tools have a very simple interface to use, and the input for one tool can be 
easily converted to the other. 
 
THE SOFTWARE VERSIONS LISTED BELOW ARE THE LATEST RELEASES AS OF 
TODAY. HOWEVER, IF AT THE TIME OF ANALYSES A MORE RECENT VERSION IS 
AVAILABLE, PLEASE USE THAT ONE. 
 
B.2.1. Download RvTests 
The source codes (version 20141006) files can be found at 
https://github.com/zhanxw/rvtests/releases/. For binary executable files, download from 
https://github.com/zhanxw/rvtests/releases/download/v1.8.4/rvtests-20141006.tar.gz and 
then unpack the downloaded file: 
tar xvzf rvtests-20140416.tar.gz 
rvtests and vcf2kinship can be found under rvtests/executable/. 
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For source code, unpack the download zipped source codes or go to your cloned github repository, 




B.2.2. Download RAREMETALWORKER 
To download the package with source code (version 4.13.5), please go to the following: 
http://genome.sph.umich.edu/wiki/RAREMETAL_DOWNLOAD_%26_BUILD#Where_to
_Download 
Then use the following command to decompress: 
tar xvzf raremetal.4.13.5.tgz 
Finally, go to 
./raremetal_4.13.5/raremetal/raremetalworker/src/ 
and use the following command to compile: 
make all 
 
4. Preparing data for analysis -- Genotypes 
Please determine if data from your study has been called by the CHARGE Exome Chip centralized 
effort led by Megan Grove at the University of Texas Health Science Center at Houston, Texas 
for the HumanExome V1.0 BeadChips, for which the best practices and joint calling procedures 
will apply (Grove et al. PloSOne 8(7) :e68095). 
For all other studies we will assume that your genotype data has been called with the Illumina 
GenomeStudio GENCALL and subsequently recalled using zCALL, applying the additional 
sample QC and variant QC as described in “Exome-chip QC SOP.v5.pdf”. 
Both Grove et al. PLoS ONE 2013.pdf and Exome-chip QC SOP.v5.pdf can be found on the 
SFTP site: /data/RELEVANT_FILES/QC/. 
 
Please, report your calling and QC procedures together with ExomeChip version in the tracking 
form ExomeFatPercentage_STUDY_PHENO_DATE.xls 
 
NOTE: You may have prepared your genotype files before for other analyses or for other 
consortia, but PLEASE DOUBLE-CHECK, whether the procedures followed before are 
consistent with the ones described below.  
 
A. QUALITY CONTROL 
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I. VARIANT EXCLUSIONS 
Variant exclusions have been applied by the central calling effort (Grove et al. PloSOne 
8(7): e68095) and/or are described by “Exome-chip QC SOP.v5.pdf” procedures. 
Please, remove all poorly genotyped and called variants that did not pass QC criteria, but 
DO NOT remove the monomorphic variants at this stage. [Monomorphic variants will be 
removed from the actual analyses at a later stage]. 
In addition, please exclude variants with: 
• Allele frequency strongly associated with plate assignment 
• Call discordance of overlapping SNPs with previous data, such as GWAS or 
custom chips 
 
II. ONLY FOR STUDIES THAT USED THE EXOME-CHIP QC SOP.V5 
PROTOCOL - UPDATE POSITIONS TO MATCH ILLUMINA MANIFEST 
 
As part of the Exome-chip QC SOP.v5.pdf, many studies updated the chr and positions 
of some SNPs with uncertain mappings (N=91). To align the positions across all studies, 
we suggest that the Illumina manifest positions are used. The two commands below will 
update these SNPs. 
 
plink --noweb --bfile QCD_UK_PLINK_FILE --update-map UK_chr_updates.txt --
update-chr \ 
--make-bed –out QCD_UK_PLINK_FILE_chr_updates 
plink --noweb --bfile QCD_UK_PLINK_FILE_chr_updates --update-map 
UK_pos_updates.txt \ 
--make-bed --out QCD_PLINK_FILE 
 
III. SAMPLE EXCLUSIONS 
Best practices for sample exclusions are described in Grove et al. PloSOne 8(7): e68095) 
and “Exome-chip QC SOP.v5.pdf”, for which exclusions include: 
• Sample call rate < 98% (after joint or zCAll calling) 
• Outlying heterozygosity rate based on global heterozygosity for >1% SNPs and 
<1% SNPs 
• Deviation from HWE P<e-06 
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• Gender mismatch 
• Discordance with existing genotype information (e.g. GWAS, custom arrays, 
fingerprint) 
• Population IBS/MDS/PCA clustering outliers (described below) 
NOTE: for studies with “unrelated” individuals (i.e. not family-based), we are specifically 
asking you to NOT exclude people who you find might be closely/cryptically related. 
Instead family/cryptic relatedness will be handled by the genomic relationship matrix 
created and used in the RAREMETALWORKER and RvTests as part of the protocol 
(described below).  
 
B. LIMIT THE STUDY TO THE AUTOSOMAL AND X CHROMOSOMES 
Only autosomal and X chromosomes are included in the analyses; variants on Y, XY and MT are 
not included. Therefore, remove variants on chromosomes 24, 25 & 26. If you genotyped the 
Illumina ExomeChip v1.0 you can use the CHR24-26.txt file, located on the SFTP site: 
/data/RELEVANT_FILES/CHR24_26/. Otherwise, create your own CHR24-26.txt file that 
contains all variants on chromosome 24, 25 & 26 (one variant per line). Please, contact us if 
creating such files is difficult. 
 
Use the following command: 
plink --noweb --bfile QCD_PLINK_FILE --exclude CHR24-26.txt \ 
--make-bed --out QCD_PLINK_FILE_CHR1_23 
where 
QCD_PLINK_FILE: the plink binary file 
CHR24-26.txt: a list of variants on Y (24), XY (25) and MT (26) chromosomes to be removed 
from the plink binary file 
QCD_PLINK_FILE_CHR1_23: the binary output file that contains variants on autosomal and 
X chromosomes 
 
C. ALLELE ALIGNMENT 
Please note that this is the only slightly fiddly section of the document – we apologize, but it is 
important that we get all alleles aligned to the correct strand, and that for each variant the correct 
allele is labelled as “reference” – two slightly different things! Again, all of this will be relevant to 
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other consortia as well, so once you have done it, running again for other phenotypes will be very 
straightforward. Prepare genotype files separately by ancestry/ethnicity. 
 
 
I. ONLY FOR STUDIES THAT HAVE NOT BEEN CALLED AS PART OF THE 
CHARGE CONSORTIUM - FLIP 23 SNPS TO “+” STRAND 
Studies that followed the Exome-chip QC SOP.v5.pdf protocol and have not been called 
as part of the CHARGE consortium have to flip 23 SNPs to the + strand. 
plink --noweb --bfile QCD_PLINK_FILE_CHR1_23 \ 
--flip SNP_list_to_be_flipped_Exome-chip_QC_SOP_studies_only_23SNPs.txt \ 
--make-bed --out QCD_PLINK_FILE_CHR1_23_STRANDALIGNED 
where 
QCD_PLINK_FILE_CHR1_23: the plink binary file 
SNP_list_to_be_flipped_Exome-chip_QC_SOP_studies_only_23SNPs.txt: a simple text 
file of the 23 SNPIDs which are to be strand-flipped -one SNP per line. 
QCD_ PLINK_FILE_CHR1_23_STRANDALIGNED: the binary output file aligned to 
the + strand. This file can then go into the forcealleles command below. 
 
II. STUDIES FROM THE CHARGE CONSORTIUM ONLY– FLIP ALLELES TO 
“+” STRAND 
For studies that were genotyped and QC’d as part of the CHARGE consortium, we would 
require that they flip SNPs to be aligned to the + strand. This can be done using the 
command below for plink. 
NOTE: Before using the command below, make sure you have not already flipped these 
(for a previous analysis). 
plink --noweb --bfile QCD_PLINK_FILE_CHR1_23 \ 
--flip SNP_list_to_be_flipped_KL_TW.txt --make-bed \ 
--out QCD_PLINK_FILE_CHR1_23_STRANDALIGNED 
where 
QCD_PLINK_FILE_CHR1_23: the plink binary file 
SNP_LIST_TO_BE_FLIPPED_KL_TW.txt: a simple text file of SNPIDs which are to 
be strand-flipped - one SNP per line. 
QCD_ PLINK_FILE_CHR1_23_STRANDALIGNED: the binary output file aligned to 








If you chose to include INDELs, please make sure to recode them using I/D only. 
 
IV. CREATE UNIFORM LIST OF REFERENCE ALLELES USING A 
FORCEALLELES COMMAND IN PLINK 
ALL STUDIES (CHARGE studies included), please, run this as default, even if you think 
your reference alleles are all coded correctly. In this step, we are making sure that for each 
variant the correct allele is labeled as “reference” allele. 
Please, force the alleles indicated as the desired reference allele prior to generating another 
VCF file using the following plink command where the FORCEALLELES_V1.0 file 
(located on the SFTP site: /RELEVANT_FILES/FORCE_ALLELES/) consists of two 
columns listing “exomechip SNP ID” and “desired reference allele”. 
NOTE: The FORCEALLELES_V1.0 file only contains the variants that were genotyped 
on the “Illumina ExomeChip 1.0”. If you have genotyped another version of the 
ExomeChip, you will have to create a bespoke FORCEALLELES files. 
 
gunzip FORCEALLELES_V1.0.gz 
plink --noweb --bfile QCD_PLINK_FILE_CHR1_23_STRANDALIGNED \ 
--reference-allele FORCEALLELES_V1.0 --make-bed \ 
--out QCD_PLINK_FILE_FINAL 
where 
QCD_PLINK_FILE_CHR1_23_STRANDALIGNED is the plink binary file which 
contains SNPs on autosomal and X chromosomes and is aligned to the + strand. 
FORCEALLELES_V1.0 is a simple text file of “exomechip SNP ID” and “desired 
reference allele” that are to be forced - one SNP per line 
QCD_PLINK_FILE_FINAL is the binary output file that contains SNPs on autosomal 
and X chromosomes, is aligned to the + strand and is coded for “desired reference allele”. 
This file can now be converted to VCF using PLINK/SEQ. See commands below. 
 
D. CREATE YOUR VCF FILE 
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In this step, you need to make a VCF file using PLINK/SEQ. Make VCF files separately by 
ancestry/ethnicity. 
I. CREATE A NEW PROJECT IN PLINK/SEQ 
pseq MY_project new-project --resources /path/to/hg19 \ 
--scratch /path/to/temporary/files 
 
II. LOAD EXISTING PLINK FILES 
pseq MY_project 
load-plink --file QCD_PLINK_FILE_FINAL \ 
--id iid --check-reference 
 
III. CREATE YOUR VCF FILE: 
pseq MY_project 
write-vcf > QCD_FILE_FINAL.vcf 
 
NOTE: if you want to re-create a project (re-start from i to iii) with the same name as an old 
project, you have to delete all the output files produced during the creating of the old project. 
 
E. CHECK ORIENTATION OF ALLELES USING CHECKVCF 
To check if the above process has worked, i.e. to check if there are any allele or strand flips or 
differences relative to the reference we need to run the following commands. 
 
I. REMOVE "CHR" PREFIX FROM THE CHROMOSOME MARKERS AND 
RENAME CHROMOSOME 23 AS “X” IN THE VCF FILE 
This step removes “chr” and renames chromosome 23 as X, and it is needed before 
VCFcheq 
sed 's/^chr//g' QCD_FILE_FINAL.vcf | sed 's/^23/X/g' > QCD_FILE_FINAL_nochr.vcf 
 
II. CHECK THE VCF FILE FOR ALLELE ALIGNMENT. 
The checkVCF package includes 3 files: checkVCF.py script, reference genome (hs37d5.fa) 
in FASTA format and its index file (hs37d5.fa.fai). Please install python and run the 
following vcf checking scripts on your final, cleaned VCF file. The following command 
will generate a list of monomorphic sites, sites with reference alleles inconsistent with the 
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reference genome, sites with invalid genotypes, non-SNP site (e.g. INDELs), and 900 
suspicious sites with allele frequencies >1: 
python checkVCF.py -r hs37d5.fa -o STUDY QCD_FILE_FINAL_nochr.vcf 
The STUDY.check.ref file will list sites with non-matching reference alleles under the 
designation example “MismatchRefBase 1:564766:T-C/T”, where the base directly 
following the position is the desired reference allele. If there are allele issues, please resolve 
based on QCD_PLINK_FILE_FINAL.bim file (please see section C-E), run 
checkVCF.py again, before moving to the next steps. 
Please contact the central team for further help if the “check.ref” file contains variants and 
you are not sure how to resolve this issue.  
 
F. CREATE FILE WITH ALLELE FREQUENCIES OF ALL CLEAN VARIANTS 
Generate a file that lists allele frequencies of ALL variants (including monomorphic SNPs) that 
passed the variant and sample QC procedures (above). This file will be used to calculate allele 
frequencies across all studies, and should not depend on phenotypes. Hence, only one file per 
study is required; i.e. not need to provide this by phenotype. However, as for the analyses, please 
stratify by ancestry 
Use command: 
pseq MY_project v-freq > STUDY_AFREQ_ANCESTRY.txt 
Where: 
STUDY_AFREQ_ANCESTRY.txt is the output file labeled as follows: 
For STUDY use: the same acronym you usually use 
For ANCESTRY use: EU: European ancestry; AA: African Ancestry; HL: Hispanic Latino; SA: 
South Asian; EA: East Asian 
e.g. MSSM_AFREQ_HL.txt 
 
NOTE ON DUPLICATED MARKERS: There will be ~800 duplicate markers; most of these 
are bi-allelic, a few are tri-allelic variants. 
For bi-allelic variants, PLINK/SEQ will integrate the genotype information from both duplicate 
markers into one unique marker, using information from both the original duplicate markers. If 
genotypes are inconsistent between the original duplicate markers, it will assign a missing value. 
For the tri-allelic variants, the allele information (three alleles in one position) of both duplicate 
makers will be retained during the file conversion. Unfortunately, these markers cannot (yet) be 





G. MULTIDIMENSIONAL SCALING (MDS) / PRINCIPAL COMPONENTS (PCS) 
FOR STRATIFICATION 
For studies with “unrelated samples” (i.e. not family-based studies), perform multidimensional 
scaling (MDS) on the basis of the IBS calculated from the LD pruned (r2 < 0.2) MAF 1% markers 
(use GWAS genotype data, if available). Record the projection of each sample onto the first ten 
principal components (PCs) for use in downstream analyses to adjust for population structure. 
Final decisions on whether to exclude samples are likely to be cohort specific, but clear ethnic 
outliers should be excluded from European-based studies at a minimum. While other methods are 
available (i.e. STRUCTURE), within PLINK this can be achieved using the command: 
--cluster --mds-plot 10 
 
H. PRINCIPAL COMPONENT ANALYSES AND PLOT 
Calculate PC1 and PC2 using common variants (MAF > 1%) and submit a scatterplot of PC1 vs 
PC2 anchored by 1000G CEU, YRI and CHB/JPT data on all samples included in analyses to 
allow comparisons of ethnic homogeneity between studies. You can use the PLINK binary files 
(AIMs.1000G.v2) to anchor your data using the script “Files_for_scatter_plots.rar”. The files and 
relevant scripts are shared at the SFTP site: 
/data/RELEVANT_FILES/FILES_FOR_PC1_PC2_SCATTERPLOTS. 
Provide this plot as PDF file and label them as SCATTER_STUDY_ANCESTRY.pdf; e.g. 
SCATTER_MSSM_HL.pdf 
For ancestry use:  
EU: European ancestry; 
AA: African Ancestry; 
HL: Hispanic Latino; 
SAS: South Asian; 
EAS: East Asian 
 
 
5. Analysis with RVTest or RAREMETALWORKER 
Rare variant analyses can be carried out either using RvTests or RAREMETALWORKER (both 
described below). Both can be used for unrelated and related individuals. We ask all studies to use 
an empirical kinship matrix (aka genomic relationship matrix) for analysis. If you do not already 
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have a kinship matrix for your study, it can be generated automatically with a specific command 
in RAREMETALWORKER or RvTests and so requires no extra hands-on time. This will increase 
the computational time for the analyses, and this time will increase exponentially with sample size. 
For example, the analyses of a sample of ~10,000 individuals using RAREMETALWORKER 
took ~22 hours (maximum memory use of 2.3GB) to finish, including generating two kinship 
matrices (one for autosome and the other for chromosome X), fitting linear mixed models using 
these two matrices, and deliver single variant analyses results using additive, recessive, and 
dominant models, and generate three separate sets of covariance matrices, together with the plots 
in PDF. The same analyses for a sample of around ~2,000 individuals took ~6 hours (max memory 
use was ~100Mb) using RvTests. Overall, metrics will depend on your server setup, but times and 
memory use seems comparable for RvTests and RAREMETALWORKER. Thus, if you have a 
large sample size, you might wish to check your servers’ capacity. Again, once made, you can use 
this matrix for future analyses and collaborations. 
Analysts are free to choose which software (RvTests or RAREMETALWORKER) they use. The 
most notable differences to users are the interface, in particular the way covariates are organized. 
RvTests organizes covariates in a similar way to PLINK, where covariates are provided in a 
separate file. RAREMETALWORKER was derived from Merlin, so it supports inputs more 
similar to Merlin, in that covariates are stored in PED file, and you also need a DAT file to describe 
the covariates. Both tools have a very simple interface to use, and the input for one tool can be 
easily converted to the other. 
For family-based studies with known pedigree structure, to ensure pedigrees are correctly 
understood by analysis tools, we recommend that all connecting individuals - including those for 
whom genotypes are not available - should be dummied into the pedigree file. For example, when 
analyzing nuclear families where only offspring are genotyped, the pedigree file should include 
additional rows for the parents. When analyzing more extended pedigrees, additional individuals 
may need to be included in the pedigree file. 
NOTE that we do not ask to perform study-specific multiple-variant analyses, but rather to 
generate output files that are being used for central multiple-variant meta-analyses (using 
rareMETALS). 
Please remember to 
Perform analyses for: 
• All individuals 
• Men only 
• Women only 
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Stratify analyses by: 
• Disease status; i.e. analyze cases and controls separately, in particular if the outcomes 
(above) are affected by disease status 
• Race/ethnicity as appropriate to your sample. 
RVTESTS 
RvTests software is fast and capable of handling large data set. The input files required (phenotype, 
covariates) are compatible with PLINK formats. It also calculates Hardy-Weinberg p-value and 
call rate for quality control purposes. Documentation of RvTests can be found in: 
https://github.com/zhanxw/rvtests 
Fat percentage and ExomeChip - Analysis plan – Dec 8th 2014 
16 
1. SUMMARY LEVEL STATISTICS FOR META-ANALYSIS OF RARE 
VARIANT ASSOCIATIONS 
The following summary level statistics will be generated for meta-analysis: 
a) Allele frequency for each variant 
b) Single variant association test statistics, including direction of effect. We use score 
statistics calculated at each variant site. 
c) Covariance matrix for each genetic region. We compute the genotype covariance 
for all variants in each gene. This matrix reflects linkage disequilibrium in the 
region. 
d) Basic VCF metrics, including reference and alternative alleles, chromosome 
positions and strand. 
The summary statistics can be calculated using the tools RvTests. These require an indexed 




2. INDEXING THE VCF FILES 
The software works with tabix, and takes indexed bgzip-ed VCF files as input. If your VCF 






Please index your bgzipp-ed VCF using the following command 
(QCD_FILE_FINAL_nochr.vcf.gz.tbi): 
tabix -f -p vcf QCD_FILE_FINAL_nochr.vcf.gz 
Please make sure there are no entries with -1’s or 0’s in the chromosome number column. 
 
3. PEDIGREE FILE FORMAT WITH PHENOTYPES 
The RvTests tool requires a simple pedigree file that starts with the standard 5 columns 
(family id, person id, father id, mother id and sex) followed by trait or trait residuals. The 
trait residuals to use are the transformed phenotypes that were obtained as described 
above. 
 
4. EXEMPLAR COMMAND 
An exemplar command for using RvTests looks like the following (please refer to section 
7. for exact commands for your respective data analysis, as trait transformation has to be 
done beforehand and no covariates are included in the analysis): 
./vcf2kinship --ped example.ped --out example 
./rvtests --inVcf QCD_FILE_FINAL_nochr.vcf.gz --pheno example.ped \ 
--kinship example.kinship --meta score,cov,dominant,recessive \ 
--out output_prefix 
 
5. SPECIFY VCF FILES 
Use --inVcf to specify which VCF to use. 
 
6. SPECIFY PHENOTYPES 
Use --mpheno phenoypeColumnNumber or --pheno-name to specify a given phenotype. 
Phenotype file is specified by the option --pheno example.ped. The default phenotype 
column header is “y1”. If you want to use alternative columns as phenotype for association 
analysis (e.g the column with header y2), you may specify the header names using either --
mpheno 2 or --pheno-name y2 
NOTE: to use --pheno-name, the header line must start with “fid iid” as PLINK requires. 
In phenotype file, missing values can be denoted by NA or any non-numeric value. 
Individuals with missing phenotypes will be automatically dropped from subsequent 
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association analysis. For each missing phenotype value, a warning will be generated and 
recorded in the log file. 
7. COMMANDS 
You need to prepare a phenotype file (example.ped in PLINK format) and a genotype file 
(QCD_FILE_FINAL_nochr.vcf.gz). You can choose one of the following two scenarios 
to use RvTests: 
a. Analysis of related individuals with known pedigree information in linear mixed 
models 
Generate kinship matrix from pedigree file: 
./vcf2kinship --ped example.ped --out output --xHemi 
Generate score statistics and covariance matrix: 
./rvtests --inVcf QCD_FILE_FINAL_nochr.vcf.gz \ 
--pheno example.ped --out output --kinship output.kinship \ 
--xLabel X --meta score,cov,dominant,recessive 
b. Analysis of unrelated and/or related individuals with empirical kinship in linear mixed 
models 
Generate empirical kinship matrix from VCF file: 
./vcf2kinship --ped example.ped --inVcf QCD_FILE_FINAL_nochr.vcf.gz \ 
--bn --out output --xLabel X --xHemi 
By default, the output file is named as output.kinship, and you can use it with the --
kinship option 
Generate score statistics and covariance matrix: 
./rvtests --inVcf QCD_FILE_FINAL_nochr.vcf.gz --pheno example.ped \ 
--out output --kinship output.kinship --xLabel X \ 
--meta score,cov,dominant,recessive 
c. Analyzing sex chromosome 
The output of the above scripts (a.- b.) also contains the association results for X linked 
markers. RvTests recognize male (coded as 1) and female (code as 2) by looking up values 
in the 5th column of the PED file. Male non-reference genotype in the non-PAR regions 
of the X chromosome will be coded as 0 and 2 in regression model. Any male sample with 
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genotypes stored as heterozygous (e.g. 0/1) in this region is skipped from the analysis. The 
definition of this hemizygote region is the X chromosome except the PAR1 region 
(X:60001-2699520) or PAR2 region (X:154931044-155270560). 
NOTE: The run of vcf2kinship with “--xHemi" option will produce the kinship files for 
both autosomal region (output.kinship) and X chromosome hemizygote region 
(output.xHemi.kinship) based on either pedigree information or common exome-chip 
SNP information. The analysis of the X chromosome hemizygote region requires 
output.xHemi.kinship file. This file name can be automatically deduced from the 
parameter of “--kinship" given by the user. For example, if the user specify “--kinship 
output.kinship”, RvTests will look for “output.kinship” as the autosomal kinship file and 
“output.xHemi.kinship” as the X chromosome hemizygote region kinship file. 
Using --out output option, the results are stored in output.MetaScore.assoc 
(output.MetaRecessive.assoc or output.MetaDominant.assoc) and 
output.MetaCov.assoc.gz (output.MetaDominantCov.assoc.gz or 
output.MetaRecessiveCov.assoc.gz). Each output file contains a header with summaries 
of trait and covariates. 
8. OUTPUT FILES 
The output.MetaScore.assoc files contain the following columns: 
CHROM Chromosome 
POS Position 
REF Reference Allele 
ALT Alternative Allele 
N_INFORMATIVE Number of samples in the analysis 
AF Allele frequency; 
INFORMATIVE_ALT_AC Number of alternative alleles 
CALL_RATE Fraction of non-missing genotypes 
HWE_PVALUE Hardy-Weinberg Equilibrium P-value. 
N_REF, N_HET, N_ALT Number of ref/ref, ref/alt, alt/alt genotypes respectively. 
U_STAT, SQRT_V_STAT U statistic and square root of V statistic as in the score test. 
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ALT_EFFSIZE Estimated effect size using alternative allele. 
PVALUE P-value when testing genetic association using score test. 
The output.MetaCov.assoc.gz files contain following columns: 
CHROM Chromosome 
START_POS Position for the first marker in Window 
END_POS Position for the last marker in Window 
NUM_MARKER Number of markers in Window 
MARKER_POS Position for the markers in Window, separated by commas 
COV Covariance matrix between test statistics 
The Log file is saved in output.log 
!! PLEASE; USE THE “FILE NAMING SCHEME” DESCRIBED BELOW BEFORE 
UPLOADING YOUR DATA !! 
 
RAREMETALWORKER 
RAREMETALWORKER provides an alternative to RvTests. This tool handles related individuals 
using either pedigree information or an empirical kinship matrix estimated from marker data. 
RAREMETALWORKER also provides an alternative tool for samples of unrelated individuals. 
1. KEY FEATURES 
Hardy-Weinberg equilibrium p-value and genotype call rate are calculated automatically 
and included in summary files for later quality control. Some options can automatically 
compress the results (--zip) to share and allows one to label the significant loci (--labelHits) 
with gene names in Manhattan plots. Genomic control information will be reported 
automatically. 
RAREMETALWORKER accepts genotypes in VCF or in Merlin pedigree files for input 
(although we recommend VCF, especially if INDELs are included in the analysis) and (in 
family samples) should correctly handle variants on the X chromosome. 
2. HOW TO EXECUTE 
a) To execute, go to /raremetal_4.13.5/raremetal/bin/, and run ./raremetalworker. 
A summary of available options will appear. 
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b) For detailed explanations of those options, please refer to the following wiki 
page: http://genome.sph.umich.edu/wiki/Rare-Metal-
Worker#Software_Options 
3. INPUT FILES 
RAREMETALWORKER reads genotypes from either a PED/DAT file pair or a VCF 
file. When genotypes are saved in a PED and DAT file, no VCF file is needed. However, 
when a VCF file is used, the pedigree structure, phenotypes and covariates must be read 
from a PED/DAT file pair. Sample IDs in the VCF file must match individual IDs (second 
field) in PED file. To handle unrelated individuals, each individual should have a distinct 
family ID in the PED file (an easy way to accomplish this is to repeat the individual ID in 
the family ID column). 
We strongly recommend VCF file as input of variant genotypes because VCF has many 
advantages compared to PED file, for example, INDELs are better defined in VCF but is 
always ambiguous in PED/DAT files. 
a. VCF File 
VCF file should be compressed by using bgzip and indexed by using tabix, please refer to 
section 8 RvTests 2 for commands. 
b. PED and DAT Files 
Trait values are saved in PED file. Trait descriptions are saved in DAT file. 
RAREMETALWORKER can handle MERLIN format or PLINK format (text-only) 
pedigree files, but the correct label for each field has to be provided in DAT file. For 
detailed descriptions and examples of Merlin format PED and DAT files or VCF file, 
refer to the following: http://genome.sph.umich.edu/wiki/Rare-Metal-
Worker#Input_Files 
In the phenotype file, missing values can be denoted by X as used in MERLIN 
(http://www.sph.umich.edu/csg/abecasis/merlin/tour/input_files.html). Individuals 
with missing phenotypes will be automatically dropped from subsequent association 
analysis. 
4. EXAMPLE USAGE 
The following examples assume the presence of VCF file. 
a. ANALYSIS OF FAMILY SAMPLES (with known pedigree information) 
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Because genotypes are saved in a VCF file, PED and DAT files are needed for specifying 
pedigree structure and trait information. This command line fits the model and generates 
summary statistics. 
raremetalworker --ped your.ped --dat your.dat \ 
--vcf QCD_FILE_FINAL_nochr.vcf.gz --kinPedigree \ 
--recessive --dominant --zip --vcX --separateX --xLabel X 
 
b. ANALYSIS USING AN EMPIRICAL KINSHIP MATRIX 
This analysis will first calculate an empirical kinship matrix, and then fits the model and 
generates the summary statistics. 
raremetalworker --ped your.ped --dat your.dat \ 
--vcf QCD_FILE_FINAL_nochr.vcf.gz --recessive --dominant \ 
--zip --kinGeno --kinSave --vcX --separateX --xLabel X 
NOTE: if you’ve already generated a kinship based genomic relationship matrix, you can 
refer point to that with --kinFile. 
c. ANALYSIS OF CHROMOSOME X LINKED MARKERS 
The output of the above scripts (a.- b.) also contains the association results for X linked 
markers. In order for RAREMETALWORKER to differentiate between male and female, 
men should be coded as 1 and women as 2 in the PED file. RAREMETALWORKER 
takes male genotype to be 0 or 2. This means that whenever an alternative allele is observed 
in male on chromosome X (non-PAR region), it is considered to have the same effect as a 
female with homozygous alternative alleles. Any male sample with genotypes stored as 
heterozygous (e.g. 0/1) in this region is skipped from the analysis. The label of 
chromosome X can be changed flexibly according to the entry in VCF file (the first 
column) using --xLabel option. The non-PAR region can also be specified using --xStart 
and --xEnd options. Then RAREMETALWORKER can automatically differentiate 
between the PAR and non-PAR region on Chromosome X and decode male genotype 
accordingly. For example, if the X chromosome in the VCF file is labeled as “X”, then 
adding the following options lets RAREMETALWORKER recognize variants with 
CHR=”X” and 2699520 ≤POS≤154931044 for chromosome X associations. 
--xLabel X --xStart 2699520 --xEnd 154931044 
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The default values for these options are --xLabel X --xStart 2699520 --xEnd 154931044. 
The start and end positions are collected from NCBI genome build 37. 
For more examples of the usage, please refer to the following: 
http://genome.sph.umich.edu/wiki/Rare-Metal-Worker#Example_Command_Lines 
For more examples of X-linked marker analysis usage, please refer to the following: 
http://genome.sph.umich.edu/wiki/RAREMETALWORKER_X 
 
5. OUTPUT FILES 
RAREMETALWORKER will generate seven files for sharing per trait, which should be 
uploaded to the SFTP site: 
o the summary statistics of single variant score tests from the additive model, 
recessive model and dominant model; 
o the linkage disequilibrium (LD) matrices summarising covariance between single 
marker score statistics from the additive model, recessive model and dominant 
model; 
o a log file with all parameter settings. 
These seven files are required for central meta-analysis and QC. 
http://genome.sph.umich.edu/wiki/Rare-Metal-Worker#Outputs 




For detailed explanations, please go to the link above. To change the prefix used to label 
files use the --prefix option. 
The following fields will be included in the output (please double check): 
CHROM Chromosome 
POS Position 
REF Reference Allele 
ALT Alternative Allele 
N_INFORMATIVE Count of individuals with genotype and phenotype 
FOUNDER_AF Allele frequency among founders 
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ALL_AF Allele frequency across entire sample 
INFORMATIVE_ALT_AC Copies of the rare allele among samples with genotype and 
phenotype 
CALL_RATE Fraction of called genotypes 
HWE_PVALUE Exact Hardy-Weinberg equilibrium p-value 
N_REF Count of reference homozygotes 
N_HET Count of heterozygotes 
N_ALT Count of alternative allele homozygotes 
U_STAT Score statistic numerator 
SQRT_V_STAT Score statistic denominator 
ALT_EFFSIZE Estimated effect size 
PVALUE P-value 
This file will also include a header with a summary of trait and covariate distributions 
(including the mean and standard deviation, for example). 




CURRENT_POS Position for the first marker in Window 
MARKERS_IN_WINDOW Position for the other markers in window, separated by 
commas 
COV_MATRICES Covariance matrix between test statistics 
3. A log file is saved in: yourPrefix.singlevar.log 
!! PLEASE; USE THE “FILE NAMING SCHEME” DESCRIBED BELOW BEFORE 
UPLOADING YOUR DATA !! 
 
9. FILE NAMING SCHEME 
Use the following file naming scheme: 
STUDY_TRAIT_SEX_STATUS_ANCESTRY_DATE_ANALYST_ ANALYSIS.TXT 
STUDY: Name of your study population 
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TRAIT: FatPCT, FFMi, LEPTIN, LEPTINadjBMI, LEPTINadjFatPCT, 
ADIPONECTIN, ADIPONECTINadjBMI or ADIPONECTINadjFatPCT 
SEX: ALL, MEN, or WOMEN 
STATUS: COHORT, CASE or CONTROL (if CASE, specify T2DCASE, or 
CADCASE, …) 
ANCESTRY: EU (European ancestry), AA (African ancestry), HL (Hispanic Latino), 
EAS (East Asian), SAS (South Asian) 
DATA: DDMMYY 
ANALYST: Initials of analyst 
ANALYSIS: use CLUSTER: for the PC cluster files 





















Please also upload the outputs (7 files) from the checkVCF scripts, using the following 
conventions: 
STUDY.check.ref, STUDY.check.nonSnp etc.  
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Analysis plan 2: Genome-wide association studies for fat and lean mass 
compartments 
 
1. Project aims 
In this project we aim to identify the genetic determinants of 16 body fat and lean mass 
compartments measured by DEXA through genome-wide association analyses. Analyses will be 
run for both sexes combined and stratified by sex. We will analyse the DEXA traits unadjusted 
and adjusted for total fat mass (fat compartments) and height-squared (lean compartments). 
This analysis plan describes the quality control (QC) and transformation of the DEXA phenotypes 
and the genome-wide association analyses of fat and lean mass compartments. Please contact 
Claudia Langenberg (Claudia.Langenberg@mrc-epid.cam.ac.uk) and Laura Wittemans 
(Laura.Wittemans@mrc-epid.cam.ac.uk) in case you have any questions. 
 
2. Phenotype QC and transformation 
a) Phenotypes 
The 16 traits that will be studied in this project are the following: 
• Total fat mass (g) (fat_tot) 
• Total lean mass (g) (lea_tot) 
• Arms fat mass (g) (fat_arm) 
• Arms lean mass (g) (lea_arm) 
• Trunk fat mass (g) (fat_tru) 
• Trunk lean mass (g) (lea_tru) 
• Android fat mass (g) (fat_and) 
• Android lean mass (g) (lea_and) 
• Gynoid fat mass (g) (fat_gyn) 
• Gynoid lean mass (g) (lea_gyn) 
• Legs fat mass (g) (fat_leg) 
• Legs lean mass (g) (lea_leg) 
• Visceral fat mass (g) (fat_vis) 
• Subcutaneous fat mass (= android fat mass – visceral fat mass) (g) (fat_scu) 
• Appendicular lean mass (= legs lean mass + arms lean mass) (g) (lea_app) 
• Peripheral fat mass (= legs fat mass + arms fat mass) (g) (fat_pri) 
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The first 13 traits are directly generated by the DEXA software, whereas the last 3 can be 
calculated with the provided formulas.  
 
b) Quality control of phenotypes  
DEXA measurements should be omitted if: 
• Some tissue is missing, e.g., very tall or broad participants, participants who 
underwent amputations etc. 
• Any other reason for low quality, incomplete or atypical DEXA measurements, 
such as movement artefacts, pregnant or transgender participants etc. 
Participants with prosthetic implants (e.g., hip and knee replacements) should not be 
excluded. 
Please generate histograms of untransformed DEXA traits after QC and provide an 
overview of your QC procedure of the DEXA data in the info file (see section 4) 
If you require assistance with this step, please contact Claudia or Laura.  
 
c) Phenotype transformation 
Unadjusted analyses (all phenotypes) 
1. Transform phenotypes for men and women separately  
2. Natural log transform all DEXA traits 
3. Fit a linear model with age and any study-specific covariates as independent 
variables and DEXA compartment as the dependent variable. Take the residuals 
4. Rank-based inverse normal transformation of residuals 














Adjusted analyses for fat compartments 
Phenotypes: peripheral fat mass, subcutaneous fat mass, visceral fat mass, leg fat mass, 
gynoid fat mass, android fat mass, trunk fat mass and arm fat mass. 
• Transform phenotypes for men and women separately  
• Natural log transform all fat DEXA traits 
• Fit a linear model with age, total body fat (natural log transformed) and any study-
specific covariates as independent variables and DEXA compartment as the 
dependent variable. Take the residuals 
• Rank-based inverse normal transformation of residuals 











Adjusted analyses for lean compartments 
Phenotypes: Appendicular lean mass, leg lean mass, android lean mass, trunk lean mass, 
arm lean mass, total lean mass, gynoid lean mass. 
• Transform phenotypes for men and women separately  
• Natural log transform all lean DEXA traits 
• Fit a linear model with age and height-squared (in cm2) and any study-specific 
covariates as independent variables and DEXA compartment as the dependent 
variable. Take the residuals 
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• Rank-based inverse normal transformation of residuals 











3. Genome-wide association analyses 
a) Quality control of genotyped data 
For QC of the genotyped data, please follow the best practices for QC suggested by the 
manufacturer of the genotyping chip.  
Recommended filters: 
Exclude participants if sex mismatch 
Exclude variants for which call rate <97% 
Exclude variants for which p-value for HWE<10-8 
Exclude participants with more than 5% missing variants 
Exclude ethnic outliers that do not cluster with their expected ancestry based on a scatter 
plot of PC1 and PC2 and the 1000G CEU, YRI and CHB/JPT reference panels 
Exclude related participants based on IBD>10% 
Please provide an overview of the QC strategy you applied for the genotyped data in the 
info file (see section 4) 
 
b) Imputation 
Preferred imputation strategy for white British cohorts (aligned to UK biobank): 
Impute genotyped data to the reference panel from the Haplotype Reference Consortium 
and UK10K-1000 Genomes (UK10K-1KG).  
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Give priority to HRC-imputed variants and fill in with UK10K-1KG-imputed variants (for 
those which are not present among the HRC imputed variants) 
Preferred imputation strategy for non-British white European cohorts: Impute 
genotyped data to reference panel from the Haplotype Reference Consortium 
Preferred imputation strategy for other ancestries: Impute genotyped data to 1000G 
reference panel for the matching ancestry. 
HRC, UK10K-1KG and 1KG imputation can be done using the Sanger 
(imputation.sanger.ac.uk/) or Michigan imputation server 
(imputationserver.sph.umich.edu). 
Please get in touch with Claudia or Laura if you have any questions regarding the 
imputation. 
 
c) Genome-wide association analyses 
To run the genome-wide association analyses, we suggest using SNPTEST or BGENIE. 
Please include at least 4 principal components and other covariates related to the 
genotyping if necessary for your cohort (e.g., include genotyping chip as covariate is several 
different types of chip were used for genotyping in your cohort). Please do not include sex 
as a covariate.  
SNPTEST runs on GEN, BGEN and VCF files and will run the traits one by one. 
Download and more info: 
https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html 
BGENIE only runs on BGEN files and has the advantage that it can analyse a large 
number of traits in one run, while decompressing and converting the BGEN files only 
once for all traits. This makes this tool more time-efficient. GWAS results for all traits are 
stored in one file, which can become very large and therefore more challenging to handle 
than the results file outputted by SNPTEST. Download and more info: 
(https://jmarchini.org/bgenie/). 
 
d Quality control of GWAS results 
1. Drop variants for which minor allele count (MAC) is less than 10. MAC=2*minor 
allele frequency*sample size 
2. Drop if info score is lower than 0.4 (INFO<0.4) 
3. Drop variants with other alleles than A, C, G or T 
Supplementary materials 
 350 
4. Drop variants for which the absolute value of the effect size or SE is larger than 
10 
 
4. Data sharing 
Please generate and upload the following figures and files. You will receive the login details to the 
SFTP in a separate email.  
General comment: Given the large number of traits and analyses, it would be very helpful if you could follow the 
recommended filename structure. 
 
a) File names 
Given the large numbers of phenotypes and analyses, could you please follow the following 
file name structure for all files for sharing: 
CohortName_trait_sex_adjustment_date_[type_of_analysis/figure/document].txt/png 
CohortName: cohort name 
trait: dexa trait using the abbreviations specified under 2.1. (e.g., fat_and) 
Sex: combined, men, women 
Adjustment: unadj or adj (for total fat or height-adjusted traits).  
Date: yymmdd (e.g., 180321 for 21th March 2018) 
 
b) Phenotypes 
Histograms of untransformed DEXA traits after QC, for sexes combined. 
CohortName_trait_date_hist.png/jpg 
Scatter plot of total mass from DEXA versus weight as measured using scales. 
CohortName_weight_dexa_date_scatter.png/jpg 
Table giving for each trait and by sex the sample size, mean, standard deviation, maximum 
and minimum, and age (mean, SD, maximum and minimum) 
Cohort_phenotypes_date_table.txt 
 
c) GWAS results 
Please provide one gzipped file per trait/analysis using the following file name structure: 
CohortName_trait_sex_adjustment_date_gwas.txt.gz 
Columns to include: 




Please provide chromosome and position in build genome build GRCh37 
Rsid 
Effect_allele (as upper case: e.g., G instead of g) 
Other_allele (as upper case) 
Chr 
Bp: basepair position in build genome build GRCh37 
EAF: effect allele frequency 
INFO: info imputation score 
Beta: effect size aligned to effect allele 
SE: standard error 
P: p-value 
	
d) Cohort info 
Please generate a .txt file (CohortName_data_info.txt) in which you specify the 
following characteristics of your cohort and data: 
DEXA technology and software 
Applied QC strategy for DEXA 
Study-specific covariates used in the phenotype transformation 
Genotyping chip 
QC of genotyped data 
Imputation reference panel and software/server 
GWAS software + version 
Covariates for GWAS: number of principal components and other covariates (if any) 
 
